32nd International Congress of the International

32nd International Congress of the International Society of Blood Transfusion, Cancún, Mexico July 7 - 12, 2012

Acknowledgements

Table of Contents

Corporate Members ISBT is pleased to acknowledge the following Corporate Members

Platinum

Introduction - Words of Welcome - Future Congresses - Committees - Reviewers - Congress Organisers - About ISBT

5-7 8 9 - 10 11 - 13 14 15 - 16

Programme - ISBT Working Party and other meetings 17 - 19

Gold

The ISBT and the Local Organising Committee of the 32 International Congress of the ISBT in joint cooperation with the 10th Congress of the AMMTAC is grateful that the following companies are willing to support the congress: nd

Bio-Rad Cerus Europe BV DAY medical SA Fresenius Kabi Deutschland GmbH GFE Blut mbH Haemonetics Corporation HELMER Immucor, Inc. Macopharma MTC INVITRO DIAGNOSTICS AG Novartis Diagnostics Octapharma AG Ortho Clinical Diagnostics Roche Terumo BCT 2

ISBT Working Party Programme

21 - 33

General Scientific Information - General Scientific Information - ISBT Prize Lectures - ISBT Mobile Application

35 - 37 38 39

Programme at a Glance

41 - 46

Scientific Programme - Saturday July 7 - Sunday July 8 - Monday July 9 - Tuesday July 10 - Wednesday July 11 - Thursday July 12

47 - 50 51 - 62 63 - 84 85 - 102 103 - 120 121 - 126

Posters - Posters published (P) - Posters not published (BP)

127 - 128 129 - 220 221 - 240

Key Information

241 - 244

General Information

245 - 248

Social Programme

249 - 252

Floor Plans

253 - 258

List of exhibitors and Exhibition Guide

259 - 296

Speaker Index

297 - 302

3

4

Word of Welcome ISBT President 32nd International Congress of the ISBT - Cancún, 2012 Nearly 500 years ago, the Conquistadores defeated Montezuma and the Aztec civilization through a great blood shedding, incorporating the European habits and culture into what could be considered the most advanced civilization in the pre Columbian period of the American Continent. In 2012, another kind of activity will be incorporated to the “blood” word: blood harmonization, when Mexico will host and receive the whole world blood transfusion community in the magnificent city of Cancún. All delegates will have the opportunity to share their knowledge in Mexico, bringing to this great country the latest scientific developments in transfusion medicine. However, as a counterpart, the scientific community will also learn from Mexico what have been the recent advances in their young, vibrant and progressive Associación Mexicana de Medicina Transfusional (AMMTAC). The scientific committee worked to guarantee a challenging, updated and interesting scientific program, honoring the ISBT International Conference’s tradition to gather what can be considered a great balance between scientific and global harmonization in transfusion medicine. In addition, all delegates will benefit from the great Mexican history, folklore, and hospitality. Mexico has the third largest population in the American continent (120 million), and one of the main aspects is the diverse cultural background. This country is equidistant from all remaining American countries (from North, Central and South America), but also from Europe and Asia. Cancún is located in the Yucatán Peninsula, with outstanding transport facilities (there are actually hundreds of direct flights from all parts of the world), an outstanding hotel infrastructure, and a modern convention centre. Surrounded by crystalline, Atlantic blue waters, it has a very pleasant climate and sunny days; this spot will be highly appreciated by all delegates, their family or accompanying persons. The rich local culture will impress those who never visited Mexico before. We expect to have a great number of Mexican attendees from AMMTAC, most of them young, promising, and interested members who will have a great opportunity to get together for the first time with global key players in the field. This is going to be a challenge for ISBT: to actively contribute to the very fast, growing and dynamic development in the Mexican transfusion medicine. The ISBT Board is proud that Mexico is our host for 2012. Together with Mexico, the blood transfusion community will benefit from being here. Enjoy Mexico and Cancún.

Silvano Wendel MD, PhD ISBT President 5

Introduction

Introduction

Introduction

Word of Welcome

Word of Welcome

Dear Colleagues, It’s a great pleasure to have you in Mexico. Our country opens its arms to give you a warm welcome. I want you to feel like you are in your own country.

In this opportunity Mexico can be considered as the entrance gate for Latin-American countries. Although due to globalization we can share a lot of scientific achievements, nothing can be compared with the delightful in one to one talks with people from many different countries.

For me it’s an honor to be the host of this magnificent event in Mexico. We hope we have a lot of delegates not only from our country but worldwide, here you will have the opportunity to enhance your knowledge of new technologies which are being developed around the world. I’m convinced your participation is very important in order for this congress to be a huge success.

As you know, my country has hosted important international meetings, due to the fact that we have world class venues, together with the worldwide known Mexican hospitality. Also we would like to share with you our rich culture; all the way from our prehispanic constructions, through the colonial buildings to the modern view of our cities. We know that we will fulfill your requirements as the host country for the 32nd International Congress of the ISBT. Participants will surely

The Mexican professional community on blood transfusion represented by the “Asociación Mexicana de Medicina Transfusional AC” –AMMTAC-, (Mexican Association of Transfusion Medicine), is pleased to host the 32nd International Congress of the International Society of Blood

experience the beauty and variety of our country, added to the scientific feast. We will be honored to receive all our International Society of Blood Transfusion colleagues, as guests in this great country. Cancún is one of the best locations in Mexico for hosting an ISBT Congress.

Transfusion (ISBT) in 2012. Hosting the congress is a great honor and an excellent opportunity to show the efforts and the development of transfusion medicine in our country, as well as the great growth in tourism, cultural and technological areas. As a country that hosts an international congress, Mexico has a great opportunity to point out the needs and achievements of our country and to make synergies with governmental and nongovernmental organizations in order to achieve the highest quality goals. Transfusion Medicine takes us deep into the human heart, because, blood donation means love for the human race. That is one of the reasons why ISBT and AMMTAC have worked together to create an academic program that gathers many professional workers in the field, not only those who do laboratory and clinical work and research, but also those who promote blood donation, having in mind that blood donors are the foundation to build blood banks and transfusion medicine services in which we have one of our main objectives: patients health.

ISBT and AMMTAC will ensure that the congress is an unforgettable experience for everyone. Both associations are collaborating together with the main objective of transmitting updated knowledge in the transfusion medicine field. All with an added Mexican flavor. Welcome to Mexico!

EBC. Julio César Martínez Álvarez President of AMMTAC Congress President

Transfusion medicine topics from donor to patient are included in the scientific program. Those who are interested in scientific research, new developments and changing insights will not be disappointed. Those who are new to the field will find an ISBT Academy program which will enable them to quickly learn about many aspects of transfusion medicine. As health workers, the congress gives us the opportunity to achieve the highest standars in the interest and care of patients, because it allows the exchange of ideas from every corner of the world. Delegates will have the chance to refresh and develop relationships with Latin America. Our health problems are similar to those in the countries of Europe, Africa and Asia and the congress is a unique opportunity to share experiences and increase knowledge. 6

7

Introduction

Introduction

Introduction

Introduction

Introduction

Future ISBT Congresses - 23rd Regional Congress of the ISBT, Amsterdam, the Netherlands, June 2 - 5, 2013 - 24th Regional Congress of the ISBT, Kuala Lumpur, Malaysia, December 1 - 4, 2013 - 33rd International Congress of the ISBT, Seoul, South-Korea, June 1 - 5, 2014

Website p-to-date information regarding the ISBT Congress programmes is available on the ISBT website: U www.isbtweb.org

Exhibition hours & Poster desk opening hours: Sunday Monday Tuesday Wednesday Thursday

8

July 8 July 9 July 10 July 11 July 12

18.30 - 21.00 hours 09.00 - 18.00 hours 09.00 - 19.00 hours 09.00 - 18.00 hours 09.00 - 13.00 hours

Committees ISBT Executive Committee President: President-Elect: Vice President: Vice President: Past President: Secretary General: Treasurer:

Silvano Wendel (2010 - 2012) Peter Flanagan (2010 - 2012) Anne Husebekk (2008 - 2012) Roger Dodd (2010 - 2014) Erhard Seifried (2010 - 2012) Geoff Daniels (2010 - 2014) Steve Morgan (2008 - 2012)

ISBT Board of Directors Africa: Northern Americas: Southern Americas: Eastern Mediterranean: Eastern Europe: Western Europe: South East Asia: Western Pacific:

Ravi Reddy (2006 - 2012) Amalia Bravo Lindoro (2010 - 2014) Oscar Torres (2010 - 2014) Salwa Ibrahim Hindawi (2010 - 2014) Eugene Zhiburt (2010 - 2014) Jean-Pierre Allain (2008 - 2012) Neelam Marwaha (2010 - 2012) Diane Teo (2006 - 2012) Erica Wood (2010 - 2014)

ISBT Executive Director Judith Chapman (Netherlands) ISBT Scientific Secretary Martin Olsson (Sweden) Congress Scientific Sub-committee Chairperson: Members:

Martin Olsson (Sweden) Michael Schmidt (Germany) Masja de Haas (Netherlands) James Zimring (USA)

9

Introduction

Introduction

Introduction

Committees

We would like to thank all reviewers for their time and efforts in reviewing the abstracts allocated to them:

Local Organising Committee President: Members:

Julio César Martínez Álvarez (Mexico) Clotilde Estrada Carsolio (Mexico) Lucia Zamudio Godinez (Mexico) Felipe De Jesús Herrera Gómez (Mexico) Anal Luisa DÁrtote González (Mexico) Javier Bautista Juárez (Mexico) Amalia Bravo Lindoro (Mexico) Ángel Guerra Márquez (Mexico) Ma. De Jesús Pichardo Martínez (Mexico) Ma. Antonieta Velez Ruelas (Mexico) Mario Alberto González Santos (Mexico) Elizabeth Guzmán Vázquez (Mexico)

Local Scientific Committee Chairperson: Members:

Amalia Bravo Lindoro (Mexico) Ana Luisa DÁrtote González (Mexico) Sergio Sánchez Guerrero (Mexico) José Luis Alcaraz López (Mexico) Araceli Malagón Martínez (Mexico) Julieta Rojo Medina (Mexico) Enrique Gómez Morales (Mexico) Jorge Espinosa Turcott (Mexico)

International Scientific Committee Jean-Pierre Allain (United Kingdom) Pia Bruce (Finland) Judith Chapman (Netherlands) Geoff Daniels (United Kingdom) Diane de Coning (South Africa) Roger Dodd (USA) Peter Flanagan (New Zealand) Gilles Folléa (Netherlands) Lin Fung (Australia) Anne Husebekk (Norway) Cécile Kaplan (France) Mickey Koh (United Kingdom/Singapore) 10

Reviewers

Loyiso Mpuntsha (South Africa) Sandra Nance (USA) Martin Olsson (Sweden) Erhard Seifried (Germany) Jill Storry (Sweden) Hans Vrielink (Netherlands) Jonathan Wallis (United Kingdom) Silvano Wendel (Brazil) Jo Wiersum (Netherlands) Erica Wood (USA) Eugene B. Zhiburt (Russian Federation)

Jean-Pierre Allain (United Kingdom) Beryl Armstrong (South Africa) Paul Ashford (USA) James Aubuchon (USA) Marja-Kaisa Auvinen (Sweden) Giorgio Baldanzi (Brazil) Claire Barrett (South Africa) Mahmut Bayik (Turkey) Allain Beauplet (France) Richard Benjamin (USA) Zarin Bharucha (India) Nidhi Bhatnagar (India) Celso Bianco (USA) Arthur Bird (South Africa) Halvard Bönig (Germany) Anneke Brand (Netherlands) Amalia Bravo Lindoro (Mexico) Dialina Brilhante (Portugal) Ewa Brojer (Poland) Pia Bruce (Finland) Thierry Burnouf (France) Mike Busch (USA) Lesley Bust (South Africa) Jose Manuel Cárdenas (Spain) Rebecca Cardigan (United Kingdom) Jean-Pierre Cartron (France) Lilian Castilho (Brazil) Emma Castro (Spain) Judith Chapman (Netherlands) Rajendra Chaudhary (India) Alejandro Chiera (Argentina) Mary Clay (USA) Yves Colin Aronovicz (France) Fabiana Conti (Brazil) Joliette Coste (France) Brian Custer (USA)

Ricardo Antonio dÁlmeida Pereira (Brazil) Geoff Daniels (United Kingdom) Rodeina Davis (USA) Diane De Coning (South Africa) Masja de Haas (Netherlands) Wim de Kort (Netherlands) Dirk de Korte (Netherlands) Francine Décary (Canada) Gilles Delage (Canada) Véronique Deneys (Belgium) Greg Denomme (USA) Dana Devine (Canada) Margriet Dijkstra-Tiekstra (Netherlands) Roger Dodd (USA) Ashley Duits (Curaçao) Walter Dzik (USA) Anne Eder (USA) Hermann Eichler (Germany) Magdy El-Ekiaby (Egypt) Diego Estol (Uruguay) Peter Flanagan (New Zealand) Willy Flegel (USA) Gilles Folléa (Belgium) Rita Fontão-Wendel (Brazil) Christian Gabriel (Austria) Olivier Garraud (France) Christoph Gassner (Switzerland) Birgit Gathof (Germany) Christof Geisen (Germany) Jørgen Georgsen (Denmark) Lawrence Goodnough (USA) Hans Gulliksson (Sweden) Snehalata Gupte (India) Roslin Hassan (Malaysia) Nancy Heddle (Canada) Hans Erik Heier (Norway) 11

Introduction

Introduction

Introduction

Introduction

Reviewers Åsa Hellberg (Sweden) Reinhard Henschler (Germany) Anne Husebekk (Norway) Per Johansson (Denmark) Cécile Kaplan (France) Alan Kitchen (United Kingdom) Jens Kjeldsen-Kragh (Sweden) Steven Kleinman (Canada) Ralph Knels (Germany) Mickey Koh (United Kingdom/Singapore) Hartmut Kroll (Germany) So Yong Kwon (South Korea) Gerhard Lanzer (Austria) David Leiby (USA) Marcel Levi (Netherlands) Che Kit Lin (Hong Kong SAR) Marie Lin (Taiwan) Sujen Lin (Taiwan) Christine Lomas-Francis (USA) Miguel Lozano (Spain) Rajnath Makroo (India) Julio Martínez Álvarez (Mexico) Neelam Marwaha (India) Gert Matthes (Germany) Wolfgang Mayr (Austria) Dora Mbanya (Cameroon) Bridon Mbaya (Malawi) Carl McDonald (United Kingdom) Faten Moftah (Egypt) Thomas Montag-Lessing (Germany) Rainer Moog (Germany) Eduardo Muñiz Diaz (Spain) Charles Munk (Switzerland) Manuel Muñoz (Spain) Mike Murphy (United Kingdom) Sandra Nance (USA) Fátima Nascimento (Portugal) Núria Nogués (Spain) France Noizat-Pirenne (France) 12

Reviewers Martin Olsson (Sweden) Jean-Claude Osselaer (Belgium) Simon Panzer (Austria) Erica Pasini (Netherlands) Geoff Poole (United Kingdom) Joyce Poole (United Kingdom) Patrick Provost (Canada) Paolo Rebulla (Italy) Ravi Reddy (South Africa) Henk Reesink (Netherlands) Maria Rios (USA) Julieta Rojo Medina (Mexico) Ulrich Sachs (Germany) Sentot Santoso (Germany) Rajesh Sawant (India) Michael Schmidt (Germany) Clive Seed (Australia) Christian Seidl (Germany) Erhard Seifried (Germany) Axel Seltsam (Germany) Alok Sen (India) Luc Sensebé (France) Daniele Sondag-Thull (Belgium) Janaki Sonoo (Mauritius) Cynthia So-Osman (Netherlands) Simon Stanworth (United Kingdom) Jill Storry (Sweden) Susan Stramer (USA) Paul Strengers (Netherlands) Michael Strong (USA) Shigeru Takamoto (Japan) Cecilia Tan (Singapore) Agneta Taune-Wikman (Sweden) Claude Tayou Tagny (Cameroon) Diana Teo (Singapore) Dafydd Thomas (United Kingdom) Oscar Torres (Argentina) Leo van de Watering (Netherlands) Peter van den Burg (Netherlands)

Pieter van der Meer (Netherlands) Claudio Velati (Italy) Ingrid Veldhuizen (Netherlands) Marion Vermeulen (South Africa) Hans Vrielink (Netherlands) Tomislav Vuk (Croatia) Franz Wagner (Germany) Jonathan Wallis (United Kingdom)

Silvano Wendel (Brazil) Connie Westhoff (USA) Jo Wiersum (Netherlands) Markus Wiesneth (Germany) Erica Wood (USA) Fumiichiro Yamamoto (Spain) Mark Yazer (USA)

13

Introduction

Introduction

Introduction

Introduction

Congress Organisers ISBT For more information about the ISBT, please contact: ISBT Central Office Marnixstraat 317 1016 TB Amsterdam, the Netherlands Telephone: +31 20 760 1760 Fax: +31 20 760 1761 Website: www.isbtweb.org E-mail: [email protected] Congress Organisers c/o MCI - Eurocongress v.o.f. Jan van Goyenkade 11 1075 HP Amsterdam, the Netherlands Telephone: +31 20 679 3411 Fax: +31 20 673 7306 E-mail: [email protected]

Official Housing and Travel Agent and Official Organiser Social Programme c/o B.P. Servimed, S.A. de C.V. Telephone: +52 55 9171 9575 Fax: +52 55 9171 9579 E-mail: [email protected] Congress Venue Cancun Center, Conventions & Exhibitions Boulevard Kukulcan KM. 9 1er Piso Zona Hotelera C.P. 77500 Cancún, Quintana Roo, México

About the ISBT The International Society of Blood Transfusion Facilitating knowledge about transfusion medicine to serve the interest of donors and patients. Everyone involved in any aspect of transfusion medicine can become a member of ISBT whether working in blood services, hospitals, research institutes, universities or industry. All professionals within the field of transfusion medicine are represented. Aims: • To connect with blood transfusion professionals • To provide opportunities for exchanging information related to blood transfusion medicine • To promote and maintain a high level of ethical, medical and scientific standards in blood transfusion medicine • To support safe and sufficient transfusion therapy globally Activities: The main activities of ISBT include: Bringing transfusion professionals together through: • Congresses; two regional congresses in odd numbered years and an international congress in even numbered years • Education through the ISBT Academy which organises or supports workshops and e ducational events • The activities of the 14 working parties which cover all aspects of transfusion medicine Join our community of professionals and: - Build productive contacts with fellow members all over the world - Access the members only content on the website including the membership directory - Receive a complimentary subscription to Vox Sanguinis and Transfusion Today with electronic access - Get discounts on registration fees for ISBT Congresses worldwide - Join our specialist working parties Visit the ISBT booth to find out more about becoming a member and how you can be active in our society. ISBT Pop- Quiz We would like to welcome you to our first ISBT Pop-Quiz! When you become a new member during the congress you will automatically enter this exciting easy quiz. On the last day of the congress a draw will be made and the winners will be announced. Make sure you are there! So come to our stand, become a new member test your knowledge and win!

14

15

Introduction

Introduction

Introduction

Introduction

Introduction

The Vox Sanguinis Best Paper Prize The Best Paper prize is granted for the best original paper published in Vox Sanguinis in the previous calendar year. The value of the prize is €10.000,-. The Editor in Chief and Section Editors of Vox Sanguinis prepare a short list of papers and the members of the Jean Julliard Prize Committee, chaired by the Past-President of ISBT, make the final selection. The 2012 winner of the Vox Sanguinis Best Paper Prize is John-Paul Tung for the paper titled: A novel in vivo ovine model of transfusion-related acute lung injury (TRALI) Tung JP, Fung YL, Nataatmjadja M, Colebourne KI, Esmaeel HM, Wilson K, Barnett AG, Wood P, Silliman CC, Fraser JF. Vox Sang 2011; 100: 219 - 230 The ISBT Award The ISBT Award is granted to a person, who has contributed in an outstanding way to the education of blood transfusion or transfusion medicine science. The selection of the Award winner(s) and the granting of this Award is a privilege of the Executive Committee of ISBT. The ISBT Developing Country Award The ISBT Award for Developing Countries was created out of the vision of Erhard Seifried, ISBT’s Past President, during his presidency of ISBT. The award enables the winner to attend an International Congress of the ISBT, organize an education symposium and/or a potential short scholarship to visit a centre of excellence. The award is open to Blood Services and/or Centres or individuals from low or medium development index countries according to the UN Development programme (UNDP) list. ISBT Members Lounge ISBT has introduced the ISBT members lounge. If you are an ISBT member you can visit the lounge where you will find cold and hot beverages, comfortable seating and some computer terminals. The ISBT lounge will also give you the opportunity to meet some of the congress invited speakers and members of the ISBT Board. The Members lounge is situated adjacent to the ISBT Stand on the first floor of the Cancun congress centre. Dr. Harold Gunson Fellowships The ISBT has awarded several young people from low and medium development index countries included in the UN Development Programme (UNDP) with a Harold Gunson Fellowship.

16

Programme

ISBT Working Party & other meetings * = by invitation only Programme

All working party meetings and other meetings will take place in the Grand Coral Hotel, unless otherwise stated. Friday July 6 08.00 - 17.30

Board of Directors Room ISBT Executive Committee Meeting

Saturday July 7 08.00 - 17.30

Coral Island Room

09.00 - 12.00

Coral Garden Ballroom 1 & 2 ISBT WP on Donors and Donation

09.00 - 13.00 Coral Sea Room 1 & 2

ISBT Board of Directors

WP on Red Cell Immunogenetics and Blood Group Terminology

09.45 - 17.00

Coral Kingdom Ballroom 2

ISBT WP on Haemovigilance*

13.00 - 15.15


Subgroup on (recipient) Haemovigilance

Coral Garden Ballroom 2

Subgroup on Donor Haemovigilance

10.00 - 17.00

Coral Kingdom Ballroom 1 ISBT WP on Information Technology*

Board of Directors Room ISBT WP on Transfusion Transmitted Infectious Diseases* (TTID) Subgroup on Cost Utility Analysis (CUA)

10.00 - 17.00

14.00 - 18.00 Board of Directors Room ISBT WP on Transfusion Transmitted Infectious Diseases* (TTID) Subgroup on Transmissible Spongiform Encephalopaties (TSE)


Subgroup on Bacteria

Coral Sea Room 1 & 2

Subgroup on Parasites

Coral Garden Ballroom 3 Subgroup on Epidemiology and Surveillance Grand Coral Ballroom Joint meeting: Subgroup on HBV Safety and Virology

17

Programme

Programme

ISBT Working Party & other meetings

* = by invitation only

* = by invitation only Tuesday July 10 07.00 - 09.00

Sunday July 8 08.30 - 09.30

11.45 - 12.45 Coba in Cancun Centre ISBT General Assembly All paid up members of ISBT are encouraged to attend the General Assembly

Board of Directors Room

ISBT WP on Rare Donors*

08.35 - 17.00

Coral Island Room ISBT WP on Transfusion Transmitted Infectious Diseases*

10.00 - 17.00


12.00 - 14.00

Coral Kingdom Ballroom 2 & 3 ISBT WP on Platelet Immunobiology

14.00 - 16.00

Coral Garden Ballroom 1 ISBT WP on Blood Supply Management*

14.00 - 16.00


08.30 - 11.30

Coral Kingdom Ballroom 2 & 3 ISBT WP on Global Blood Safety

16.00 - 17.30

Board of Directors Room

ISBT WP on Cellular Therapies

Monday July 9 07.00 - 08.00

Coral Sea Room 1

Presidents of National Societies

07.00 - 09.00


Quality Management

08.30 - 10.30

Coral Island Room 1 & 2

ISBT WP on Rare Donors

12.30 - 14.00

Coral Sea Room 1

ISAC Meeting*

14.30 - 15.30

Coral Sea Room 1 Corporate Sector Meeting*

16.00 - 17.30

Coral Sea Room 1 ISBT WP on Granulocyte Immunobiology

ISBT WP on Information Technology*

Coral Sea Room 1

15.00 - 16.00 Coral Sea Room 1 Wednesday July 10 12.00 - 14.00 Coral Island Room 1 & 2

Programme

Programme

All working party meetings and other meetings will take place in the Grand Coral Hotel, unless otherwise stated.

18.00 - 19.00 Coba in Cancun Centre

18

ISBT Working Party & other meetings

ISBT WP on Clinical Transfusion*

Industry Meeting

ISBT Board of Directors

ISBT WP on Apheresis*

AMMTAC Meeting (for members only)

19

20


ISBT Working Party Programme Saturday July 7


09.00 - 12.00

ISBT WP on Donors and Donation Chairperson: Diane de Coning Coral Garden Ballroom 1 & 2

Welcome Introduction Acceptance of the minutes of the Lisbon WP meeting

1. Progress report ISBT Working Party Programme

2. Feedback from task teams: Low haemoglobins in regular voluntary blood donors, particularly in the youth, under the leadership of Jo Wiersum and in collaboration with the ISBT WP on Haemovigilance Recognition versus incentives” under the leadership of Pip Hetzel 3. Hot topics - Challenges regarding recognition, incentives and rewards including free medical treatment for blood donors as an incentive - Successful educational programmes to be posted on the website to be shared with membership - Domaine Manual to be reviewed by the working party and to be used as a recommended reference for ISBT membership - Donor vigilance, particularly haemoglobin deferrals

4. Other matters

5. Closing

21







ISBT WP on Red Cell Immunogenetics and Blood Group Terminology

Chairperson: Jill Storry Coral Sea Room 1 & 2

- Apologies for absence - Minutes of Berlin meeting in 2010 - Membership -N ew members and retiring members Working Party Chair Working Party Secretary Working Party Treasurer Honorary members - Treasurer and finances - Evaluation of the Terms of reference - Reports of changes to blood group systems, collections and series. - Discussion of proposals received. - Gene terminology - Any other business

09.45 - 17.00

ISBT WP on Haemovigilance*

Chairperson: Jo Wiersum Coral Kingdom Ballroom 2 and Coral Garden Ballroom 2

09.45 - 12.15 Plenary 13.00 - 15.15 • Special interest group on (recipient) haemovigilance • Special interest group on donor haemovigilance 15.45 - 17.00 Plenary

22

10.00 - 17.00

ISBT WP on Information Technology (IT)*

10.00 - 12.00 12.30 - 14.30 15.00 - 17.00

RFID Task Force Meeting Interface Task Force Meeting Traceability Task Force Meeting

10.00 - 18.00

ISBT WP on Transfusion Transmitted Infectious Diseases (TTID)*

Chairperson: Silvano Wendel

Chairperson: Ralf Knels Coral Kingdom Ballroom 1



09.00 - 13.00

10.00 - 12.00 Subgroup on Cost Utility Analysis (CUA) Board of Directors Room 14.00 - 18.00 Subgroup on Transmissible Spongiform Encephalopaties (TSE) Board of Directors Room 14.00 - 18.00

Subgroup on Bacteria Coral Garden Ballroom 1

14.00 - 16.00

Subgroup on Parasites Coral Sea Room 1 & 2

14.00 - 18.00 Subgroup on Epidemiology and Surveillance Coral Garden Ballroom 3 14.00 - 18.00 Joint Meeting: Subgroup on HBV Safety and Virology Grand Coral Ballroom

23



ISBT Working Party Programme Sunday July 8




ISBT WP on Rare Donors *

11.30 - 12.00

Executive Committee Meeting Chairperson: Sandra Nance Board of Directors Room

3.5. Subgroup on Parasites David Leiby

12.00 - 13.00

Lunch Break

08.35 - 17.00

ISBT WP on Transfusion Transmitted Infectious Diseases (TTID)* – General Assembly

13.00 - 13.30

3.6. Subgroup on Transmissible Spongiform Encephalopathies (TSE) Joliette Coste

Chairperson: Silvano Wendel Coral Island Room Words of Welcome Silvano Wendel

13.30 - 14.00

3.7. Subgroup on Virology Mike Busch, Syria Laperche

14.00 - 16.00

4. Scientific Session Presentations to be defined

08.35 - 08.50

16.00 - 17.00

5. Corporate Members Session Agenda to be defined

10.00 - 17.00

ISBT WP on Information Technology (IT)*


1. Organizing Committee Reports 1.1. Annual Report and Discussion Emma Castro

08.50 - 09.00

1.2. Financial Report and Discussion Ravi Reddy 09.00 - 09.15 2. Organizing Committee Elections

24

09.15 - 09.45

3. Subgroup Reports and Discussion 3.1. Subgroup on HBV Safety Jean-Pierre Allain

09.45 - 10.15

3.2. Subgroup on Bacteria Thomas Montag, Erica Wood

10.15 - 10.30

Coffee Break

10.30 - 11.00

3.3. Subgroup on Cost Utility Analysis (CUA) Brian Custer

11.00 - 11.30

3.4. Subgroup on Epidemiology and Surveillance Gilles Delage


08.30 - 09.30

Chairperson: Ralf Knels Coral Kingdom Ballroom 1 10.00 - 13.00 Executive Committee Meeting 14.00 - 17.00 WP on IT Assembly Meeting Agenda 1. Minutes of the previous meeting, Attachment 1 2. Executive Committee report including the Treasurer's report (Ralf Knels, Paul Ashford) 3. Actual news from Validation TF (Ralf Knels) 4. RFID TF report (Ralf Knels, Lynne Briggs) 5. Interface TF report (Pia Bruce, Paul Ashford) 6. Traceability TF (Michael Breard) 7. Further strategies and activities (Ralf Knels) 8. Any other issues

9. Next Meeting at the next ISBT Congress 25






ISBT WP on Platelet Immunobiology Chairperson: Cécile Kaplan-Gouet Coral Kindgdom Ballroom 2 & 3

Welcome and presentation The 16th International Workshop: results and discussion Advice for the next International Workshop Election for the Platelet Working Party Chair 2012 - 2014

14.00 - 16.00

ISBT WP on Blood Supply Management *

Welcome and introductions - Annual Report - ISBT Congress 2012 – Review of the BSM WP presentation for July 10 parallel session - Further preparing an academic session for the 2013 ISBT meeting - Action Plan 2012/13 (To be tabled for discussion) - Any other business

Chairperson: Loyiso Mpuntsa Co-Chairperson: Gilles Folléa Coral Garden Ballroom 1

14.00 - 16.00

ISBT WP on Apheresis

Chairperson: Hans Vrielink Coral Garden Ballroom 3

1. Introduction 2. Fixing the agenda 3. Minutes 4. Specifications for rbc’s 5. Specifications for plt’s 6. Educational course for apheresis nurses 7. Input from members

08.30 - 11.30

ISBT WP on Global Blood Safety Chairperson: Jean-Pierre Allain Coral Kingdom Ballroom 2 and 3

08.30 - 08.40 Introduction, J-P. Allain (chair) 08.40 - 08.50 TOR, J. Epstein (vice chair) 08.50 - 09.00 Objectives of the meeting J-P. Allain 09.00 - 10.00 Break-out groups - Regulatory convergence (J. Epstein) - Accreditation according to regions (K. Lipton) - Blood systems: supply, demand, safety and sustainability (J-P. Allain) 10.00 - 10.30 Reports and discussion 10.30 - 11.00 Identification of projects and closing 11.00 - 11.30 Elections

16.00 - 17.30

ISBT WP on Cellular Therapy

Chairperson: Mickey Koh Board of Directors Room



12.00 - 14.00

26


• Welcome new members • Role of cell therapy within ISBT • Future Planned Activities • Any other matters

27



ISBT Working Party Programme Monday July 9




07.00 - 08.00 Presidents of National Societies Chairperson: Silvano Wendel Coral Sea Room 1 1. Welcome – Silvano Wendel 2. T he ISBT Strategic Plan 2012 – 2015 and report of membership survey 3. The ISBT Academy – report from Anne Husebekk 4. Reports from the National Presidents 5. Close

ISBT WP on Quality Management

1. Opening 2. Roll call 3. Formal approval of the last minutes 4. Quality indicators project 5. Status of WP-QM Survey 6. Error management in blood establishments 7. Collaboration with other ISBT WPs 8. Any other business 9. Date and venue of the next meeting

Chairperson: Paul Strengers Coral Garden Ballroom 1

ISBT WP on Rare Donors Chairperson: Sandra Nance Coral Island Room 1 & 2

Welcome to members and visitors 1.1 Members review address list for accuracy 1.2 Apologies 2. Appreciation to retiring members 3. Minutes of WP meeting held in Berlin 26 Jun 2010 4. Matters Arising from the Minutes 4.1. Master list of Blood Services. Further review and questionnaire on Rare Blood Use MN. 4.2. Medical Dilemma paper. VY/GW 4.3. Standardised Feedback form and Shipping Outcome Form Grant. SN 4.4. Leaflet on Rare Blood. SN 4.5. Presentations on Rare Blood and Bibliography. All 4.6. ISBT Rare Donor Web Page SN 4.7. Propose countries to join Working Party 5. Chairman’s report 2012 6. Report on IRDP from IBGRL. Report/ statistical data by J. Poole, IBGRL 7. Report on Rare Donor Activities from the attending members of the Working Party 7.1. Brazil 7.2. China 7.3. France 7.4. Germany 7.5. India 7.6. Iran 7.7. Israel 7.8. Japan 7.9. The Netherlands 7.10. New Zealand 7.11. South Africa 7.12. Spain 7.13. Switzerland 7.14. Taiwan 7.15. United Kingdom 7.16. United States of America 8. Working Party Member Agenda Items 9. Venue and date of next meeting



28

07.00 - 09.00

08.30 - 10.30

29







12.30 - 14.30

International Scientific Committee (ISAC)* Coral Sea Room 1

16.00 - 17.30

14.30 - 15.30

ISBT and Corporate Sector Meeting*

16.00 - 16.30

Coral Sea Room 1

ISBT WP on Granulocyte Immunobiology Chairperson: Lin Fung Coral Sea Room 1

Welcome and introduction to the Granulocyte Immunobiology Working Party Review of results from 11th International Granulocyte Immunobiology Workshop

30



16.30 - 17.30 Dr Paul Kubes, University of Calgary New Neutrophil Horizons for the Neutrophil Serologist

31


ISBT Working Party Programme Tuesday July 10


07.00 - 09.00

ISBT WP on Clinical Transfusion* Chairperson: Jonathan Wallis Coral Sea Room 1


Agenda 1. Apologies 2. Minutes of the last meeting 3. Officers: New Chair 4. Activities: i) Apps for transfusion medicine ii) Educational materials iii) International indications and standards for Transfusion 5. Future direction 6. Future meetings 7. AOB

32



33



34

General Scientific Information

General Scientific Information Important Notice for Chairpersons and Speakers All chairpersons and speakers are kindly requested to be in the session room at least 10 minutes before the beginning of the session. Abstracts Abstracts are printed as a supplement of Vox Sanguinis. All abstracts are listed in the Programme Book. Individual abstracts may be printed out at the terminals provided in the exhibition area on the first floor. The terminals are clearly marked. Please remember that others may wish to print abstracts and therefore you should restrict your time at the terminals. Accreditation Statement The 32nd International Congress of the ISBT is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medial specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 32nd International Congress of the ISBT is designated for a maximum of (or ‘for up to’) 33 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. General Scientific Information

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA. Certificates of Attendance Certificates of Attendance will be available at the registration desk as of Tuesday, July 10, at 12.00 hours. ISBT Science Series Papers of the invited speakers are printed in the ISBT Science Series. Power Point presentations Only PowerPoint presentations made in Microsoft Office XP or earlier versions will be accepted.

35


Programme changes The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances. Changes will be mentioned on the message board in the registration area. Speaker Ready Room The Speaker Ready Room is located in the Isla Contoy on the second floor in the Cancún Centre. Speakers are requested to bring their presentations to the Speaker Ready Room on an USB stick or CD-Rom at least 3 hours prior to their presentation time schedule. You may also bring your laptop for copying your presentation to the main computer, which will be used for sending the presentations to the different meeting rooms. The use of your own laptop during your presentation is NOT possible.


Standing Committee of the ISBT Academy The goals of the ISBT Academy are to host workshops or educational activities, or support educational activities in conjunction with international and national meetings and to develop educational tools. The Standing Committee is chaired by the ISBT Senior Vice President and monitors the activities of the Academy and reviews applications for support from the ISBT Academy. Each WHO region is represented on the Standing Committee.

Opening hours of the speaker ready room are as follows Monday July 9 07.00 - 17.30 hours Tuesday July 10 07.00 - 17.30 hours Wednesday July 11 07.30 - 17.30 hours Thursday July 12 07.30 - 12.00 hours



Young Investigators Breakfast Session The opportunity to discuss your research work with experts in the field in an informal setting. This session will be held on Monday, July 9 from 07.30 - 08.30 hours at the Beach Restaurant, Fiesta Americana Grand Coral Hotel. You must have signed up for this session to attend. International Scientific Advisory Committee (ISAC) Membership of ISAC includes the chairs of the ISBT working parties, the Past President and the Secretary General. The President is an ex officio member. ISAC generally meets once a year and gives the working party chairs an opportunity to update the members of ISAC about their working party. Opportunities for collaboration are shared. National Presidents Meeting ISBT offers the National Presidents meeting as an opportunity for Presidents of National Blood Transfusion Societies to meet and to share their experiences of developments in transfusion medicine in their own country and discuss issues that are of particular concern to them.

36

37



ISBT Prize Lectures

ISBT Mobile Application

ISBT Presidential Award The ISBT Presidential Award was instituted at the initiative of the Foundation Transfusion Medicine (FTM) in Amsterdam, The Netherlands. This foundation also sponsors the Award. The Award is granted to a senior person who has made eminent contributions to transfusion medicine or a related field through basic or applied research, the practice of transfusion therapy or through significant educational and/or service contributions to the field.

ISBT is launching a smartphone mobile application to give delegates a convenient and comprehensive way to navigate through ISBT 2012 and a way to receive and utilize industry information before, during and after the Congress.

The goal of these contributions and their effect must have had a significant input in transfusion medicine. The ISBT Award winner receives a special medal, a certificate and a prize in cash. The ISBT Presidential Award symposium is held at ISBT international congresses and consists of presentations by specialists in the field of the nominee.

• Interactive Exhibitor List • Exhibitor Information • Overview of Congress Programme • Real-time Congress alerts via text messaging • Social media interaction with live feed of Tweets including #ISBT • All abstracts

Robert H. Purcell M.D., Chief, Hepatitis Viruses Section (HVS), Laboratory of Infectious Diseases (LID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), U.S.A. will receive the ISBT Presidential Award on Tuesday July 10, during the ISBT Presidential Award Symposium in room Gran Cancun 2.

This mobile application provides delegates with Congress information and allows delegates to engage with each other before, during and after the Congress.



The Board of the Foundation Transfusion Medicine: Prof. Dr. W.G. (Pim) van Aken, President Prof. Dr. C.Th. Smit Sibinga, Vice-president Ass. Prof. Dr. Henk W. Reesink, Secretary-general Mr. Rudolf F. de Soet, Treasurer Dr. Paul F. W. Strengers, Member Prof. Wolfgang Mayr, Member

The ISBT application features include:

The mobile application is supported by

Jean Julliard Prize Lecture The Jean Julliard Prize was established in memory of the first Secretary-General of the society. It is awarded to a doctor and or a scientist under 40 years of age in recognition of recently completed work on blood transfusion medicine and science. The Prize is awarded every two years at the International Congress. This year the 22nd prize is awarded to Prof. Peter Horn for his paper “Advances towards in vitro generation of patient-specific cellular blood products” Prof. Peter Horn will receive the Jean Julliard Prize on Tuesday, July 10, between 08.15 - 09.30 hours in Gran Cancun 2.

38

39



40


Spanish Educational Day Saturday July 7 Grand Coral Ballroom 1 08.00 - 08.15

Opening

08.15 - 10.00

Clinical use of Blood

10.00 - 10.30

Coffee Break

10.30 - 12.30

Transfusion Transmitted Infectious Diseases

12.30 - 14.00

Lunch and Satellite Symposium

14.00 - 15.30

Blood Donation

15.30 - 16.00

Coffee Break

16.00 – 17.30

Cellular Therapy


41

Safe Plasma Products

Disorders of Haemostasis and the role of Transfusion to their Treatment

Opening Ceremony (Gran Cancun 2) Opening of the Trade Exhibition and Welcome Reception

Closing

Panel Discussion on Best Practices by Blood Centres – questions and answers

Best Practices by Blood Centres

Coffee Break

13.00 New Marketing Methods to Attract Donors

Maternal/fetal Relationship

18.00 - 19.00

16.00 - 17.30

S13 Working Party: Platelet Immunobiology

S7 Working Party: Granulocyte

14.00 - 15.30

S14 Parallel Session: TRALI

S8 Parallel Session: Hemolytic Transfusion Reactions

PL1 Plenary Session 1: Cells in the Making

S10 Parallel Session: Component Quality

Satellite Symposium: Fresenius Kabi Deutschland GmbH

Lunch

S15 Parallel Session: Transfusion in Sickle Cell Disease

S16 Parallel Session: Pathogen Reduction Roundtable

Coffee Break

Satellite Symposium: Roche Molecular Systems, Inc S9 Working Party: Clinical Transfusion

S4 Working Party: Donor Recruitment Strategies

Cozumel 1

Coffee Break

S3 Parallel Session: Extracorporeal Membrane Oxygenation (ECMO)

Gran Cancun 5

S17 Parallel Session: The new Bylaws and Statutes of the ISBT

S11 Parallel Session: Implementing and Maintaining a Haemovigilance System

Satellite Symposium: Octapharma AG

S5 Parallel Session: Organization of Blood Establishments

Cozumel 3

(Members only)

AMMTAC Meeting

S18 Parallel Session: Cord Blood and Stem Cells

S12 Parallel Session: TTID: Prevention from Donor to Patient

Programme at a Glance Monday July 9

15.30 - 16.00

Satellite Symposium: Ortho Clinical Diagnostics

12.00 - 14.00

12.00 - 14.00

10.30 - 12.00

10.00 - 10.30

S1 Working Party: Molecular Genotyping Workshop

08.30 - 10.00

S2 Parallel Session: Blood Donation Testing Testing

Young Investigators Breakfast Session Beach restaurant in the Fiesta Americana Grand Coral Hotel (Only for those who have registered for this meeting)

Gran Cancun 2

07.30 - 08.30

Gran Cancun 1

Coba

Clinical Significance of Alloantibodies

Blood Groups Update

Quality in Storage and Donation of Blood Products

Grand Coral Ballroom 3 ISBT Academy Day

The ISBT Academy Day is supported by the Corporate Members Roche, Haemonetics and Diasorin.

17.45 - 21.00

16.00 - 17.30

15.30 - 16.00

14.00 - 15.30

12.30 - 14.00

Lunch

Understanding your Current and Prospective Donor Base

Treatment of Acute, Uncontrolled Bleeding

10.30 - 12.30

Understanding your Current and Prospective Donor Base

Welcome and Opening

Coffee Break

Establishing good practice in difficult settings

Grand Coral Ballroom 2 ISBT/ADRP Donor Recruitment Workshop

Programme at a Glance Sunday July 8


42 10.00 - 10.30

08.30 - 10.00


Grand Coral Ballroom 1 ISBT Academy Day

Programme at a Glance Programme at a Glance

 Immunobiology of Blood Cells  Adverse Effects of Transfusion  Clinical  Donors/Donation/Component  Management & Organization  Cellular Therapies  Plenary  Oral Abstracts

43

S42 Parallel Session: New Blood Groups

S37 Parallel Session: Fetomaternal Immunology

S31 Parallel Session: What makes Erythrocytes (S)tick?

Gran Cancun 1

S43 Parallel Session: Chagas Disease

S39 Parallel Session: Emergency Planning and Outcome

PL4 Plenary Session 4: New Vs. Old Blood Anything New?

S32 Parallel Session: Bacterial Testing

Gran Cancun 2

S26 Working Party: TTID

S20 Parallel Session: Malaria by Transfusion: Scope of the Problem and New Host Factors

PL3 Plenary Session 3: Presidential Award Session

S22 Working Party: Donation by Apheresis

Satellite Symposium: GFE Blut mbH

S34 Parallel Session: Young Blood Donors

Cozumel 1

Congress Party

S45 Working Party: Rare Donor

Coffee Break

S40 Parallel Session: Donor Adverse Events

Lunch

Coffee Break

S44 Parallel Session: Appropriate Use of RBCs

S33 Parallel Session: Plasma Therapy

Gran Cancun 5

Poster Session: Costa Maya, Cozumel 2

S28 Parallel Session: Promoting Voluntary Donation

Coffee Break S27 Parallel Session: Intervention in Bleeding Patients

S21 Parallel Session: Massive Bleeding

Satellite Symposium: Cerus Europe BV

Lunch

Cozumel 1

Coffee Break

Gran Cancun 5

S46 Working Party: IT

S38 Working Party: Quality Management

S35 Working Party: Haemovigilance

Cozumel 3

S29 Parallel Session: Blood Management

S23 Working Party: Blood Supply Management

Satellite Symposium: Novartis Diagnostics

Cozumel 3

S47 Parallel Session: Cellular Therapy in Regenerative Medicine

S41 Parallel Session: Training and Education

S36 Working Party: Cellular Therapies

Coba

S30 Parallel Session: Component Quality

S24 Parallel Session: Cell Therapy

11.45 – 12.45 ISBT General Assembly

Coba

Programme at a Glance Wednesday July 11

19.30

16.00 - 17.30

15.30 - 16.00

14.00 - 15.30

12.00 - 14.00

10.30 - 12.00

10.00 - 10.30

08.30 - 10.00

17.45 - 18.45

16.00 - 17.30 S25 Parallel Session: Large-scale Non Invasive Prenatal Diagnosis Screening

S19 Parallel Session: Immune Destruction of Blood Cells

14.00 - 15.30

15.30 - 16.00

Satellite Symposium: Immucor, Inc.

12.00 - 14.00

12.00 - 14.00

10.00 - 11.30

Plenary Session: Noninvasive Fetal Testing - New Concepts

PL2 Plenary Session 2: Jean Julliard Award

Gran Cancun 2

Programme at a Glance Tuesday July 10  Immunobiology of Blood Cells  Adverse Effects of Transfusion  Clinical  Donors/Donation/Component  Management & Organization  Cellular Therapies  Plenary  Oral Abstracts


44 09.30 - 10.00

08.30 - 09.30


Gran Cancun 1

Programme at a Glance  Immunobiology of Blood Cells  Adverse Effects of Transfusion  Clinical  Donors/Donation/Component  Management & Organization  Cellular Therapies  Plenary  Oral Abstracts


45


Programme at a Glance Thursday July 12

08.30 - 10.00

Gran Cancun 1

Gran Cancun 2

Gran Cancun 5

Cozumel 1

S48 Parallel Session: Platelet Functions beyond Hemostasis

S49 Parallel Session: Transfusion-Transmitted Disease

S50 Parallel Session: Alternatives to Transfusion

S51 Parallel Session: The Multi-Ethnic Donor Challenge

10.00 - 10.30


46

Coffee Break

10.30 - 11.30

PL5 Plenary Session 5: Blood Philosophy

11.30 - 12.00

Closing Ceremony

12.00

 Immunobiology of Blood Cells  Adverse Effects of Transfusion  Clinical  Donors/Donation/Component  Management & Organization  Cellular Therapies  Plenary  Oral Abstracts

Farewell Lunch Exhibition Area

Saturday July 7

Spanish Day 08.15 - 10.00

Grand Coral Ballroom 1

Clinical Use of Blood Moderator: V.J. Barreto (Mexico)

08.00 - 08.15

WORD OF WELCOME S.N. Wendel Research and Education Institute, Hospital Sírio-Libanês, Sao Paulo, Brazil

08.15 - 08.45

MANEJO TRANSFUSIONAL DE LA HEMORRAGIA MATERNA O.W. Torres Hospital Materno-Infantil Ramón Sardá, Buenos Aires, Argentina

08.45 - 09.30

REQUERIMIENTOS PARA ESTABLECER UN SISTEMA DE HEMOVIGILANCIA FUNCIONAL EN LOS PAISES DE AMERICA LATINA M. Contreras National Health Service Blood and Transplant, London, United Kingdom

09.30 - 10.00

USO DE LOS ERITROCITOS EN EL TRATAMIENTO DE LA ANEMIA G. León de González Banco Municipal de Sangre del DC, Caracas, Venezuela

10.00 - 10.30

Coffee Break

47

Scientific Programme Saturday

Scientific Programme


Saturday July 7

Spanish Day

Spanish Day

10.30 - 12.30

14.00 - 15.30


Transfusion Transmitted Infectious Diseases


Blood Donation Moderator: A. Malagón Martinez (Mexico)

Moderator: A.L. D’Artote (Mexico)

14.00 - 14.30

10.30 - 11.00

ENFERMEDADES TRANSMISIBLES POR TRANSFUSIÓN SEGURIDAD DE LA TRANSFUSIÓN SANGUÍNEA J. Rojo-Medina, J.A. Arroyo-Pérez Centro Nacional de la Transfusión Sanguínea, Secretaría de Salud, México

11.00 - 11.45

ENFERMEDADES EMERGENTES: IMPACTO EN TRANSFUSIÓN C. Bianco Executive Vice President, America's Blood Centers, Washington, USA

11.45 - 12.30

VIEJAS ENFERMEDADES, NUEVOS DESAFÍOS: DENGUE, MALARIA Y CHAGAS G.A. Schmunis Washington, USA

12.30 - 14.00

Lunch and Satellite Symposium Novartis

14.30 - 15.00

48

Saturday July 7

DONACIÓN DE SANGRE, CAPTACIÓN Y SELECCIÓN DE DONANTES SEGUROS: DECISIONES BASADAS EN EVIDENCIAS A.B.F. Carneiro-Proietti Fernando Basques Valadares, Júnia Mourão Guimarães Cioffi, Fundación Hemominas, Belo Horizonte, Brazil

DONACIÓN VOLUNTARIA DE SANGRE EN LA AMÉRICA LATINA: RETOS Y DESAFÍOS J. Ramiro Cruz Ashburn, USA

15.00 - 15.30

ESTRATEGIAS PARA MEJORAR LA DONACIÓN DE SANGRE R.J. Roig Centro de Transfusión de la Comunidad Valenciana, Spain

15.30 - 16.00

Coffee Break

49






Saturday July 7

Spanish Day 16.00 - 17.30


Cellular Therapy Moderator: J.C. Martinez Álvarez (Mexico) 16.00 - 16.30

LA RELEVANCIA DE HLA EN EL TRASPLANTE DE CELULAS MADRES J.A. Madrigal Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom

16.30 - 17.00

EL BANCO DE SANGRE DEL CORDÓN UMBILICAL: CELULAS TRONCALES DE DONANTES NO-RELACIONADOS P. Rubinstein New York Blood Center, New York, USA

17.00 - 17.30

50

LAS CÉLULAS MESENQUIMALES Y SU APLICACIÓN EN LA CLÍNICA J. García López, Arnau Pla Calvet XCELIA. División de Terapias Avanzadas. Banc de Sang i Teixits Cátedra de Medicina Transfusional y Terapia Celular y Tisular. Universidad Autónoma, Barcelona, Spain

Sunday July 8

08.30 - 10.00


ISBT Academy

Establishing Good Practice in Difficult Settings Moderator: B. Armstrong (South Africa) 08.30 - 09.00 2A-D1-01

BLOOD MANAGEMENT IN DISASTER SITUATIONS IN PAKISTAN H.A. Zaheer National Blood Transfusion Programme, Islamabad, Pakistan

09.00 - 09.30 2A-D1-02

CHALLENGES IN SETTING UP AN ACCREDITATION SYSTEM IN AFRICA - WHAT CAN BE LEARNT B.C. Armstrong Africa Society for Blood Transfusion, Durban, South Africa

09.30 - 10.00 2A-D1-03

THE STEPS TAKEN FOR ESTABLISHING A BLOOD SERVICE IN CHILE M. Contreras, C. Martínez, M. Larrondo, C. Cárdenas Blood Transfusion International Londres, Minsal, Chile

51

Scientific Programme Sunday



Sunday July 8

08.30 - 10.00


ISBT/ADRP Donor Recruitment Workshop

Understanding your current and prospective donor base

Sunday July 8

08.30 - 10.00


ISBT Academy Quality in Storage and Donation of Blood Products Moderator: C. Seidl (Germany)

Moderator: D. Graham (USA) 08.30 - 09.00 Welcome and opening C. Mitchell, President of ADRP, Canada D. De Coning, Chairman of Working Party on Donors and Donation, South Africa

52

09.00 - 09.30

Understanding the South American situation M. Garcia, Colombia

09.30 - 10.00

Family replacement versus VNRBD D. De Coning, South Africa

08.30 - 09.00 2A-D2-01

QUALITY MANAGEMENT OF BLOOD COLLECTION P. Strengers Sanquin Blood Supply, Amsterdam, Netherlands

09.00 - 09.30 2A-D2-02

BLOOD COLLECTION AND PROCESSING. QUALITY GUIDELINES AND STANDARDS REFLECTING COMMON BEST PRACTICE STANDARDS REFERRING TO THE EUBIS MANUAL AND GUIDE C. Seidl, T. Müller-Kuller, W. Sireis, A. Aquilina, K. Barotine-Toth, J.M. Cardenas, J. Ceulemans, Z. Cermakova, J.P. Jansen van Galen, G. Grazzini, B. Hinloopen, M. Heiden, H. Huber, M. Nightingale, S. Pupella, F. Teskrat, J. Wit, E. Seifried The EuBIS Academy, Frankfurt am Main, Germany

09.30 - 10.00 2A-D2-03

QUALITY INDICATORS: A TOOL FOR QUALITY MONITORING AND IMPROVEMENT T. Vuk Croatian Institute of Transfusion Medicine, Zagreb, Croatia

10.00 - 10.30

Coffee Break

53





Sunday July 8

10.30 - 12.00


ISBT Academy

Treatment of Acute, Uncontrolled Bleeding Moderator: J. Wallis (United Kingdom) 10.30 - 11.00 2B-D3-01

MANAGEMENT OF PATIENTS WITH ACUTE BLEEDING WHO REFUSE BLOOD TRANSFUSION P. Brooks University of Florida College of Medicine, Gainesville, USA

11.00 - 11.30 2B-D3-02

GI HAEMORRHAGE S. Stanworth Consultant Haematologist, National Health Service Blood & Transplant/ Oxford University, Oxford, United Kingdom

11.30 - 12.00 2B-D3-03

54

UPDATE ON TRAUMA R. Hess University of Maryland, Baltimore, USA

Sunday July 8

10.30 - 13.00


ISBT/ADRP Donor Recruitment Workshop Understanding your current and prospective donor base Moderator: D. Graham (USA) 10.30 - 11.00

11.00 - 11.30

Recruiting 101 - discussing donor center versus. mobile recruitment strategies and market segmentation for optimal penetration rates T. Abner, USA

New recruitment tactics focused simultaneously on donors aged 22-39 and donors aged 35-55 J. Tinker, USA

11.30 - 12.00

Costing analysis with mobile accounts S. Miller, USA

55





Sunday July 8

Sunday July 8

10.30 - 12.00

14.00 - 15.30

ISBT Academy

ISBT Academy

Grand Coral Ballroom 3 Blood Groups Update Moderator: J. Storry (Sweden)

Grand Coral Ballroom 1 Disorders of Haemostasis and the Role of Transfusion to their Treatment Moderator: S. Stanworth (United Kingdom)

56

10.30 - 11.00 2B-D4-01

GENETIC CLASSIFICATION OF BLOOD GROUPS J.R. Storry University & Regional Laboratories, Lund, Sweden

11.00 - 11.30 2B-D4-02

NEW DEVELOPMENTS IN CARBOHYDRATE BLOOD GROUPS M. Olsson Lund University, Lund, Sweden

11.30 - 12.00 2B-D4-03

PROTEIN BLOOD GROUP SYSTEMS: BERLIN AND BEYOND M.E. Reid New York Blood Center, New York, USA

12.00 - 14.00

Lunch

14.00 - 14.30 THROMBOTIC THROMBOCYTOPENIC PURPURA: MANAGEMENT 2C-D5-01 ISSUES J.E. Kiss University of Pittsburgh, Pittsburgh, USA 14.30 - 15.00 2C-D5-02

ANTICOAGULANTS AND THEIR REVERSAL: THE ROLE OF TRANSFUSION J.P. Wallis Freeman Hospital, Newcastle upon Tyne, United Kingdom

15.00 - 15.30 2C-D5-03

MANAGEMENT OF ACQUIRED COAGULOPATHIES IN ITU D.W. Thomas ABMUHB, Swansea, Wales, United Kingdom

57





Sunday July 8

13.00 - 15.30



New marketing methods to attract donors

Sunday July 8

14.00 - 15.30


ISBT Academy

Clinical Significance of Alloantibodies Moderator: M. de Haas (Netherlands)

Moderator: D. Montgomery (USA)

58

13.00 - 13.30

Marketing moving forward S. Daigneault, Canada

13.30 - 14.00

Youth recruitment tactics C. Tan, Singapore

14.00 - 14.30

ADRP webinars – live demonstration D. Swift, USA

14.30 - 15.00

Managing Recruitment and Collection Strategies that maximize automation capabilities for red cell collections C. Hayes, USA

15.00 - 15.30

How to increase the return of lapsed donors M. Germain, Canada

14.00 - 14.30 2C-D6-01

WHAT IS A CLINICALLY SIGNIFICANT ANTIBODY? G. Garratty American Red Cross, United States, USA

14.30 - 15.00 2C-D6-02

WHAT METHODS AND PROCESS FLOW CAN ASSIST IN ALLOANTIBODY IDENTIFICATION J. Poole IBGRL, Bristol, United Kingdom

15.00 - 15.30 2C-D6-03

WHERE DO WE GET BLOOD FOR DIFFICULT CASES? M. de Haas, R. Koopman Sanquin Blood Supply, Amsterdam, Netherlands

15.30 - 16.00

Coffee Break

59





Sunday July 8

Sunday July 8

16.00 - 17.30

16.00 - 17.30



ISBT Academy


Safe Plasma Products Moderator: T. Burnouf (France)

Best practices by blood centres Moderator: J. Ridley (USA)

16.00 - 16.30 2D-D7-01

GMP FOR COLLECTION OF PLASMA FOR FRACTIONATION A. Padilla Essential Medicines, Geneva, Switzerland

16.30 - 17.00 NEEDS AND AVAILABILITY OF PLASMA DERIVED MEDICINAL 2D-D7-02 PRODUCTS P. Strengers Sanquin Blood Supply, Amsterdam, Netherlands 17.00 - 17.30 2D-D7-03

PLASMA FRACTIONATION T. Burnouf Human Protein Process Sciences, Lille, France

16.00 - 16.30 16.30 - 17.15

Panel discussion on best practices by blood centres – questions and answers Chair: C. Mitchell (Canada) Panel: D. Graham, USA M. Granato, USA M. Garcia, Colombia C. Tan, Singapore 17.15 - 17.30

60

Strategies for achieving collection goals C. Petersen & M. Gomez, USA

Closing C. Mitchell, Canada D. De Coning, South Africa

61






Sunday July 8

16.00 - 17.30


ISBT Academy

Maternal/Fetal Relationship Moderator: A. Husebekk (Norway) 16.00 - 16.30 PREGNANCY IMMUNOLOGY AND MATERNAL ALLOIMMUNE 2D-D8-01 RESPONSES B.M. Kumpel Bristol Institute for Transfusion Sciences, Bristol, United Kingdom

62

16.30 - 17.00 2D-D8-02

HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN: FROM BENCH TO BEDSIDE B. Carbonne, A. Mailloux, A. Cortey, V. Castaigne, Y. Brossard Centre National de Reference en Hemobiologie Perinatale; Hopital Trousseau, Paris, France

17.00 - 17.30 2D-D8-03

FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA: FROM BENCH TO BEDSIDE C. Kaplan INTS, Paris, France

17.45 - 18.45

Opening Ceremony (Cancun Center)

18.45 - 21.00

Opening of the Trade Exhibition and Welcome Reception

Monday July 9

08.30 - 10.00

Gran Cancun 1

Immunobiology of Blood Cells

Working Party S1

WP: Molecular Genotyping Workshop Moderator: J. Storry (Sweden)   08.30 - 08.55 The Zurich MALDI-TOF genotyping project 3A-S1-01 S. Meyer, Switzerland 08.55 - 09.15 3A-S1-02

Results of the Real-Time analysis of plasma DNA samples M. de Haas, Netherlands

09.15 - 09.40 3A-S1-03

Results of DNA samples 1-4 J. Storry, Sweden

09.40 - 10.00

Discussion

63

Scientific Programme Monday



Monday July 9

08.30 - 10.00

Gran Cancun 2

Adverse Effects of Transfusion

Monday July 9

08.30 - 10.00

Gran Cancun 5

Clinical

Parallel Session S2

Parallel Session S3

Blood Donation Testing 

Extracorporeal Membrane Oxygenation (ECMO) 

Moderator: R. Dodd (USA)

Moderators: D.A. Escobar (Mexico), D. Thomas (United Kingdom)

08.30 - 09.00 3A-S2-01

A BLOOD-BASED ASSAY FOR DETECTION OF PRION INFECTION: CAN IT BE USED TO SCREEN BLOOD DONATIONS ? G.S. Jackson MRC Prion Unit, London, United Kingdom

08.30 - 09.00 3A-S3-01

09.00 - 09.15 3A-S2-02

OPTIMIZATION, EVALUATION AND VALIDATION OF A PROTEIN MISFOLDING CYCLIC AMPLIFICATION (PMCA) BASED CONFIRMATORY SCREENING ASSAY TO DETECT PRIONS IN HUMAN BLOOD M. Jones, D. Bougard, M. Moudjou, I. Quadrio, C. Ségarra, H. Laude, E. Levavasseur, S. Simoneau, B. Flan, S. Haik, A. Perret-Liaudet, V. Béringue, M. Head, J. Coste Scottish National Blood Transfusion Service, Edinburgh, United Kingdom

09.15 - 09.45 3A-S2-03

TTID RISKS IN THE CARIBBEAN AND LATIN AMERICA : RECOMMENDATIONS TO IMPROVE SAFETY J. Rojo, A. Arroyo Centro Nacional de Transfusion Sanguinea, Mexico

09.45 - 10.00 3A-S2-04

THE ISBT WORKING PARTY FOR TRANSFUSION-TRANSMITTED INFECTIOUS DISEASE (WP-TTID) SURVEY FOR NAT TESTING IN LATIN AMERICA S. Wendel, M.E. Acevedo, C. Baungarten, F.J. Benati, A. Bravo, B. Camacho, A. Cudola, A. Del Pozo, G.B.B. Evangelista Barban, D.A. Escobar, F.F. Fay, S.V. Gallego, G. Genovez, M.A.S. Gonzalez, S.G. Jaramillo, C.M. Melo Tavares, R. Pereira, R. Ponde, S.A. Sanchez, S. Silva Gonçalves Cordeiro Research and Education Institute, Hospital Sírio-Libanês, Sao Paulo, Brazil

64

  09.00 - 09.30 3A-S3-02 09.30 - 10.00 3A-S3-03

ECMO- THE CLINICIAN’S VIEW F. Fraser, L. Fung, S. Diab, S. Shekar, D. Platts, C.I. McDonald, M. Spanavello, J. Roberts Critical Care Research Group, Brisbane, Australia PREDICTORS OF INCREASED TRANSFUSION REQUIREMENTS AND OPTIMIZING TRANSFUSION SUPPORT IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) A.L. Ang Blood Services Group, Health Sciences Authority, Singapore, Singapore EXTRACORPOREAL LESSONS FROM SHEEP Y.L. Fung, S. Diab, K. Dunster, S.R. Foley, C.I. McDonald, M. Passmore, D. Platts, G. Simonova, K. Shekar, D. Stewart, J.F. Fraser The University of Queensland & The Prince Charles Hospital, Brisbane, Australia

65





Monday July 9

08.30 - 10.00

Cozumel 1

Donors/Donation/Component

Monday July 9

08.30 - 10.00

Cozumel 3

Management & Organization

Working Party S4

Parallel Session S5

WP: Donor Recruitment Strategies 

Organization of Blood Establishments

Moderator: D. de Coning (South Africa)

Moderators: M. González Santos (Mexico), T. Krusius (Finland)

08.30 - 08.50 3A-S4-01

08.30 - 09.00 3A-S5-01

PUBLIC VERSUS PRIVATE FUNDING FOR BLOOD SERVICES: WHICH IS BETTER FOR PATIENTS? C. Bianco America’s Blood Centers, Washington, DC, USA

09.00 - 09.30 3A-S5-02

ORGANIZING BLOOD ESTABLISHMENT IN LAOS C. Souksakone, D. Kongphaly Lao Red Cross, Vientiane, Laos

09.30 - 10.00 3A-S5-03

THE NATIONAL ORGANISATION IN A SHRINKING ECONOMY T. Krusius Finnish Red Cross Blood Service, Helsinki, Finland

Social marketing in donor recruitment S. Daigneault Héma-Québec, Montreal, Canada

08.50 - 09.15 Harnessing the 3 forces of the long tail for blood 3A-S4-02 donation C. Tan Singapore Red Cross, Singapore 09.15 - 09.35 Transition from the Replacement Donors to VNRD in 3A-S4-03 Colombia M. Garcia Gutierrez Blood Service and Safety Consultant, Colombia 09.35 - 09.55 Networking and educational opportunities for Donor 3A-S4-04 Recruiters C. Mitchell President of ADRP, Texas, USA

66

67






Monday July 9

10.30 - 12.00

Gran Cancun 2

Plenary Session 1

Plenary Session 1

Cells in the Making 

Moderators: A. Malagón Martínez (Mexico), G. Daniels (United Kingdom) 10.30 - 11.00 3B-PL1   11.00 - 11.30 3B-PL2

PRODUCTION AND CHARACTERIZATION OF CULTURED RED CELLS D.J. Anstee Bristol Institute for Transfusion Sciences, Bristol, United Kingdom PROGENY GENERATION FROM PLATELETS: WHAT WE KNOW AND WHERE WE NEED TO GO? S. Weyrich, H. Schwertz University of Utah, Salt Lake City, USA

11.30 - 12.00 NEW APPROACHES IN THE SELECTION OF UNRELATED BONE MARROW 3B-PL3 DONORS A. Madrigal Anthony Nolan Research Centre, London, United Kingdom 12.00 - 14.00

68

Lunch Break and Satellite Symposia

Monday July 9 12.00 - 14.00 

Gran Cancun 1

Satellite Symposium 

Organized By Ortho Clinical Diagnostics Delivering Safety & Efficiency in Today’s Transfusion Medicine Labs through Innovation Today’s transfusion medicine laboratories - like many other areas in healthcare– are learning to do more with less. There is simply less funding, fewer workers, and scarcer resources to meet more requests, complete more testing, and serve more patients. Yet the focus on protecting the precious life that will receive a unit of blood remains at the forefront of blood bankers everywhere. And as the pressure rises, labs are finding ways to be efficient and hemovigilent, while never losing sight of the real person at the end of the bloodline, through innovation. Innovation leads to standardized and more reliable results, hemovigilance compliance, and productivity workflow improvement through automation within the laboratory. We encourage you to come and learn how fellow laboratory directors/managers have proactively embraced innovation to achieve science driven safety and efficiency. Scheduled Speakers:

Satellite Symposium

Ana María Mejía (Jefa de Banco de Sangre Blood Bank Manager, Instituto Nacional de Cardiología, México D.F., México José Antonio Arroyo, Sub-Director Técnico de Banco Sangre, Blood Bank Technical sub-Director, Centro Nacional de la Transfusión Sanguínea, Mexico D.F., México

69




Monday July 9 12.00 - 14.00 

Gran Cancun 5


Organized By Roche Molecular Systems, Inc Blood Screening from all Angles In this Roche satellite symposium, a panel of expert speakers will discuss how the combined use of both serological and nucleic acid amplification technology (NAT) tests can be used to meet the needs of the blood and plasma screening laboratories for quality and efficiency. Results from a multicentre evaluation study of Roche serology assays will provide evidence of the accurate performance and reliable detection of transfusion transmitted infectious diseases. Recent advances in pre-analytical devices will demonstrate how Roche solutions optimize the performance and workflow, ensuring timely availability of safe blood and plasma products. Routine use of the Roche cobas® TaqScreen DPX Test*, the first duplex, multi-dye NAT test for the simultaneous detection and quantification of human parvovirus B19 (B19V) and the detection of hepatitis A virus (HAV), will be presented to illustrate the medical value and advantages of this technology for blood and plasma screening. Look out for further information on speakers for this interesting symposium on the flyer that will be provided in the delegate bag! * This test is not an FDA-licensed product. It is available to US laboratories with

70

Satellite Symposium

appropriate FDA authorization.

Monday July 9  12.00 - 14.00 

Cozumel 1


Organized by Fresenius Kabi Deutschland GmbH CompoFlow©: Efficient Blood Processing OPENING AND INTRODUCTION BY CHAIRMAN Wolfgang Boecker, Senior Vice President, Business Center Transfusion Technology, Fresenius Kabi Deutschland GmbH, Germany INTRODUCTION TO THE COMPOFLOW© CONCEPT  Stefan Kolb, Director BPS Equipment Business Center Transfusion Technology, Fresenius Kabi Deutschland GmbH, Germany EVALUATION OF COMPOMAT G5© AND COMPOFLOW© SYSTEMS IN THE ROUTINE OF HEMOMINAS FOUNDATION  Flavia Navas Givisiez, MD, Quality Control Manager, Hemominas Foundation, Brazil AUTOMATION IN BLOOD PROCESSING AND IMPROVEMENT IN QUALITY OF THE BLOOD COMPONENTS  Ricardo Omoto, Pharmacist, MS, Brazil

Satellite Symposium

OVERVIEW OF PLASMA PRODUCTION FROM WHOLE BLOOD DONATIONS IN FRENCH TRANSFUSION CENTERS  Philippe Ligot, Biomedical Engineer, Etablissement Français du Sang, France Q&A 

71




Monday July 9 

12.00 - 14.00 

14.00 - 15.30


Working Party S7

Cozumel 3

Organized By Octapharma AG

Monday July 9

Gran Cancun 1


WP: Granulocyte  

Moderator: Y.L. Fung (Australia)

Octaplas(LG)® - when Tolerability is Equal Important to Bleeding Control WELCOME & INTRODUCTION  Benjamin Batista Guizar EXPERIENCE OF OCTAPLAS® IN FINLAND - PREVENTION OF TRALI AND REDUCTION OF SERIOUS ADVERSE EVENTS  Tom Krusius, Finnish Red Cross Blood Service, Finland BLEEDING TREATMENS: PLASMA OR SINGLE FACTOR CONCENTRATES?  Benjamin Batista Guizar, Blood Bank Service of the CIMA Hospital, México

14.00 - 14.30 Welcome and brief background on Working party on 3C-S7-01 Granulocyte Immunobiology Results of the 11th International Granulocyte Immunobiology Workshop Future directions: Tokyo Granulocyte Serology Practicum New horizons for neutrophils Y.L. Fung University of Queenland, The Prince Charles Hospital, Brisbane, Australia 14.30 - 15.30 New horizons for neutrophils: Neutrophil behaviour in 3C-S7-02 tissues during infection B.G. Yipp Clinical Scholar, Paul Kubes Research Laboratory, University of Calgary, Canada

THREE YEARS OF EXPERIENCE IN THE USE OF OCTAPLAS ® IN A PLOT GROUP OF PATIENTS,MÉXICO  Celia Carela Sandoval Villa, Department of Hematology ISSSTELEON Hospital, México

72

Satellite Symposium

Q&A

73




Monday July 9

14.00 - 15.30

Gran Cancun 2


Monday July 9

14.00 - 15.30

Gran Cancun 5

Clinical

Parallel Session S8

Working Party S9

Hemolytic Transfusion Reactions

WP: Clinical Transfusion 

Moderators: L. Contreras Trajuno (Mexico), G. Garratty (USA)

Moderator: J. Wallis (United Kingdom)

14.00 - 14.30 3C-S8-01

14.00 - 14.15 3C-S9-01

RECENT CHANGES IN UK BLOOD USE AND INTERNATIONAL COMPARATORS J. Wallis, United Kingdom

14.15 - 14.45 3C-S9-02

EDUCATION AND BLOOD USE IN AUSTRALIA E. Wood, Australia

14.45 - 15.05 3C-S9-03

IMPROVING BLOOD USE IN MEXICO S.A. Sánchez-Guerrero, Mexico

MODELING TRANSFUSION REACTIONS WITH KODECYTES AND ENABLING ABO-INCOMPATIBLE TRANSFUSION WITH FUNCTIONSPACER-LIPID CONSTRUCTS M. Henry, K.L. Barr, C.A. Oliver AUT University, Auckland, New Zealand

14.30 - 15.00 3C-S8-02

Lysis of compatible old red cells following transfusion E. Hod Columbia University Medical Center, New York, USA 

15.00 - 15.15 DEL BLOOD DONORS ALLOIMMUNISED PATIENTS: THE CANADIAN 3C-S8-03 EXPERIENCE R. St-Louis, A. Lebrun, M. Goldman, M. Lavoie Héma-Québec, Québec (Qc), Canada

15.05 - 15.20 DUTCH ‘GUIDELINE BLOOD TRANSFUSION’, IT’S CREATION AND 3C-S9-04 EFFECTS P. van den Burg, Netherlands 15.20 - 15.30

15.15 - 15.30 3C-S8-04

74

Overall Discussion

RHD PCR OF BLOOD DONORS IN NORTHERN GERMANY: USE OF ADSORPTION/ELUTION TO DETERMINE D ANTIGEN STATUS F.F. Wagner, I. Mardt, R. Bittner, A. Döscher DRK Blutspendedienst NSTOB, Springe, Germany

75





Monday July 9

14.00 - 15.30

Cozumel 1


Parallel Session S10

Component Quality 

Moderators: J. Espinosa Tuscott (Mexico), Y. Ayob (Malaysia)

Monday July 9

14.00 - 15.30

Cozumel 3



Implementing and Maintaining a Haemovigilance System 

Moderators: A.L. DÁrtote González (Mexico), D. Sarlija (Croatia) 14.00 - 14.30 APHERESIS VERSUS WHOLE-BLOOD-DERIVED PLATELETS: PROS AND 3C-S10-01 CONS P.F. van der Meer Sanquin Blood Supply, Amsterdam, Netherlands 14.30 - 14.45 3C-S10-02

GENERATION OF POLYMORPHONUCLEAR NEUTROPHILS PRIMING ACTIVITY BY PLATELET-DERIVED MICROPARTICLES IN STORED APERESIS PLATELET CONCENTRATES R.F. Xie, W. Li, Z.Y. Wang, F.F. Fan Shanghai Blood Center, Shanghai, China

14.45 - 15.00 3C-S10-03

A NEW DEHYDRATION METHOD TO STORE BLOOD PLATELETS: ZEODRATION F. Rendu, T. Donnet, J.-P. Cazenave, C. Gachet Inserm, Paris, France

15.00 - 15.15 3C-S10-04

ROOM TEMPERATURE EXPOSURE ON RED BLOOD CELLS: EFFECTS ON BACTERIAL GROWTH S.M. Ramirez-Arcos, H. Perkins, Y. Kou, C. Mastronardi, E. Kahwash, N. McLaughlin, Y. Lin, A. Tinmouth, J. Acker Canadian Blood Services, Ottawa, Canada

15.15 - 15.30 3C-S10-05

76

14.00 - 14.30 3C-S11-01

HEMOVIGILANCE IN HONDURAS, THE BLOOD CENTER PERSPECTIVE E. Vinelli Cruz Roja Hondureña, Tegucigalpa, Honduras

14.30 - 15.00 3C-S11-02

DEVELOPING HAEMOVIGILANCE IN LATIN AMERICAN COUNTRIES J.C. Faber ConsulTrans, Luxembourg, Luxembourg

15.00 - 15.15 3C-S11-03

RISK OF MAJOR ALLERGIC REACTIONS IN RECIPIENTS OF BLOOD FROM ALLERGIC DONORS P. Robillard, G. Delage, A. DesRoches, K.I. Nawej Hema-Quebec, Saint-Laurent, Canada

15.15 - 15.30 3C-S11-04

NATIONAL DATABASE OF IRREGULAR ANTIBODIES NOW FUNCTIONAL: ESTIMATION OF AVOIDABLE ADVERSE REACTION AND INCIDENT REPORTS TO HEMOVIGILANCE REGISTRY J.C. Wiersum-Osselton, P.Y. Zijlker-Jansen, A.J.W. Van Tilborgh-de Jong, M. Beunis, M.R. Schipperus TRIP Dutch National Hemovigilance Office, The Hague, Netherlands

IRRADIATED RED CELL CONCENTRATES: ACCELERATED STORAGE LESION AND ALTERATIONS IN MEMBRANE PROTEIN COMPOSITION D. Devine, S. Zolfaghari, K. Serrano, P. Schubert, E. Levin, B. Culibrk, D. Coupland Canadian Blood Services, Vancouver, Canada

77





Monday July 9

14.00 - 15.30

Coba

Cellular Therapies

Monday July 9

16.00 - 17.30

Gran Cancun 1



Working Party S13

TTID: Prevention from Donor to Patient 

WP: Platelet Immunobiology

Moderators: M. Rios (USA), M. Schmidt (Germany)

Moderator: C. Kaplan (France)

14.00 - 14.20 3C-S12-01

ESTIMATED TRANSFUSIONAL RISK OF HIV IN COLOMBIA, FROM 2007 TO 2010 M. Beltran Instituto Nacional de Salud, Bogota, Colombia

16.00 - 16.30 Back to the Future - current and future laboratory 3D-S13-01 techniques diagnosing platelet immunology disorders O. Frenkel MDA Blood Services, Israel

14.20 - 14.40 3C-S12-02

PREVALENCE AND INCIDENCE OF HIV INFECTION AT FIVE CHINESE BLOOD CENTERS, 2008-2010 J. Wang, J. Liu, T. Yang, G. Wen, J. Li, Y. Huang, Y. Lv, X. Wen, D. Wright, Q. Yu, N. Guo, P. Ness, H. Shan Chinese Institute of Blood Transfusion, Chengdu, China

16.30 - 17.00 3D-S13-02

16th International platelet workshop: Results and discussion R. Fontão-Wendel Hospital Sirio Libanes, Sao Paulo, Brazil

17.00 - 17.30 3D-S13-03

MOLECULAR HPA GENOTYPING BY MICROARRAY IN BRAZILIAN BLOOD DONORS M Mota, F. Conti, M. Dezan, T.H. Costa, M.G. Aravechia, R. Ricardo, L. Castilho, J.M. Kutner Hospital Israelita Albert Einstein, São Paulo, Brazil

14.40 - 15.00 3C-S12-03

A MATHEMATICAL APPROACH TO DETERMINE EFFICACY OF NAT IN REMOVING TRANSMISSION RISK OF OCCULT HBV INFECTION BY BLOOD COMPONENTS M. Vermeulen, C. Coleman, J. Mitchel, R. Reddy, H. van Drimmelen, T. Ficket, N. Lelie SANBS, Roodepoort, South Africa

15.00 - 15.20 3C-S12-04

RESULTS OF THE IMPLEMENTATION OF A COMPUTER-BASED SELF-INTERVIEW SYSTEM (CBSIS) FOR BLOOD DONORS M.J. Lee, J.N. Kim, I.K. Hur, W.H. Lee, C.Y. Kim, S.Y. Kwon, N.S. Cho Blood Service Headquarters, Korean Red Cross, Seoul, South-Korea

15.20 - 15.30

Overall Discussion

15.30 - 16.00

Coffee Break

78

79





Monday July 9

16.00 - 17.30

Gran Cancun 2


Monday July 9

16.00 - 17.30

Gran Cancun 5

Clinical



TRALI

Transfusion in Sickle Cell Disease

Moderators: H. Rodríguez Moyado (Mexico), Y.L. Fung (Australia)

Moderators: G.E. Guerrero (Mexico), M. Telen (USA)

16.00 - 16.30 3D-S14-01

16.00 - 16.30 3D-S15-01

RED BLOOD CELL ALLOIMMUNIZATION AND ANTIGEN MATCHING IN SICKLE CELL DISEASE - THE AFRICAN PERSPECTIVE B. Natukunda Mbarara University of Science and Technology, Mbarara, Uganda

16.30 - 17.00 3D-S15-02

RELEVANCE OF RH VARIANTS IN TRANSFUSION OF SICKLE CELL DISEASE PATIENTS F. Noizat-Pirenne Etablissement Français du Sang, Créteil, France

17.00 - 17.15 3D-S15-03

TRANSFUSION CHALLENGES IN PATIENTS WITH THE RARE S-s- (MNS:-3,-4) BLOOD TYPE: A 15-YEAR EXPERIENCE T. Peyrard, J. Nataf, C. Menanteau, S. Ramelet, D. Gien, S. Poupel, M. Ripaux, S. Bourgouin, P.-Y. Le Pennec, P. Rouger Institut National de la Transfusion Sanguine, Paris, France

16.30 - 16.45 3D-S14-02 16.45 - 17.00 3D-S14-03 17.00 - 17.15 3D-S14-04 17.15 - 17.30 3D-S14-05

NEW INSIGHTS INTO TRALI: ACTIVATION OF MONOCYTES AND ENDOTHELIAL CELLS AS TRIGGERS OF TRANSFUSION-RELATED ACUTE LUNG INJURY S. Santoso Justus Liebig University Giessen, Giessen, Germany THE RESIDUAL RISK OF TRALI IN A LARGE U.S. BLOOD SYSTEM REFLECTS THE ONGOING RELIANCE ON AB PLASMA FROM FEMALE DONORS TO MEET DEMAND F. Eder, B. Dy, M. Rambaud, R.J. Benjamin American Red Cross, Rockville, USA CHARACTERIZATION OF IGA DEFICIENCY, IDENTIFIED AMONG PATIENTS WHO HAD EXPERIENCED NONHEMOLYTIC TRANSFUSION REACTIONS AND AMONG HEALTHY BLOOD DONORS E. Shimada, T. Shimoyamada, Y. Watanabe, M.Y. Miyoshi, J. Nakamura, T. Abe, H. Tonami, Y. Suzuki, H. Okazaki, M. Satake, K. Tadokoro Japanese Red Cross Society, Tokyo, Japan EFFECTS OF STORED RED BLOOD CELL TRANSFUSION IN CARDIOPULMONARY FUNCTION AND INFLAMMATION: AN EXPERIMENTAL MECHANISTIC STUDY S. Biagini, P.A. Costa, C.S. Dale, E.S. Monte-Real, C.R.R. Carvalho, G.P.P. Schettino, S. Wendel, L.C.P. Azevedo Research and Education Institute, Hospital Sírio-Libanês, São Paulo, Brazil

17.15 - 17.30 3D-S15-04  

IDENTIFICATION OF GENETIC POLYMORPHISMS ASSOCIATED WITH RESPONSE TO RHD IMMUNISATION FOR THE DEVELOPMENT OF A GENOTYPING ASSAY TO PREDICT RESPONSE STATUS J.C.G. Tan, N. Armstrong, R.L. Flower, W.B. Dyer Australian Red Cross Blood Service, Alexandria, Australia

Best Paper Prize A NOVEL IN VIVO OVINE MODEL OF TRANSFUSION-RELATED ACUTE LUNG INJURY J.P. Tung, Y.L. Fung, M. Nataatmjadja, K.I. Colebourne, H.M. Esmaeel, K. Wilson, A.G. Barnett, P. Wood, C.C. Silliman, J.F. Fraser Australian Red Cross Blood Service, Kelvin Grove, Australia

   80

81





Monday July 9

16.00 - 17.30

Cozumel 1


82

Monday July 9

16.00 - 17.30

Cozumel 3




Pathogen Reduction Roundtable

The new Bylaws and Statutes of the ISBT

Moderators: D. Devine (Canada), R. Roig (Spain)

(ISBT Members only)

16.00 - 16.20 3D-S16-01

Pathogen reduction in European Union E. Castro Centro de Transfusiónde Cruz Roja Espanola, Madrid, Spain

Speakers: S. Wendel  Research and Education Institute, Hospital Sírio-Libanês, Sao Paulo, Brazil

16.20 - 16.40 3D-S16-02

Pathogen reduction in middle east region B.G. Solheim Institute of Immunology, Oslo University Hospital – Rikishospitaet, Oslo, Norway

P. Flanagan New Zealand Blood Service, Auckland, New Zealand

The current Statutes were developed when ISBT moved its headquarters to Amsterdam over ten years ago. A number of issues have been identified with them over the years and around three years ago the Board decided to undertake a formal revision of the Statutes. A committee was established to undertake the review which has also been supported by legal advice from the ISBT notary and lawyer. A final draft has now been developed and will be submitted to a formal consultation process before being submitted to the General Assembly in Amsterdam 2013 for approval. This session is open to all members of the society and will provide an opportunity for open discussion on a number of key issues arising from the review. Your presence will be important and will help us ensure a successful outcome to the review.

16.40 - 17.00 3D-S16-03

Pathogen reduction in north america R. Benjamin American Red Cross, USA

17.00 - 17.30

Overall discussion

83






Monday July 9

16.00 - 17.30

Coba

Cellular Therapies


Cord Blood and Stem Cells Moderators: I. Perez (Peru), M. Koh (Singapore/United Kingdom) 16.00 - 16.30 WHAT IS THE APPROPRIATE SIZE OF THE WORLDWIDE CORD BLOOD 3D-S18-01 INVENTORY? L. Querol-Giner, S. Marsh, E. Palou, M. Torrabadella, S. Gomez, P. Ortiz, L.l. Puig, A. Madrigal Banc Sang i Teixits, Barcelona, Spain 16.30 - 16.45 TRANSPLANTATION OF UNRELATED PLACENTAL BLOOD STEM CELLS IN 3D-S18-02 MEXICO E.H. Montaño-Figueroa, L. Alcantara-Quintero, J.V. Tapia-Vieyra, A. Arroyo-Perez, J. Rojo-Medina Centro Nacional de la Transfusiòn Sanguinea, Mexico City, Mexico 16.45 - 17.00 3D-S18-03   17.00 - 17.15 3D-S18-04 17.15 - 17.30 3D-S18-05

84

CORRELATION OF HLA-G EXPRESSION WITH GRAFT-VERSUS-HOST REACTION FOLLOWING HSCT J.P. Yin Wuhan Blood Centre, Wuhan, China EXPANSION OF MESENCHYMAL STEM CELLS FROM CORD BLOOD FOR CLINICAL APPLICATION L.E. Alcantara-Quintero, E.H. Montaño-Figueroa, A. Arroyo-Perez, J. Rojo-Medina Centro Nacional de la Transfusiòn Sanguinea, Mexico City, Mexico

EX VIVO DIFFERENTIATION OF PLACENTAL MESENCHYMAL STEM CELLS TOWARDS HEPATIC AND PULMONARY EPITHELIAL COMPARTMENTS F. Colombo, V. Paracchini, S. Mazzucchelli, A. Carbone, M. Seia, C. Colombo, M. Conese, P. Rebulla, L. Porretti Fondazione IRCCS Ca’ Granda, Milan, Italy

18.00 - 19.00

AMMTAC Meeting (Coba) (members only)

Tuesday July 10

08.15 - 09.30

Gran Cancun 2

Plenary Session 2

Plenary Session 2

ISBT Prize Lecture

Moderators: S. Wendel (Brazil), E. Seifried (Germany) 08.15 - 08.25

Welcome and Opening

08.25 - 08.55 4A-PL2-01

JEAN JULLIARD PRIZE LECTURE (ISBT) Advances towards in vitro generation of patient-specific cellular blood products P. Horn, University Hospital Essen, Essen, Germany

08.55 - 09.00

Presentation of Award

09.00 - 09.30 4A-PL2-02

Non-invasive fetal testing - new concepts New concepts in noninvasive prenatal diagnosis using cell-free DNA in maternal plasma: from the gene to the chromosome to the genome Y.M.D. Lo, The Chinese University of Hong Kong, Hong Kong SAR

09.30 - 10.00

Coffee Break

85

Scientific Programme Tuesday




Tuesday July 10

10.00 - 11.30

Gran Cancun 2

Plenary Session 3

Plenary Session 3

Presidential Award

Moderators: W.G. van Aken and S.N. Wendel 10.00 - 10.02

Opening W.G. van Aken

10.02 - 10.15

Laudatio H.W. Reesink Amsterdam Medical Centre, Amsterdam, Netherlands

10.15 - 10.35

Emerging viral infections / pathogens and the safety of the blood supply M.P. Busch Blood Systems Research Institute, San Francisco, USA

10.35 - 10.55

10.55 - 11.25

86

Occult hepatitis B: is it a threat for the safety of the blood supply? J.P. Allain University of Cambridge, Cambridge, United Kingdom

How bad things really were: a reanalysis of transfusionassociated hepatitis before the screening of blood R. Purcell National Institute of Allergy and Infectious Diseases, Bethesda, USA

11.25 - 11.30

AWARD CEREMONY

11.45 - 12.45

ISBT General Assembly (Coba) All paid up members of ISBT are encouraged to attend the General Assembly.

12.00 - 14.00

Lunch and Satellite Symposia

Tuesday July 10 12.00 - 14.00

Gran Cancun 1

Satellite Symposium Organized By Immucor, Inc.

Novel Approaches to Improving Efficiency in Transfusion Laboratories LEAN EFFICIENCIES GAINED IN THE TRANSFUSION SERVICE LABORATORY THROUGH BLOOD BANK AUTOMATION, A U.S. EXAMPLE Mary Ann Womack, MBA (ASCP) SBB, Transfusion Service Manager at Florida Hospital, Orlando, Florida, United States of America USING MOLECULAR TESTING TO SUPPORT TRANSFUSION IN PATIENTS WITH SICKLE CELL DISEASE: THE BRAZILIAN EXPERIENCE Lilian Castilho, PhD, Professor and Researcher at HemocentroUnicamp, Campinas-SP; Scientific Consultant at Albert Einstein Hospital and Colsan, São Paulo, Brazil

Satellite Symposium

FULL TRACEABILITY AND WORKFLOW OPTIMIZATION IN MOLECULAR GENOTYPING THROUGH THE INTEGRATION OF TRANSFUSION MEDICINE DATA MANAGEMENT SOFTWARE Cinzia Paccapelo, Centro Trasfusionale e di Immunoematologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

87




Tuesday July 10 12.00 - 14.00

Gran Cancun 5

Satellite Symposium

Organized By Cerus Europe BV The past, present and future of the INTERCEPT Blood System: the INTERCEPT platelet and plasma experience and upcoming Phase III red cell trials The INTERCEPT Blood System is used to inactivate pathogens in platelets and plasma at over 100 centers in 16 countries across Europe, CIS and the Middle East. With kits sold to produce over 1 million INTERCEPT units to date, and clinical and hemovigilance data collected throughout Europe, the clinical performance of INTERCEPT components has been established as comparable to untreated platelets or plasma. INTERCEPT users have also been able to replace safety methods such as gamma irradiation, CMV testing and bacterial detection. This symposium will provide an update on the INTERCEPT platelet and plasma user experience, the expected impact of pathogen inactivation (PI) introduction in South America, and the development status of INTERCEPT for red blood cells. SPEAKERS & TOPICS: PROGRAM INTRODUCTION Richard Benjamin, USA, chairperson

88

Satellite Symposium

INTERCEPT PATHOGEN INACTIVATION AS AN EMERGING STANDARD OF CARE IN EUROPE Lydia Blanco, Spain PATHOGEN INACTIVATION FOR BRAZIL: POTENTIAL IMPACT OF INTRODUCTION IN SOUTH AMERICA Luiz Amorim, Brazil INTERCEPT RBC IN PHASE III: CLINICAL DEVELOPMENT PROGRAM IN EUROPE AND USA Richard Benjamin, USA Q&A

Tuesday July 10 12.00 - 14.00

Cozumel 1

Satellite Symposium Organized by GFE Blut mbH

Evolving Blood Safety Strategies INTRODUCTION W. Kurt Roth PATHOGEN REDUCTION BY UVC LIGHT Axel Seltsam HIV-1 NAT BREAKTHROUGH CASE W. Kurt Roth

Satellite Symposium

FUTURE TARGETS FOR NAT Roger Dodd

89




Tuesday July 10

12.00 - 14.00

14.00 - 15.30

Satellite Symposium


Cozumel 3

Organized by Novartis Diagnostics

Tuesday July 10

Gran Cancun 1


Immune Destruction of Blood Cells

Moderators: A. Chiera (Argentina), A. Husebekk (Norway)

Global Advances in NAT Screening WELCOME NOVARTIS DIAGNOSTICS INTRODUCTION Emma Castro, MD, Medical Director and CEO of the Transfusion Center of the Spanish Red Cross in Madrid INTRODUCTION OF ID-NAT IN MEXICO Barbara Novelo-Garza, MD, Servicio Integral de Bancos de Sangre IMSS, Ciudad de Mexico

14.00 - 14.30 4B-S19-01

SUGAR-FREE ANTIBODIES: A NEW TREATMENT MODEL FOR ITP AND AIHA M. Collin Lund University, Lund, Sweden

14.30 - 14.45 4B-S19-02

PHASE-II RANDOMIZED, DOSE-FINDING STUDY OF ROLEDUMAB, A NOVEL MONOCLONAL ANTI-RHD IGG1, COMPARED TO POLYCLONAL ANTI-RHD IGG IN CLEARING RHD POSITIVE RED BLOOD CELLS IN RHDNEGATIVE HEALTHY VOLUNTEERS A. Yver, H. Watier, P. Gueret, E. Guemas, J.-F. Prost, F. Dhainaut, R. Beliard, D. Quagliaroli, B. Carbonne Centre National de Reference en Hemobiologie Perinatale; Hopital Trousseau, Paris, France

IN-PROCESS TESTING FOR PARVO B19 AND HAV Jeffrey M Linnen, PhD, Director Product Development, Gen-Probe Incorporated ADVANCES IN NAT AUTOMATION Silvia Sauleda, PhD, Head Molecular Biology Department, Blood and Tissue Bank, Catalonia-Spain

90

Satellite Symposium

DISCUSSION Emma Castro, MD, Medical Director and CEO of the Transfusion Center of the Spanish Red Cross in Madrid

14.45 - 15.00 4B-S19-03

RELATIONSHIP OF WARM AUTOIMMUNE HAEMOLYTIC ANEMIA TO NORMAL RED BLOOD CELL SENESCENCE E.M. Bloch, D.R. Branch Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

15.00 - 15.15 4B-S19-04

THE CONUNDRUM WHEN USING DIFFERENT MOUSE BACKGROUNDS TO ESTABLISH THE ROLE OF THE INHIBITORY FC RECEPTOR IN THE MECHANISM OF IVIG IN AUTOIMMUNE DISEASES D.R. Branch, Y Katsman, D Leontyev Canadian Blood Services, Toronto, Canada

15.15 - 15.30 4B-S19-05

SPECIFIC DAT - TEN YEARS EXPERIENCE WITH DC SCREENING I ID-GELCARD U. Sprogøe, M.G. Pedersen, B. Antonsen Odense University Hospital, Odense, Denmark

91




Tuesday July 10

14.00 - 15.30

Cran Cancun 2



Malaria by Transfusion: Scope of the Problem and New Host Factors

Tuesday July 10

14.00 - 15.30

Gran Cancun 5

Clinical


Massive Bleeding Moderators: J.L. Salazar (Mexico), E. Seifried (Germany)

Moderators: R. Reddy (South Africa), O. Garraud (France) 14.00 - 14.35 4B-S20-01

TRANSFUSION-TRANSMITTED MALARIA IN COUNTRIES WHERE MALARIA IS ENDEMIC A.K.K. Owusu-Ofori, I. Bates Komfo Anokye Teaching Hospital, Kumasi, Ghana

14.35 - 15.05 4B-S20-02

BASIGIN IS AN ESSENTIAL RECEPTOR FOR ERYTHROCYTE INVASION BY PLASMODIUM FALCIPARUM C. Rayner, C. Crosnier, L.Y. Bustamante, S.J. Bartholdson, A.K. Bei, M.T. Duraisingh, G.J. Wright Wellcome Trust Sanger Institute, Cambridge, United Kingdom

15.05 - 15.20 4B-S20-03

VALIDATION OF MODELS FOR MALARIA RISK IN UNITED STATES BLOOD DONORS DEFERRED FOR TRAVEL TO MEXICO BY ANTIBODY TESTING D.A. Leiby, M.L. Nguyen, T. Goff, P.D. Borge, B.R. Spencer

American Red Cross Holland Laboratory, Rockville, USA

15.20 - 15.30

Overall discussion

14.00 - 14.30 4B-S21-01

DEVELOPMENT AND IMPLEMENTATION OF A PEDIATRIC MASSIVE TRANSFUSION PROTOCOL J. Hendrickson Emory University, Atlanta, USA

14.30 - 15.00 4B-S21-02

SUMMARY OF THE CONSENSUS REPORT ON MASSIVE BLEEDING S. Stanworth Consultant Haematologist, National Health Service Blood & Transplant/ Oxford Univeristy, Oxford, United Kingdom

15.00 - 15.15 4B-S21-03

IMPACT OF MASSIVE TRANSFUSION DEFINITIONS ON CRITICAL BLEEDING EVENT CAPTURE AND OUTCOMES A.J. Zatta, Z. McQuilten, B. Mitra, D. Roxby, R. Sinha, S. Whitehead, S. Dunkley, S. Kelleher, E. Wood, L.E. Phillips Monash University, Melbourne, Australia

15.15 - 15.30 4B-S21-04

92

PREOPERATIVE HEMOSTASIS AND ITS ASSOCIATION WITH PERIOPERATIVE BLEEDING AND BLOOD COMPONENT TRANSFUSION REQUIREMENTS IN CARDIOPULMONARY BYPASS SURGERY P. Hellstern City Hospital, Ludwigshafen, Germany

93





Tuesday July 10

14.00 - 15.30

Cozumel 1


Tuesday July 10

14.00 - 15.30

Cozumel 3


Working Party S22

Working Party S23

WP: Donation by Apheresis

WP: Blood Supply Management

Moderator: H. Vrielink (Netherlands)

Moderators: L. Mpuntsha (South Africa), G. Folléa (Belgium)

14.00 - 14.30 4B-S22-01

Certification of donor apheresis nurses: keys to develop an effective training program P. van den Burg Sanquin Blood Supply, Amsterdam, Netherlands

14.00 - 14.30 Red Blood Cell supply management: tools for assessment 4B-S23-01 and improvement G. Folléa, M.E. Behr-Gross, W.L.A.M. de Kort, L. Mpuntsha European Blood Alliance, Brussels, Belgium

14.30 - 15.00 4B-S22-02

Granulocyte collection H. Vrielink Sanquin Blood Supply, Amsterdam, Netherlands

14.30 - 15.00 ELECTRONIC ENHANCEMENTS FOR PATIENT SAFETY AND BLOOD 4B-S23-02 MANAGEMENT M. Yazer University of Pittsburgh, USA

15.00 - 15.15 4B-S22-03

UTILIZATION OF THERAPEUTIC APHERESIS IN THE UNITED STATES S. Blumenthal, S. Sundararajan, J. Winters, B. Khatri, A. Odette, E. Buenz Terumo BCT, Lakewood, USA

15.15 - 15.30 4B-S22-04

MONITORING THE EFFECTIVENESS OF PLASMA-EXCHANGE IN ACUTE IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) WITH A REAL-TIME ASSAY FOR DOSAGE OF ADAMTS-13 ANTIGEN, ACTIVITY AND INHIBITOR P. Manzini, A. Bianchi, S. D’Antico, E. Venturino, G. Zecchina, G. Rege Cambrin, M.A. Ciocca, I. Cristofori, R. Marchesini, E. Monterzino, T. Francisci, V. Tassi, F. Curti AOU S. Giovanni Battista, Torino, Italy

94

15.00 - 15.30 4B-S23-03

Patient Blood management: experience from australia J. Pink Australian Red Cross Blood Service, Alexandria NSW, Australia

95





Tuesday July 10

14.00 - 15.30

Coba

Cellular Therapies


Cell Therapy

Moderators: K. Loper (USA), P. Horn (Germany)

Tuesday July 10

16.00 - 17.30

Gran Cancun 1



Large-scale Non Invasive Prenatal Diagnosis Screening Moderators: H. Rodríguez Moyado (Mexico), M. Olsson (Sweden)

14.00 - 14.30 4B-S24-01

CLINICAL EXPANSION OF CYTOLKINE INDUCED KILLER (CIK) CELLS M.B.C. Koh, Y.C. Linn Blood Services Group, Health Sciences Authority, Singapore, Singapore

14.30 - 15.00 4B-S24-02

NATURAL KILLER CELL THERAPY IN CANCER AND TRANSPLANTATION J. Miller University of Minnesota, Minneapolis, USA

15.00 - 15.15 4B-S24-03

EFFECTIVE THERAPY BY TRANSFUSING ALLOGENEIC TOLEROGENIC DENDRITIC CELLS IN THE MODEL OF AUTOIMMUNE ARTHRITIS J. Yang Shanghai Blood Centre, Shanghai, China

15.15 - 15.30 4B-S24-04

INFLUENCE OF CELL CONCENTRATION ON THE EXPANSION OF MESENCHYMAL STROMAL CELLS DERIVED FROM BONE MARROW OR ADIPOSE TISSUE AND CULTURED IN MEDIUM ADDITIONED WITH PATHOGEN-FREE PLATELET LYSATE P. Iudicone, G. Lucchetti, D. Fioravanti, G. Bonanno, C. Lavorino, M. Possenti, A.M. Berti, L. Pierelli S. Camillo-Forlanini Hospital, Rome, Italy

15.30 - 16.00

Coffee Break

16.00 - 16.20 4C-S25-01

96

16.20 - 16.40 4C-S25-02

NONINVASIVE PRENATAL SCREENING FOR RHD: THE 1ST NATIONAL ANTENATAL DIRECTED RH PROPHYLAXIS PROGRAMME - THE DANISH MODEL M.H. Dziegiel, M. Christiansen, R. Steffensen, S. Jørgensen, C. Nielsen, M. Jakobsen, R. Madsen, K. Jensen, G. Krog, K. Rieneck, U. Sprogøe, K. Homburg, N. Grunnet, F. Clausen Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark NONINVASIVE PRENATAL SCREENING FOR RHD IN THE NETHERLANDS: ONE TEST FOR TARGETED ANTENATAL AND POSTNATAL ANTI-D PROPHYLAXIS M. de Haas, C.E. van der Schoot, C.P.B. van der Ploeg, F. Abbink Sanquin Blood Supply, Amsterdam, Netherlands

16.40 - 17.00 NONINVASIVE PRENATAL SCREENING FOR RHD: THE STOCKHOLM 4C-S25-03 STUDY T. Wikman, E. Tiblad, M. Westgren Karolinska University Hospital, Stockholm, Sweden 17.00 - 17.15 4C-S25-04

IMPLEMENTATION OF ROUTINE OF FETAL RHD TYPING IN ALL RHDNEGATIVE PREGNANT WOMEN: TIMING, COSTS, AND EFFICIENCY G. Daniels, K. Finning, A. Wade, E. Massey, P. Soothill, C.J. Phillips, W.L. Martin, L.S. Chitty NHSBT, Bristol, United Kingdom

17.15 - 17.30 4C-S25-05

RHD ALLELES IN ISOIMMUNIZED AND NON-ISOIMMUNIZED RHD NEGATIVE PREGNANT WOMEN C.A. Hyland, G. Millard, H. O’Brien, S. Scott, R.L. Flower, G. Gardener Australian Red Cross Blood Service, Brisbane, Australia

97





Tuesday July 10

16.00 - 17.30

Gran Cancun 2


16.00 - 17.30

Cran Cancun 5

Clinical

Working Party S26


WP: TTID

Intervention in Bleeding Patients

Moderator: S. Wendel (Brazil)

Moderators: O.W. Torres (Argentina), M. Pisacka (Czech Republic)

16.00 - 16.30 4C-S26-01

OCCULT B HEPATITIS J.P. Allain University of Cambridge, United Kingdom

16.00 - 16.30 4C-S27-01

16.30 - 17.00 4C-S26-02

THE RISK ASSESSMENT OF INFECTIOUS DISEASES IN AFRICA S. Laperche National Institute of Blood Transfusion, Paris, France

17.00 - 17.30 CURRENT INFECTIOUSDISEASE PROBLEMS IN THE PACIFIC 4C-S26-03 REGION C. Seed Australian Red Cross Blood Service, Perth, Australia

EARLY TREATMENT WITH TRANEXAMIC ACID SAFELY REDUCES MORTALITY IN BLEEDING TRAUMA PATIENTS AND ITS USE SHOULD NOT BE RESTRICTED TO THE MOST SEVERELY INJURED G. Roberts LSHTM, London, United Kingdom

16.30 - 17.00 4C-S27-02

FIBRINOGEN CONCENTRATES IN BLEEDING TRAUMA PATIENTS M.A.S. Meyer, P.I. Johansson Rigshospitalet, Copenhagen, Denmark

17.00 - 17.15 4C-S27-03

HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE ANEMIA AFTER PRIMARY POSTPARTUM HEMORRHAGE: A RANDOMIZED CONTROLLED TRIAL OF RED BLOOD CELL TRANSFUSION VERSUS EXPECTANT MANAGEMENT: THE WOMB STUDY B.W. Prick, A.J.G. Jansen, E.A.P. Steegers, W.C.J. Hop, M.L. Essink-Bot, C.A. de Uyl-Groot, B.M.C. Akerboom, M. van Alphen, K.W.M. Bloemenkamp, K.E. Boers, H.A. Bremer, A. Kwee, A.J. van Loon, G.C.H. Metz, D.N.M. Papatsonis, J.A.M. van der Post, M. Porath, R.J.P. Rijnders, F.J.M.E. Roumen, H.C.J. Scheepers, D.H. Schippers, N.W.E. Schuitemaker, M.E.A. Spaanderman, R.H. Stigter, B.W.J. Mol, D.J. van Rhenen, J. Duvekot Erasmus MC, Rotterdam, Netherlands

17.15 - 17.30 4C-S27-04

98

Tuesday July 10

THE FREQUENCY OF CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PLATELET TRANSFUSION DEPENDENT PATIENTS BEFORE AND AFTER INTRODUCTION OF PATHOGEN INACTIVATED COMPONENTS: A NINE YEAR HEMOVIGILANCE SURVEY J.-C.O. Osselaer, B.D. DeCoene, M.-C.T. Thonet, C. Corlier, C. Sherman, L.M. Corash, K. Steiger, C. Doyen Univ de Mont Godinne, Univ Cath de Louvain, Yvoir, Belgium

99





Tuesday July 10

16.00 - 17.30

Cozumel 1


100

Tuesday July 10

16.00 - 17.30

Cozumel 3




Promoting Voluntary Donation

Blood Management

Moderators: A.L. DÁrtote González (Mexico), D. Teo (South Africa)

Moderators: G. Folléa (Belgium), J. Chapman (Netherlands)

16.00 - 16.30 4C-S28-01

INTRODUCTION OF A PROGRAM FOR VOLUNTARY BLOOD DONATIONS IN IRAN (BLOOD TRANSFUSION STATUS IN IRAN) A. Gharehbaghian Shahid Beheshti University of Medical Sciences and Research Center of Iranian Bl, Tehran, Iran

16.00 - 16.30 4C-S29-01

HOW TO IMPLEMENT A HOSPITAL-BASED BLOOD MANAGEMENT PROGRAM J. Waters University of Pittsburgh, Pittsburgh, USA

16.30 - 17.00 4C-S28-02

INTRODUCTION OF PROGRAMS FOR VOLUNTARY BLOOD DONATION IN CENTRAL AMERICA J.R. Cruz Consultant, Ashburn, USA

16.30 - 17.00 4C-S29-02

END-TO-END ELECTRONIC TRANSFUSION MANAGEMENT IN HOSPITAL PRACTICE M.F. Murphy NHS Blood & Transplant, Oxford, United Kingdom

17.00 - 17.10 4C-S28-03

17.00 - 17.15 4C-S29-03

ALIGNING SUPPLY WITH DEMAND J. Caulfield, D. Portbury, N. Beckman, S. Gibson Australian Red Cross Blood Service, Melbourne, Australia

CHANGING FROM PERMANENT TO TEMPORARY DEFERRAL FROM BLOOD DONATION AFTER RISK BEHAVIOR - A MODEL FOR EVALUATING RISK OF TRANSFUSION TRANSMITTED HIV, HEPATITIS B AND HEPATITIS C IN A SWEDISH SETTING G. Edgren, R. Norda, T. Berglund, M. Camitz Karolinska Institutet, Stockholm, Sweden

17.15 - 17.30 4C-S29-04

17.10 - 17.20 4C-S28-04

‘BRING THE FAMILY’: EVALUATION OF A DONORS RECRUIT DONORS BLOOD DONATION STRATEGY G. Smith, D. Waller Australian Red Cross Blood Service, Melbourne, Australia

THE DEVELOPMENT AND INSTITUTION OF A COLLECTIONS MANAGEMENT SYSTEM AND ITS ROLE IN ACHIEVING ORGANISATIONAL GOALS AT THE SOUTH AFRICAN NATIONAL BLOOD SERVICE T.E. Scanes, J. Scholtz, W. Van der Merwe, V. Reddy South African National Blood Service, Roodepoort, South Africa

17.20 - 17.30 4C-S28-05

DONOR RECRUITMENT IN UNEXPLORED AREAS Y.S. Khyalia ISBTI, Jind, India

101






Tuesday July 10

16.00 - 17.30

Coba

Oral Abstracts


Component Quality Moderators: A. Arroyo-Perez (Mexico), A. Seltsam (Germany) 16.00 - 16.15 4C-S30-01

PRESERVED FUNCTIONAL AND BIOCHEMICAL CHARACTERISTICS OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA FOR PATHOGEN INACTIVATION B. Hechler, P. Ohlmann, P. Chafey, C. Ravanat, A. Eckly, E. Maurer, H. Isola, J.-P. Cazenave, C. Gachet Etablissement Français du Sang-Alsace, Strasbourg, France

16.15 - 16.30 4C-S30-02

QUALITY PARAMETERS OF RED CELLS AND PLASMA MANUFACTURED BY HOLLOW-FIBRE SEPARATION M. Bohonek, M. Kricnerova, E. Sladkova, T. Hradek, M. Petras Central Military Hospital Prague, Prague, Czech Republic

16.30 - 16.45 4C-S30-03

PRBC MEMBRANE FRAGILITY AS A POTENTIAL STORAGE-TIMEINDEPENDENT QUALITY METRIC M. Tarasev, K. Alfano, S. Chakraborty, M. Bertholf, A. Zubair Mayo Clinic, Jacksonville, FL, USA

16.45 - 17.00 4C-S30-04

EFFECT OF LIPEMIC PLASMA ON THE IN VITRO QUALITY OF CELLULAR BLOOD COMPONENTS DURING STORAGE J.W. Lagerberg, L.A. de Laleijne-Liefting, P.F. van der Meer, D. de Korte Sanquin Research, Amsterdam, Netherlands

17.00 - 17.15

PATHOGEN REDUCTION TECHNOLOGY: EFFECT OF PROTEINS RELEASED BY TREATED PLATELET CONCENTRATES ON ENDOTHELIAL CELLS D. Devine, P. Schubert, L. Culibrk, B. Culibrk Canadian Blood Services, Vancouver, Canada

4C-S30-05 17.15 - 17.30 4C-S30-06

17.45 - 18.45 102

INACTIVATION OF HUMAN WHITE BLOOD CELLS IN PLATELET CONCENTRATES AFTER PATHOGEN REDUCTION BY UVC-LIGHT IN THE THERAFLEX UV-PLATELETS SYSTEM A. Seltsam, P. Pohler, M. Mueller, C. Winkler, T.H. Müller Fraunhofer Institute of Toxicology and Experimental Medicine, Hanover, Germany Poster Session

Wednesday July 11

08.30 - 10.00

Gran Cancun 1



What makes Erythrocytes (s)tick?

Moderators: F. Herrera Gómez (Mexico), C. Westhoff (USA) 08.30 - 09.00 MECHANISMS BEHIND ADHESIVE ERYTHROCYTES IN SICKLE CELL 5A-S31-01 DISEASE J. Telen Duke University, Durham, USA 09.00 - 09.30 5A-S31-02

CIRCADIAN RHYTHMS OF METABOLISM IN HUMAN ERYTHROCYTES J. O’Neill, A.B. Reddy University of Cambridge, United Kingdom

09.30 - 10.00 5A-S31-03

ESTABLISHMENT OF IMMORTALIZED HUMAN ERYTHROID PROGENITOR CELL LINES ABLE TO PRODUCE ENUCLEATED RED BLOOD CELLS Y. Nakamura RIKEN BioResource Center, Tsukuba, Japan

103

Scientific Programme Wednesday



Wednesday July 11

08.30 - 10.00

Gran Cancun 2


08.30 - 10.00

Gran Cancun 5

Clinical



Bacterial Testing

Plasma Therapy

Moderators: S.A. Sánchez Guerrero (Mexico), E. Zhiburt (Russia)

Moderators: A. Arroyo Pérez (Mexico), R. Norda (Sweden)

08.30 - 09.00 5A-S32-01

08.30 - 09.00 5A-S33-01

A PRIMER ON EVIDENCE BASED PLASMA THERAPY H. Yazer University of Pittsburgh, Pittsburgh, USA

09.00 - 09.20 5A-S33-02

REDUCED NUMBER OF ADVERSE EVENTS WITH METHYLENE-BLUE TREATED PLASMA COMPARED WITH QUARANTINE STORED PLASMA: A SINGLE CENTER’S THREE YEAR EXPIRIENCE W. Nussbaumer, P. Mayersbach, E. Gächter, H. Schennach, W. Mayer Univ.-Hospital Innsbruck, Innsbruck, Austria

CURRENT STATUS OF BACTERIAL DETECTION IN BLOOD COMPONENTS - SUCCESSES AND CHALLENGES M. Schmidt, E. Seifried German Red Cross, Frankfurt, Germany

09.00 - 09.30 BACTERIAL CONTAMINATION, SCREENING AND FOLLOW UP: CLINICAL 5A-S32-02 ASPECTS E.M. Wood, M. Borosak Monash University, Melbourne, Australia 09.30 - 09.45 5A-S32-03

BIOFILM FORMATION BY STAPHYLOCOCCUS CAPITIS STRAINS ISOLATED FROM CONTAMINATED PLATELET CONCENTRATES S.M. Ramirez-Arcos, V.S. Greco-Stewart, H. Ali, I.G.H. Rood, D. Kumaran, D. De Korte Canadian Blood Services, Ottawa, Canada

09.45 - 10.00 5A-S32-04

AN INNOVATIVE BIOLOGICAL RECYCLING PROCESS TO PRODUCE ACTIVE ANTIMICROBIAL PEPTIDES L. Vossier, F. Leon, C. Bachelier, J. Coste, C. Fournier-Wirth Etablissement Français du Sang (EFS), Montpellier, France

09.20 - 09.40 5A-S33-03 09.40 - 10.00 5A-S33-04

104

Wednesday July 11

PLASMA TRANSFUSION IN LIVER TRANSPLANTATION: A RANDOMIZED, DOUBLE BLIND, MULTICENTER CLINICAL COMPARISON OF THREE VIRALLY SECURED PLASMAS T. Bartelmaos, A. Chabanel, J. Léger, L. Villalon, M.C. Gillon, C. Rouget, A. Gomola, B. Giraudeau, Y. Ozier Hôpital Paul Brousse, Villejuif, France APHERESIS FOR PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA MAY LEAD TO RESOLUTION OF ATHEROMATOUS PLAQUES; WEEKLY LDL-A IS SUPERIOR TO THE BIWEEKLY REGIMEN OR PLASMAPHERESIS E.J. Dann, R. Shamir, R. Mashiach, R. Shaoul, A. Badian, T. Stravets, Y. Kerzman, S. Finkelbaum, D. Gaitini, L. Bonstein Rambam Health Care Campus, Haifa, Israel

105





Wednesday July 11

08.30 - 10.00

Cozumel 1


Wednesday July 11

08.30 - 10.00

Cozumel 3



Working Party S35

Young Blood Donors

WP: Haemovigilance

Moderators: C. Estrada Carsolio (Mexico), S. Daigneault (Canada)

Moderator: J. Wiersum (Netherlands)

08.30 - 09.00 5A-S34-01

CAN WE IMPROVE SAFETY FOR YOUNG BLOOD DONORS? A. Eder American Red Cross, Rockville, USA

08.30 - 08.40 WELCOME AND INTRODUCTION TO THE ACTIVITIES OF THE WORKING 5A-S35-01 PARTY J. Wiersum, Netherlands

09.00 - 09.30 5A-S34-02

ADOLESCENTS AND BLOOD DONATION: MOTIVATIONS, HURDLES AND POSSIBLE RECRUITMENT STRATEGIES E. Zito Fondazione IRCSS Ca’ Granda, Ospedale Maggiore Policlicnico, Milano, Tradate (Va), Italy

08.40 - 09.10 5A-S35-02

BIOVIGILANCE IN THE US: A HOSPITAL VIEW P.M. Ness, USA

09.10 - 09.35 5A-S35-03

BLOOD DONORS AND IRON STATUS M. Goldman, Canada

09.30 - 09.45 ‘SAVE THE LIFE’: AVIS AND THE PROMOTION OF BLOOD DONATION ON 5A-S34-03 FACEBOOK V. Saturni, S. Valtolina, B. Zuccon, F. Cavazza, P. Dematteis, R. Robiglio, P. Boccardi, A. Gidoin, M. Johansson, F. Magaraggia, B. Valtolina, M. Capitanio AVIS Nazionale, Milan, Italy

09.35 - 10.00 5A-S35-04

MONITORING OPTIMAL BLOOD USE: DEVELOPMENTS J. Wallis, United Kingdom

09.45 - 10.00 5A-S34-04

106

VASOVAGAL REACTION AMONG YOUNG FIRST-TIME DONORS: PREDICTION BY BODY DIMENSION AND REDUCTION BY LESS COLLECTION H.K. Wong, C.K. Lee, J.N.S. Leung, I.Y.M. Lee, C.K. Lin Hong Kong Red Cross Blood Transfusion Service, Hong Kong, Hong Kong SAR

107





Wednesday July 11

08.30 - 10.00

Coba

Cellular Therapies

108

Wednesday July 11

10.30 - 12.00

Gran Cancun 2

Plenary Session 4

Working Party S36

Plenary Session PL4

WP: Cellular Therapies

New vs. Old Blood - Anything New?

Moderator: M. Koh (Singapore/United Kingdom)

Moderators: J.C. Martínez Álvarez (Mexico), P. Flanagan (New Zealand)

08.30 - 09.00 5A-S36-01

AABB AND INITIATIVES IN CELL THERAPY K. Loper, USA

09.00 - 09.30 5A-S36-02

ISBT AND INITIATIVES IN CELL THERAPY M. Koh, Singapore/United Kingdom

09.30 - 10.00 5A-S36-03

title to be confirmed P. Horn, Germany

10.00 - 10.30

Coffee Break

10.30 - 11.00 5B-PL4-1

CLINICAL EFFECTS OF TRANSFUSING OLDER RED CELL CONCENTRATES: AN UPDATED OVERVIEW L.M.G. van de Watering Sanquin Blood Supply, Leiden, Netherlands

11.00 - 11.30 5B-PL4-2

OLD OR FRESH BLOOD- WHICH IS WORSE? A STORY, A HYPOTHESIS AND IMPLICATIONS N. Heddle McMaster University, Hamilton, Canada

11.30 - 12.00 5B-PL4-3

ONGOING RANDOMIZED CONTROLLED TRIALS OF RED CELL STORAGE D. Triulzi University of Pittsburgh, USA

12.00 - 14.00

Lunch

109





Wednesday July 11

14.00 - 15.30

Gran Cancun 1


14.00 - 15.30

Cozumel 3

Management and Organisation


Working Party S38

Fetomaternal Immunology

WP: Quality Management

Moderators: H. Baptista González (Mexico), C. Westhoff (USA)

Moderator: P. Strengers (Netherlands)

14.00 - 14.30 5C-S37-01

14.00 - 14.15 5C-S38-01

TOWARDS A PROPHYLACTIC TREATMENT OF HPA-1A-RELATED FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA (FNAIT) A. Husebekk, H. Tiller, M.K. Killie, M.E Eksteen, M.T. Ahlen, T. Stuge, H. Ni, J. Kjeldsen-Kragh, B.R. Skogen University of Tromsø, Tromsø, Norway

14.30 - 14.45 5C-S37-02

FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA: AN UPDATE ON PRIVATE AND RARE HUMAN PLATELET ANTIGENS G. Bertrand, V. Jallu, C. Martageix, C. Kaplan INTS, Paris, France

14.15 - 14.30 5C-S38-02

15.00 - 15.15 5C-S37-03

HPA GENOTYPING IN PREGNANT WOMEN: VALIDATION OF ID-HPA XMAP LUMINEX® TECHNOLOGY D. Londero, F. Boschiero, C. Sindici, V. Miotti, V. De Angelis Azienda Ospedaliero-Universitaria SMM Udine, Udine, Italy

15.15 - 15.30 5C-S37-04

TITRATION OF IGG ANTIBODIES IN PREGNANCY - A SNAPSHOT OF PERFORMANCE AND POLICY IN THE UK J.L. White, C Milkins, A. Mavurayi, M. Rowley UK NEQAS (BTLP), Watford, United Kingdom

15.15 - 15.30 ROUTINE ANTENATAL ANTI-D PROPHYLAXIS AND PATIENT 5C-S37-05 COMPLIANCE R. Steffensen, K. Nielsen, J. Vad, G. Faergemann, L. Falk, J. Baech Aalborg Hospital, Aalborg, Denmark

14.30 - 14.45 5C-S38-03

14.45 - 15.00 5C-S38-04 15.00 - 15.15 5C-S38-05

110

Wednesday July 11

PLATELET RICH PLASMA VS BUFFY COAT METHOD - IN VITRO QUALITY ASSESSMENT OF RANDOM DONOR PLATELET CONCENTRATE BY A TERTIARY CARE HOSPITAL IN INDIA S. Agarwal, S. Rai Fortis Escorts Heart Institute, New Delhi, India MANAGED CONVERGENCE, A POTENTIAL COLLABORATION BETWEEN BLOOD ESTABLISHMENTS, SUPPLIERS AND REGULATORS: IMPROVING SAFETY OF APHERESIS CONNECTORS G. Folléa, R. Foster, J. Epstein, D. Sherratt, J. MacPherson, H.J.C. de Wit, G. Sher European Blood Alliance, Brussels, Belgium MEXICAN PROGRAM FOR EXTERNAL QUALITY ASSURANCE IN INFECTIOUS SEROLOGY, GENERAL RESULTS OF THE FIRST YEAR OF ACTIVITIES, INSTITUTO LICON P.E. Sánchez-Montero, L. Contreras Trujano Instituto Licon, Tlalnepantla, Mexico ESTABLISHMENT OF A NATIONAL ACCREDITATION PROGRAM FOR BLOOD BANKS (BB) IN INDIA UNDER NATIONAL ACCREDITATION BOARD OF HOSPITALS AND HEALTHCARE PROVIDERS (NABH) N. Choudhury, B.K. Rana, G. Gupta Tata Medical Center, Kolkata, India

SURVEY OF QUALITY ASSURANCE IN HEMOTHERAPY IN THE VARIOUS MEDICAL FACILITIES L. Oustianskaia, V.M. Petrescu-Jipa, S. Radojska, A. Harbrecht, I. Kaul, D. David, B.S. Gathof University Hospital, Cologne, Germany

15.15 - 15.30

Overall discussion 111





Wednesday July 11

14.00 - 15.30

Gran Cancun 2


112

Wednesday July 11

14.00 - 15.30

Cozumel 1




Emergency Planning and Outcome

Donor Adverse Events

Moderators: R. Benjamin (USA), J.E. Orozco Bustillos (Mexico)

Moderators: M. González Santos (Mexico), P. van den Burg (Netherlands)

14.00 - 14.30 5C-S39-01

RESTORING BLOOD PRODUCTION IN HAITI AFTER THE EARTHQUAKE OF JANUARY 12TH, 2010 E. Noel NBSP/ MOH, Port-au-Prince, Haiti

14.30 - 15.00 5C-S39-02

THE OSLO MASSACRE 2011 C.A. Akkok Oslo University Hospital, Oslo, Norway

15.00 - 15.30 5C-S39-03

BLOOD SUPPLY SYSTEM IN MEXICO J. Rojo, A. Arroyo Centro Nacional de Transfusion Sanguinea, Mexico

14.00 - 14.30 5C-S40-01

DONOR VIGILANCE: PROGRESS AND CHALLENGES J.C. Wiersum-Osselton, T. Marijt-van der Kreek, W.L.A.M. de Kort TRIP Dutch National Hemovigilance Office, The Hague, Netherlands

14.30 - 14.45 5C-S40-02

IRON AND CARDIAC ISCHEMIA: A NATURAL, QUASI-RANDOM EXPERIMENT COMPARING ELIGIBLE WITH DISQUALIFIED BLOOD DONORS M. Germain, G. Delage, C. Blais, E. Maunsell, F. Décary, Y. Grégoire Héma-Québec, Quebec City, Canada

14.45 - 15.00 5C-S40-03

FREQUENCY AND RISK FACTORS FOR DONOR REACTIONS R. Goldman, L. Osmond, Q.-L. Yi, S.F. O’Brien Canadian Blood Services, Ottawa, ON, Canada

15.00 - 15.15 5C-S40-04

REDUCING THE RISK OF PRE-SYNCOPE AND SYNCOPE IN HIGH VOLUME PLASMAPHERESIS COLLECTIONS B.M. Bell, J.M. Pink, A.J. Keller, H. Yang, J. Lee Australian Red Cross Blood Service, Alexandria NSW, Australia

15.15 - 15.30

Overall discussion

113





Wednesday July 11

14.00 - 15.30

Coba

Oral Abstracts

16.00 - 17.30

Gran Cancun 1




Training and Education

New Blood Groups

Moderators: I. Ibarra Blancas (Mexico), N. Marwaha (India)

Moderators: J. Batista Juárez (Mexico), J. Storry (Sweden)

14.00 - 14.18 5C-S41-01

MANAGEMENT AND IMPLEMENTATION OF CONTINUING EDUCATION IN BLOOD CENTER OF ZHEJIANG PROVINCE B. Dai, Z.H. Meng, F.M. Zhu Blood Center of Zhejiang Province, Hangzhou, China

16.00 - 16.30 5D-S42-01

14.18 - 14.36 5C-S41-02

A ‘WIN-WIN’ APPROACH TO SUCCESSFULLY IMPLEMENT COMPETENCY ASSESSMENT FOR ALL MEDICAL TRAINEES AT A TERTIARY LEVEL LONDON TEACHING HOSPITAL A.M.Y. Li, M. Sekhar, E. Salgado Royal Free Hospital, London, United Kingdom

14.36 - 14.54 5C-S41-03

DEVELOPING A PACIFIC TRANSFUSION LEADERSHIP NETWORK TO STRENGTHEN REGIONAL TRANSFUSION PRACTICE N. Waters, S.-R. Pasricha, Z. Yates, E. Wood Australian Red Cross, Melbourne, Australia

14.54 - 15.12 5C-S41-04

THE ROLE OF TRAINING AND EDUCATION IN IMPROVING QUALITY IN BLOOD TRANSFUSION SERVICES M.T. Bahgat, F. Moftah, N. Mohamed, S. Rasmy Abbasia Regional Blood Transfusion Center, Cairo, Egypt

15.12 - 15.30 5C-S41-05

ISBT Developing Country Award DEVELOPMENT OF TRAINING AND EDUCATION IN TRANSFUSION MEDICINE IN SRI LANKA S. Jayasekara National Blood Transfusion Service, Colombo, Sri Lanka

15.30 - 16.00

Coffee Break

IDENTIFICATION OF HUMAN ATP-BINDING CASSETTE (ABC) TRANSPORTERS AS CARRIERS OF HIGH-INCIDENCE ANTIGENS IN TWO NOVEL BLOOD GROUP SYSTEMS L. Arnaud National Institute of Blood Transfusion, Paris, France

16.30 - 17.00 5D-S42-02

THE JR BLOOD GROUP SYSTEM: GENETIC AND MOLECULAR INVESTIGATIONS M. Reid New York Blood Center, New York, USA

17.00 - 17.15 5D-S42-03

A NOVEL CROMER BLOOD GROUP SYSTEM ANTIGEN, CRUE, ARISING FROM TWO HETEROZYGOUS DAF MUTATIONS IN ONE INDIVIDUAL WITH THE CORRESPONDING ANTI-CRUE V. Karamatic Crew, J. Poole, R. Mathlouthi, L. Wall, G. Daniels BITS and IBGRL, Bristol, United Kingdom

17.15 - 17.30 5D-S42-04

114

Wednesday July 11

PARG: A NEW LOW PREVALENCE RH BLOOD GROUP ANTIGEN A. Scharberg, N. Kanbur, R. Baudendistel, S. Roth, S. Seyboth, E. Richter, G. Rink, B. Gathof, P. Bugert, J. Burkhart Red Cross Transfusion Service Baden-Wuerttemberg-Hessen, Baden-Baden, Germany

115





Wednesday July 11

16.00 - 17.30

Gran Cancun 2


16.00 - 17.30

Gran Cancun 5

Clinical



Chagas Disease

Appropriate Use of RBCs

Moderators: S. Wendel (Brazil), M. Busch (USA)

Moderators: A. Bravo Lindoro (Brazil), S. Stanworth (United Kingdom)

16.00 - 16.30 5D-S43-01

CHAGAS DISEASE: A THREAT FOR SAFE BLOOD TRANSFUSION? M.A. Shikanai Yasuda Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

16.00 - 16.30 5D-S44-01

Patterns of blood use: How to deal with overconsumption K. Titlestad Department of Clinical Immunology, Odense University Hospital, Odense, Copenhagen

16.30 - 17.00 5D-S43-02

Strategies for Chagas prevention in Mexico A. Malagón Martínez Banco Central de Sangre, Centro Médico Nacional La Raza, IMSS, México D.F., Mexico

16.30 - 16.45 5D-S44-02

17.00 - 17.15 5D-S43-03

NO EVIDENCE OF TRYPANOSOMA CRUZI INCIDENCE IN UNITED STATES BLOOD DONORS: A 4-YEAR STUDY L. Stramer, E.P. Notari, L. Townsend, B. Custer, H. Kamel, P. Busch, Y. Dodd American Red Cross/Scientific Support Office, Gaithersburg, USA

TRANSFUSION RISK SCORE AND BLOOD USE IN CARDIAC SURGERY PATIENTS: A CARDIOVASCULAR HOSPITAL EXPERIENCE IN BOGOTÁ, COLOMBIA O. Penuela, J. Perea, B. Espitia, L. Gomez Clinica Shaio, Bogota, Colombia

17.15 - 17.30 5D-S43-04

TRYPANOSOMA CRUZI PARASITEMIA STATUS DETERMINED BY A SENSITIVE, QUANTITATIVE PCR ASSAY CORRELATES WITH CLINICAL MANIFESTATIONS OF CHAGAS HEART DISEASE IN A COHORT OF SEROPOSITIVE BLOOD DONORS E.C. Sabino University of Sao Paulo, São Paulo, Brazil

16.45 - 17.00 5D-S44-03

17.00 - 17.15 5D-S44-04

17.15 - 17.30 5D-S44-05

116

Wednesday July 11

DESIGNING A STRATEGY TO IMPLEMENT A COST-EFFECTIVE BLOOD TRANSFUSION POLICY IN ELECTIVE HIP AND KNEE ARTHROPLASTIES: A STUDY PROTOCOL V.M.A. Voorn, C So-Osman, T.P.M. Vliet Vlieland, R.G.H.H. Nelissen, A.W. Koopman - van Gemert, P.J. Marang - van de Mheen, L. Bodegom - Vos Leiden University Medical Centre, Leiden, Netherlands EVIDENCE-BASED PATIENT BLOOD MANAGEMENT GUIDELINES FOR MEDICAL PATIENTS J. Roberts, M. Dean, L. Bandler, D. Bowden, J. Duggan, S. Farmer, C. French, C. Hogan, R. Lindeman, L. McMahon, P. O’Beid, K. Robinson, A. Thomson National Blood Authority, Canberra, Australia RBC TRANSFUSION PRACTICE IN GENERAL SURGERY, EXPERIENCE FROM A SINGLE PORTUGUESE CENTRE A.I. Spínola, E.C. Campos Costa, C.M. Silva, A.S. Jorge, C. Mello de Carvalho, M. Bini-Antunes, M. Amil, J. Coutinho Centro Hospitalar do Porto, Porto, Portugal

117





Wednesday July 11

16.00 - 17.30

Cozumel 1


Wednesday July 11

16.00 - 17.30

Cozumel 3


Working Party S45

Working Party S46

WP: Rare Donors

WP: IT

Moderator: S. Nance (USA)

Moderator: R. Knels (Germany)

16.00 - 16.15 5D-S45-01

Introduction to Programme S. Nance American Red Cross, Philadelphia, USA

16.00 - 16.30 5D-S46-01

From Inspiration to Implementation C.P. Hohberger BloodCenter of Wisconsin, Milwaukee, USA

16.15 - 16.30 5D-S45-02

National Rare Donor Program Experience and Challenges C. Olsen SANBS, Kwa-Zulu Natal, South Africa

16.30 - 16.45 5D-S45-03

Regional Network Rare Donor Program Experience and Challenges E. Muñiz-Diaz Banc de Sang i Teixits, Barcelona, Spain

Have you had great ideas that never managed to get off the ground? Did you intend to do something about it but fail to follow through? Did the daily routine push them out of your mind? Dr Clive Hohberger, Consultant in Technology Based Strategic Planning and holder of numerous patents will discuss the creative process and hard work that turns moments of inspiration into production solutions. This talk may help you to turn your next brainwave into tomorrow’s new technology.

16.45 - 17.00 5D-S45-04

Starting a Rare Donor Program Experience and Challenges M. Moghaddam IBTO, Teheran, Iran

17.00 - 17.30 5D-S45-05

The Global Experience: International Rare Donor Panel J. Poole IBGRL, Bristol, United Kingdom

16.30 - 16.50 5D-S46-02

Optimize Overall Performance of Transfusion with Appropriate IT solutions L. Briggs BloodCenter of Wisconsin, USA

16.50 - 17.10 5D-S46-03

ACCEPTANCE ANALYSIS AND PILOT TESTING OF A NEW ELECTRONIC BLOOD DONOR ID-CARD AT GERMAN RED CROSS BLOOD DONATION SERVICES R. Knels, N. Gräulich, T. Rau, F. Gillert, W. Stangenberg German Red Cross Blood Donor Service, Cottbus, Germany 17.10 - 17.30 5D-S46-04

Electronical administration and archiving of quality management documents T. Müller-Kuller RCBDS - Baden Württemberg-Hessen, Frankfurt am Main, Germany

118

119






Wednesday July 11

16.00 - 17.30

Coba

Cellular Therapies


Cellular Therapy in Regenerative Medicine Moderators: A. Arrazola García (Mexico), M. Koh (Singapore/United Kingdom) 16.00 - 16.30 5D-S47-01

STEM CELL THERAPY IN CARDIAC DISEASES A.C. Campos de Carvalho National Cardiology Institute, Rio de Janeiro, Brazil

16.30 - 17.00 5D-S47-02

CHALLENGES FOR SUCCESSFUL TRANSLATION OF CELLULAR THERAPY K.C. Gunter Hospira Inc., Illinois, USA

17.00 - 17.30 STEM CELL DONOR REGISTRIES: donor search and its impact 5D-S47-03 on the clinical outcome of patients with malignant hematological diseases E. Seifried DRK Blutspendedienst Baden-Württemberg-Hesse gGmbH, Frankfurt, Germany

120

Thursday July 12

08.30 - 10.00

Gran Cancun 1



Platelet functions beyond Hemostasis

Moderators: A. Taune-Wikman (Sweden), M. Lozano (Spain) 08.30 - 09.00 6A-S48-01

PLATELETS AND THE IMMUNE CONTINUUM J.W. Semple Keenan Research Center in the Li Ki Shing Knowledge Institute, Toronto, Canada

09.00 - 09.15 6A-S48-02

AUTOLOGOUS PLATELET DERIVED GROWTH FACTORS AS A TREATMENT MODALITY IN EARLY OSTEOARTHRITIS KNEE - A PROSPECTIVE RANDOMIZED CONTROL TRIAL A. Jain, S. Patel, S. Aggarwal, N. Marwaha, M.S. Dhillon PGIMER, Chandigarh, India 09.15 - 09.30 6A-S48-03 09.30 - 09.45 6A-S48-04

09.45 - 10.00 6A-S48-05

APPLICATION OF PLATELET-RICH PLASMA (PRP) IN DIABETIC FOOT WOUND HEALING IN A PUBLIC HOSPITAL OF BUENOS AIRES ARGENTINA A. Arcuri, S. Rosell, M. Calvagno, P. Carras, M. Sáenz, K. Marconi, B. Chantefort Hospital E .Tornu, Buenos Aires, Argentina PLATELET PARTICIPATION TO INFLAMMATION IN HIV-1 INFECTED PATIENTS IS AFFECTED BY HAART P. Damien, F. Cognasse, F. Lucht, B. Pozzetto, O. Garraud, H. Hamzeh-Cognasse GIMAP-EA3064, Université de Saint-Etienne-membre de l’Université de Lyon, Saint-Etienne, France USE OF VINCRISTINE LADEN PLATELETS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES REFRACTORY TO PLATELET TRANSFUSION F. Martinez, G. Mattiuzzi, V. Reddy, B. Lichtiger The University of Texas MD Anderson Cancer Center, Houston, TX, USA

121

Scientific Programme Thursday



Thursday July 12

08.30 - 10.00

Gran Cancun 2


Thursday July 12

08.30 - 10.00

Gran Cancun 5

Clinical



Transfusion-Transmitted Disease

Alternatives to Transfusion

Moderators: A. Chiera (Mexico), J-P. Allain (United Kingdom)

Moderators: F. Herrera Gómez (Mexico), E. Wood (Australia)

08.30 - 09.00 6A-S49-01

DENGUE VIRUS AND OTHER ARBOVIRUSES: A GLOBAL VIEW OF THE RISKS M. Rios, G. Añez, C. Chancey, A. Grinev US Food and Drug Administration/ CBER/OBRR, Bethesda, USA

08.30 - 09.10 6A-S50-01

09.00 - 09.15 6A-S49-02

HIV TRANSMISSION RISK AND EFFICACY OF SCREENING STRATEGIES ESTIMATED FROM DATA PROVIDED BY AN INTERNATIONAL NAT STUDY GROUP R.L. Bruhn, S.H. Kleinman, N. Lelie, B. Custer, M. Busch Lelie Research, Paris, France

PREOPERATIVE ANEMIA: THE NATA CONSENSUS E. Bisbe Parc de Salut Mar, Barcelona, Spain

09.10 - 09.40 SURGICAL AND ANAESTHETIC MANAGEMENT OF ANAEMIA: PROS AND 6A-S50-02 CONS OF CELL SALVAGE DEVICES D.W. Thomas ABMUHB, Swansea, Wales, United Kingdom 09.40 - 10.00

Overall Discussion

09.15 - 09.30 6A-S49-03

COMPARISON OF HIV ASSAYS IN WINDOW PHASE AND ELITE CONTROLLER SAMPLES: VIRAL LOAD DISTRIBUTION AND IMPLICATIONS FOR TRANSMISSION RISK M. Vermeulen, C. Coleman, J. Mitchel, R. Reddy, H. van Drimmelen, T. Ficket, M. Busch, N. Lelie SANBS, Roodepoort, South Africa 09.30 - 09.45 6A-S49-04

WHICH HBV DNA SENSITIVITY LIMIT IS REQUIRED FOR THE SWISS BLOOD DONOR POPULATION C. Niederhauser, C. Tinguely, S. Fontana, M. Stolz Blood Transfusion Service SRC Berne, Berne, Switzerland

09.45 - 10.00 6A-S49-05

SPONTANEOUS HBV CLEARANCE AND OCCULT HBV INFECTION IN BLOOD DONORS WITH ANTI-HBC-ONLY PROFILES: CONTRIBUTION OF KIR AND SPECIFIC HLA-C GENE COMBINATIONS AND NK CELL ACTIVITY P.R.B. Araujo, F. Latini, R. Dodd, F. Carvalho Oliveira, O. Costa Ferreira Jr, G. Albertoni, J. Cardoso de Oliveira, L.C. Moraes Sobrino Porto, R. Diaz, J.A. Barreto Colsan-Associação Beneficente de Coleta de Sangue, São Paulo, Brazil

122

123





Thursday July 12

08.30 - 10.00

Cozumel 1


124

Thursday July 12

10.30 - 11.30

Gran Cancun 2

Plenary Session 5


Plenary Session PL5

The Multi-Ethnic Donor Challenge

Blood Philosophy

Moderators: R. Bolaños (Guatemala), D. de Coning (South Africa)

Moderators: A. Guerra Márquez (Mexico), P. Strengers (Netherlands)

08.30 - 09.00 6A-S51-01

MINORITY BLOOD DONATION IN THE UNITED STATES B.H. Shaz New York Blood Center, New York, USA

10.30 - 11.00 6B-PL5-01

BLOOD TRANSFUSION AND THE SOCIAL CONTRACT M. Franklin Irish Blood Transfusion Service, Dublin, Ireland

09.00 - 09.30 6A-S51-02

BLOOD DONATION PATTERNS AND CHALLENGES IN SOUTHERN AFRICA R. Reddy South African National Blood Service, Johannesburg, South Africa

11.00 - 11.30 6B-PL5-02

THE ISBT CODE OF ETHICS AND THE ALTRUISTIC DONOR P. Flanagan New Zealand Blood Service, Auckland, New Zealand

09.30 - 09.45 6A-S51-03

NEW METHOD FOR RARE DONOR SCREENING USING A MULTIPLEX PCR WITH A POOL SYSTEM Z. Zhu Shanghai Blood Center, Shanghai, China

11.30 - 12.00

Closing Ceremony

12.00 - 13.00

Farewell Lunch (Exhibition area)

09.45 - 10.00 6A-S51-04

SELFREPORTED MENTAL HEALTH PREDICTS DONATION FREQUENCY O.B. Pedersen, C. Erikstrup, S.R. Kotzé, E. Sørensen, K. Grau, M.S. Petersen, K.O. Kyvik, H. Ullum

Næstved Hospital, Næstved, Denmark

10.00 - 10.30

Coffee Break

125






126

Posters

Posters Posters

Poster Area All accepted posters (publication and display) will be presented in the Cost Maya on the first floor (P-144-P-662) and in Cozumel 2 (P-001-P-143) on the second floor. Borderline posters (accepted for display only) will be presented in a separate area of the Cozumel 2 and will be clearly marked. A list of the posters on display can be found in the congress Abstract book. The abstract topics are set out on page 133 and 134. The posters are set out according to the topic, the number of the abstract is displayed in the Abstract book and on the poster board. Poster Session A Poster session will be held to enable delegates to gain the maximum benefit from the scientific work presented and to create a lively interaction with poster authors. The Poster Session will be organised on Tuesday July 10, from 17.45 - 18.45 hours. Poster authors and interested delegates are kindly requested to be present at their poster during the entire session. Snacks and drinks will be served for those attending the Poster Session. Poster Mounting Posters can be mounted as of Sunday, July 8 at 18.30 hours. On Monday and Tuesday posters can be mounted as of 09.00 hours. • The number of your poster can be found in the Abstract book. • Posters should be mounted with double sided tape only. Assistance and material for mounting the posters will be available from set-up time, at the poster desk in the poster area on the first floor. Setting-up a poster generally takes at least 10 minutes. Poster Material Removing Material should be taken on Thursday July 12, after the morning coffee break. Material that has not been taken down by the author(s) in time, will be removed and destroyed. Poster Prizes Best rated poster abstracts presented during the poster session will be evaluated by experts in the field. These experts will meet as a poster award committee and grant poster awards to the best poster presentations. Therefore, only posters, which are presented by the responsible author during the poster session, will qualify for a poster award. The poster prize winners will receive their awards from the ISBT Scientific Secretary at the conclusion of the Poster Session on Tuesday July 10, 2012

127

Posters

Posters Published

Posters Published

Responsibility for poster presentations The ISBT and Local Organising Committee do not assume any responsibility for material displayed on the poster boards.

Posters P-001 – P-143 will be displayed at Cozumel 2, second floor Posters P-144 – P-662 will be displayed at Costa Maya, first floor 1. Management and Organisation 1.2 Information technology 1.3 Cost/Effectiveness 1.4 Training and Education 1.5 Risk Models and Risk Analysis 1.6 Blood Supply Management and Utilization 1.8 Quality Management 2. Blood Donation 2.1 Blood Donor Recruitment 2.2 Blood Collection incl. Apheresis 2.3 Donor Adverse Events 3. Blood Products 3.1 Blood Processing, Storage and Release 3.2 Blood Components 3.3 Plasma Products 3.4 Pathogen Inactivation 3.5 Biologicals 3.6 Novel Blood Products 4. Transfusion Transmitted Infections 4.1 Screening strategies for TTI 4.2 Hepatitis B (HBV) 4.3 Hepatitis C (HCV) 4.4 HIV 4.5 Bacteria 4.6 Parasites 4.7 Newly emerging pathogens and other transfusion related pathogens

128

Posters Published

Posters

Poster Viewing and Presentation Posters will be on display in the poster area for 3 days and will also be open for viewing during exhibition hours.

P-001 - P-004 P-005 - P-007 P-008 - P-011 P-012 - P-015 P-016 - P-034 P-035 - P-056

P-057 - P-112 P-113 - P-133 P-134 - P-143

P-144 - P-168 P-169 - P-198 P-199 - P-213 P-214 - P-244 P-245 P-246 - P-252

P-253 - P-292 P-293 - P-321 P-322 - 329 P-330 - 340 P-341 - P-352 P-353 - P-364 P-365 - P-388

129

Posters Published

Posters Published

Posters Published

Topic 1: Management and Organisation

5. Immune Haematology 5.1 Red Cell Immunology: Serology 5.2 Red Cell Immunology: Molecular 5.3 Platelet Immunology 5.4 Granulocyte Immunology 5.5 Fetal-Maternal Immunology

P-389 - P-449 P-450 - P-506 P-507 - P-517 P-518 - P-519 P-520 - P-534

6. Clinical Transfusion 6.1 Neonatal and Pediatric Transfusion 6.2 Therapeutic Apheresis 6.3 Evidence Based Transfusion Medicine Practice 6.4 Haemorrhage and massive transfusion 6.5 Adverse events, incl. TRALI 6.6 Haemovigilance and transfusion safety 6.7 Alternatives to Blood Transfusion

P-535 - P-538 P-539 - P-545 P-546 - P-555 P-556 - P-562 P-563 - P-567 P-568 - P-590 P-591 - P-596

7. Cellular Therapies 7.1 Stem Cell and Tissue Banking, incl. Cord Blood 7.2 Collection, Processing, Storage and Release 7.3 Clinical Applications

P-597 - P-614 P-615 - P-626 P-627 - P-639

8. Clinical Immunogenetics 8.1 HLA in Transfusion Medicine 8.2 Histocompatibility in Stem Cell Transplantation 8.3 Histocompatibility in organ transplantation

P-641 - P-645 P-646 - P-650 P-651 - P-655

9. Novel Development 9.1 Novel development

P-656 - P-662

Posters Published

Posters Published

130

Posters Published

1.2 Information technology P-001 GEODÁDIVAS - GEOGRAPHIC INFORMATION SYSTEM FOR BLOOD DONATION MANAGEMENT IN PORTUGAL J. Leal, J. Condeço, J. Gaspar, J. Azevedo, R. Cruz-Correia Porto Regional Blood Centre - Portuguese Blood Institute, I.P., Porto, Portugal P-003 ISBT 128 - STANDARDIZED IDENTIFICATION FOR PRODUCTS OF HUMAN ORIGIN E. Cabana ICCBBA, San Bernardino, USA P-004 LEGITIMATE MANAGEMENT INFORMATION SYSTEM OF BLOOD TRANSFUSION SERVICE OF INDONESIA UNDERWEB DESIGN (SIMUDDA) F. Nugroho Blood Transfusion Unit Tangerang City, Tangerang, Indonesia

1.3 Cost/Effectiveness P-005 BLOOD DONOR SCREENING BY NAT OR SEROLOGY SCREENING METHODS - WHICH STRATEGY IS MORE COST EFFECTIVENESS? E. Seifried, M.K. Hourfar, W. Sireis, M. Schmidt German Red Cross, Institute Frankfurt, Frankfurt, Germany

131

Posters Published

P-007 REDUCTION IN TIME CONSUMPTION FOR PACKING AND RETRIEVAL OF REPOSITORY BLOOD DONATION SAMPLES USING LEAN SIX SIGMA TOOLS F.H Tan, K.S Ng, W.C Tan, K.L Tan, M. Saudna, S.S Chua, S.Lam, D.Teo Blood Services Group, Health Sciences Authority, Singapore

P-008 INTERNATIONAL COOPERATION PROGRAMMES AT EFS: FOR WHOM AND HOW ARE THEY HELPFUL? B. David, L. Sobaga, O. Nasr, A. Beauplet Etablissement Français du Sang, La Plaine Saint Denis, France P-009 CONTINUING MEDICAL EDUCATION AT NATIONAL INSTITUTE OF TRANSFUSION MEDICINE IN MACEDONIA - CURRENT SITUATION AND PERSPECTIVES L. Mitevska, M. Blagoevska, R. Dukovski, A. Hristova-Dimceva, O. Todorovska National Institute of Transfusion Medicine, Skopje, Macedonia P-010 PICASSOS UNDER THE PAVILION: A CREATIVE APPROACH TO COMMUNITY AWARENESS M.B. Fisk, M. Dial, J. Perparas South Texas Blood & Tissue Center, San Antonio, USA P-011 BLOODSAFE ELEARNING AUSTRALIA: FOUR YEARS OF ONLINE TRANSFUSION EDUCATION J. Roberts, S. Russell, T. Verrall, R. Sprod, M. Abbott, M. Wood Blood Sector Clinical Development, National Blood Authority

1.5 Risk Models and Risk Analysis P-012 MANAGING RISK UNDER A NEW BLOOD POLICY R. Schwabe, S. Thomas, M. Wsolak Transfusion SRC Switzerland, Bern, Switzerland

132

P-013 TRENDS IN INFECTIOUS DISEASES AMONG EUROPEAN DONORS: AN ANALYSIS OF COUNCIL OF EUROPE DATA COLLECTED BETWEEN 2001 AND 2008 M.P. Janssen, M.-E. Behr-Gross, C.L. van der Poel University Medical Center Utrecht, Utrecht, Netherlands P-014 HOW THE ECONOMIC CRISES COULD DECREASE BLOOD SAFETY C. Koch, J.M. Sobral, G. Oliveira, F. Araújo S. João Hospital, Porto, Portugal

Posters Published

Posters Published

1.4 Training and Education

Posters Published

1.6 Blood Supply Management and Utilization P-016 IMPROVING PRODUCTIVITY IN THE BLOOD SERVICE SUPPLY CHAIN K. Walker, J. Caulfield, N. Beckman Australian Red Cross Blood Service, Melbourne, Australia P-018 DEVELOPMENT AND IMPLEMENTATION OF STRATEGIES TO REDUCE RED CELL WASTAGE ACROSS PUBLIC AND PRIVATE HEALTHCARE SECTORS G.I. Simon Queensland Health, Tanawha, Australia P-019 EFFICACY OF BROAD-AREA INVENTORY CONTROL OF RED BLOOD CELL PRODUCTS IN 9-PREFECTURE-COMBINED AREA COMPARED WITH THAT IN 9 INDIVIDUAL PREFECTURES IN JAPAN K. Ikeda, T. Imawaki, F. Murakami, N. Tomita, I. Ogo, S. Naito, H. Okada, K. Naoki, K. Fujiwara Japanese Red Cross Okayama Blood Center, Okayama, Japan P-020 WASHED BLOOD: INCREASING CUSTOMER SATISFACTION ON THE WORK FLOW PROCESS S.G. Sangalang, W.Y. Ng, E.M. Tang, T.H. Neo, S.K. Lim, M.N. Abella, M. Mohamed, D. Teo Health Sciences Authority, Singapore, Singapore P-021 EXPERIENCE WITH REGIONAL BLOOD SERVICE UNDER THE NUCLEAR POWER PLANT ACCIDENTS CAUSED BY THE EAST JAPAN DISASTER T. Kunori, M. Kashimura, H. Sawada, S. Fujita, Y. Oki, K. Suzuki, K. Yoshida Iwaki Red Cross Blood Center, Iwaki, Japan 133

Posters Published

P-031 PUBLIC PRIVATE PARTNERSHIP FOR STATEWIDE CONSOLIDATION AND CENTRALIZED INDIVIDUAL DONATION NUCLEIC ACID TESTING IN INDIA: KARNATAKA STATE EXPERIENCE V. Shyamala, Karnataka State Government Novartis Diagnostics, Bangalore, India

P-023 BLOOD SUPPLY MANAGEMENT IN BLOOD TRANSFUSION INSTITUTE OF VOJVODINA R. Jovanovic, M. Milosavljevic Blood Transfusion Institute of Vojvodina, Novi Sad, Serbia

P-032 BLOOD MANAGEMENT IN THE GERMAN COMBAT SUPPORT HOSPITALS IN AFGHANISTAN W.F. Madei, M. Schilha, W.U. Weinert German Armed Forces, Munich, Germany

P-024 CLINICAL USE OF BLOOD IN GRADE-III HOSPITALS IN SHANGHAI Y.G. Zhu, H.L. Cao, Q. Chen, T.Y. Zhang Shanghai Blood Administration Office, Shanghai, China

P-033 RATIONAL USE OF BLOOD COMPONENTS AND PRODUCTS IN GENERAL HOSPITAL CELJE FROM THE PERIOD 2007 TO 20011 J. Pajk, V.U.S. Urlep Salinovic General Hospital Celje, Celje, Slovenia

P-027 AUDITING FFP USAGE: USING PRE AND POST COAGULATION TESTING AS A TOOL F. Anwar, Y Mahmoud, Z.A. Merenkov, F.A. Mohd, A. Al Malki Hamad General Hospital, Doha, Qatar P-028 BLOOD COMPONENTS COLLECTION IN RUSSIAN FEDERATION E.A. Selivanov, A.V. Chechetkin Russian Research Institute of Haematology and Transfusiology, St.Petersburg, Russian Federation P-029 THE TREND AND ASSOCIATED FACTORS OF PLATELET COMPONENTS UTILIZATION IN TAIWAN C.-T. Lu, K.-T. Lin, H. Hung, L. Lin, C. Chang Kaohsiung Blood Center, Kaohsiung, Taiwan P-030 EFFECTS OF THE PROBLEMS FACED BY PATIENTS WITH THALASSEMIA DURING SUPPLY OF BLOOD AND BLOOD TRANSFUSION S. Basak Aliz, M. Yildirim, H. Altunay, R. Uluhan, D. Canatan Turkish Red Crescent Blood Centre Of The Northern Marmara Region, Istanbul, Turkey

Posters Published

Posters Published

P-022 THE IMPACT OF ECONOMIC DEVELOPMENT ON BLOOD AGENCIES IN ZHEJIANG PROVINCE AND CHINA Q. Feng, M. Meng, L. Lvhangjun, Y. Yangjing Zhejiang Blood Center China, Hangzhou, Zheijang, China

P-026 EFFECTIVE BLOOD DONATION MANAGEMENT B. Prcic Kneževic General Hospital Subotica, Subotica, Serbia

134

Posters Published

P-034 STRATEGIES FOR THE SAFETY OF PLATELET CONCENTRATE TRANSFUSIONS M. Miceli, L. Marinelli, A. Agresti, M. Palange, G.A. Gallo, M.N. Mirante, A. Matteocci, S. Chiarioni, D. Fioravanti, L. Perelli S.Camillo-Forlanini Hospital, Rome, Italy

1.8 Quality Management P-035 ERROR MANAGEMENT IN BLOOD ESTABLISHMENTS: RESULTS OF EIGHT-YEAR (2003-2010) EXPERIENCE AT CROATIAN INSTITUTE OF TRANSFUSION MEDICINE T Vuk, M. Barišic, T. Ocic, I. Mihaljevic, D. Šarlija, I. Jukic Croatian Institute of Transfusion Medicine, Zagreb, Croatia P-039 PRODUCT RECALL - CROATIAN EXPERIENCE (2000-2010) T Vuk, M. Barišic, J. Ljubicic, A. Hecimovic, N. Jurakovic-Loncar, D. Šarlija, I. Jukic Croatian Institute of Transfusion Medicine, Zagreb, Croatia P-040 EVALUATING ADP, COLLAGEN AND EPINEPHRINE AS PLATELET AGONISTS FOR QUALITY CONTROL OF PLATELET COMPONENTS USING FLOW CYTOMETRY J.S. Lin, Y.W. Lin, J.Y. Lyou, Y.J. Chen, T.J. Chiou Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan 135

Posters Published

P-042 ENSURING BLOOD/BLOOD PRODUCT QUALITY FOR BETTER TRANSFUSION OUTCOME J. Thilakavathi, K.K. Leou Health Sciences Authority, Singapore, Singapore

P-045 DEVELOPMENT OF QUALITY INDICATORS FOR BLOOD SCREENING LABORATORY W.R. Raina Beijing Red Cross Blood Center, Beijing, China P-046 OPTIMIZATION OF PREPARATION TECHNOLOGY OF INTERNAL QUALITY CONTROL PRODUCTS FOR BLOOD TRANSFUSION COMPATIBILITY TESTING Y. Yu, C. Ma, Q. Feng, L. Chen, H. Li, Y. Zhuang, D. Wang Chinese PLA General Hospital, Beijing, China P-047 IMPLEMENTATION OF LEAN TO TRANSFUSION SERVICE IN THAILAND P. Kitpoka, S. Onseedaeng, P. Suksomboonvong, T. Silthara, W. Thienphopirak Blood Bank, Faculty of Medicine, Ramathibodi Hospital,Mahidol University, Bangkok, Thailand P-048 EVALUATION OF ADAMRWBC SYSTEM FOR RESIDUAL LEUKOCYTE COUNT IN LEUKOREDUCED BLOOD COMPONENTS E. Lachert, A. Plodzich, J. Kubis, J. Antoniewicz-Papis, A. Rosiek, M. Letowska Institute of Hematology and Transfusion Medicine, Warsaw, Poland

P-051 QUALITY INDICATORS TRENDS IN THE INSTITUTE OF TRANSFUSION MEDICINE SKOPJE, MACEDONIA O. Todorovska Damevska, A. Hristova-Dimceva, R. Dukovski, T. Makarovska-Bojadzieva Institute of Transfusion Medicine of the Republic of Macedonia, Skopje, Macedonia P-052 NONCONFORMITIES OF INCOMING MATERIALS IN CENTER FOR TRANSFUSION MEDICINE MARIBOR B. Bizjak, L. Lokar, V.B. Majcen, D. Ulezic Paucic University Clinical Centre Maribor, Maribor, Slovenia

Posters Published

Posters Published

P-044 COMPREHENSIVE ANALYSIS OF THE TECHNIQUES USED FOR TESTS IN BLOOD BANK LABORATORIES IN KOREA FOR RECENT 4 YEARS Y.A. Lim Ajou University School of Medicine, Suwon, South-Korea

Posters Published

P-053 CONTINUOUS IMPROVEMENT IN BLOOD BANK BASED ON THE KAIZEN METHODOLOGY D. Arellano, M.d.C. Santamaría, H. Baptista Médicas Sur, DF, Distrito Federal, Mexico P-054 INTEGRATION OF STATISTICAL PROCESS CONTROL PROGRAM IN BLOOD BANK IT SYSTEM A.H. Llohn, R. Skagestad, T. Knutsen, A. Flesland, E. Ødegaard, K. Nafstad Akershus University Hospital, Loerenskog, Norway P-055 HUMAN LEUKOCYTE ANTIGEN PROFICIENCY TESTING IN SOUTHERN ITALY M. Sessa, M. Resse, A. Picascia, P.B. Minucci, V. Grimaldi, D. Parente, O. Pignalosa, A. Russo, F.P. De Luca, F. Cavalca, A. Casamassimi, C. Napoli Division of Immunohematology, School of Medicine, Second University of Naples., Naples, Italy P-056 APPLICATION OF RISK MANAGEMENT METHODOLOGY IN IMPROVING THE PERFORMANCE OF BLOOD TRANSFUSION SERVICES S. EL-Wakil Saudi German Hospital, Aseer, Saudi Arabia

P-049 USE OF EP15 A2 PROTOCOL FOR VERIFICATION OF PRECISION IN DONOR SCREENING TESTS M.G. Martínez Posada, A. Ramírez Morales, G. Cortes Rivera, L. Contreras Trujano Instituto Locon, S.C., Tlalnepantla, Mexico P-050 QUALITY IMPROVEMENT USING CLINICAL INDICATOR PARAMETERS IN THE FIELD OF TRANSFUSION K. Lee, T.S. Kim, Y.J. Hong, K.U. Park, K.S. Han Seoul National University College of Medicine, Seoul, South-Korea 136

137

Posters Published

Topic 2: Blood Donation 2.1 Blood Donor Recruitment

P-059 WORKING TOGETHER TO MEET TODAY’S RECRUITMENT CHALLENGE-INVITING DEDICATED WHOLE BLOOD DONORS TO BECOME PLATELET DONORS O. Bezjak, D.M. Graham, A. Geneser, R.M. Needham Donor Dialogue, Michigan, USA P-060 OPTIMIZING THE IRON STATUS OF REGULAR CHINESE BLOOD DONORS H.K. Wong, C.K. Lee, J.N.S. Leung, I.Y.M. Lee, W.C. Tsoi, C.K. Lin Hong Kong Red Cross Blood Transfusion Service, Hong Kong, SAR P-061 PSYCHOLOGICAL DONOR REACTIONS TO EXCLUSION FOLLOWING FALSE POSITIVE OR INDETERMINATE SCREENING TEST RESULTS G. Delage, G.C. Myhal, Y. Grégoire, G.M. Simmons Hema-Quebec, Saint-Laurent, Canada P-062 MOTIVATIONS FOR DONATING AND TEST SEEKING AMONG PROSPECTIVE BLOOD DONORS IN BRAZIL. T. Goncalez, C. Moreno, C. Miranda, M. Larsen, J. Wright, C. Rocha, S. Leão, I. Lopes, L. Oliveira, C. De Almeida-Neto, B. Custer, C. Sabino, C. Sabino Blood Systems Research Institute, San Francisco, USA P-063 OFF-SITE THIRD PARTY TELEPHONE RECRUITING OF LAPSED DONORS IS A COST-EFFECTIVE METHOD TO INCREASE BLOOD DONATIONS IN GENERAL HOSPITALS F. Brown, P Brooks U. of Texas Health Science Center, San Antonio, San Antonio, USA

138

P-064 INTENTION TO DONATE BLOOD AND RISK BEHAVIOUR: A STUDY ON ADOLESCENTS S. Alfieri, P. Guiddi, E. Marta, V. Saturni Catholic University of Sacred Heart, Milano, Italy P-065 DONOR DEFERRAL IN VOLUNTARY NON-REMUNERATED BLOOD DONORS IN ALBANIA I. Seferi, M. Vila, Z.H. Abazaj, J. Pengu, A. Metka, R Kardashi National Blood Transfusion Centre, Tirana, Albania

Posters Published

Posters Published

P-058 HOW CAN WE INCREASE THE RETURN OF LAPSED DONORS ? RESULTS OF A RANDOMIZED, CONTROLLED INTERVENTION M. Germain, G. Godin, M. Conner, P. Sheeran, G. Delage Héma-Québec, Quebec City, Canada

Posters Published

P-066 FACEBOOKING TO START YOUR DAY SAVING LIVES S. Choliluddin Singapore Red Cross, Singapore, Singapore P-067 BARRIERS TO THE INITIAL CONVERSION AND CONTINUATION OF PLASMA DONATION K.L. Bagot, B. Masser, L. Bove, T.C. Bednall University of Queensland and Australian Red Cross Blood Service, Melbourne, Australia P-068 SCREENING OF DEFERRED BLOOD DONORS FOR HEMOGLOBINOPATHIES: IMPACT ANALYSIS IN A HIGH PREVALENCE ZONE R. Sawant, R. Chawda, M. Bhuva, K. Mehta Rajkot Voluntary Blood Bank and Research Centre, Rajkot, India P-069 DONOR MOTIVATION IN XI’AN, CHINA: COMPARISON WITH CANADIAN DONORS F O’Brien, Z.J. Shao, L. Osmond, Q.L. Yi, C.L. Li, Q.X. An Canadian Blood Services, Ottawa, Canada P-070 SOCIAL NETWORKS AS AN EFFECTIVE TOOL TO IMPROVE THE NUMBER OF VOLUNTEER BLOOD DONORS IN A THIRD LEVEL HOSPITAL’S BLOOD BANK IN MEXICO A.M. Dorantes, A. Bravo, D.V. Aguilar, L.J. Salazar National Institute of Pediatrics, Mexico, Mexico, Mexico P-072 MEASUREMENT OF A PRE-DONATION HEMOGLOBIN WITH A NON-INVASIVE METHODOLOGY M.L. Dobao González, D. Brito, M. Abreu, S. Maia Instituto Português do Sangue, Porto, Portugal

139

Posters Published

Posters Published

P-080 BLOOD DONATION AND DONOR MOTIVATION IN OMAN - ACHIEVING 100% VOLUNTARY NONREMUNERATED BLOOD DONATION T. Ashraf, C. Smit Sibinga Ministry of Health, Muscat, Oman

P-074 SERUM FERRITIN LEVELS FOR NORMAL HEMOGLOBIN BLOOD DONORS IN A KOREAN POPULATION K. Lee, M. Han, K.U. Park, K.S. Han Seoul National University College of Medicine, Seoul, South-Korea

P-082 BLOOD DONORS DEFERRAL IN THE STATE OF QATAR: REASONS AND PROSPECTS A. Al-Malki, F. Anwar, Z. Merenkov, S. Al Mahmoudi, E. Yambao, C. Paz, M. Paul Hamad Medical Corporation, Doha, Qatar

P-075 DETERRENTS AND MOTIVATING FACTORS FOR REPEAT DONATION AMONG FIRST-TIME PLATELET DONORS Z. Qu, H.X. Lu Wuhan Blood Center, Wuhan, China P-076 DETERMINANTS OF DONOR RETURN AMONG CHINESE BLOOD DONORS N. Guo, Q. Yu, Y. Huang, Z. Zhou, M. Huang, M. Tiemuer, X. Dong, Z. Yun, J. Liu, P. Ness, H. Shan Johns Hopkins University, Baltimore, USA P-077 BLOOD DONOR RECRUITMENT AT VILA CENTRAL HOSPITAL BLOOD BANK PORT VILA, VANUATU G. Pakoa, S. Lercet, N.C. Tasavi, C.-L. Yap, R. Lee Vila Central Hospital, Port Vila, Vanuatu P-078 DONOR RECRUITEMENT IN COMMUNITIES WITH INADEQUATE HEALTH CARE SYSTEMS P.H. von Bukenya Uganda Blood Transfusion Service, Kampala, Uganda P-079 BLOOD DONATIONS IN MACEDONIA-TWENTY YEARS OF EXPERIENCE M. Blagoevska, L. Mitevska, T. Makarovska-Bojadzieva, R. Dukovski, J. Samonikov-Tosevska National Institute of Transfusion Medicine, Skopje, Macedonia

Posters Published

Posters Published

P-073 COMPARISON OF THREE METHODS FOR DETERMINATION OF HAEMOGLOBIN LEVELS IN PREDONATION SCREENING OF BLOOD DONORS E. Klausa, A. Misiaszek, W. Kosmider, M. Szymczyk-Nuzka, R. Kozlowski Regional Centre of Transfusion Medicine and Blood Bank, Wroclaw, Poland

P-083 CAN SUPAR BE USED AS A BIOMARKER OF INFLAMMATION IN THE BLOOD DONOR QUALIFICATION PROCESS ? E. Klausa, E. Swiatek, R. Kozlowski Regional Centre of Transfusion Medicine and Blood Bank, Wroclaw, Poland P-084 THE UMBILICAL CORD BLOOD IN GREECE A. Kriebardis, L. Karagiogrou, M.-N. Pantazopoulou, N. Mainas, A. Beloukas, G. Farmakidis Technological Educational Institute, Athens, Greece P-086 FEASIBILITY AND ACCEPTABILITY OF SMS TECHNOLOGY AMONG BLOOD DONORS IN NAIROBI J.N. Wangendo Bloodlink Foundation, Nairobi, Kenya P-087 USE OF TEST CARDS FOR VIROLOGICAL PRE DONATION SCREENING:PRELIMINARY DATA S.I.C. Sagliano, M.R. Dell’Aversana, E. Munno, R. Tomeo, R. D’Ambrosio, G. De Caprio, P. Pecora, S. Misso Servizio Trasfusionale ASL Caserta, Aversa, Italy P-088 DONOR SATISFACTION IN THE CONTEXT OF ISO 9001:2008 M. Szymczyk-Nuzka Regional Centre of Transfusion Medicine and Blood Bank, Wroclaw, Poland P-089 ARE THE INCENTIVES INFLUENCING FACTOR FOR BLOOD DONOR RECRUITMENT IN MACEDONIA? M. Blagoevska, L. Mitevska, R. Dukovski, S. Stojkoska, K. Kacarski, E. Petkovikj National Institute of Transfusion Medicine, Skopje, Macedonia

140

141

Posters Published

P-091 INTERDISCIPLINARY EDUCATION IN UNIVERSITY POPULATION: A STRATEGY FOR INCREASE SOCIAL SENSIBILITY AND VOLUNTARY BLOOD DONATION M. Chudoba, C.A. Gomez, G. Di Franco, J.L. Olivares, M. Villarreal, J. Perez, D. Olivetto, G. Alfonso Fundaleu, Ciudad Autónoma de Buenos Aires, Argentina

P-100 BENEFITS FROM I A COMPUTERIZED BLOOD DONOR QUESTIONNAIRE M.E. Lund, L. Espensen, J. Georgsen Department of Clinical Immunology, Odense University Hospital, Denmark

P-093 EVALUATION OF RAPID METHODS FOR HEMOGLOBIN MEASUREMENT IN A BLOOD DONOR SETTING IN COTE D’IVOIRE M. Diane, B. Dembele NBTS of Cote d’Ivoire/ Collection Site of General Hospital of Yopougon, Abidjan, Cote d’Ivoire

P-101 THE IMPACT OF SEVERAL NEW OUTBREAKS OF INFECTIOUS DISEASES IN EUROPE ON THE SELECTION OF OUR REGULAR AND NEW DONORS IN THE TRANSFUSION CENTRE IN GENERAL HOSPITAL CELJE J. Pajk General Hospital Celje, Slovenia

P-094 ANALYSIS OF SOCIO-DEMOGRAPHIC CHARACTERISTICS OF BLOOD DONORS IN THE DEPARTMENT OF TRANSFUSION MEDICINE - STRUMICA, REPUBLIC OF MACEDONIA IN 2011 T. Timova, L. Maninska, D. Stambolieva, T. Malinova, E. Kocovska, S. Ortakovska, V. Gorgevska, J. Vitlarova, T. Momirovska Institute of Transfision Medicine Macedonia, Strumica, Macedonia

P-103 SURVEY OF THE DEMOGRAPHIC CHANGES OF THE BLOOD DONORS IN SHIRAZ BLOOD SERVICE IN 2005–2011 A.R. Salah, M.A. Jalali Far, A.R. Tavassoli, M. Shirmohammadi Asafeh Blood Transfusion Research Center High Institute For Research and Education in T, Shiraz, Iran Thalasemia and Hemoglobinopathy Research Center of Ahvaz Jundishapur University, Ahwaz, Iran

P-095 IMPACT OF FACE TO FACE EDUCATION ON BLOOD DONATION M.S. Mirrezaie, M. Jamali, B. Hajibeigi, M.M. Golmakani, H. Sadegh, B. Daneshfar, M. Sadeghi, M. Zeidi, M. Mirzamoradi, R. Moradi Tbtc, Tehran, Iran

P-104 IMPROVING THE SAFETY OF BLOOD PRODUCTS THROUGH STRINGENT DONOR SELECTION,PRE AND POST DONATION SCREENING OF BLOOD S. Khan North West General Hospital, Peshawar, Pakistan

P-096 HEMOGLOBIN DISTRIBUTION OF BLOOD DONORS IN KOREA S.H. Kim, M.H. Kim, M.J. Kim, Q.H. Park, Y.-S. Hwang, H.G. Kim, S.W. Lee, Y.H. Shin, Y.A. Lim Jeju National University Hospital, Jeju-si, Jeju Province, South-Korea

P-105 BLOOD DONATION: LET’S TALK MORE M. Danzi, P. Walter Pica, D. Borzacchiello, G. Di Lemma, N. Cantelli, M. Carmina Biangardo, M. Saverio Servizio Medicina Trasfusionale, Aversa, Italy

P-097 ACHIEVING QUALITY OF BLOOD DONATION THROUGH CREATING AWARENESS AMONG BLOOD DONATION CAMPAIGN ORGANIZERS IN SRI LANKA P. Arewatte National Blood Transfusion Service, Colombo, Sri Lanka

142

P-099 CHANGE OF THE STRUCTURE OF BLOOD DONORS IN THE REGIONAL CENTER TETOVO E. Kocovska National Institute for Transfusion Medicine – Regional Centre, Tetovo, Macedonia

Posters Published

Posters Published

P-092 VOLUNTARY BLOOD DONATION: UNDERSTANDING STUDENTS MOTIVATIONS AND ATTITUDES A. Kriebardis, F. Giortsiou, G. Barbalias, A. Beloukas Technological Educational Institute, Athens, Greece

Posters Published

P-106 ASSESSMENT RESULT OF AN EDUCATIONAL INTERVENTION TO IMPROVE THE PERCEPTION OF VOLUNTARY BLOOD DONATION J. Castell, A. Cruz Valdez, J, Ramiro Cruz Instituto Nacional de Salud Publica, Cuernavaca, Morl, Mexico

143

Posters Published

P-107 NON-INVASIVE HEMOGLOBIN SENSOR PERFORMANCE IN ANEMIA SCREENING A. Weinstein, O. Herzenstein, A. Kononenko, E. Gabis, A. Korenberg, P.V. Holland OrSense LTD, Nes Ziona, Israel

P-109 STUDY OF BLOOD DONOR RETENTION AMONG AHVAZ MEDICAL STUDENTS IN 2010- 2011 F. Ghanavati, M.A. Jalali Far, N. Saki, N. Heidari, S. Ghasemi Ahvaz Jundishapur University of medical sciences, Ahwaz, Iran P-110 ARE REPEAT BLOOD DONORS BASED FROM A CLOSED SOCIAL COMMUNITY GROUP SAFER? R. Sawant, J. Gami, K. Bhatt, S. Mukhida Rajkot Voluntary Blood Bank and Research Centre, Rajkot, India P-111 FIFTEEN CAUSES OF REJECTION OF CANDIDATES FOR BLOOD DONATION AT THE BANCO DE SANGRE DEL HOSPITAL CIVIL DE CULIACÁN Y CENTRO DE INVESTIGACIÓN Y DOCENCIA EN CIENCIAS DE LA SALUD FROM 2011-2012. L.J. Ochoa Aldana, J.A. González Valdés, Y.L. Avila Garcia Hospital Civil de Culiacán, Culiacán, Mexico P-112 MOTIVATOR AND BARRIERS OF BLOOD DONATION AMONG FEMALE MEDICAL STUDENTS OF AHVAZ JUNDISHAPUR UNIVERSITY M.A. Jalali Far, F. Ghanavati, N. Saki, S. Negravi, M. Kavianpour Ahvaz Jundi Shapur University of Medical Sciences, Ahwaz, Iran

2.2 Blood Collection incl. Apheresis P-113 TEMPORARY IMPACT OF BLOOD DONATION ON HAEMOGLOBIN, FERRITIN AND PHYSICAL PERFORMANCE IN MODERATELY PHYSICALLY ACTIVE MEN K. Magnussen, J. Grand, A. Ziegler, F. Dela, J.W. Helge Rigshospitalet/Hvidovre Hospital, Hvidovre, Denmark

144

P-114 INFECTIOUS DISEASE MARKERS IN PRESENTING DONORS DEFERRED FOR HIGHER RISK BEHAVIORS IN BRAZIL T. Goncalez, C Miranda, K. Schlumpf, D. Wright, A. Mendrone, A.B. Proietti, M.E. Lopes, N.A.F. Ferreira, D. Sampaio, V. Lopes, L. Capuani, C. Sabino, B. Custer Blood Systems Research Institute, San Francisco, USA Posters Published

Posters Published

P-108 CREATION OF AN ENABLING ENVIRONMENT FOR VOLUNTARY BLOOD DONATION IN PAKISTAN A.P.M. Los, U. Waheed, P. Kohorst, W.M. Smid Sanquin Consulting Services, IDTM Groningen, Netherlands

Posters Published

P-115 INTERDONATION INTERVAL AND NUMBER OF PREVIOUS BLOOD DONATIONS DO NOT PREDICT FUTURE HEMOGLOBIN DEFERRAL AS WELL AS DONOR HEMOGLOBIN LEVEL AT LAST PRESENTATION B. Custer, M. Bravo, P.A. Tomasulo, M.P. Busch, H. Kamel Blood Systems Research Institute, San Francisco, USA P-116 CHARACTERIZATION OF BLOOD DONORS WITH HIGH HAEMOGLOBIN CONCENTRATION K. Magnussen, H.C. Hasselbalch, O. Weis Bjerrum, H. Ullum Rigshospitalet/Hvidovre Hospital, Hvidovre, Denmark P-117 EVALUATION OF A NON INVASIVE PRE DONATION HEMOGLOBULIN SCREEINING M. Gavalaki, E. Kalfa, H. Myriokefalitaki, A. Marinaki, T. Adraktas, G. Kanellopoulou, O. Katsaroy Blood Transfusion Center Laiko General Hospital, Athens, Greece P-118 EVALUATION OF HEMATOLOGY ANALYZERS FOR THE DETERMINATION OF PLATELET COUNTS IN INTERSOL® APHERESIS PLATELETS L. Kline, S. Seetharaman, J. Kurtz American Red Cross Holland Laboratory, Rockville, MD, USA P-119 IMPLEMENTATION AND OPERATIONAL IMPACT OF COLLECTION AND MANUFACTURE OF APHERESIS PLATELETS STORED IN INTERSOL® L. Kline, N. Meyer, B.R.M. Rosenthal, D. Dulaney, D.C. Mair, M. Kelch, K. Williams, J. Wheelock, W. Koetz American Red Cross Holland Laboratory, Rockville, MD, USA P-120 IMPROVED UTILIZATION OF APHERESIS TECHNOLOGY POTENTIAL THROUGH THE CONVERSION OF STANDARD PLATELET COLLECTIONS (SPC) TO PLASMA REDUCED PLATELET COLLECTIONS (PPC) D. Benomar, D. Lemau de Talence, F. Charpentier, P. Bierling EFS Ile de France, Saint Maur des Fossés, France 145

Posters Published

P-132 PERIPHERAL BLOOD STEM CELL HARVESTING WITH KABI COM.TEC M. Gupta, N. Mehta, P.S.R.K. Sastry Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

P-124 IN-VITRO STUDY OF THE QUALITY OF APHERESIS RED BLOOD CELLS (RBC) FOR PEDIATRIC USE, OBTAINED WITH THE CELL SEPARATOR TRIMA ACCELⓇ V6.0, STORED FOR 21 DAYS M.L. Dobao González, D. Brito, S. Oliveira, P. Mesquita, M. Abreu, T. Cunha, C. Resende, M. Bessa Instituto Português do Sangue, Porto, Portugal

P-133 HIGH SCHOOL STUDENT DONATIONS IN SKOPJE, MACEDONIA - A TWO YEAR SURVEY F. Raka, M. Blagoevska, L. Mitevska, I. Nikoloska National Institute for Transfusion Medicine, Skopje, Macedonia

P-126 POTENTIAL ADVERSE REACTIONS ASSOCIATED WITH APHERESIS MULTICOMPONENT (MAC) DONORS E. Cesario, M. Sessa, T. Di Mauro, B. Damiano, O. Pignalosa, A. Belsito, M. Rusciano, M. Ferriero, D. Di Troia, B. Bibba, F. Ziello, I. Caiafa, S. Conte, L. Sommese, C. Napoli Division of Immunohematology,School of Medicine, Second University of Naples, Naples, Italy

2.3 Donor Adverse Events

P-127 A ONE YEAR COMPARATIVE ANALYSIS OF SINGLE NEEDLE PLATELETPHERESIS PROCEDURES PERFORMED ON TWO DIFFERENT CELL SEPARATORS M. Gupta, N. Mehta Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

P-135 CHEST PAIN REPORTED DURING OR AFTER BLOOD DONATION H. Kamel, M. Bravo, B. Custer, P. Tomasulo Blood Systems, Inc., Scottsdale, USA

P-130 CONTRIBUTION OF PLASMA COLLECTION ON TERRITORY TO REGIONAL BLOOD PRODUCT SELF SUFFICIENCY M. D'Onofrio, L. Paesano, G.M. Leonardi, G. Vaccaro, A. D'Ambrosio, F. Annarumma, R. Romano, C. Nocera UOC di Medicina Trasfusionale -PO “S. Giovanni Bosco” - ASL Na1 Centro, Napoli, Italy P-131 VERIFICATION OF THE TRIMA ACCEL SYSTEM PERFORMANCE DURING THE GATHERING OF RED-CELL PACKAGES BY APHAERESIS H. Baptista, C. Martinez, A. Martinez, Medica Sur, Distrito Federal, Mexico

Posters Published

Posters Published

P-123 SCREENING FOR SICKLE CELL TRAIT IN BLOOD DONORS BY HEA BEADCHIP™ TEST J.C. Yang, S. Vege, C. Westhoff, E. Enriquez, T. Hutchinson BioArray Solutions, an Immucor Company, Warren, USA

P-128 REDUCING PLATELET TARGET YIELD WITHOUT COMPROMISING PLATELET COLLECTION EFFICACY AND WORKFLOW AT A LOCAL UNIVERSITY HOSPITAL P.L.K. Lim, J. Mah, S. Lim, M.L. Tung, L.K. Tan Blood Transfusion Service, Department of Laboratory Medicine, National University Hospital, Singapore

146

Posters Published

P-134 DONOR AWARENESS OF HEALTH EFFECTS OF BLOOD DONATION R. Goldman, T. Steed, S.F. O’Brien Canadian Blood Services, Ottawa, ON, Canada

P-136 EVALUATION OF AN ESTIMATED BLOOD VOLUME-BASED INTERVENTION TO DECREASE VASOVAGAL REACTIONS IN YOUNG BLOOD DONORS R.O. Francis, D.A. Kessler, B.H. Shaz Columbia University Medical Center/New York Presbyterian Hospital, New York, USA P-137 YOUNG DONORS WITH HIGH BODY MASS INDEX AND LOW BLOOD VOLUME PREDISPOSED TO DONATION RELATED VASOVAGAL REACTIONS S. Agarwal Fortis Escorts Heart Institute, New Delhi, India P-138 INVESTIGATION OF DELAYED ADVERSE REACTIONS K.M. Matsuzaki, A. Kuwano, Y. Matsuda, M. Kondo, Y. Nishitani, Y. Ono, M. Satake, K. Nakajima Japanese Red Cross Tokyo Blood Center, Tokyo, Japan

147

Posters Published

P-139 RISK FACTORS FOR VASOVAGAL REACTIONS IN A COHORT OF FIRST-TIME DONORS T. Marijt-van der Kreek, J.C. Wiersum-Osselton, W.L.A.M. de Kort Sanquin Blood Supply, Rotterdam, Netherlands

P-141 DONOR ADVERSE REACTIONS IN POLISH BLOOD TRANSFUSION SERVICE A. Rosiek, J. Antoniewicz-Papis, E. Lachert, A. Dabrowska, M. Letowska Institute of Hematology and Transfusion Medicine, Warsaw, Poland P-142 ADVERSE REACTIONS IN BLOOD DONORS: EXPERIENCE OF A PORTUGUESE BLOOD CENTRE M.A. Escoval, M. Santos, A.P. Sousa, L. Outerelo Instituto Português do Sangue e da Transplantação, Lisboa, Portugal P-143 DONOR IRON STATUS MONITORING AND ONGOING DONOR MANAGEMENT E. Svirnouskaya, H. Khulup, L. Smirnova, O. Klimovich, V. Pasiukou Belarussian Academy of Postgraduate Education, Minsk, Republic of Belarus

Topic 3: Blood Products 3.1 Blood Processing, Storage and Release P-145 QUALITY OF COMPONENTS PREPARED USING THE REVEOS AUTOMATED BLOOD PROCESSING SYSTEM L.N. Johnson, K.M. Winter, S.J. Reid, T. Hartkopf-Theis, M. Kwok, D.C. Marks Australian Red Cross Blood Service, Alexandria, Australia P-146 EFFECT OF NITRIC OXIDE ON THE DEFORMABILITY OF RED BLOOD CELLS WITH DIFFERENT BUOYANT-DENSITIES Q. Yu, H. Wang, Y. Cao, Z. He, Y.L. He, J.X. Liu Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China 148

P-148 NON-DEHP BLOOD BAG SYSTEM CONSTITUTED WITH A NEW ADDITIVE SOLUTION CONTAINING VITAMIN E DERIVATIVE AND NON-LEACHABLE PVC MATERIAL N. Takeda, Y. Nagasaki, S. Kora Terumo Corp., Kanagawa, Japan P-149 1HOUR RESTING EFFECT ON DAY1 COULD BE MIMICKED BY 6 HOURS RESTING ON 48HOURS STORED PCS BY INTERRUPTION OF AGITATION AT ROOM TEMPERATURE IN PERMEABLE BAGS B. Badlou, H. Timori High Institute for Research and Education, Tehran, Iran

Posters Published

Posters Published

P-140 ADVERSE REACTIONS DURING WHOLE BLOOD DONATION - A 12 YEARS EXPERIENCE FROM A SINGLE CENTRE G.F.P. Coutinho, G. Melo, M.J. Vaz, E. Esteves, A. Monteiro, F. Felícia, C. Silva, M. Bini-Antunes, M. Amil, J. Coutinho Centro Hospitalar do Porto, Porto, Portugal

Posters Published

P-150 THE COMPARISON OF POLY(VINYL CHLORIDE) WITH DIFFERENT PLASTICIZER IN COMPLEMENT ACTIVATION R. Zhong, H. Wang, Y. Cao, Z. He, Y.L. He, J.X. Liu Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China P-151 EVALUATION OF STABILITY OF COAGULATION FACTORS IN THAWED PLASMA DURING 5-DAY STORAGE AT 2-6°C. M. Bohonek, V. Maskova, E. Sladkova, I. Hrachovinova Central Military Hospital Prague, Prague, Czech Republic P-152 USE OF ITRACE DATA COLLECTION SYSTEM WITH PLASMAPHERESIS AUTOPHERESIS-C AT THE ETS CHARLEROI IN BELGIUM L. Lecomte, C. Pernom, T.V. Nguyen, I. Fouyn Asbl La Transfusion du Sang, Charleroi, Belgium P-153 ATREUS COMPONENT PROCESSING SYSTEM: A MARRIAGE OF CONVENIENCE OR A HAPPY ENDING F. Anwar, Z.A. Merenkov, Z. Fawzi, A. Al Malki Hamad General Hospital, Doha, Qatar P-154 COMPARISON OF THREE DIFFERENT METHODS FOR DETECTION OF BACTERIAL CONTAMINATION IN PLATELET CONCENTRATES G.H. Bian, C.H. Yang, H. Yang, W.P. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

149

Posters Published

P-155 MULTIPLE EXPOSURES OF RED BLOOD CELL CONCENTRATES TO 30 °C - IN VITRO QUALITY ASSESSMENT OF RED CELLS S. Thomas, V. Hancock, R. Cardigan NHS Blood and Transplant, Brentwood, United Kingdom

P-157 EVALUATION OF LEUKOREDUCTION EFFICIENCY AND IN VITRO STORAGE CHARACTERISITICS OF RED CELLS PROCESSED THROUGH A NEW RED CELL FILTRATION SYSTEM E. Shafizadeh, W. Luty, R. Paradiso, A. Ronquillo, S. Mansoor, R. Gagnon, J. Peterson, J. DelGiacco Pall Corporation, Port Washington, NY, USA P-158 SHOULD PREOPERATIVELY DONATED AUTOLOGOUS BLOOD WITH POSITIVE DIRECT ANTIGLOBULIN TESTS BE TRANSFUSED? C.H. Fletcher, J.P. Brooks University of Florida, Gainesville, USA P-160 DEHP-FREE CONTAINERS FOR COLLECTION, PROCESSING AND STORAGE OF LABILE BLOOD PRODUCTS - COMPARATIVE EVALUATION OF FFPS O. Fontaine, S. Melique, M.C. Doolaeghe, J.J. Huart, F. Goudaliez, T. Verpoort, D. Dekerle, J. Poplineau Etablissement Francais du Sang, Lille Cedex, France P-161 COMPARISON OF THREE DIFFERENT PRODUCTION PROCEDURES OF LEUCOREDUCED PLATELET CONCENTRATES OVER A STORAGE TIME OF SEVEN DAYS S. Suessner, B. Reisinger, G. Schuster, C. Gabriel Red Cross Blood Transfusion Service of Upper Austria, Linz, Austria P-162 THE INCIDENCE OF RED BLOOD CELL TRANSFUSION IN SOUTH AFRICA, 2010 T.N. Muthivhi, E.L. Murphy, B. Custer, E. Kuun, L. Mpuntsha South African National Blood Services, Roodepoort, South Africa 150

P-163 VALIDATION OF THE OVERNIGHT HOLD OF WHOLE BLOOD AT ROOM TEMPERATURE AND THE BUFFY-COAT METHOD FOR THE PRODUCTION OF BLOOD COMPONENTS AT BLOOD CENTER OF PARA (HEMOPA) C. Borges Silva, N. Chaves, A. Estácio, S. Ferreira, L. Maradei Fundação Hemopa, Belém, Brazil Posters Published

Posters Published

P-156 COMPARISON OF THREE TOP AND BOTTOM DISPOSABLES TO PRODUCE LABILE BLOOD PRODUCTS: IMPACT ON QUALITY OF PRODUCTS AND ORGANIZATION OF PRODUCTION PROCESS IN THREE BLOOD BANK PRODUCTION CENTER H. Isola, C. Vignoli, C. Naegelen, J. Chiaroni, P. Morel, J.-P. Cazenave EFS Alsace, Strasbourg, France

Posters Published

P-164 STORAGE OF INTERIM PLATELET UNITS FOR 36 OR 48 HOURS PRIOR TO POOLING G. van Waeg, S. Legoínha, A. Ramoa, S. Maia TerumoBCT, Zaventem, Belgium P-165 EVALUATION OF ARCHIMEDE AUTOMATED SEPARATOR FOR THE PREPARATION OF BLOOD COMPONENTS AT ETS CHARLEROI, BELGIUM A. Volckaert, J. Pineau, H. Goossens Fenwal Europe, Mont-Saint-Guibert, Belgium P-166 USE OF MIRASOL®-TREATED PLATELETS IN THE BLOOD BANK OF NAVARRA, SPAIN L. Ayape BSTN, Pamplona, Spain P-167 SICKLE CELL ANAEMIA IN BLOOD DONORS DETECTED BY LEUCODEPLECTION E. Meireles, E. Abreu, D. Hortelão, T. Melo, F. Guimarães, V. Cunha, M.L. Reis, F. Araújo Centro hospitalar S. João - EPE, Oporto, Portugal P-168 BACTERIAL GROWTH IN PLATELET ADDITIVE SOLUTION FOR USE WITH TRIMA ACCEL S.D. Keil, D.I. Gilmour, J. Rice, L. Rouse, A. Razatos Terumo BCT Biotechnologies, Lakewood, USA P-168a PERFORMANCE EVALUATION OF LEUCOFLEX LCRD and LCRD2 FILTRATION AT 4°C OF UNITS OF RED CELL CONCENTRATES STORED UP TO 48 HOURS AFTER COLLECTION AT 4°C M.B. Seremet, R.K. Christensen, M. Jespersgaard, L. Larsen, A.M. Hoff Andersen, A.L.F. Bilde, K. Varming, T.G. Hvid, H.D. Jepsen, B.K. Petersen, K.M. Homburg, A. Tolf, C. Mathiesen, F. Persson, M. Robiquet, P. Pale Aalborg Regional Centre for Blood Transfusion & Clinical Immunology, Denmark

151

Posters Published

3.2 Blood Components

P-170 REDUCED SINGLE DONOR PLATELET (SDP) DOSING AND ASSOCIATION WITH DECREASED PLATELET REACTIONS W.A. Heaton, F.N. Boctor, R. Galloway-Haskins, N.M. Nikolis, B. Sheahan Hofstra North Shore-LIJ School of Medicine and North Shore-LIJ Health System, Ma, Manhasset, USA P-171 THROMBOLUX DONOR SCREENING FOR EFFECTIVE PLATELET TRANSFUSIONS E. Maurer-Spurej, N.V. Lee, N. Nakane, J. Leung, J. Berkowitz University of British Columbia, Vancouver, Canada P-172 IN VITRO EVALUATION OF THE QUALITY OF RED BLOOD CELLS COLLECTED AND STORED IN SYSTEMS COMPLETELY FREE OF DEHP PLASTICIZED MATERIALS J.W. Lagerberg, R. Vlaar, C.W. Gouwerok, D. de Korte Sanquin Research, Amsterdam, Netherlands P-173 DOUBLE DOSE PLATELETS PRODUCED FROM BC POOLS AND PATHOGEN INACTIVATED USING INTERCEPT PROVIDE ADEQUATE PATIENT SUPPORT WITH LOW ADVERSE EVENTS F. Knutson, H. Löf Uppsala University, Uppsala, Sweden P-174 PERCENTAGE RESIDUAL PLASMA OF PLATELET CONCENTRATES IN ADDITIVE SOLUTION AFFECTS IN VITRO QUALITY P.F. van der Meer, R. Hoenderdaal, J.W. Lagerberg, D. de Korte Sanquin Blood Bank, Amsterdam, Netherlands P-175 LIPID INTERFERENCE IN PLATETET QUALITY TESTING E. Maurer-Spurej, J. Leung University of British Columbia, Vancouver, Canada 152

P-176 IN VITRO EVALUATION OF BUFFY COAT DERIVED PLATELET CONCENTRATES RESUSPENDED IN 70% PAS IV OR SSP+ A. Seltsam, U. Gravemann, T. Volgmann, A. Uyttenhove, R. Philipp, B. Lambrecht, J.-M. Payrat German Red Cross Blood Service NSTOB, Springe, Germany P-177 RED CELL STORAGE WITH E-SOL 5 ADDITIVE SOLUTION IN STORAGE CONTAINERS WITH OR WITHOUT DEHP PLASTICIZER KR Radwanski, S Cope, C Sandford, K Min Fenwal Inc, Lake Zurich, USA

Posters Published

Posters Published

P-169 A MULTICENTRE EFFORT TO STANDARDIZE THE FLOW CYTOMETRIC MEASUREMENT OF PLATELET-ASSOCIATED P-SELECTIN, CD62P D. Devine, E. Levin, K. Serrano Canadian Blood Services, Vancouver, Canada

Posters Published

P-178 EFFECT OF EXTENDED ROOM TEMPERATURE HOLD ON RED CELL CONCENTRATES STORED IN VARIOUS ADDITIVE SOLUTIONS KR Radwanski, M Thill, K Min Fenwal Inc, Lake Zurich, USA P-179 IN VITRO ANALYSIS QUALITY OF FROZEN APHERESIS RBCS STORAGE WITH 10-DAY POST THAW STORAGE IN SAG-M: COMPARISON BASED ON THE INITIAL LEUCODEPLETION J. Tupý, M. Tupá, O. Chrenková, O. Husarcíková, M. Lorencíková, M. Mitura, A. Lacko The Catholic University in Ruzomberok, Ružomberok, Slovakia P-180 RANDOMIZED CROSS-OVER IN VITRO AND IN VIVO EVALUATION OF A PROTOTYPE ANAEROBIC CONDITIONING AND STORAGE SYSTEM VERSUS STANDARD AEROBIC STORAGE L.J. Dumont, Z.M. Szczepiorkowski, A.H. Siegel, L. Herschel, K. Calcagni, S. Waters, T. Yoshida Dartmouth Medical School, Lebanon, USA P-181 PLATELET CRYOPRESERVATION USING TREHALOSE AND PHOSPHATE AS CRYOPRESERVATION SOLUTION Y.J. Guo Fujian Provincial Blood Center, Fuzhou, China P-182 FLOW CYTOMETRIC DETECTION AND CHARACTERIZATION OF PLATELET MICROPARTICLES IN PLATELET CONCENTRATE AT EXPIRY D. Devine, K. Serrano, E. Levin, J. Boudreau Canadian Blood Services, Vancouver, Canada

153

Posters Published

P-192 THE INFLUENCE OF AUTOMATIC VALVE BREAKER, TEMPERATURE, PRESSURE AND TIME OF EXTRACTION ON COMPONENT QUALITY V. Libek, A. Kulic, A. Strugar, I. Simic, N. Rankovic CHC Zemun Belgrade, Belgrade, Serbia

P-184 SERIAL CHANGES IN MORPHOLOGY AND BIOCHEMICAL MARKERS IN PLATELET PREPARATIONS WITH STORAGE A. Jain, N. Marwaha, R.R. Sharma, J. Kaur PGIMER, Chandigarh, India

P-193 THE EVALUATION OF QUALITY OF BLOOD COMPONENTS FROM WHOLE BLOOD HELD OVERNIGHT AT 4 °C OR ROOM TEMPERATURE S. Zhao, S.C. Wang Southwest Hospital, Chongqing, China

P-185 ASSESSMENT OF CELLULAR ACTIVATION MARKERS EXPRESSION AFTER LEUKODEPLETION OF PLATELETS CONCENTRATES Z. Stanojkovic, A. Antic, B. Balint, M. Stanojkovic Faculty of Medicine, University of Nis,Blood Transfusion Institute Nis, Nis, Serbia

P-194 COAGULATION FACTOR XIII ACTIVITY IN STORED FRESH FROZEN PLASMA AND PLASMA OF PACKED RED BLOOD CELL I.B. Suh, T.H. Jung Kangwon National University School of Medicine, Chuncheon, South-Korea

P-186 EFFICACY AND SAFETY OF SOLVENT/DETERGENT-FILTERED (S/D-F) CRYOPRECIPITATE PREPARED BY BLOOD ESTABLISHMENTS: ONE-YEAR FOLLOW-UP T. Burnouf, H.A. Goubran, M. Radosevic, A. El-Ekiaby, M. El-Ekiaby Human Protein Process Sciences, Lille, France College of Oral Medicine, Taipei Medical University, Taipei, Taiwan

P-195 COMPARISON OF TWO FILTERS FOR RED CELL LEUKOREDUCTION G.E. Barco, G.S. Mejia, C. Echeverri, J. Donado, S. Jaramillo Hospital Pablo Tobón Uribe, Medellin, Colombia

P-190 COMPARISON BETWEEN TWO MODELS OF BLOOD BAG SYSTEMS AND TWO GENERATIONS OF SEMI-AUTOMATED EXTRACTORS IN BLOOD PROCESSING F.N. Givisiez, J.G.M. Cioffi, F.V. Basques, A.M. Ferreira, A.M. Ferreira, C.E.S. Ferreira, C.Z.M. Cecilio, E.L. Madeira, R. Omoto, E.G. Pires, F.A.M. Ramos, G.C.R. Rezende, V.A.M.S. Santos Fundacao Hemominas, Belo Horizonte, Brazil P-191 AN EXTERNAL PLATELET EVALUATION SCHEME USING INTERCEPT-TREATED PLATELET CONCENTRATES E. Vasconcelos, F. Pereira, A.C. Figueiredo Lisbon Blood Transfusion Centre, Lisboa, Portugal

Posters Published

Posters Published

P-183 TRIMA ACCEL V6 PRESS THROUGH VERSUS GRAVITY DRAIN RBC LEUKOREDUCTION. HEMOLYSIS IN RBC UNITS STORED 42 DAYS IN SAGM M.J. McAteer, M. McPeck, J. Rice, R. Anderson, D. Ambruso Terumo BCT, Lakewood, Colorado, USA

P-187 CAN THE RANGE OF PH BE A PREDICTIVE VALUE IN THE QUALITY OF PLATELET CONCENTRATES? A. Castrillo Fernández, C. Arcas Otero, M.I. Rodríguez Calvo Centro de Transfusión de Galicia, Santiago de Compostela, Spain

154

Posters Published

P-196 A PROSPECTIVE STUDY TO ACCESS THE EFFECT OF LEUCOCYTE DEPLETED PACKED CELLS TRANSFUSION IN MULTIPLY-TRANSFUSED THALASSEMIA MAJOR PATIENTS R. Jain, P. Jain, J.T. Perkins, V. Harimoorthy, U. Chudgar, N. Choudhury R.D.Gardi Medical College, Ujjain, M.P., India P-197 EFFECT OF GLUCOSE SOLUTIONS ON ERYTHROCYTE MEMBRANE N. Lerda Physics Institute, Rosario, Argentina P-198 MEASUREMENT OF EXACT RESIDUAL WHITE BLOOD CELL (WBC) CONTENTS: DETECTION OF WBC FRAGMENTATION IN LEUKOCYTE-REDUCED RED BLOOD CELLS AND LEUKOCYTEREDUCED RED BLOODS AND LEUKOCYTE-REDUCED PLATELETS Y.J. Hong, K.U. Park, K.S. Han Seoul National University College of Medicine, Seoul, South-Korea

155

Posters Published

3.3 Plasma Products

P-200 COMPARISON OF SOURCE PLASMA QUALITY IN THREE DIFFERENT APHERESIS SET-UPS T. Kiessig, P. Hellstern, K.-P. Krause Haema AG, Dortmund, Germany P-201 EFFICACY, SAFETY AND TOLERABILITY OF A SOLVENT/DETERGENT (S/D) TREATED AND PRION SAFEGUARDED TRANSFUSION PLASMA IN A RANDOMISED, CROSS-OVER, CLINICAL TRIAL IN HEALTHY VOLUNTEERS B. Jilma, F. Kursten, G. Leitner, J. List, M. Horvath, P. Jilma-Stohlawetz Medical University of Vienna, Vienna, Austria

P-208 PREPARATION OF HUMAN COAGULATION FACTOR VII CONCENTRATE FROM FRESH FROZEN PLASMA BY USING QAE-SEPHADEX CHROMATOGRAPHY S. Nasiri High Institute for Research and Education in Transfusion Medicine, Tehran, Iran P-209 HOW IMPORTANT IS THE TIME BETWEEN COLLECTION AND SEPARATION OF WHOLE BLOOD UNITS ON THE QUALITY? M.R. Dell’Aversana, E. Munno, S.I.C. Sagliano, G. De Caprio, R. Tomeo, R. D’Ambrosio, R. Gloria, S. Misso Servizio Trasfusionale ASL Caserta, Aversa, Italy

P-203 QUALITY OF OCTAPLASLG® BASED ON VARIANT PLASMA SOURCES A. Heger, J. Römisch Octapharma PPGmbH, Vienna, Austria

P-210 COLLABORATIVE STUDY FOR THE ESTABLISHMENT OF KOREAN STANDARD FOR BLOOD COAGULATION FACTOR IX CONCENTRATE J.S. Seo, Y.K. Lee, D.H. Ryu, S.J. Ban Korea Food and Drug Administration, Chengwongun, Chungbuk, South-Korea

P-204 PURIFICATION OF HUMAN ∝1-ANTITRYPSIN WITH HIGH SPECIFIC ACTIVITY USING A NEW PROCEDURE X. Zhang, H. Cao, Z. Wang, X. Du, Y. Xie, C. Li Institute of Blood Transfusion, CAMS, Chengdu, China

P-211 STUDY OF CAPILLARY ZONE ELECTROPHORESIS FOR PLASMA PROTEIN MIXTURE ANALYSIS W. Wei, X. Du, X. Zhang, Z. Wang, C. Li, F. Lin, X. Xiao Peking Union Medical College＆Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China

P-205 ISOLATION OF IGA-ENRICHED COMPONENT FROM POOLED HUMAN PLASMA M. Pourmokhtar, K. Mousavi Hosseini, S. Banazadeh High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

P-212 EFFECT OF GEL EQUILIBRATION CONDITIONS ON YIELD OF FOUR COAGULATION FACTORS IN PROTHROMBIN COMPLEX CONCENTRATES PRODUCTION H. Cao, X. Du, S. Ye, Z. Wang, X. Zhang, F. Lin, X. Shi, C. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, China

P-206 UNIVERSAL POOLED PLASMA (UNIPLAS®) DOES NOT INDUCE COMPLEMENT-MEDIATED HEMOLYSIS OF HUMAN RED BLOOD CELLS IN VITRO A. Heger, H. Brandstätter, B. Prager, J. Brainovic, R. Cortes, J. Römisch Octapharma PPGmbH, Vienna, Austria

156

P-207 SIMPLE METHOD FOR PREPARATION OF HUMAN FACTOR VIII CONCENTRATE FROM FRESH FROZEN PLASMA M. Heidari, S. Nasiri, K. Mosavi Hosseini Blood Transfusion Research Center, High Institute for Research and Educattion, Tehran, Iran Posters Published

Posters Published

P-199 LOT RELEASE OF THE MANAGEMENT SYSTEM OF CHINESE BLOOD PRODUCTS SUPPLY 20072011 X.J. Zhang, S. Ye, X. Du, Y. Xie, C. Zhao, C. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

Posters Published

157

Posters Published

P-213 CONSTRUCTION OF HIGH-CAPACITY HUMAN RIBOSOME DISPLAY SINGLE CHAIN FV LIBRARY AND ANALYSIS OF ITS DIVERSITY B. Liu, C.G. Li, F.Z. Lin, X.P. Xiao Xiao Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, China

P-214 EFFICACY AND SAFETY OF SOLVENT/DETERGENT-FILTERED (S/D-F) PLASMA PREPARED BY BLOOD ESTABLISHMENTS: ONE-YEAR FOLLOW-UP T. Burnouf, H.A. Goubran, M. Radosevic, A. El-Ekiaby, M. El-Ekiaby Human Protein Process Sciences, Lille, France College of Oral Medicine, Taipei Medical University, Taipei, Taiwan P-215 RBCS DERIVED FROM DIFFERENT WHOLE BLOOD HOLD CONDITIONS ARE COMPATIBLE WITH THE S-303 TREATMENT SYSTEM A. Erickson, B. Donnelly, M.A. Schott, C. Sherman, M. Palascak, R. Franco, N. Mufti Cerus Corporation, Concord, USA P-216 FRANGIBLE ANCHOR EFFECTOR LINKER COMPOUNDS STRUCTURE OPTIMIZATION FOR PATHOGEN INACTIVATION IN WHOLE BLOOD A. Stassinopoulos, L. Pinkoski, M. Postich, S. Szczepanski, N. Mufti, L. Sawyer Cerus Corporation, Concord, USA P-217 THE MIRASOL® SYSTEM FOR WHOLE BLOOD, AN ALTERNATIVE TO GAMMA-IRRADIATION IN THE PREVENTION OF TA-GVHD? S. Marschner, M. Nevola, J. Tavares, H.L. Reddy, R.P. Goodrich, L.D. Fast CaridianBCT Biotechnologies, Lakewood, USA P-218 IMPACT OF MIRASOL® PRT TREATMENT ON MITOCHONDRIAL DNA IN PLATELETS BY A REALTIME PCR INHIBITION METHOD S. Bakkour, D. Chafets, L. Wen, M.P. Busch, T-H. Lee Blood Systems Research Institute, San Francisco, USA

158

P-219 MIRASOL PATHOGEN REDUCTION TECHNOLOGY (PRT) TREATMENT OF P. YOELII CONTAMINATED PLASMA NEUTRALIZES PARASITE IN A MURINE MODEL FOR MALARIA P. Kiser, S. Keil, S. Marschner, A. Avery Colorado State University, Fort Collins, USA P-220 EFFICIENT INACTIVATION OF DENGUE VIRUS BY MINI-POOL SOLVENT/DETERGENT TREATMENT OF PLASMA AND CRYOPRECIPITATE T. Burnouf, M.L. Chou, L.H. Cheng, H.R. Li, Y.W. Wu, M. El-Ekiaby, K.H. Tsai Human Protein Process Sciences, Lille, France College of Oral Medicine, Taipei Medical University, Taipei, Taiwan

Posters Published

Posters Published

3.4 Pathogen Inactivation

Posters Published

P-221 BACTERIAL CONTAMINATION OF PLATELETS CONCENTRATE: COULD RESVERATROL BE AN ALTERNATIVE TO BACTERIA REDUCTION? C.B. Costa, G. Albertoni, F. Carvalho Oliveira, S.S. Andrade, J. AuBuchom, J.A. Barreto, P.R. Araujo Colsan-Associação Beneficente de Coleta de Sangue, São Paulo, Brazil P-222 INACTIVATION OF PLASMODIUM FALCIPARUM-INFECTED WHOLE BLOOD WITH MIRASOL M. El Chaar, S. Atwal, G.L. Freimanis, S. Keil, B. Dinko, R. Goodrich, C. Sutherland, J.-P. Allain University of Cambridge, Cambridge, United Kingdom P-223 EVALUATION OF PATHOGEN REDUCTION SYSTEMS TO INACTIVATE DENGUE AND CHIKUNGUNYA VIRUSES IN APHERESIS PLATELETS SUSPENDED IN PLASMA S. Lam, L.K. Tan, L.C. Ng, D. Teo Health Sciences Authority, Singapore, Singapore P-224 FVIII AND FIBRINOGEN RECOVERY AFTER THERAFLEX MB-PLASMA PROCCEDURE FOLLOWING PLASMA SOURCE AND TREATMENT TIME A. Rapaille Belgium Red Cross, Suarlée, Belgium P-225 IN VITRO VALIDATION OF THE S-303 TREATMENT SYSTEM A. Erickson, H. Isola, M. Laforet, J.-P. Cazenave, C. Ripaud, N. Mufti Cerus Corporation, Concord, USA

159

Posters Published

P-233 THE GENOTOXICITY STUDY OF YWW007, A NEW PHOTOSENSITIZER DERIVED FROM PHENOTHIAZINE C.H. Yang, Y. Huang, G.H. Bian, H. Yang, J.J. Wang Institute of Blood Transfusion, Chinese Academy of Medical Science, ChengDu, China

P-227 ANNEXIN V BINDING DURING STORAGE OF PLATELET CONCENTRATE FROM BUFFY COAT, AFTER PATHOGEN REDUCTION TREATMENTS A. Castrillo Fernández, C. Arcas Otero, M.I. Rodríguez Calvo Centro de Transfusión de Galicia, Santiago de Compostela, Spain

P-234 VALIDATION OF HIV INACTIVATION CAPACITY OF THE THERAFLEX MB-PLASMA SYSTEM WITH HIGH SENSITIVITY S. Reichenberg, C. Sumian, M. Volmer Maco Pharma International GmbH, Langen, Germany

P-228 QUALITY OF PRION REDUCED AND CONVENTIONAL RED CELLS AFTER TREATMENT WITH THE S-303 SYSTEM FOR PATHOGEN INACTIVATION M. Wiltshire, M.A. Schott, A. Erickson, N. Mufti, R.A. Cardigan NHSBT, Brentwood, United Kingdom

P-235 ROUTINE PRODUCTION AND CLINICAL USE OF MIRASOL®-PLATELETS AND FFP AT THE REGIONAL BTS WARSAW D. Piotrowski, Z. Przybylska-Baluta, M. Leleno, A. Uszynska, M. Cardoso Regional Blood Transfusion Service of Warsaw, Warsaw, Poland

P-229 WHOLE BLOOD PATHOGEN INACTIVATION AND STORAGE USING THE S-303 TREATMENT SYSTEM N. Mufti, A. Erickson, L. Pinkoski, A. North, L. Sawyer, L. Corash Cerus Corporation, Concord, USA

P-236 BACTERIAL GROWTH AND BIOFILM FORMATION IN PLATELET POOLS THAT HAVE BEEN INOCULATED AFTER PATHOGEN INACTIVATION TREATMENT S.M. Ramirez-Arcos, Y. Kou, Q.-L. Yi, T. Stewart Canadian Blood Services, Ottawa, Canada

P-230 MAXIMIZING FVIII ACTIVITY IN PLASMA BEFORE AND DURING INTERCEPT TREATMENT L. Pinkoski Cerus Corporation, Concord, USA

P-237 VIRUS REMOVAL BY VIRAL AGGREGATION WITH LARGER PORE-SIZE NANOFILTER T. Yokoyama, K. Murai, H. Shibata, H. Miura, A. Wakisaka Japanse Red Cross Plasma Fractionation Center, Chitose, Japan

P-231 COMPLETE INACTIVATION OF HIGH BACTERIAL TITER CHALLENGES IS ACHIEVED WITH THE INTERCEPT PI SYSTEM L. Sawyer, R. Dikeman, A. Stassinopoulos Cerus Corporation, Concord, USA

P-238 OUTPUT OF HIGH YIELD PLATELET (PLT) APHERESIS BEFORE AND AFTER PATHOGEN REDUCTION WITH AMOTOSALEN AND UVA: TRIPLE DOSE PLT ARE CHALLENGING, BUT STILL UP-TO-DATE S. Fontana Blood Transfusion Service SRC Berne, Berne, Switzerland

Posters Published

Posters Published

P-226 IN VITRO ANALYSIS OF PROTEINS IN FRESH FROZEN PLASMA OBTAINED FROM WHOLE BLOOD DONATIONS AND PREPARED WITH THREE PHOTOCHEMICAL TREATMENTS L. Luis, J. Rivera, V. Roldán, M. Guinot, M.I. Ortiz de Salazar, A. Caceres, V. Vicente, R. Roig Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain

P-232 WHOLE BLOOD FILTER RZ-2000 EFFICIENTLY LEUKODEPLETES POOLED PLASMA PRIOR TO PATHOGEN INACTIVATION WITH INTERCEPT D. Goslings, A. Valek, B.M. Frey Blood Transfusion Service Zurich, Zurich, Switzerland

160

Posters Published

P-239 STORAGE OF PACKED RED BLOOD CELLS DERIVED FROM WHOLE BLOOD TREATED WITH THE MIRASOL® SYSTEM S.K. Doane, S. Wilkinson, N. Hovenga, L. Rouse, M. Miklauz, H. Reddy, S. Marschner, R.P. Goodrich Terumo BCT Biotechnologies, Lakewood, USA 161

Posters Published

P-240 COMPARISON OF TWO DIFFERENT INACTIVATION METHODS; OUR OWN EXPERIENCE J. Antoniewicz-Papis, E. Lachert, J. Kubis, A. Rosiek, D. Piotrowski, Z. Przybylska, M. Letowska Institute of Hematology and Transfusion Medicine, Warsaw, Poland

P-242 THE OBSERVATION OF THE EFFECT OF METHYLENE BLUE PHOTOCHEMICAL VIRUS INACTIVATION ON THE PLASMA WITH HBV INFECTION IN WINDOW PERIOD BY NUCLEIC ACID TEST B.H. Bi, J. Yu. L. Zhao, G. Shen, X.G. Wang, H.X. Lu Wuhan Blood Center, Wuhan, China P-243 VIRAL REDUCTION OF INTRACELLULAR HIV USING THE MIRASOL® SYSTEM FOR WHOLE BLOOD S. Keil, R. Rapaport, S.K. Doane, R. Young, S. Marschner, T.B. Campbell Terumo BCT Biotechnologies, Lakewood, USA P-244 EVALUATION OF APOPTOSIS MARKER AT THE MEMBRANE SURFACE OF RESIDUAL LYMPHOCYTES IN PHOTOCHEMICALY TREATED PLATELET CONCENTRATES M. Ogorodnikova, T.N. Zabotina, A.A. Borunova, A.D. Onufrievich, E.V. Ogorodnikova, O.A. Rukavitzin N.N. Burdenko Main Military Clinical Hospital, Moscow, Russian Federation

3.5 Biologicals P-245 MICROPARTICLES FROM STORED RED BLOOD CELLS INDUCE THROMBIN GENERATION O. Rubin, N. Lion, A. Angelillo-Scherrer, J.-D. Tissot Service de Transfusion Sanguine, Epalinges, Switzerland

3.6 Novel Blood Products P-246 THE NETHERLANDS EXPERIENCE WITH FROZEN -80°C RED CELLS, PLASMA AND PLATELETS IN COMBAT CASUALTY CARE J.F. Badloe, F. Noorman MIlitary Blood Bank, Leiden, Netherlands

Posters Published

Posters Published

P-241 TRANSFUSION OF PATHOGEN INACTIVATED BLOOD PRODUCTS USING RIBOFLAVIN AND ULTRAVIOLET LIGHT - TWO YEARS OF EXPERIENCE A. Antic, Z. Stanojkovic, B. Balint, M. Jelic Blood Transfusion Institute Nis, Serbia

Posters Published

P-247 BACTERICIDAL ACTIVITY OF PLATELET-POOR-PLASMA, PLATELET-RICH-PLASMA, PLATELET GEL AND SOLVENT/DETERGENT-TREATED PLATELET LYSATE: INTEREST FOR WOUND HEALING T. Burnouf, M.L. Chou, Y.W. Wu, C.Y. Su, L.W. Lee Human Protein Process Sciences, Lille, France College of Oral Medicine, Taipei Medical University, Taipei, Taiwan P-248 CONSTRUCTION OF THE EXPRESSION VECTOR FOR RECOMBINANT HUMAN COAGULATION FACTOR? W. Xiao, F. Li, C. Li, R. Zhao Institute of Blood Transfusion, CAMS, Chengdu, China P-249 THE EFFECT OF PROSTAGLANDINE E1 ON PLATELET AGGREGATION DURING PREPARATION OF LYOPHILIZED HUMAN PLATELET S. Nasiri High Institute for Research and Education in Transfusion Medicine, Tehran, Iran P-250 THE AUSTRALIAN EXPERIENCE WITH DEEP FROZEN BLOOD PRODUCTS L.N. Johnson, S.J. Reid, K.M. Winter, F. Noorman, J.F. Badloe, A. Holley, D.C. Marks Australian Red Cross Blood Service, Alexandria, Australia P-251 PREPARATION OF HEPARIN-MODIFIED PBT NONWOVEN FABRICS AND THEIR APPLICATION AS LEUKOCYTE REMOVAL FILTERS Y. Cao, H. Wang, R. Zhong, J.X. Liu Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China P-252 PROLIFERATION ACTIVITY OF EXPIRED PLATELETS J. Yu, X. Liu, H. Wang, J. Liu Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, China

162

163

Posters Published

Topic 4: Transfusion Transmitted Infections 4.1 Screening strategies for TTI

P-254 PERFORMANCE CHARACTERISTICS OF THE PROCLEIX PARVO/HAV ASSAY ON THE PROCLEIX TIGRIS SYSTEM, A DUPLEX ASSAY FOR QUANTITATIVE DETECTION OF PARVOVIRUS B19 AND QUALITATIVE DETECTION OF HEPATITIS A VIRUS J.M. Linnen, K. Gao, C.T. Nugent, J. Knight, R. Cory, J . Wellbaum, H.T.M. Cuijpers, M.H.G.M. Koppelman, A. Janssen, M. Babizki Gen-Probe Incorporated, San Diego, USA P-255 REINFORCEMENT OF THE TRANSFUSION SAFETY FOR BLOOD-BORNE VIRUSES ON AFRICAN CONTINENT THROUGH A MULTINATIONAL STUDY S. Laperche National Institute of Blood Transfusion, Paris, France P-256 EVALUATION OF A NATIONAL QUALITY CONTROL PROGRAM FOR MALAYSIAN BLOOD SCREENING LABORATORIES W. Dimech, A.H. Bon NRL, Fitzroy, Australia P-257 IMPACT OF INDIVIDUAL DONOR NUCLEIC-ACID AMPLIFICATION TESTING OF BLOOD DONORS IN INTERDICTING THE TRANSMISSION OF TRANSFUSION TRANSMITTED HIV, HEPATITIS B AND HEPATITIS C IN INDIA A. Sen, S. Arora Armed Forces Transfusion Centre, New Delhi, India P-258 INDONESIA INDIVIDUAL DONATION BLOOD SCREENING EXPERIENCE WITH THE IMPROVED SENSITIVITY ULTRIOPLUS® REAGENT ON PROCLEIX® TIGRIS® SYSTEM FOR THE DETECTION OF HIV-1, HCV AND HBV NUCLEIC ACIDS Y.S. Soedarmono, A. Lusinanto Indonesian Red Cross, Jakarta, Indonesia 164

P-259 IMPROVING BLOOD DONOR SCREENING BY NUCLEIC ACID TECHNOLOGY /UAE.EXPERIENCE M. Raouf, A. Amiri, M. Al Mulla, F. Al Khatteri Ministry of Health, Sharjah, United Arab Emirates P-260 VIRAL TRANSMISSION RISK ASSESSMENT ON INDIVIDUAL-DONATION NUCLEIC ACID TESTING IN KUALA LUMPUR, MALAYSIA T.P. Lam National Blood Centre Kuala Lumpur, Kuala Lumpur, Malaysia

Posters Published

Posters Published

P-253 PERFORMANCE CHARACTERISTICS OF THE PROCLEIX ULTRIO ELITE ASSAY ON THE FULLY AUTOMATED PROCLEIX PANTHER INSTRUMENT PLATFORM M.L. Deras, K. Pekny, D. Self, L. Scribner, J.M. Linnen Gen-Probe Incorporated, San Diego, USA

Posters Published

P-262 COMMUTABILITY OF INACTIVATED VIRAL STANDARDS USED FOR EXTERNAL QUALITY CONTROL OF NUCLEIC ACID AMPLIFICATION TESTING OF BLOOD DONATIONS H.A. van Drimmelen, W. Quint, P.N. Lelie Bioqcontrol, Rijswijk, Netherlands P-263 RESULTS OF CONFIRMATORY TESTING OF ARCHITECT SYPHILIS TP REPEATEDLY REACTIVE DONATIONS IN CROATIA IN 2011 M. Lovric, M. Stojic Vidovic, I. Mihaljevic Croatian Institute of Transfusion Medicine, Zagreb, Croatia P-264 NAT POSITIVE DETECTION IN BLOOD DONOR AFTER SIX DAYS RISK SITUATION EXPOSITION C. Baungarten, D. Fitarelli, L. Comerlato, V. Cantarelli Vicente, P. Schafer Brandt Laboratorio Qualita, Novo Hamburgo, Brazil P-265 INITIAL EXPERIENCE OF BLOOD SCREENING USING NUCLEIC ACID TESTING (NAT) IN POOLS OF 6 IN A TERTIARY CARE HOSPITAL, NEW DELHI, INDIA S. Pathak, G. Pandey Max Super Speciality Hospital, New Delhi, India P-266 PERFORMANCE OF NEW DIASORIN LIAISON® XL MUREX HBSAG QUANT IMMUNOASSAY FOR DETECTION OF HBSAG IN HUMAN SERUM AND PLASMA C. Hintze, M. Fiedler, L. Pallavicini, D. Lang, F. Garetto DiaSorin Deutschland GmbH, Dietzenbach, Germany

165

Posters Published

P-267 NAT YIELD IN A UNIVERSITY BLOOD BANK OF BUENOS AIRES J.A. Rey, M. Fernández Toscano, A. Toledano, A. Vellicce, A. Tomeo Hospital de Clínicas - University of Buenos Aires, Buenos Aires, Argentina

P-276 USE OF PROCLEIX ULTRIO NUCLEIC ACID TESTING ASSAY FOR HIV-1 / HCV / HBV SCREENING IN INDIA S. Agarwal Fortis Escorts Heart Institute, New Delhi, India

P-269 OUTCOME OF NAT IMPLEMENTATION IN A REGIONAL BLOOD CENTER IN ARGENTINA M.E. Acevedo, A.J. Alter, L.M. Pavic, N.A.P. Rodriguez Monzon, M.N. Artal, J.L. Blejer, E. Rodriguez, R.J. Fernandez Fundacion Hemocentro Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

P-277 HTLV 1/2 PREVALENCE AMONG IRANIAN BLOOD DONORS, 2009-2011 S. Amini Kafi-Abad, M. Shariati Iranian Blood Transfusion Organization, Research Center, Tehran, Iran

P-270 COMPARISON OF SYPHILIS REJECTION RATE AND DONOR DEFERRAL RATE AFTER THE IMPLEMENTATION OF SYPHILIS TESTING USING TPPA TEST P.H. Shu, S.S. Chua, D. Teo Health Sciences Authority, Singapore, Singapore

P-278 INTEGRAL MEDICAL SERVICES AND SANGUINEOUS SAFETY INSTITUTO MEXICANO DEL SEGURO SOCIAL EXPERIENCE M.L. Gasca-Leyva, G. Benitez-Arvizu, B. Novelo-Garza, J. Galvan-Cervantes, A. Morales-Rojas IMSS, Mexico City, Mexico

P-271 HIV PREVALENCE IN FIRST-TIME AND REPEAT BLOOD DONATIONS IN ZIMBABWE, IMPACT ON BLOOD SAFETY T. Mapako, D.A. Mvere, M.E. Chitiyo, E. Gomo, M.J. Postma, M. van Hulst University of Groningen - Netherlands, Harare, Zimbabwe

P-279 FREQUENCY AND EPIDEMIOLOGICAL PROFILE OF BLOOD DONORS INFECTED BY HTLV-I/II A. Endara, M. Maestri, M. Bellezza, O.W. Torres Hospital Materno-Infantil Ramón Sardá, City of Buenos Aires, Argentina

P-272 EVALUATION OF NAT IMPLEMENTATION IN THE HEMOTHERAPY SERVICE OF INCA/RJ - BRAZIL S.G.C. Da Silva, R.O.J Santos, W.S.V. Sandes, M.M.A.F. Lima, F. Motta Iara de Jesus Instituto Nacional de Câncer, Rio de Janeiro, Brazil P-273 IMPLEMENTATION OF NUCLEIC ACID TECHNOLOGY (NAT) A MULTICENTER RETROSPECTIVE STUDY IN THE INSTITUTO MEXICANO DEL SEGURO SOCIAL FROM 2008 TO 2011 B. Novelo-Garza, G.. Benitez-Arvizu, J. Galvan-Cervantes, A. Morales-Rojas IMSS, Mexico City, Mexico

166

P-274 RESULTS OF NAT IN TERTIARY CARE HOSPITAL IN INDIA AND INTERESTING CASE REPORT OF NAT-YIELD USING PROPOSED ALGORITHM A. Deshpande, A. Pathare, S. Kalgutkar, P. Satawase Hinduja Hospital, Mumbai, India Posters Published

Posters Published

P-268 IMPLEMENTATION OF THE FULLY AUTOMATED, MULTIPLEXED NUCLEIC ACID TESTING (NAT) AT QINGDAO BLOOD CENTRE, CHINA Z. Yang, L. Xu, L. Liu, M. Wang, L. Zhao Qingdao Blood Centre, Qingdao, China

Posters Published

P-280 THE ID-NAT IMPLEMENTATION EXPERIENCE IN THE BLOOD BANK OF MEXICO’S NORTHEASTERN REGION M.-A. Gonzalez-Santos IMSS, Monterrey Nuevo Leon, Mexico P-281 COMPARISON OF HIV, HEPATITIS B, HEPATITIS C AND SYPHILIS SEROPREVALENCE AMONG DONORS BETWEEN HOSPITAL BASED AND COMMUNITY BASED BLOOD CENTER IN YOGYAKARTA INDONESIA T. Triyono, H.M.S. Fauzi, U. Sukorini Sardjito Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia

167

Posters Published

P-291 EPIDEMIOLOGICAL SITUATION IN VERACRUZ, MEXICO ON BLOOD TRANSFUSION TRANSMITTED INFECTIONS AND MOLECULAR DIAGNOSIS APPLICATION P.A. Hernandez Romano, M. Cámara Contreras, E. Bravo Sarmiento, N.A. López Balderas CETS Veracruz, Boca Del Rio Veracruz, Mexico

P-283 CMV INFECTION IN IMMUNOCOMPROMISED AND MULTITRANSFUSED PATIENTS I. Seferi, X. Pal, T. Ervin, Z.H. Abazaj, M. Vila, A. Metka, J. Pengu National Blood Transfusion Centre, Tirana, Albania

P-292 Performance of Triplex Nucleic Acid Testing in Dalian Blood Donors X.L. Deng, Z.J. Yu, W.X. An, X.H. Liang, L. Zang, D. Wang, Y. Yu The Laboratory Department, Dalian Blood Center, Dalian, China

P-285 HIV AND HCV INCIDENCE ESTIMATION IN FIRST TIME BLOOD DONORS H.S. Saber, S.M. Mirrezaie, B. Hagibeigi, A. Abbasian, E. Salekmoghadam, S.M. Alavian, H. Abolghasemi Tehran Blood Transfusion Center, Tehran, Iran P-286 PREVALENCE OF TRANSFUSION TRANSMISSABLE INFECTIONS AMONG BLOOD DONORS IN KATHMANDU, NEPAL C.R. Ojha, A. Mandal, N. Gurung Tribhuvan University Teaching Hospital, Kathmandu, Nepal P-287 PREVALENCE OF HEPATITIS B AND HEPATITIS C VIRUSES IN BLOOD DONORS AT THE CLINICAL HOSPITAL CENTER ‘DR DRAGISA MISOVIC - DEDINJE’ B. Mihic-Tomic CHC Dr. Dragisa Misovic-Dedinje, Belgrade, Serbia P-290 EXPERIENCE WITH THE EVIDENCE OF NUCLEIC ACIDS (NAT) IN BLOOD DONORS FROM THE NATIONAL INSTITUTE OF PEDIATRICS G. Martínez, A. Bravo, D.V. Aguilar, G. Escamilla National Institute of Pediatrics, Mexico, México, Mexico

Posters Published

Posters Published

P-282 TRUE INFECTIOUS STATUS OF BLOOD DONORS WITH ANTI HEPATITIS C (HCV) ENZYME IMMUNE ASSAY (EIA) REACTIVE RESULTS: A PROSPECTIVE STUDY N. Choudhury, S. Tulsiani, J. Shah, R. Shah, A. Mathur, V. Harimurthy Tata Medical Center, Kolkata, India

P-284 TRANSFUSION TRANSMITTED INFECTIONS AMONG BLOOD DONORS OF A TEACHING HOSPITAL IN ISLAMABAD, PAKISTAN U. Waheed, H.A. Zaheer, S. Astori Quaid-i-Azam University, Islamabad, Pakistan

168

Posters Published

4.2 Hepatitis B (HBV) P-293 AN ABORTIVE WILD-TYPE HBV INFECTION IN A BLOOD DONOR APPARENTLY NONRESPONDER TO HBV IMMUNIZATION: ANOTHER CASE OF AN ACUTE PRIMARY OCCULT HBV INFECTION P. Manzini, C. Di Chio, F. Danielle, C. Valpreda, F. Curti, M. Rizzetto, M. Abate AOU S. Giovanni Battista, Torino, Italy P-294 ARE HEPATITIS B VIRUS ESCAPE MUTANTS A RISK TO BLOOD SAFETY O. Larralde, B. Dow, L. Jarvis, F. Davidson, J. Petrik Scottish National Blood Transfusion Service, Edinburgh, United Kingdom P-295 ENHANCEMENT OF HBV NAT YIELD RATE AFTER INTRODUCTION OF THE ULTRIO PLUS ASSAY M. Vermeulen, C. Coleman, N. Lelie, H. van Drimmelen, R. Reddy SANBS, Roodepoort, South Africa P-296 ENHANCED HBV DETECTION IN HONG KONG BLOOD DONORS WITH THE SECOND GENERATION TRIPLEX TRANSCRIPTION MEDIATED AMPLIFICATION ASSAY W.-C. Tsoi, N. Lelie, C.-K. Lin Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China P-297 SPLICED AND UNSPLICED HEPATITIS B VIRUS VARIANTS OF GENOTYPE A-E: IMPLICATIONS FOR BIOLOGY AND QUANTIFICATION OF HBV GENOME M. El Chaar, T. El Jirs, J.-P. Allain University of Cambridge, Cambridge, United Kingdom 169

Posters Published

P-298 A STUDY ON NUCLEIC ACID TESTING BY TMA TECHNOLOGY FOR HBV,HCV AND HIV-1 IN BLOOD SCREENING W.G. Zhu ShenZhen Blood center, ShenZhen, China

P-300 COMPARISON OF PROCLEIX ULTRIO ASSAY AND NESTED-PCR FOR DETECTION OF OCCULT HBV INFECTION S.H. Ou, J.Z. Xie, C.R. Chen Xiamen Blood Service, Xiamen, China P-301 ALGORITHM TO USE HEPATITIS CORE ANTIBODY AND/OR ID-NAT TO ENHANCE THE BLOOD SAFETY IN TERTIARY CARE HOSPITAL HBV FOR SCREENING H. Singh, R. Choudhary, J. Singh Alchemist Institute of Medical Sciences, Gurgaon, India P-302 LOW EFFICACY OF CURRENT NUCLEIC ACID TESTING (NAT) ASSAY FOR THE IDENTIFICATION OF OCCULT HBV INFECTION (OBI) AND CONSEQUENCES FOR SAFETY OF BLOOD SUPPLY IN ITALY M. Spreafico, B. Foglieni, A. Berzuini, L. Raffaele, I. Guarnori, A. Colli, D. Prati Azienda Ospedaliera della Provincia di Lecco, Lecco, Italy P-303 PREVALENCE AND DEMOGRAPHIC DETERMINANTS OF HEPATITIS B VIRUS IN FIRST-TIME U.S. BLOOD DONORS, 2004-2009 E.L. Murphy, J. Lam, Z. Kaidarova, S. Cyrus, M.P. Busch, E.L. Murphy UCSF/BSRI, San Francisco, USA P-304 SURVEILLANCE FOR OCCULT HBV INFECTION AND HBSAG VARIANTS IN BLOOD DONORS S.H. Ou, J.Z. Xie, C.R. Chen Xiamen Blood Service, Xiamen, China

170

P-305 THE PREVALENCE OF HBSAG AND ANTI-HCV IN BLOOD DONORS OF TIRANA I. Seferi, Z.H. Abazaj, M. Vila, A. Metka, J. Pengu, A. Koraqi National Blood Transfusion Centre, Tirana, Albania P-306 INCIDENCE OF HBV INFECTION IN RELATION TO THE AGE IN A BLOOD DONOR POPULATION IN ITALY M. Miceli, I. Iudicone, A. Agresti, M. Palange, S. Berardini, C. Paluzzi, M. Perret, L. Perelli S.Camillo-Forlanini Hospital, Rome, Italy

Posters Published

Posters Published

P-299 PLASMA PROTEOMIC ANALYSIS IN BLOOD DONORS WITH OCCULT HEPATITIS B VIRUS INFECTION L. Li, C.C. Liao, C.T. Chang, M.H. Yang, Y.S. Hung, C.S. Hung, S.J.L. Tsai, K.S. Lin Taipei Blood Center, Taipei, Taiwan

Posters Published

P-307 HBV DNA SCREENING IN HEPATITIS B HIGH-PREVALENCE AREAS CAN FURTHER ENSURE THE SAFETY OF BLOOD TRANSFUSION Y.Z. Xie Shanghai Blood Center, Shanghai, China P-308 PREVALENCE AND INCIDENCE OF HBV AND HCV AT FIVE CHINESE BLOOD CENTERS, 20082010 Y. Huang, N. Guo, F. Yao, X. Bi, W. He, H. Ma, M. Huang, Q. Yu, H. Qiao, D. Wright, J. Wang, P. Ness, H. Shan Chinese Institute of Blood Transfusion, Chengdu, China P-309 FOUR YEARS’ SURVEILLANCE OF OCCULT HEPATITIS B IN GREEK BLOOD DONORS C. Politis, L. Kavallierou, E. Zervou, M. Asariotou, C. Richardson Hellenic Coordinating Haemovigilance Centre (SKAE), Athens, Greece P-310 MOLECULAR CHARACTERIZATION OF OCCULT HEPATITIS B INFECTION IN BLOOD DONORS FROM MEXICO B.M. García-Montalvo, L.P. Ventura-Zapata Instituto Mexicano del Seguro Social, Mérida, Mexico P-311 HBV NAT RESULTS FROM PILOT NUCLEIC ACID TESTING AT A CENTRAL BLOOD BANK IN INDONESIA Y. Soedarmono, M. Octavia, A. Lusinanto Central Blood Transfusion Services, South Jakarta, Indonesia

171

Posters Published

P-320 STUDY ON Pre-C/C GENE MUTATION OF OCCULT HEPATITIS B VIRUS FROM BLOOD DONORS L. Lu Shenzhen Blood Center, Shenzhen 518035, China

P-313 NAT EXPERIENCE FOR HEPATITIS B INFECTION IN AN ARGENTINEAN BLOOD BANK M.C. Remesar, M.C. Latini, C. Fernandez, A. Suris, B. Milanesio, C.I. Echeverria, A.E. Del Pozo Hospital de Pediatria Garrahan, Capital Federal, Argentina

P-321 EVALUATION OF HBV VIREMIA IN HBEAB POSITIVE CHB PATIENTS F.R. Kermani, Z. Sharifi, Z. Paz, F. Ferdosian, M. Zamanian, F. Tavassoli High Institute for Research and education in Transfusion Medicine, Research center of blood transfusion, Tehran, Iran

4.3 Hepatitis C (HCV)

P-315 FREQUENCY OF PRECORE MUTATION IN HBV INFECTED BLOOD DONORS AND PATIENTS Z. Sharifi, M. Mahmoudian-Shooshtari Blood Transfusion Research Center, High Institute for Research and Education in, Tehran, Iran

P-322 PERFORMANCE ASSESSMENT OF A NEW ANTI-HCV ASSAY N. Groleau, M. Cardona, S. Gadelle, V. Prigent, C. Bonchamp, I. Thoumazet, M. Costaille, A. Estampes-Barthélémie, P. Chaumat Bio-Rad, Marnes-La-Coquette, France

P-316 THE DETECTION OF HBV DNA G1896A POINT MUTATION WITH LOCKED NUCLEIC ACID TECHNOLOGY COMBINED WITH MOLECULAR BEACON X. Zheng, J.F. Zeng, B. Yang, W. Zhu, L. Lu ShenZhen Blood Center, ShenZhen, China

P-323 DEVELOPMENT OF A REVERSE-TRANSCRIPTION ISOTHERMAL AMPLIFICATION ASSAY FOR RAPID DETECTION AND GENOTYPING OF HEPATITIS C VIRUS INFECTION IN BLOOD R. Taylor, D.C. Nyan, M. Rios CBER/FDA, Bethesda MD, USA

P-317 IMPROVEMENT BLOOD TESTING STRATEGY OF HBSAG BY USING OF ROC CURVES Z. Li, H.W. Ge Beijing Red Cross Blood Center, Beijing, China

P-324 GENERATION AND CHARACTERIZATION OF MOUSE MONOCLONAL ANTIBODIES RECOGNIZING EPITOPES OF NONSTRUCTURAL PROTEIN 3 IN HCV INFECTED CELLS C. Li, Y. Bian, S. Zhu, S. Zhao, T. Li, Y. Wang, H. Zhu, Y. Zhou, J.-P. Allain Southern Medical University, Guangzhou, China

P-318 IMPACT OF HBV VACCINATION ON PREVALENCE OF HEPATITIS B IN TEHRAN BLOOD DONORS M.S. Mirrezaie, S.M. Alavian, B. Hajibeigi, H.R. Saber, E. Salekmoghadam, A. Abbasian, H. Mehrabadi Tbtc, Tehran, Iran P-319 A NAT-ONLY HBV POSITIVE DONATION: POSSIBLY A BREAKTHROUGH SUBCLINICAL INFECTION IN A HBV VACCINATED BLOOD DONOR J. Gottschalk, A. Glauser, K. Hardegger, B.M. Frey Blood Transfusion Service SRC, Zurich, Schlieren, Switzerland

Posters Published

Posters Published

P-312 DETECTION OF HBSAG IN RECENTLY VACCINATED BLOOD DONORS P. Jovanovic, U. Rahne Potokar, S. Levicnik Stezinar, P. Jovanovic Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia

P-314 A WINDOW-PERIOD HBV NAT DONATION FROM A VACCINATED DONOR J.E. Levi, R.A. D’Almeida Pereira, M.B. Carvalho Polite, S.P. Nunez, J.M. Kutner Hospital Albert Einstein, São Paulo, Brazil

172

Posters Published

P-325 IL - 28B GENETIC VARIATION AND ITS ASSOCIATION WITH SUSCEPTIBILITY TO HEPATITIS C VIRUS OF CHINESE BLOOD DONORS L. Yu, J.X. Wang, M. Xu, L. Gui, L. Ke, H. Ma, S.H. Chen Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China P-326 RELIABLE HCV TESTING WITH A NEW ANTIBODY ASSAY: ENZYGNOST ANTI-HCV 4.0 *) U. Krupka, W. Schmandt, F. Vitzthum Siemens Healthcare Diagnostics Products GmBH, Marburg, Germany 173

Posters Published

P-327 COMPARISON OF TWO COMMERCIAL SCREENING ASSAYS FOR DIAGNOSIS OF HEPATITIS C M. Moghtadaei, S. Amini Kafi-Abad, S. Raman, A. Soleimani, N. Amirhakimi, H. Gholizadeh Iranian Blood Transfusion Organization (IBTO), Tehran, Iran

P-329 EIA HCV AG/AC UTILITIES IN BLOOD DONORS TESTING A.O. Chiera, M.L. Punzi, C. Bonacina, G. Larrañaga, G. Borrajo, E. Lara, N. Etchenique Hemotherapy Insitute of Buenos Aires Province, La Plata, Argentina

4.4 HIV P-330 RISK FACTORS FOR HIV IN BRAZILIAN BLOOD DONORS - A PRELIMINARY ANALYSIS B. Custer, T.T. Goncalez, S. Maia, L. Capuani, R.J. Birch, S. Leao, C. Miranda, A.B. Proietti, B. Johnson, D. Wright, C. de Almeida-Neto, E.L. Murphy Blood Systems Research Institute, San Francisco, USA P-331 INVESTIGATION OF CASES OF SUSPECTED TRANSFUSION TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS REPORTED TO THE AMERICAN RED CROSS K.A. Dorsey, P.L. Page, R. Steele, D.E. Krysztof, G.A. Foster, B.A. Dy, A.F. Eder, R.Y. Dodd, S.L. Stramer American Red Cross, Rockville, USA P-332 A SURVEILLANCE OF HIV-1 DRUG RESISTANCE MUTATIONS AMONG HIV-1 INFECTED VOLUNTARY BLOOD DONORS AND CLINICAL PATIENTS IN CHENGDU, SICHUAN, CHINA P.B. Zeng, W.P. Li, Y. Liu, M. He, Y.H. Yuan, M. Xu, J.X. Wang Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

P-334 SOCIAL PROFILE OF REPEAT REACTIVE DONORS FOR HIV 1/2 MARKERS IN UKRAINE DURING 2008-2010 A.N. Chugriiev, I.N. Ivashchenko Zhitomir Regional Blood Center, Zhitomir, Ukraine P-335 DIAGNOSTIC SENSITIVITY PERFORMANCE OF THE MPD HIV BLOT 2.2 A. Cucchietti, M. Mak, S.H. Wee, H. Wei Ping, C. Chee Poh, D. Chin, S. Er, S.K. Bijon, C.F. Leng DiaSorin S.p.A., Saluggia, Italy

Posters Published

Posters Published

P-328 EVALUATION OF HCV REACTIVE DONORS ACCORDING TO TYPE OF DONOR, GENDER (SEX) & AGE GROUPS AT SHEBIN EL KOM REGIONAL BLOOD TRANSFUSION CENTER (RBTC) (From January 2011 to December 2011) A.R. Maha, S. El Kareh, A. Afaf Shebin El Kom RBTC, Shebin El Kom, Egypt

Posters Published

P-336 RISK BEHAVIOURS OF MSM AND BLOOD SAFETY: DONATING OR TESTING? THE EUROPEAN MSM INTERNET SURVEY (EMIS) IN GREECE C. Politis, P. Damaskos, M. Kloka, M. Asariotou, C. Richardson Hellenic Coordinating Haemovigilance Centre (SKAE), Athens, Greece P-337 RELATION OF THE VIRAL LOAD AND CYTOMETRICS OF FLOW IN SEROPOSITIVE PATIENTS OF THE PAEDIATRICS NATIONAL INSTITUTE OF MEXICO P. Sanchez Sanchez, A.G. Bravo Lindoro, D.V. Aguilar Escobar, G. Escamilla Guerrero Instituto Nacional de Pediatria, Mexico D.F., Mexico P-338 PREVALENCE OF HIV INFECTION AMONG PATIENT ATTENDING DELTA STATE UNIVERSITY TEACHING HOSPITAL, OGHARA DURING THE PERIOD OF JANUARY 2011 TO APRIL 2011 I. Olajide, A.M. Oyovwevotu, M.E. Borke, M.U. Nwagu DELSUTH, Oghara, Nigeria P-339 THE LACK OF THE „BLOOD DONOR CANDIDATE” STATUS AND ITS INFLUENCE ON THE DETECTIONS OF THE HIV INFECTIONS IN THE REGIONAL BLOOD DONOR CENTRE IN POZNAŃ A. Łaba, M. Krug-Janiak, K. Piersiala, K. Olbromski, H. Skalisz Blood Center Poznan, Poznan, Poland P-340 PRELEVANCE OF HIV INFECTION IN OUR BLOOD DONOR POPULATION J. Vitlarova, M. Shorova, V. Dejanova, A. Petrusheva, M. Jovanova, N. Vitlarov ITM Skopje, Stip, Macedonia

P-333 EVALUATION OF GEENIUS HIV 1/2 CONFIRMATORY ASSAY M. Ferret, F. Minard, S. Gadelle, P. Chaumat, M. Cardona Bio-Rad, Marnes La Coquette, France 174

175

Posters Published

4.5 Bacteria

P-342 DETECTION OF ASYMPTOMATIC ESCHERICHIA COLI BACTEREMIA IN A BLOOD DONOR BY BACT/ALERT: A CASE REPORT STUDY T.L. Titze, F. Ezligini, N.O. Hermansen, F. El-Hage, T.O. Myhre, J. Kjeldsen-Kragh Oslo University Hospital, Oslo, Norway P-343 RAPID DETECTION OF BACTERIAL CONTAMINATION OF PLATELET-RICH PLASMA-DERIVED PLATELET CONCENTRATES USING FLOW CYTOMETRY K.U. Park, H.R. Lee, J.-W. Seo, K.S. Han Seoul National Univ. Bundang Hospital, Seongnamsi, South-Korea P-344 ROUTINE BACTERIAL SCREENING IN PLATELETS WITH A GENERIC 16S DNA NAT SYSTEM ON ZELOS X100 PLATFORM AND BACTIFLOW (AES, CHEMUNEX) B. Ruester, W. Sireis, U. Mayr-Wohlfart, U.M. Liebscher, M.K. Hourfar, G. Capalbo, H. Schrezenmeier, T. Tonn, E. Seifried, M. Schmidt German Red Cross, Institute Frankfurt, Frankfurt, Germany P-345 MICROBIAL CONTAMINATION OF PERIPHERAL BLOOD PROGENITOR CELL PRODUCTS: A CHINESE BLOOD CENTER’S INVESTIGATION L. Zhu, Z. Meng, B. Ni, Y. Wang, H. Lv Blood Center of Zhejiang Province, Hangzhou, China P-346 ARE THERE RECOGNIZED BENEFIT FROM PAIRED SYPHILIS ANTIBODY PLUS CONFIRMATORY TESTING OF BLOOD DONORS? D. Vucetic, B. Balint, M. Todorovic, E. Ristanovic, V. Protic-Djokic, M. Ljubenov, D. Jovicic Institute of Transfusiology and Hemobiology of MMA, Belgrade, Serbia P-347 STREPTOCOCCUS SANGUINIS-INDUCED CYTOKINE RELEASE FROM PLATELETS O. Garraud, A. McNicol, A. Agpalza, E.C. Jackson, H. Hamzeh-Cognasse, O. Garraud, F. Cognasse EFS Auvergne-Loire, Saint-Etienne, France 176

P-348 PROSPECTIVE EVALUATION OF 2% (W/V) ALCOHOLIC CHLORHEXIDINE GLUCONATE AS AN ANTISEPTIC AGENT FOR BLOOD DONOR ARM PREPARATION N. Mehta, S. Shah, S. Jadhav, R. Patil Kokilaben Dhirubhai Ambani Hospital & Medical Research Center, Mumbai, India P-349 MICROBIOLOGICAL ENVIRONMENTAL MONITORING IN BLOOD COMPONENTS PRODUCTION DEPARTMENT AND BLOOD COLLECTION DEPARTMENT I. Batarilo, M. Strauss Patko, C. Maglov, I. Jukic Croatian Institute of Transfusion Medicine, Zagreb, Croatia

Posters Published

Posters Published

P-341 THE FIRST YEAR OF BACTERIAL SCREENING OF PLATELET COMPONENTS - THE ENGLISH EXPERIENCE P. McDonald, J. Ball, J. Allen, S. Robbins, I. Reeves, B. Hirst, L. Byrne, S. Lattimore, S. Brailsford NHS Blood and Transplant, London, United Kingdom

Posters Published

P-350 BRUCELLOSIS SURVEY IN FIVE MOST PREVALENT REGIONS ON IRANIAN BLOOD DONORS M.A. Zadsar, Shirzadi, Zeinali, Maghoudlou, Shariati, Hajibeigi IBTO Research Center, Tehran, Iran P-351 ENVIRONMENTAL SURVEILLANCE IN BLOOD BANK: VALUABLE TOOL FOR MONITORING RISK OF MICROBIAL CONTAMINATION OF BLOOD COMPONENTS M. Patel, R. Sawant, R. Chavda Rajkot Voluntary Blood Bank and Research Centre, Rajkot, India P-352 BACTERIAL CONTAMINATION M.R. Rivera IMSS, México City, Mexico

4.6 Parasites P-353 COST-EFFECTIVENESS OF SCREENING BLOOD DONORS FOR CHRONIC Q FEVER IN THE NETHERLANDS M.P. Janssen, H.L. Zaaijer, B.M. Hogema, C.L. van der Poel University Medical Center Utrecht, Utrecht, Netherlands P-354 TRYPANOSOMA CRUZI ANTIBODY SCREENING IN U.S. BLOOD DONORS: FOUR-YEAR EXPERIENCE AND CHARACTERIZATION OF ANTIBODY REACTIVE DONORS W.R. Steele, R.L. Townsend, B.A. Lenes, D. Krysztof, J.P. Brodsky, R.Y. Dodd, S.L. Stramer American Red Cross, Holland Laboratory, Rockville, USA 177

Posters Published

P-355 REFERENCE VALUES FOR LEISHMANIA INFANTUM PARASITEMIA IN ASYMPTOMATIC INFECTED BLOOD DONORS AND LEISHMANIASIS PATIENTS FROM AN ENDEMIC REGION R. Fisa, C. Riera, E. Girona-Llobera, L. Iniesta, M. Sedeño, C. Guillen, A. Pujol, A. Saura, M. Tomas-Perez, T. Jimenez-Marco Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain

P-357 TRYPANOSOMA CRUZI INFECTION IN NORTH AMERICA AND SPAIN: ESTIMATING THE RISK OF TRANSFUSION TRANSMISSION R.J. Benjamin, S.L. Stramer, D.A. Leiby, R.Y. Dodd, M. Fearon, E. Castro American Red Cross, Rockville, USA P-358 CYTOKINE PROFILE IN ASYMPTOMATIC LEISHMANIA INFANTUM INFECTION IN BLOOD DONORS L. Iniesta, T. Jimenez-Marco, R. Fisa, E. Girona-Llobera, C. Guillen, A. Pujol, M. Tomas-Perez, A. Saura, M. Sedeño, C. Riera Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain P-359 SEROLOGICAL SCREENING FOR CHAGAS DISEASE IN SWISS BLOOD DONORS C. Tinguely, G. Canellini, S. Waldvogel, S. Fontana, C. Niederhauser Blood Transfusion Service SRC Berne, Berne, Switzerland P-360 T. CRUZI REMOVAL FILTER DEVELOPMENT FOR WHOLE BLOOD S. Inoue, S. Ide, M. Miura, K. Yajima, F. Tatsuya, S. Miura Asahi Kasei Medical Co., Ltd., Oita City, Japan

P-362 SEROPREVALENCE OF TRYPANOSOMA CRUZI ANTIBODIES IN BLOOD DONORS IN CENTRAL BLOOD BANK OF CENTRO MÉDICO NACIONAL LA RAZA, MÉXICO CITY R.C. Gutiérrez Hernández, L. Vásquez del Ángel, L. Vera Ramírez, J.A. Pérez López Central Blood Bank CMN La Raza Mexico City, Mexico P-363 CHAGAS DISEASE IN MEXICAN BLOOD DONORS J. Rojo, A. Arroyo National Center of Blood Transfusion, Ministry of Health, Mexico

Posters Published

Posters Published

P-356 TEN-YEAR INCIDENCE OF CHAGAS CARDIOMYOPATHY AMONG ASYMPTOMATIC T. CRUZI SEROPOSITIVE, FORMER BLOOD DONORS E.L. Murphy, E. Sabino, A. Ribeiro, V. Salemi, A. Antunes, M. Menezes, B. Ianni, L. Nastari, F. Fernandez, G. Patavino, V. Sachdev, L. Capuani, C. De Almeida Neto, C. Di Lorenzo Oliveira, D. Carrick, D. Wright, B. Custer, M.P. Busch, E.L. Murphy UCSF/BSRI, San Francisco, USA

Posters Published

P-364 EVALUATION AND UTILITY OF MALARIA ANITBODY AND MALARIA ANTIGEN KITS IN BLOOD DONORS A. Al-Malki, F. Anwar, Z. Merenkov, A. Almarwani, F. Sawali, S. Abouhasera, B. Elkahlout, E. Abdul Hamad Medical Corporation, Doha, Qatar

4.7 N ewly Emerging Pathogens and other Transfusion Related Pathogens P-365 EVALUATION OF LEUCODEPLETION AND PRION REDUCTION FILTERS FOR ENDOGENOUS INFECTIVITY REMOVAL FROM BLOOD PRODUCT IN A SHEEP SCRAPIE EXPERIMENTAL MODEL D. Bougard, J. Coste, R. Tardivel, D. Dernis, C. Lacroux, O. Andréoletti Etablissement Français du Sang - Pyrénées Méditerranée, Montpellier, France P-366 CORRELATION BETWEEN THE LEVELS OF WNV VIRAL LOAD, MODULATION OF CYTOKINES/ CHEMOKINES AND CLINICAL DISEASE IN WNV+ BLOOD DONORS M.C. Lanteri, Z. Kaidarova, J. Heitman, S. Keating, L. Montalvo, T.H. Lee, P.J. Norris, M.P. Busch Blood Systems Research Institute, San Francisco, USA P-367 SEROLOGIC AND MOLECULAR EVIDENCE OF A PLAUSIBLE TRANSMISSION OF HEPATITIS E VIRUS (HEV) THROUGH POOLED PLASMA A. Andonov, G. Rock, L. Lin, J. Borlang, J. Hooper, E. Grudeski, J. Wu Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Canada

P-361 MOLECULAR CHARACTERIZATION OF ENZYMES INVOLVED IN OXIDATIVE STRESS ON CHAGAS DISEASE M. D’Arrigo, G. Gerrard, S. Lioi, C. Zumoffen, J. Beloscar Facultad de Ciencias Bioquimicas Universidad Nacional de Rosario, ROSARIO, Argentina 178

179

Posters Published

P-375 DYNAMICS IN EVOLUTION OF WEST NILE VIRUS FROM HUMAN INFECTIONS IN THE US AFTER 2006 G. Añez, A. Grinev, V. Winkelman, S.L. Stramer, M. Rios US Food and Drug Administration, Bethesda, USA

P-369 COMPARING THE YIELD OF DENGUE VIREMIC BLOOD DONATIONS USING NS1 ANTIGEN (AG) AND NUCLEIC ACID TESTING (NAT) L. Stramer, M. Carrick, J. Linnen, L. Muñoz-Jordán, E. Hunsperger, G.A. Foster, C. Boucher, D. Miller, S. Dickson, C. Lanteri, C. Bentsen American Red Cross/Scientific Support Office, Gaithersburg, USA

P-376 IMPLEMENTATION OF WEST NILE VIRUS NAT SCREENING IN GREEK BLOOD DONORS A. Varaklioti, A. Papachronis, A. Kapsalis, Ch. Gouloumis, Th. Pirpiri, P. Korakianitis, G. Sakellarakis, P. Kotsi, O. Katsarou Blood Center, Laiko General Hospital, Greece, Athens, Greece

P-371 ESTIMATING THE TRANSFUSION TRANSMISSION RISKS OF Q FEVER IN THE NETHERLANDS W. Oei, M.E.E. Kretzschmar, H.L. Zaaijer, C.L. van der Poel, R. Coutinho, M.P. Janssen UMC Utrecht, Utrecht, Netherlands P-372 INACTIVATION OF VARIOUS BACTERIA, VIRUSES AND PARASITES IN RED BLOOD CELLS BY TREATMENT WITH S-303 L. Sawyer, D. Hanson, D. Arnold, T. Diaz, R. Ord, C. Lobo, K. Dupuis, N. Mufti Cerus Corporation, Concord, USA P-373 EMERGING INFECTIOUS DISEASE RISKS FOR TRANSFUSION PRACTICE: A MODELING APPROACH W. Oei, M.P. Janssen, C.L. van der Poel, S. Rehmet, J. van der Steenbergen, M.E.E. Kretzschmar UMC Utrecht, Utrecht, Netherlands P-374 PHYLOGENETIC AND TIME-SCALE ANALYSIS OF DENGUE VIRUS TYPES 1 AND 4 CIRCULATING IN BLOOD DONORS FROM PUERTO RICO AND KEY WEST, FLORIDA, DURING 2010 EPIDEMICS G. Añez, D.A.R. Heisey, L.M. Espina, S.L. Stramer, M. Rios US Food and Drug Administration, Bethesda, USA

Posters Published

Posters Published

P-368 AN EVIDENCE-BASED EVALUATION OF THE RISK POSED BY ROSS RIVER VIRUS TO THE SAFETY OF THE AUSTRALIAN BLOOD SUPPLY H. Faddy, M. Dunford, C. Seed, R. Flower Australian Red Cross Blood Service, Brisbane, Australia

P-370 ARE AUSTRALIAN BLOOD DONORS EXPOSED TO DENGUE VIRUS DURING LOCAL OUTBREAKS? H. Faddy, J. Fryk, C. Hyland, J. McBride, S. Ritchie, R. Flower Australian Red Cross Blood Service, Brisbane, Australia

180

Posters Published

P-377 P-CAPT PRION REMOVAL FILTER DELAYS ONSET OF ATYPICAL NEUROLOGICAL DISEASE OBSERVED IN PRIMATES EXPOSED TO V-CJD INFECTED RED BLOOD CELL CONCENTRATES C.C. Sumian, N. Lescoutra-Etchegaray, A. Culeux, N. Jaffre, J.P. Deslys, E. Comoy Macopharma, Tourcoing, France P-378 PHOTOCHEMICAL INACTIVATION OF USUTU VIRUS USING THE MIRASOL PATHOGEN REDUCTION TECHNOLOGY (PRT) SYSTEM FOR PLATELETS G. Rossini, S. Silenzi, M. Govoni, V. Randi, A.M. Pierro, P. Gaibani, F. Cavrini, M.P. Landini, V. Sambri Orsola University Hospital, University of Bologna, Bologna, Italy P-379 PILOT STUDY OF HEPATITIS E VIRUS DETECTION IN BLOOD DONORS WITH A MULTIPLEX MINI POOL NAT ASSAY ON ZELOS X100 PLATFORM M.K. Hourfar, G. Capalbo, W. Sireis, E. Seifried, M. Schmidt German Red Cross, Institute Frankfurt, Frankfurt, Germany P-380 WEST NILE VIRUS IN SPAIN. YEARS 2010 AND 2011 A. Salat Marti Centro Regional de Transfusión Sanguínea de Cádiz, Jerez de la Frontera, Spain P-381 DEVELOPMENT OF P-CAPT FILTER FOR REDUCTION OF PRION INFECTIVITY AND VCJD TRANSMISSION OF RED BLOOD CELL CONCENTRATES C.C. Sumian, P.V. Gurgel, I. Walicka, N. Lescoutra-Etchegaray, L. Gregori, R.G. Carbonell, R. Rohwer, S. Burton Macopharma, Tourcoing, France 181

Posters Published

P-382 DETERMINATION OF IGG/ IGM ANTI DENGUE VIRUS ANTIBODIES IN BLOOD BLANKS OF 2 DIFFERENT GEOGRAPHIC AEREAS OF ARGENTINA , THE CITY OF BUENOS AIRES VS THE CITY OF SANTO TOME , CORRIENTES A. Arcuri, J. Salim, C. Krakowiesky, M.I. Rocculi, A. Zerdiew, S. Rosell Hospital E .Tornu, Buenos Aires, Argentina

P-384 THE SEROPREVALENCE OF IGG ANTI-HAV ANTIBODIES AMONG SLOVENIAN BLOOD DONORS P. Jovanovic, S. Levicnik Stezinar Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia P-385 BLOOD DONATIONS FROM POLAND AND GERMANY WERE NEGATIVE FOR XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS (XMRV) M.K. Hourfar, E. Brojer, P. Zwolinska, P. Swanson, X. Qiu, J. Hackett, W. Sireis, E. Seifried, M. Schmidt German Red Cross, Institute Frankfurt, Frankfurt, Germany

182

Topic 5: Immune Haematology 5.1 Red Cell Immunology: Serology P-389 DEVELOPMENT OF NOVEL MONOCLONAL ANTIBODIES TO MOUSE RED CELLS FOR STUDYING EARLY ERYTHROPOIESIS IN MOUSE MODELS G. Halverson, X. An, J. Liu New York Blood Center, New York, USA

Posters Published

Posters Published

P-383 POST-TRANSFUSION TRANSMISSION OF HEPATITIS A VIRUS (HAV) S.G.C. Da Silva, L. Amado, V. De Paula, S.M. Brito, J.M. Oliveira, M.A. Pinto, L.A.P. Ferreira, M.M.A.F. Lima, F. Motta Iara de Jesus Instituto Nacional de Câncer, Rio de Janeiro, Brazil

Posters Published

P-390 LOW-GRADE INFLAMMATION AND HAEMOGLOBIN LEVELS IN DANISH BLOOD DONORS S.R. Kotzé, O.B.V. Pedersen, M.S. Petersen, K. Grau, E. Soerensen, H. Ullum, C. Erikstrup Aarhus University Hospital, Aarhus N, Denmark P-391 IMPROVING SKILL IN SEROLOGIC REACTION GRADING WITH A+B KODECYTES S.M. Henry, H. Perry AUT University, Auckland, New Zealand P-392 NOVEL APPLICATION OF GOLD NANOPARTICLES FOR ANTIBODY SCREENING TEST P. Ammaranond, N. Choktaweesak, P. Krasathong, P. Deesin Chulalongkorn University, Bangkok, Thailand

P-386 DENGUE NS1 ANTIGEN DETECTION AMONG SELECTED BLOOD DONORS IN A DENGUEENDEMIC PROVINCE IN NORTHERN PHILIPPINES A. Fellizar Mariano Marcos Memorial Hospital and Medical Center, City of Batac, Ilocos Norte, Philippines

P-393 C3B DEPOSITION ON HUMAN ERYTHROCYTES OF DIFFERENT AGES M.A. Ensick, G. Fiorenza, A. Rucci, C. Biondi, L. Racca, A. Racca Facultad de Ciencias Bioquímicas y Farmacéuticas.Universidad Nacional de Rosario, Rosario, Argentina

P-387 EVALUATION OF DENGUE VIRUS INFECTION FREQUENCY IN VOLUNTARY DONORS IN SISTAN AND BALUCHESTAN PROVINCE A. Aghaie, J. Aaskov, S. Chinikar, M. Niedrig, S. Banazadeh, S. Hashemi, H. Khorsand Mohammadpour High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

P-394 PHYLOGENESIS OF AFRICAN RHD CLUSTERS: IDENTIFICATION OF RELATED VARIANTS AND ANTI-D IMMUNIZATION IN ITALY A. Matteocci, A. Moscetti, C. Spaccino, R. Borgogno, G. De Rosa, D. Inverardi, D. Londero, M. Pasin, M. Pavan, C. Vio, M. Waldner S.Camillo Hospital, Rome, Italy

P-388 THE EFFECT OF PATHOGEN REDUCTION TECHNOLOGY (MIRASOL) ON THE INFECTIVITY OF DENUGE VIRUSES H. Faddy, J. Fryk, P. Young, D. Watterson, R. Goodrich, D. Marks Australian Red Cross Blood Service, Brisbane, Australia

P-395 CHALLENGES FACED BY A TRANSFUSION SERVICE IN A DEVELOPING COUNTRY TO MEET THE NEEDS OF RARE BLOOD TYPES: THE IMPORTANCE OF MAINTAINING A RARE DONOR PANEL C.N. Olsen, V. Reddy SANBS, Kwa-Zulu Natal, South Africa 183

Posters Published

P-403 PREVALENCE OF RED CELL ALLOANTIBODIES IN PATIENTS OF TERTIARY CARE HOSPITAL IN NORTH INDIA OVER A PERIOD OF THREE YEARS R.N. Makroo, A. Bhatia, U.K. Thakur Indraprastha Apollo Hospitals, New Delhi, India

P-397 BIOPATH EXPERIENCE WITH IH-1000: INTEGRATION SOLUTIONS & PERFORMANCE CHARACTERISTICS IN A LARGE LABORATORY TESTING CENTER C. Faucher, A. Beauchamp-Nicoud, G. Jeanne, M. Berdah, F. Hayoun, J. Jonte Biopath, Bry/Marne, France

P-404 FREQUENCY OF APPEARANCE OF LOW EXPRESSION RHD AND SUBGROUPS WITHIN THE AB0 SYSTEM E. Klausa, A. Duszynska, K. Pawlus, A. Smolarczyk, R. Kozlowski Regional Centre of Transfusion Medicine and Blood Bank, Wroclaw, Poland

P-398 THE CURIOUS CASE OF THE MISSING S ANTIGEN G. Halverson New York Blood Center, New York, USA

P-405 ALLOANTIBODIES IN PATIENTS …… EXPERIENCE OF DETECTING AND PROVIDING COMPATIBLE ANTIGEN NEGATIVE RED CELL UNITS IN A TERTIARY CARE CENTRE IN INDIA A. Deshpande, S. Kalgutkar, S. Shah Hinduja Hospital, Mumbai, India

P-400 RESULTS OF RHD TYPING IN A WEAK D RECIPIENT. ANALYSIS OF NATIONAL EXTERNAL QUALITY ASSESSMENT PROGRAM EXERCISE H. Lopienska, B. Michalewska, M. Michalik, W. Zablocki, B. Wojciechowska, J. Bednarz, M. Pelc-Klopotowska, E. Brojer Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Posters Published

Posters Published

P-396 RED BLOOD CELLS PRESERVATION FOR HEMAGGLUTINATION ASSAYS BY THE DROPLET FREEZING WITH POLYVINYLPYRROLIDONE C. Través Polo, C. Astasio, A. Salazar, N. Núria, E. Muñiz-Diaz, D. Martorell Diagnostic Grifols, S.A., Parets del Vallès, Spain

P-399 SOLUBLE AND CELLULAR ABH ANTIGENS IN SEMEN. ALTERNATIVE TOOLS TO STUDY HUMAN INFERTILITY A.S. Brufman, M.M.E. García Rosasco, N.S. Castro, M. Torrez National University of Rosario, Rosario, Argentina

184

Posters Published

P-406 MILD HAEMOLYTIC DISEASE OF FETUS AND NEWBORN DUE TO ANTI-GE3 Z. Hundric Haspl, N. Jurakovic-Loncar, S. Jagnjic, Z. Kruhonja Galic, M. Tomicic, M. Balija, I. Jukic, J. Poole Croatian Institute of Transfusion Medicine, Zagreb, Croatia P-407 FIRST REPORT OF RH NULL FROM INDIA K. Vasantha, S.A. Jadhav, S. Kulkarni, K. Ghosh National Institute of Immunohaematology, Mumbai, India

P-401 DEL RBC TRANSFUSION SHOULD BE AVOIDED IN PARTICULAR BLOOD RECIPIENTS IN EAST ASIAN AS ALLOSENSITIZATION AND INEFFECTIVE TREATMENT S. Chao-Peng, B.C. Yang, H. Xu Shenzhen Blood Center, Shenzhen, China

P-408 IRREGULAR ANTIBODIES SCREENING VALIDATION ON QWALYS 3® EQUIPMENT WITH THE MAGNETIC ERYTHROCYTE TECHNOLOGY L.C. Cayres Schmidt, D. Martinez, P. Loiacono, F. Valadares Basques, A. Delanoe, G. Abib, A.S. Degryse Hemominas, Minas Gerais, Brazil

P-402 ABO GROUP SUSCEPTIBILITY TO MALARIA: INFLUENCE OF ABO GROUPS IN SEVERE MALARIA S.C. Gupte Surat Raktadan Kendra and Research Centre, Surat, India

P-410 RESEARCH ON DISTRIBUTION OF BLOOD TYPES IN THE TERRITORY OF TAJIKISTAN B. Bakhovadinov, A.B. Satorov, A.B. Hojiev Republican Scientific Center of Blood, Dushanbe, Tajikistan

185

Posters Published

P-418 EVALUATION OF IH-1000 ON AUTOMATED ABO-RH TYPING AND IRREGULAR ANTIBODY SCREENING S.H. Koo, J. Lim, J.M. Kim, K.C. Kwon Chungnam National University Hospital, Daejeon, South-Korea

P-412 AN AUTOMATED ANTIBODY IDENTIFICATION VALIDATION EXPERIENCE AT EXEMPLA GOOD SAMARITAN MEDICAL CENTER K.S. Evans, C. Lucke Exempla Good Samaritan Medical Center, Lafayette, Colorado, USA

P-419 IMPROVED ABO/RH(D) TYPING IN JAPANESE POPULATION USING GRIFOLS DG GEL® SYSTEM A. Kokubunji, R. Murata, N. Fujita, R. Irie, J. Ikemoto, K. Maeda, K. Matsushita, T. Koritani, Y. Fujimori, S. Kai Hyogo College of Medicine, Nishinomiya/Hyogo, Japan

P-413 DISTRIBUTION PATTERN OF IRREGULAR RED CELL ALLOANTIBODIES IN PATIENT WITH THALASSEMIA MAJOR IN NORTHERN IRAN A. Davoudi-Kiakalayeh, G. Toogeh, Z. Seyeri Guilan Blood Transfusion Center,Rasht,Iran, Rasht, Iran

P-420 EVALUATION OF THE NEW IMMUNOHEMATOLOGICAL FULLY-AUTOMATED ERYTRAⓇ SYSTEM: PRELIMINARY RESULTS H. Schoenfeld, S. Spenke, M. Korb, K.J. Pretzel, A. Pruss Institute of Transfusion Medicine, Berlin, Germany

P-414 CASE REPORT: ALLOIMMUNIZATION ANTI-PP1PK IN PREGNANCY E. Erba, S. Scognamiglio, F. Rocca, N. Revelli, A. Manazza, G.R. Cormaci, M.A. Villa, M. Marini, M. Marconi Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

P-421 ANTI-HLA-B7 REACTIVE IN COLUMN AGGLUTINATION AND ELUTED AFTER ABSORBTION FROM RBCS M. Pisacka, H.T. Bolckova, E. Matejkova, M. Kralova, M. Sklenarova Institute of Haematology and Blood Transfusion, Prague 2, Czech Republic

P-415 DETERMINATION OF THE CLINICAL SIGNIFICANCE OF M, N AND LEWIS BLOOD GROUP SYSTEM ANTIERYTHROCYTE ANTIBODIES SPECIFICITIES N. Mladenovic Blood Transfusion Institute of Serbia, Belgrade, Serbia

P-422 PERFORMANCE OF THE AUTOMATED IMMUNOHEMATOLOGY ANALYZER WITH GLASS BEADS COLUMN AGGLUTINATION TECHNOLOGY J. Arroyo, S. Guerrero, J. Rojo Centro Nacional de Transfusion Sanguinea, Mexico, Mexico

P-416 EVALUATION OF NEW RAPID MNSS TYPING BY FULLY AUTOMATED SYSTEM NEO IMMUCORⓇ R. Conradi, D. Marandiuc, D. Kreutzmann, W.E. Hitzler Universitaetsmedizin Mainz, Mainz, Germany

P-423 MOLECULAR AND SEROLOGIC CHARACTERIZATION OF ABO DISCREPANCIES IN KOREAN POPULATION J.N. Lee, M.-Y. Lee, J.Y. Lee, S.H. Oh, K.R. Jun, J.H. Shin, H.R. Kim, S.H. Lee Inje University College of Medicine, Busan, South-Korea

Posters Published

Posters Published

P-411 A COMPARATIVE ANALYSIS OF EFFECTS OF DIFFERENT REAGENT RED CELLS IN REVERSE ABO GROUPING Z.L Zhao Wuhan Blood Center, Wuhan, China

P-417 COMPARATIVE TESTING FOR WEAK AND PARTIAL EXPRESSION OF D ANTIGEN: DIAGAST E.M.® TECHNOLOGY VS ORTHO BIOVUE™ SYSTEM AND IMMUCOR GAMMA CAPTURE-R® SELECT TECHNOLOGY C. Nöcker, G. Hafner ZLM GmbH, Essen, Germany

186

Posters Published

P-424 AN EXAMPLE OF PREFERENTIAL BINDING OF ANTI FY5 TO RH-LITTLE-E POSITIVE CELLS M. de Haas, P.C. Ligthart, H. de Waard, W. Vleeming, A. van den Bos, E.C.M. van Pampus, C.C. Folman Sanquin Blood Supply, Amsterdam, Netherlands

187

Posters Published

P-425 VALIDATION OF NEO AUTOMATED IMMUNOHEMATOLOGY ANALYZER D. Neurath, M. Pilon, A. Giulivi The Ottawa Hospital, Ottawa, Canada

P-427 EVALUATION OF THE AUTOMATED QWALYS 3 SYSTEM FOR ABO/D GROUPING AND UNEXPECTED ANTIBODY SCREENING J. Kim, Y.H. Ko, K. Kwon, J.S. Lim Chungnam National University Hospital, Daejeon, South-Korea P-429 FREQUENCY OF COMMON RH ANTIGENS AND RH PHENOTYPES IN THE INDIAN BLOOD DONOR POPULATION R.N. Makroo, R. Gupta, A. Bhatia, J. Phillip Indraprastha Apollo Hospitals, New Delhi, India P-430 SCIENTIFIC SUPPORT OF INSTITUTO LICON TO MEXICAN HEALTH INSTITUTIONS, FOR THE CONTINUING EDUCATION IN BLOOD BANKS THROUGH IMMUNOHEMATOLOGICAL CASES RESOLUTION G. Abarca, J. Uribe Vázquez, J.C. Gracia Rosales, M.L. Tavira Mendoza, R. Castillo Trigueros, L. Contreras Trujano Licon Institute, Estado de México, Mexico P-431 COMPARISON OF DIRECT ANTIGLOBULIN TESTS USING E.M.® TECHNOLOGY AND ORTHO BIOVUE™ SYSTEM C. Nöcker ZLM GmbH, Essen, Germany

188

P-432 IRREGULAR ANTIBODIES IN DONATED BLOOD, CENTER FOR BLOOD TRANSFUSION, PUEBLA, MÉXICO: JUNE 2009 - DECEMBER 2011 D. Velazquez, A. Aida, A. Calzada CETS Puebla, Puebla, Mexico P-433 A PREGNANT WOMAN WITH ANTIBODIES AGAINST A HIGH-FREQUENCY RH ANTIGEN M. de Haas, P.C. Ligthart, L. Haer, A. Leyte, M. Klaphake, S. Hogenboom, P. van de Burg, B. Veldhuisen Sanquin Blood Supply, Amsterdam, Netherlands

Posters Published

Posters Published

P-426 EVALUATION OF ERYTRA®, A FULLY AUTOMATED INSTRUMENT WITH A HIGH PROCESSING CAPACITY FOR PRE-TRANSFUSION COMPATIBILITY TESTS, IN THE VALPARAÍSO BLOOD CENTRE (CHILE) M.C. Lyng, K. Martinez, P. Rojas, M. Marquez, V. Garay, R. Schifferli, P. Ojeda, L. Pérez, V. Ibarra, P. Ortega Centro de Sangre y Tejidos de Valparaíso, Valparaíso, Chile

Posters Published

P-434 FACTORS AFFECTING RED CELL ALLOIMMUNIZATION (A RETROSPECTIVE STUDY OF 206 EGYPTIAN MULTITRANSFUSED PATIENTS) R.M. ELdeeb, F. Moftah, A. Ahmed, M. Aly, N. Fahmy NBTS, Cairo, Egypt P-435 BLOOD GROUP ANTIGEN DISTRIBUTION IN LAO BLOOD DONORS Y. Urwijitaroon, Ch. Keokhamphoui Centre for Research and Development of Medical Diagnostic Laboratories, Khon Kaen, Thailand P-436 DONORS WEAK D ANTIGEN DETECTION THANKS TO ERYTHROCYTE MAGNETIZED TECHNOLOGY - QWALYS SYSTEM D. Martinez, APL Moreira, L.M. de Carlos, T.M. de Oliveira, P.V. Loiacono, J.M.P. de Oliveira, C.M. de Castro, F.B.L. da Silva, E.M. de Oliveira Diagast, Loos, France P-437 IMMEDIATE SPIN CROSSMATCH IN PATIENTS WHO HAD NEGATIVE IRREGULAR ANTIBODY: PRELIMINARY DATA IN THAI PATIENTS C. Promwong, S. Siammai, S. Hassarin, J. Buakaew, W. Yindee, K. Wongba Sanpasitthiprasong Hospital, Ubon Ratchathani, Thailand P-438 RED CELL ANTIBODY DETECTION AND IDENTIFICATION - ONE YEAR STUDY IN A DELHI BLOOD BANK P. Shrivastava Lions Blood Bank Delhi, New Delhi, India

189

Posters Published

P-447 EVALUATION OF ERYTRA® IN A BLOOD CENTER WITH SIGNIFICANT ACTIVITY OF COLLECTION, PROCESSING AND STORAGE OF BLOOD COMPONENTS C. Villalobos, O. Gajardo, E. Zamorano Immunohematology Department, Centro Metropolitano de Sangre y Tejidos, Santiago de Chile

P-440 A STUDY OF PREVALENCE OF RED CELL AUTOANTIBODIES AND ALLOANTIBODIES IN A POPULATION OF SINGAPORE PATIENTS IN 2010 S. Afzal, H.H. Tan Health Sciences Authority, Singapore, Singapore

P-448 EVALUATION ON THE REAGENTS AND FULLY AUTOMATED MACHINE ERYTHROCYTE MAGNETIZED TECHNOLOGY (EMT) QWALYS3 R.S.E.G. Prihanto, T.H. Iqbal, E. Handy Suryadarma, C. Muhamad, D.T.I. Herman Central Blood Transfusion Services, Jakarta, Indonesia

P-441 RH SYSTEM ANTIGEN DISTRIBUTION IN A LARGE POPULATION OF DONORS IN LIMA, PERU J.A. Paredes, A.A. Pajares, S. Leon, J. Maguiña, M. Paiva, R. Kamiya, A. Sagastegui, H. Reyna, I. Perez, R. Torres, J. Cornejo, R. Zapata Edgardo Rebagliati Hospital, Lima, Peru

P-449 IMPORTANCE OF COLD AUTOIMMUNE ANTIBODIES IN REGULARLY TRANSFUSED PATIENT WITH HEMATOLOGY DISORDERS E. Velkova, A. Hristova-Dimceva, M Blagoevska, T. Makarovska-Bojadzieva, I. Nikoloska, J. Angelovski, J. Samonikova Institute for Transfusion Medicine, Skopje, Macedonia

P-444 RED CELL ALLOIMMUNIZATION IN TRANSFUSION- DEPENDENT THALASSAEMIC PATIENTS J. Pengu, I. Seferi, M. Xhetani National Blood Transfusion Center Tirana, Albania P-445 TRANSFUSION THERAPY FOR PATIENT’S WITH AUTO IMMUNE HEMOLYTIC ANEMIA: LEAST INCOMPATIBLE OR PARTIAL PHENOTYPE MATCHED BLOOD TRANSFUSION R. Sawant, S. Mukhida, J. Bhatt, C. Karia, B. Radadiya, M. Dave Rajkot Voluntary Blood Bank and Research Centre, Rajkot, India P-446 FREQUENCY AND SPECIFICITY OF IRREGULAR RED CELL ANTIBODIES IN CARDIAC SURGERY IN 2351 PATIENTS AT THE NATIONAL INSTITUTE OF CARDIOLOGY “IGNACIO CHAVEZ” C.M.A. Soster, C.J. Argott, P.M.P. Macias, D.A.M. Mejía Instituto Nacional de Cardiologia "Ignacio Chavez", Mexico City, Mexico

Posters Published

Posters Published

P-439 A HIGH TITRE COLD AUTO-AGGLUTININ IN A SEPTUAGENARIAN WOMAN COMPLICATING PRETRANSFUSION COMPATIBILITY TESTS S.R. Joshi, A. Al Harthy, A. Al Harthy, M.K. Mallick Advanced Medical and Dental Institute, Bertam, Kepala Batas, Malaysia

P-443 AUTOMATED TPHA SCREENING ON GALILEO AND NEO SYSTEMS M. Enterline, G. Patel, S. Chesla Immucor, Inc, Norcross, USA

190

Posters Published

5.2 Red Cell Immunology: Molecular P-450 SYNONYMOUS NUCLEOTIDE POLYMORPHISMS IMPACT DOMBROCK BLOOD GROUP ALLELE EXPRESSION IN K562 TRANSDUCED CELLS S. Chapel-Fernandes, C. Durousseau, G. Halverson, J. Chiaroni, P. Bailly Etablissement Français du Sang, Marseille, France P-451 NOVEL KEL HETEROZYGOUS MUTATIONS ASSOCIATED WITH WEAKENING OF KELL ANTIGENS KEL1 AND KEL2 V. Karamatic Crew, J. Poole, N. Burton, H. Hustinx, R. Aznar, R. Moule, R. Stamps, P. Madden, G. Daniels BITS and IBGRL, Bristol, United Kingdom P-452 A NEW CASE AND A NOVEL MOLECULAR BACKGROUND IN A MER2-NEGATIVE (RAPH:-1) INDIVIDUAL WITH ANTI-MER2 V. Karamatic Crew, J. Poole, T. Bullock, N. Burton, E. Muniz-Diaz, G. Daniels BITS and IBGRL, Bristol, United Kingdom

191

Posters Published

P-460 THE HYBRID RHD ALLELE RHD-CE(3-4)-D REPRESENTS DFR-5, A NEW MEMBER IN THE DFR FAMILY OF PARTIAL D I. von Zabern, A. Doescher, W.A. Flegel, F.F. Wagner, A. Gropp, E.A. Scharberg, J. Burkhart Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, Ulm, Germany

P-454 A HIGH-THROUGHPUT METHOD FOR ACCURATE DETECTION OF RHD*D-CE(4-7)-D VARIANT A. Molano-Bilbao, D. García-Crespo, I. Apraiz, G. Ochoa, D. Tejedor, M. López Progenika Biopharma S.A., Derio, Spain

P-461 MOLECULAR AND SEROLOGICAL CHARACTERIZATION OF THE RARE P PHENOTYPE IN ISRAEL V. Yahalom, S. Ben - Zaken, O. Asher, O. Saloman, E. Shinar, A. Zivelin Magen David Adom - NBS, Ramat Gan, Israel

P-455 CRAG: A NEW HIGH-PREVALENCE ANTIGEN IN THE CROMER BLOOD GROUP SYSTEM C. Lomas-Francis, A. Fuchisawa, J. Hamilton, K. Hue-Roye, S.B. Pelton, S. Vege, C.M. Westhoff New York Blood Center, Long Island City, USA

P-462 INTRONIC POLYMORPHISM I8-32C WITHIN RHD GENE AS A MARKER OF A PECULIAR RHCE HAPLOTYPE: PRELIMINARY STUDY IN 104 CASES L. Salvaneschi, I. Sbarsi, P. Isernia, C. Badulli, A. Pasi, A. De Silvestri, M. Martinetti IRCCS Policlinico San Matteo Foundation, Pavia, Italy

Posters Published

Posters Published

P-453 IDENTIFICATION OF GENOMIC BREAKPOINT IN (C)CES TYPE 1 VARIANT AND DEVELOPMENT OF A NEW MOLECULAR TOOL FOR ITS SPECIFIC DETECTION M. Silvy, T. Granier, S. Beley, J. Chiaroni, P. Bailly EFS-AM, Marseille, France

P-456 CROK - A NOVEL MUTATION OF THE CROMER BLOOD GROUP SYSTEM V. Yahalom, L. Finkel, J. Poole, V. Crew, J. Chezar, L. Akaria, E. Shinar, O. Asher Magen David Adom - NBS, Ramat Gan, Israel

192

Posters Published

P-463 KLF1 MUTATIONS IN JAPANESE INDIVIDUALS WITH IN(LU) PHENOTYPE K. Ogasawara, H. Tsuneyama, M. Uchikawa, H. Okazaki, K. Tadokoro Japanese Red Cross Central Blood Institute, Tokyo, Japan

P-457 A NEW GLYCOPHORIN B ALLELE, GYPB(IVS5+3G>A), IN TRANS TO GYPB (IVS5+5G>T) IS ASSOCIATED WITH DISCREPANT PREDICTION OF S AND U ANTIGEN STATUS M. Westhoff, S. Vege, T. Copeland, E. Baker, R. Velliquette, C. Lomas-Francis New York Blood Center, New York, USA

P-464 A NEW GP(B-A-B) HYBRID MOLECULE (GP.YAK) WITH MILTENBERGER PHENOTYPE M. Uchikawa, K. Ogasawara, Y. Suzuki, M. Saito, H. Tsuneyama, K. Morimoto, K. Nakajima Tokyo Blood Center, Tokyo, Japan

P-458 APPLICATION OF THE NOVEL HIGH-THROUGHPUT GENOTYPING MLPA ASSAY IN RHD GENOTYPING FOR A CHINESE PEDIGREE WITH DEL PHENOTYPE Y. Ji, Y. Zhao, Z. Wang, R.Q. Zhang, H. Luo, C.Y. Mo, L. Wei, G.P. Luo Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, China

P-465 EVALUATION OF A LUMINEX BASED ASSAY FOR BLOOD GROUP GENOTYPING IN A POPULATION OF HIGHLY DIVERSE ANCESTRY L. Castilho, G. Guelsin, K.B. Torres, D. Machado, A.C. Gaspardi, K.A. Ribeiro Hemocentro-Unicamp, Campinas, Brazil

P-459 CHARACTERIZATION OF THREE NOVEL ABCG2 NULL ALLELES; THE JR BLOOD GROUP SYSTEM (PROVISIONALLY ISBT 032) M.E. Reid, K. Hue-Roye, C. Lomas-Francis, G. Coghlan, T. Zelinski New York Blood Center, New York, USA

P-466 NON-INVASIVE FETAL RHD GENOTYPING BY REAL-TIME PCR: THREE YEARS OF EXPERIENCE IN PORTUGAL F. Monteiro, P. Bastos, A. Amorim, M. Ferreira, G. Tavares, F. Araújo Molecular Biology Center, Blood Transfunsion Department- Hospital de São João, Porto, Portugal

193

Posters Published

P-467 MOLECULAR BASIS OF WEAK D AND DEL IN ANHUI CHINESE HAN POPULATION L. Zhong Anhui Blood Center, Hefei, China

P-474 RHD ZYGOSITY BY SEROLOGICAL AND MOLECULAR METHODS IN THE DONOR POPULATION OF MUMBAI, INDIA S. Kulkarni, K. Vasantha, K. Ghosh National Institute of Immunohaematology, Mumbai, India P-475 SCREENING AND CHARACTERIZATION OF DEL BY SEROLOGIC AND GENETIC METHODS IN A KOREAN POPULATION K.U. Park, K. Lee, Y.J. Hong, K.S. Han Seoul National Univ. Bundang Hospital, Seongnamsi, South-Korea

P-469 RED CELL BLOOD GROUP GENOTYPING: A COMPARISON OF THE PROGENIKA BLOODCHIP AND EXISTING METHODS IN A TERTIARY REFERENCE LABORATORY S.P. Grimsley, K. Finning, J. Hosken, G. Daniels NHSBT, Bristol, United Kingdom

P-476 MOLECULAR CHARACTERIZATION OF A NEW D-- ALLELE IN COMORIAN M. Silvy, S. Chapel-Fernandes, S. Beley, C. Durousseau, T. Granier, J.P. Zappitelli, J. Chiaroni, P. Bailly EFS-AM, Marseille, France

P-470 THE LU7/LU:-7 POLYMORPHISM IS DEFINED BY A MISSENSE NUCLEOTIDE CHANGE: LU*1274A>C M.E. Reid, K. Hue-Roye New York Blood Center, New York, USA

P-478 STRATEGY TO IDENTIFY D VARIANTS IN A MULTIETHNIC POPULATION C.P. Arnoni, J.G. Muniz, R.D.M. Person, F.R.M. Latini, W. Baleotti Jr, F.O. Carvalho, L. Castilho, J.A. Barreto Colsan Associação Beneficente de Coleta de Sangue, São Paulo, Brazil

P-471 INTRODUCTION OF AN VALIDATED IN-HOUSE HIGH THROUGHPUT BLOOD GROUP GENOTYPING SYSTEM INTO A ROUTINE SETTING S. Lejon Crottet, P. Gowland, H. Hustinx, S.F. Fontana, M. Stolz, C. Niederhauser Blood Transfusion Service SRC Berne Ltd., Berne, Switzerland

P-479 A NOVEL MUTATION OF RHD ANTIGEN M.A. Villa, N. Revelli, P. Ponzo, C. Paccapelo, G. Portella, F. Truglio, F. Sironi, A. Molano, M. Lopez, M. Marconi Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

P-472 RHD ALLELES ASSOCIATED WITH AUTO ANTI-D IN PATIENTS OF DIVERSE ANCESTRY L. Castilho, G. Guelsin, K.A. Ribeiro, J. Pellegrino Jr Hemocentro-Unicamp, Campinas, Brazil

P-480 ASSOCIATION OF ALTERED E RHCE*CE(697G,712G,733G,744C) WITH ALTERED D RHD*46C G. Ochoa, N. Nogues, E. Muñiz-Diaz, M. Tarrago, J. Cote, M. Goldman, S. Vege, C. Westhoff, C. Vietz, M. Lujan, C. Trucco, C. Cotorruelo Progenika Inc, Medford, USA

Posters Published

Posters Published

P-468 RHD VARIANTS AMONG POLISH D NEGATIVE BLOOD DONORS A. Orzinska, K. Guz, H. Polin, M. Pelc-Klopotowska, A. Gielezynska, B. Sliwa, M. Kowalewska, E. Pawlowska, B. Wlodarczyk, M. Malaga, A. Zmudzin, M. Krzemienowska, J. Bednarz, B. Michalewska, C. Gabriel, E. Brojer Institute of Hematology and Transfusion Medicine, Warsaw, Poland

P-473 WEAKENED EXPRESSION OF K11 ON RBCS LACKING KANT (KEL33), AND KETI (KEL36) M.E. Reid, R.W. Velliquett, C. Lomas-Francis New York Blood Center, New York, USA

194

Posters Published

P-481 MOLECULAR MATCHING OF RED BLOOD CELLS IS SUPERIOR TO THE SEROLOGICAL MATCHING IN SICKLE CELL DISEASE PATIENTS L. Castilho, K.A. Ribeiro, G. Guelsin, S. Gilli, J. Pellegrino Jr Hemocentro-Unicamp, Campinas, Brazil

195

Posters Published

P-482 MOLECULAR GENOTYPING AND FREQUENCES OF BLOOD GROUP ANTIGENS IN KUWAIT CENTRAL BLOOD BANK H. Alshatti, O. Alayyady, R. Alradwan Kuwait Central Blood Bank, Kuwait, Kuwait

P-484 PATIENTS AND DONORS BLOOD GROUP GENOTYPING FOR AN EFFICIENT BLOOD THERAPY S. Manfroi, P. Pagliaro Policlinico S.Orsola-Malpighi, Bologna, Italy P-485 MOLECULAR BASIS OF WEAK EXPRESSION OF D ANTIGEN IN POLAND M. Pelc-Klopotowska, K. Guz, H. Polin, A. Orzinska, B. Sliwa, M. Watman Danielkiewicz, A. Gielezynska, G. Zajaczkowska, M. Kowalewska, J. Bednarz, M. Krzemienowska, C. Gabriel, B. Michalewska, E. Brojer Institute of Hematology and Transfusion Medicine, Warsaw, Poland P-486 SEROLOGIC REACTIVITY AND MOLECULAR ANALYSIS OF A VARIANT D PHENOTYPE C. Trucco Boggione, M. Luján Brajovich, M. Leri, C. Fornes, S. Bonetti, S. Chialina, A. Racca, C. Cotorruelo Universidad Nacional de Rosario, Rosario, Argentina P-487 EVALUATION OF A BLOOD GROUP GENOTYPING PLATFORM IN JAPANESE SAMPLES M. Tanaka, I. Kamada, J. Takahashi, F. Hirayama, Y. Tani Japanese Red Cross Osaka Blood Center, Osaka, Japan P-488 A NEW STRATEGY TO IDENTIFY RARE BLOOD DONORS: SINGLE PCR MULTIPLEX SNAPSHOT REACTION FOR DETECTION OF 16 BLOOD GROUP ALLELES F Roche Moreira Latini Colsan Associação Beneficente de Coleta de Sangue, São Paulo, Brazil

196

P-489 MOLECULAR CHARACTERIZATION OF D VARIANTS IN BRAZILIANS REVEALS A HIGH FREQUENCY OF THE PARTIAL D DFR M Mota, M.G. Aravechia, M.R. Dezan, V.B. Bezerra, P.B.C. Freire, M.M. Sirianni, L.F. Almeida, J.P. Santos, N.C. Silva, A.A.H. Hirano, L.V. Visciglia, L. Castilho, J.M. Kutner Hospital Israelita Albert Einstein, São Paulo, Brazil Posters Published

Posters Published

P-483 A NOVEL RHCE ALLELE: RHCE*CE(254G, 733G) J.A. Crowley, T. Horn, C. Chiappa, C. Melland, C. Vietz, L. de Castilho, M.A. Keller American Red Cross, Philadelphia, USA

Posters Published

P-490 IDENTIFICATION OF RHCE VARIANT ALLELES: A COMPARISON OF LABORATORY-DEVELOPED DNA TESTS AND A COMMERCIAL DNA ARRAY METHOD L. Castilho, G. Guelsin, K.A. Ribeiro Hemocentro-Unicamp, Campinas, Brazil P-491 NEW RHD VARIANT FOUND IN PORTUGUESE BLOOD DONORS J.A. Duran, I.M. Moser, J. Pereira, M.J. Rodrigues, P. Costa, M.J. Miguel Portuguese Blood Institute, Porto, Portugal P-492 HLA ALLOIMMUNIZATION IS ASSOCIATED WITH RBC ANTIBODIES IN MULTIPLY TRANSFUSED PATIENTS FROM BRAZIL E.L. Visentainer, G.A. Guelsin, K.A. Ribeiro, M.A. Braga, F.C. Melo, E.C. Corradine, S.B.D. Marques, L. Castilho Universidade Estadual de Campinas, Campinas, Brazil P-493 RHD*DIII.4 ALLELE WITH ADDITIONAL NUCLEOTIDE CHANGE 307 T>C T. Horn, J.A. Crowley, T. Diebold, P. Wilkerson, L. Brownstein, L. de Castilho, M.A. Keller American Red Cross, Philadelphia, USA P-494 CERN/CEBP: A RARE RHCE COMPOUND HETEROZYGOTE J.A. Crowley, P. Nickle, J. Christensen, T. Horn, L. de Castilho, S. Nance, M.A. Keller American Red Cross, Philadelphia, USA P-495 ALLELIC PREVALENCE OF ABO BLOOD GROUP GENES USING MULTIPLEX ALLELE- SPECIFIC PCR IN IRANIAN AZARI POPULATION K. Shamsasenjan, M. Nojavan, A.A. Movassaghpour, P. Akbarzadehlaleh Iranian Blood Transfusion Organization, Tabriz, Iran

197

Posters Published

P-496 APPLICATION OF HIGH-THROUGHPUT GENOTYPING MLPA ASSAY TO ASSIST DIAGNOSIS OF A SEVERE CASE OF HEMOLYTIC DISEASE OF THE NEWBORN CAUSED BY ANTI-DIA G.P. Luo, C.Y. Mo, L. Wei, Y. Zhao, H. Luo, Z. Wang, R.Q. Zhang, Y.L. Ji Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, China

P-498 THE GENE FREQUENCIES OF 8 MINOR BLOOD GROUP SYSTEMS IN BLOOD DONORS OF GROUP O FROM MEISHAN CITY IN CHINA N. Song, L. Tian, H. Li, Z.Q. Yao, Y.F. Deng Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China P-499 BIORHEOLOGIC ACTION OF PHYLLANTHUS SELLOWIANUS EXTRACTS ON ERYTROCYTE ADHESION BY IMAGES DIGITAL ANALYSIS P.A. Buszniez Universidad Nac Rosario, Funes, Argentina P-500 TWO MUTATION FOUND INΑ(1,4) GALACTOSYLTRANSFERASE GENE IN TWO CHINESE INDIVIDUALS WITH THE P PHENOTYPE X. Hong, X.G. Xu, Y.L. Ying, Y. Liu, K.R. Ma, X.F. Lan, J. He, F.M. Zhu, H.J. Lv Blood center of Zhejiang Province, Hangzhou, China P-502 BLOOD TYPE BY GENOTYPING TECHNIQUE VERSUS HAEMAGGLUTINATION IN TUBE TECHNIQUE IN PATIENTES AND BLOOD DONORS AT NATIONAL MEDICAL CENTRE BLOOD BANK “LA RAZA” IMSS M.L. Gasca-Leyva, G. Benitez-Arvizu, E.D. Juarez-Cortes, M. Alvarez-Galan, R.M. Macias-Medrano, M. Rodriguez-Bartolo, P. Sanchez-Pozos, M. Campomanes-Flores IMSS, Mexico City, Mexico P-503 FACTITIOUS DISORDER BY PROXY: TWO DIFFERENT CASES C. Monteiro, A. Leite, F. Monteiro, L. Goncalves, A. Bonito-Vitor, E. Trindade, F. Araujo Department of Transfusion Medicine and Blood Bank, Centro Hospitalar S João, EPE, Porto, Portugal

198

P-504 RHD*WEAK 4.3 IS ASSOCIATED WITH AN ALTERED RHCE*CE EXPRESSING CX AND VS H. Polin, W. Gaszner, C. Hackl, M. Danzer, N. Niklas, C. Gabriel Red Cross Transfusion Service of Upper Austria, Linz, Austria P-505 MOLECULAR IDENTIFICATION OF CERTAIN ALLELES IN ERYTHROCYTE SYSTEMS (KPA, KBP, LUA, LUB, DIA, DIB, WRA, WRB, YTA, YTB, COA, COB, KNA, KNB, DOA, DOB) IN BLOOD DONORS LIVING IN MEXICO CITY H.A. Baptista-González, R. Trueba Instituto Nacional de Perinatología, Mexico

Posters Published

Posters Published

P-497 A NOVEL O ALLELE CAUSED BY A IN-FRAME TRIPLET DELETION IN ABO GENE L. Tian, N. Song, H. Li, Z.Q. Yao, W.C. Fan Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

Posters Published

P-506 ASSOCIATION OF BLOOD GROUP ALELES AND ANCESTRY J.G. Muniz, C.P. Arnoni, F.R.M. Latini, R.D.M. Person, D.C. Credidio, F.O. Carvalho, J.A. Barreto, W. Baleotti Jr, L. Castilho Colsan Associação Beneficente de Coleta de Sangue, São Paulo, Brazil

5.3 Platelet Immunology P-507 16TH ISBT INTERNATIONAL PLATELET IMMUNOLOGY WORKSHOP - PRELIMINARY ANALYSES R. Fontão-Wendel, B. Bertrand, S. Santoso, U.J. Sachs, W. Chong, P. Metcalfe, Y. Merieux, N. Tsuno, G. Teramura, L. Porcelijn, C. Kaplan Hospital Sirio Libanês Blood Bank, São Paulo, Brazil P-508 FAILURE DETECTION OF ANTI-HPA-1A ANTIBODY IN THE SERUM OF A PLATELET REFRACTORINESS PATIENT DUE TO HPA-1A+ PLATELET TRANSFUSION ABSORPTION R. Fontão-Wendel, A. Balthazar, A. Lazar, R. Souto, S. Biagini, S. Wendel Hospital Sirio Libanês Blood Bank, São Paulo, Brazil P-510 PREPARATION AND ACTIVITY ANALYSIS OF MOUSE ANTI HUMAN PLATELET CD36 MONOCLONAL ANTIBODY L. Chen, J. Zhang, W. Deqing, Z. Yuan, L. Hui, F. Qian General Hospital of PLA, Beijing, China

199

Posters Published

P-511 FREQUENCY OF ANTI-PLATELET ANTIBODIES IN POLYTRANSFUSED HEMATOLOGIC PATIENTS ON SOLID PHASE TESTS E.C. Carrillo, A.A. Pajares, W. Ceron, R. Cordova, C. Penailillo, L. Hinojosa, J. Manzano Rebagliati Hospital, Lima, Peru

P-513 PLATELET CROSSMATCH TEST USING SOLID-PHASE MICROPLATE TECHNIQUES Y.J. Hong, S. Chung, J. Hyun, K.U. Park, K.S. Han Seoul National University College of Medicine, Seoul, South-Korea P-514 PLATELET GENOTYPING AT THE BLOOD BANK AT THE NATIONAL MEDICAL CENTRE “LA RAZA”, MEXICAN INSTITUTE OF SOCIAL SECURITY: FIRST REPORT IN MEXICO B. Novelo-Garza, G. Benitez-Arvizu, M.R. Alvarez-Galan, K. Sanchez-Pozos, M.G. Campomanes-Flores IMSS, Mexico City, Mexico P-515 THE ESTABLISHMENT OF CELL ENGINEERING LABORATORY FOR THE STUDY ON BLOOD CELLS POLYMORPHISM H. Li, W.D. Sheng, X.J. Liu, L.L. Li, F. Lu, Y. Zhou, G.G. Wu Nanning Blood Center, Nanning, China P-516 THE RESEARCH OF ALLOIMMUNIZATION IN PLATELETS TRANSFUSION REFRACTORY AT PATIENTS WITH ACUTE LEUKEMIA I. Djunic, T. Srdic-Rajic, M. Virijevic, A. Novkovic, V. Djurasinovic, N. Colovic, A. Vidovic, N. Suvajdzic-Vukovic, D. Tomin Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia P-517 THE NEW CD36 DEFICIENCY CASES IN 4 GUANGZHOU BLOOD DONORS X. Ye, H.Q. Deng, J.L. Wang, W.J. Xia, X.Z. Xu, J. Deng, Y.K. Chen, Y. Shao Guangzhou Blood Center, Guangzhou, China

200

5.4 Granulocyte Immunology P-518 HUMAN NEUTROPHIL ANTIGEN (HNA)-1, HNA-3, HNA-4 AND HNA-5 ALLELE FREQUENCIES IN A PANEL OF APHERESIS DONORS FROM ENGLAND USING A HIGH THROUGHPUT MULTIPLEX LUMINEX DNA BEAD ASSAY S.M. Pinto Cardoso, W. Chong, G. Lucas, A. Green, C. Navarrete National Health Service Blood and Transplant (NHSBT), London, United Kingdom

Posters Published

Posters Published

P-512 DETECTION AND DIAGNOSIS OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIA PURPURA CAUSED BY ANTI HPA-3A ANTIBODY Y. Zhou, Zh.L. Zhong, L.L. Li, W.D. Shen, J.L. Liu, G.G. Wu Nan-ning Blood Center, Nan-ning, China

Posters Published

P-519 THE FREQUENCIES OF HUMAN NEUTROPHIL ALLOANTIGENS-1,2,4,5 IN SOUTHERN CHINESE POPULATION N. Xia, X. Xu, X. Ye Guangzhou Blood Center, Guangzhou, China

5.5 Fetal-Maternal Immunology P-520 RATES AND CAUSES OF FALSE POSITIVE RESULTS OF NONINVASIVE DETERMINATION OF ANTENATAL RHD STATUS M.A. Jakobsen, U. Sprogøe Odense University Hospital, Odense C, Denmark P-521 MICROCHIMERISM IN THE TRANSFUSED OBSTETRIC POPULATION E. Bloch, M.P. Busch, T.H. Lee, L. Montalvo, A. Bird, Y. Matthews, V. Stefan Blood Systems Research Institute, San Francisco, USA P-523 IMPORTANCE OF SAMPLING TIME FOR THE KLEIHAUER - BETKE METHO M. Maestri, A. Endara, O. Torres Hospital Materno Infantil Ramón Sardá, City of Buenos Aires, Argentina P-524 THE INCIDENCE OF ERYTHROCYTE ALLOIMMUNIZATION IN PREGNANT WOMEN I. Holuskova, M. Lubusky, M. Studnickova, D. Galuszkova, K. Vomackova Faculty Hospital, Olomouc, Czech Republic P-525 SEVERE HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN DUE TO ANTI-G I. Sareneva, K. Haimila, A.E. Korhonen, V. Stefanovic, M. Kuosmanen, S. Sainio Finnish Red Cross Blood Service, Helsinki, Finland 201

Posters Published

P-527 THE DECREASE OF SOLUBLE HLA-G MOLECULES IN FETAL AND MATERNAL BLOOD TRIGGERS PARTURITION MIMICKING FETAL REJECTION L. Salvaneschi, C. Capittini, P. Bergamaschi, S. Sachetto, M. Truglio, M. Viola, M. Repossi, A. Marchesi, V. Genovese, B. Romano, R. Poma, C. Tinelli, A. Spinillo IRCCS Policlinico San Matteo Foundation, Pavia, Italy P-528 COMPARISON OF ESTIMATION OF FETOMATERNAL HEMORRHAGE USING KLEIHAUER BETKE TEST AND MICROCOLUMN GEL TECHNIQUE IN RH D- NEGATIVE NON ISOIMMUNISED MOTHERS K. Mittal, N. Marwaha, P. Kumar, S.C. Saha, B. Thakral PGIMER, Chandigarh, India P-529 COMPARISON OF GEL TEST AND CONVENTIONAL TUBE TEST FOR ANTIBODY DETECTION AND TITRATION IN D-NEGATIVE PREGNANT WOMEN N. Marwaha, M.K. Thakur, B. Thakral, K. Saluja, S.C. Saha Postgraduate institute of medical education and research, Chandigarh, India P-530 SPONTANEOUS ANTEPARTAL RHD ALLOIMMUNIZATION I. Holuskova, M. Lubusky, M. Studnickova, D. Galuszkova, K. Vomackova Faculty Hospital, Olomouc, Czech Republic P-532 PROFILE OF MATERNAL RED CELL ALLO-ANTIBODIES IN PREGNANCY:REPORT FROM A DEVELOPING COUNTRY S Basu, D. Chawla, A. Huria, P. Goel Government Medical College Hospital, Chandigarh, Chandigarh, India P-533 USE OF MONOCLONAL IGM ANTI-D TO SCREEN FOR FETO-MATERNAL HEMORRHAGE K. Haupt, J. Kern, D. Stone Immucor, Inc., Norcross, USA 202

P-534 THE EVALUATION OF TRANSCUTANEOUS BILIRUBIN MEASUREMENT FOR DIAGNOSING NEWBORNS WITH ABO HEMOLYTIC DISEASE J.P. Yin Wuhan Blood Centre, Wuhan, China Posters Published

Posters Published

P-526 PHARMACOKINETICS AND SAFETY OF ROLEDUMAB, A NOVEL HUMAN RECOMBINANT MONOCLONAL ANTI-RHD ANTIBODY WITH AN OPTIMIZED FC FOR IMPROVED ENGAGEMENT OF FCGRIII, IN HEALTHY VOLUNTEERS A. Yver, H. Watier, P. Gueret, E. Fuseau, E. Guemas, D. Quagliaroli, R. Beliard, J.-F. Prost, B. Carbonne LFB Biotechnologies, Les Ulis, France

Posters Published

Topic 6: Clinical Transfusion 6.1 Neonatal and Pediatric Transfusion P-535 TO ASSESS THE FEASIBILITY OF DEDICATED DONOR UNITS FOR TRANSFUSION IN NEONATES AND INFANTS (< 3 MONTHS) UNDERGOING SURGERY S. Arora, N. Marwaha, K.L.N. Rao Post Graduate Institute of Medical Education and Research, Chandigarh, India P-537 AUTOLOGOUS BLOOD TRANSFUSION IN CHILDREN O. Serbic Nonkovic, I. Sehic, D. Veljkovic, M. Stajevic, Z. Radonjic Mother and Child Health Institute, Belgrade, Serbia P-538 DETERMINATION OF THE MEAN RED CELL TRANSFUSION REQUIREMENT COMPARED ON THE BASIS OF IRON OVERLOAD AND TYPE OF CHELATION THERAPY IN PEDIATRIC MULTIPLY TRANSFUSED THALASSEMIA MAJOR PATIENTS R. Jain, P. Jain, J.T. Perkins, S.T. Johnson, Ch. Vora, V. Harimoorthy, P. Desai, U. Chudgar, N. Choudhury R.D.Gardi Medical College, Ujjain, M.P., India

6.2 Therapeutic Apheresis P-539 ANALYSIS OF STRATEGIES FOR ABO INCOMPATIBLE KIDNEY AND LIVER TRANSPLANTATION D. Won, W. Choe, H.-J. Kim, S.-W. Kwon, D.J. Han, S.-G. Lee, S.K. Park Asan Medical Center, Seoul, South-Korea P-540 ROLE OF THERAPEUTIC PLASMA EXCHANGE IN VARIOUS CLINICAL SETTINGS R.N. Makroo, R.S. Walia, V. Hegde, M. Chowdhry, A. Bhatia Indraprastha Apollo Hospitals, New Delhi, India 203

Posters Published

P-541 MONONUCLEAR CELL COLLECTION FOR EXTRACORPOREAL PHOTOCHEMOTHERAPY: A COMPARATIVE STUDY ON THE NEW AUTOMATED SPECTRA OPTIA V 5.0 AND THE COBE SPECTRA MNC APHERESIS DEVICES C. Del Fante, G. Viarengo, L. Scudeller, M. Cervio, G. Discenza, C. Perotti Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

P-543 CURRENT SITUATION OF THERAPEUTIC APHERESIS IN NATIONAL BLOOD TRANSFUSION CENTRE OF TIRANA I. Seferi, V. Spahiu, L. Nunci, E. Mjekaj, H. Sula, I. Ohri National Blood Transfusion Centre, Tirana, Albania P-544 REVIEW OF THERAPEUTIC APHERESIS PROCEDURES IN A TERTIARY CARE HOSPITAL IN INDIA A. Deshpande, S. Kalgutkar, M. Kulkarni Hinduja Hospital, Mumbai, India P-545 THERAPEUTIC PLASMA EXCHANGE IN NEUROLOGICAL PATIENTS IN 2011 - OUR EXPERIENCE V. Srejic Blood Transfusion institute of Serbia, Belgrade, Serbia

6.3 Evidence Based Transfusion Medicine Practice P-546 RED BLOOD CELL ALLOIMMUNIZATION RISK IS NOT ASSOCIATED WITH STORAGE TIME OF TRANSFUSED CELLS S. Zalpuri, H. Schonewille, R. Middelburg, L. Van Watering, K. De Vooght, J.G. Van der Bom, J.J. Zwaginga Sanquin Blood Supply, Leiden, Netherlands

204

P-547 COLLOID TREATMENT IN SEPSIS PATIENTS IN INTENSIVE CARE - USE OF ALBUMIN VERSUS HYDROXYETHYL STARCH (HES) IS COST-EFFECTIVE IN A DECISION ANALYSIS MODEL A. Farrugia, A. Balboni, J. Cassar, M.C. Kimber Plasma Protein Therapeutics Association, Annapolis, USA P-548 THE EFFECT OF DONOR SEX ON TRANSFUSION RECIPIENT MORTALITY - RESULTS FROM A SECOND HOSPITAL C. Caram, R.A. Middelburg, J.G. Van der Bom Sanquin, Leiden, Netherlands

Posters Published

Posters Published

P-542 BLOOD DONATION INDUCED LOWERED PLASMA LIPIDS - AN INDICATION FOR ITS THERAPEUTIC ADAPTATIONS IN NIGERIANS O.I. Ajayi, G. Nwaeke, A.M. Bivan University of Benin, Benin City, Nigeria

Posters Published

P-549 ASSESSMENT OF BLOOD COMPONENTS NEEDS IN A HIGH COMPLEXITY PEDIATRIC HOSPITAL A.M. Pugliese, A.E. Del Pozo Hospital de Pediatría “Prof. Dr. JP Garrahan”, Buenos Aires, Argentina P-550 INFLUENTIAL FACTORS IN THE EFFICACY OF BLOOD COMPONENT TRANSFUSION IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT Z.J. Li, Q. Ran Xinqiao Hospital, Third Military Medical University, Chongqing, China P-551 AUDIT OF ROLE OF BLOOD BANK IN RENAL TRANSPLANTATION M. Sekhar, A. Li, A. Warrington, A. Kinga, E. Clarke, E. Salgado Royal Free Hospital NHS Trust, London, United Kingdom P-552 THROMBOCYTOPENIA IN PERINATAL PERIOD: A PREDICTOR OF CONSUMPTION COAGULOPATHY L. Nikolic, N. Vukovic Suvajdzic, D. Plecas Clinical Center of Serbia KGA, Belgrade, Serbia P-553 THE USE OF LARGE DOSE OF RH-IMMUNOGLOBULIN FOR THE PREVENTION OF ANTI-D ALLOIMMUNIZATION IN RHD-INCOMPATIBLE LIVER TRANSPLANTATION H.-J. Kim, W.H. Choe, M.-C. Cho, S.-W. Kwon Asan Medical Center, University of Ulsan College of Medicine, Seoul, South-Korea

205

Posters Published

P-554 BLOOD TRANSFUSION AND ANEMIA IN ELDERLY PATIENTS L. Ilincic Franciskovic, B. Mihic-Tomic CHC Dr. Dragisa Misovic Dedinje, Belgrade, Serbia

6.4 Haemorrhage and Massive Transfusion P-556 TRACKING ECMO INDUCED CHANGES TO HAEMOSTASIS WITH ROTEM® AND MULTIPLATEⓇ ANALYSER IN AN OVINE MODEL S.R. Foley, J.F. Fraser, G. Simonova, C. Solano, M.M. Spanevello, R.J. Bird, Y.L. Fung Critical Care Research Group, Uni of Queensland & The Prince Charles Hospital, Brisbane, Australia

6.5 Adverse Events, incl. TRALI P-563 A FOUR-YEAR SURVEY OF TRANSFUSION REACTIONS AT THE SWEDISH UNIVERSITY HOSPITAL IN UPPSALA B. Persson, R.A.C. Norda, N. Lubenow Uppsala University, Uppsala, Sweden P-564 INFLUENCE OF PLATELET ADDITIVE SOLUTION ON FREQUENCY OF ADVERSE EVENTS FOCUSED ON THE ABO-MATCH OF THE DONOR WITH THE RECIPIENT W. Nussbaumer, P. Mayersbach, W. Mayer, E. Gächter Univ.-Hospital Innsbruck, Innsbruck, Austria

P-557 PRELIMINARY RESULTS OF ROUTINE COAGULATION PARAMETERS DURING ECMO IN AN OVINE MODEL M.M. Spanevello, C. Solano, S.R. Foley, G. Simonova, R.J. Bird, Y.L. Fung, J.F. Fraser Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia

P-565 ACUTE RESPIRATORY INSUFICIENCY AND TRANSFUSION. COMPLEX ETIOLOGY SYNDROME H. Rodriguez-Moyado Instituto Mexicano del Seguro Social, Mexico City, Mexico

P-559 MASSIVE TRANSFUSION: ACTIVATION OF A NEW PROTOCOL M. Mottola, V. Mininni, P. Bevilacqua, E. Tremiterra, B. Zuccarelli A.O.R.N.“Ospedale dei Colli”, Naples, Italy

P-566 THE DIAGNOSIS AND STUDY OF CLINICAL HEMOLYTIC TRANSFUSION REACTIONS IN CHINA M. Jiang WuHan Blood Center, WuHan, China

P-560 ACQUIRED HEMOPHILIA A IN A PATIENT WITH PREVIOUSLY HEALTHY : CASE REPORT R.D. Ramanayake National Blood Center, Colombo 05, Sri Lanka P-561 ACQUIRED HEMOPHILIA, OUR EXPERIENCE V. Jovanoska, I. Jovanoski Institute of Transfusion Medicine Republic of Macedonia, Prilep, Macedonia

206

P-562 INTRAOPERATIVE CELL SALVAGE IN MAJOR VASCULAR SURGERIES S. Miladinovic Blood Transfusion Centre, Clinic for Vascular Suregy, Nis, Serbia

Posters Published

Posters Published

P-555 IMPLIMENTATION OF MAXIMUM SURGICAL BLOOD ORDERING SHEDULE A.H. De Alwis, J. Senevirathne National Blood Transfusion Service, Colombo, Sri Lanka

Posters Published

6.6 Haemovigilance and Transfusion Safety P-568 DETERMINATATION OF DI(2-ETHYLHEXYL)PHTHALATE(DEHP) RELEASED IN BLOOD FROM DISPOSABLE EXTRACORPOREAL CIRCULATION PVC TUBE BY HPLC X. Liu, J.X. Liu, J.J. Yu, S. Li, H. Wang Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

207

Posters Published

P-569 COMPARATIVE EFFECTIVENESS OF PLASMA PREPARED WITH PATHOGEN INACTIVATION (INTERCEPT™) AND QUARANTINE PLASMA (PFCS) FOR THERAPEUTIC PLASMA EXCHANGE OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA R. Herbrecht, D. Kientz, E. Remy, L.M. Corash, C.D. Sherman, J.-P. Cazenave Hopital de Hautpierre, Strasbourg, Cedex, France

P-571 TRANSFUSION REACTION REPORTS BEFORE AND AFTER INTRODUCTION OF MALE ONLY PLASMA IN STOCKHOLM AREA B.C. Diedrich, M.K. Auvinen, A. Johnsson, G. Edgren, A. Taune-Wikman Karolinska University Hospital, Stockholm, Sweden P-572 ANALYSIS OF NATIONAL SURVEYS RELATED TO ABO-INCOMPATIBLE BLOOD TRANSFUSION IN JAPAN Y. Yonemura, Y. Fujii, A. Tanaka, S. Makino, K. Sagawa, H. Ohto, K. Takahashi Kumamoto University Hospital, Kumamoto, Japan P-573 RECEPTOR NOTIFICATIONS FROM 2007 TO 2011: THE EVOLUTION OF THE PORTUGUESE HAEMOVIGILANCE SYSTEM J. Condeco, M.A. Escoval, I. Miranda, M. Chin, M. Santos Portuguese Blood Institute, IP., Porto, Portugal P-574 A COMPARATIVE STUDY OF THE EFFICIENCY OF PLASMA AND ADDITIVE SOLUTION PRESERVED PLATELET CONCENTRATES R. Tardivel, J. Vasse, S. Gaucheron, J.-P. Lebaudy, T. Lamy de la Chapelle, G. Semana Etablissement Français du Sang Bretagne, Rennes, France P-575 DONOR HEMOVIGILANCE: THE USEFULNESS OF EARLY POST-DONATION INFORMATION NOTIFICATION T. Jimenez-Marco, E. Girona-Llobera, M. Sedeño Fundació Banc de Sang i Teixit de les Illes Balears, Palma de Mallorca, Spain 208

P-576 HAS TRANSFUSION PRACTICE IMPROVED IN AUSTRALIAN HOSPITALS? L.J. Bielby, L.J. Stevenson, J. Perillo, B. Glazebrook Blood Matters Program, Melbourne, Australia P-577 COMPARATIVE EFFECTIVENESS OF PLASMA PREPARED WITH PATHOGEN INACTIVATION (INTERCEPT™) AND QUARANTINE FOR SUPPORT OF LIVER TRANSPLANTATION J. Cinqualbre, D. Kientz, E. Remy, C.D. Sherman, L.M. Corash, J.P. Cazenave Hopitaux Universitairies de Strasbourg, Strasbourg, Cedex, France

Posters Published

Posters Published

P-570 ALLERGIC TRANSFUSION REACTIONS IN FRANCE DUE TO METHYLENE BLUE-TREATED PLASMA: ONE SET OF DATA TWO SETS OF CONCLUSIONS S. Reichenberg, I. Alvarez, N. Goodman Maco Pharma International GmbH, Langen, Germany

Posters Published

P-578 HEMOVIGILANCE: AN ANALYSIS OF ADVERSE TRANSFUSION REACTIONS NOTIFIED IN THE STATE OF SÃO PAULO - BRAZIL M.F.A. Fernandes Secretaria de Estado da Saúde de São Paulo, São Paulo - SP, Brazil P-580 USE OF RED BLOOD CELL CONCENTRATES IN SURGERY: EVIDENCES OF INADEQUATE INDICATIONS J. Rojo, D. Quezada, A. Arroyo, P. Lopez Centro Nacional de Transfusion Sanguinea, Mexico, Mexico P-581 HAEMOVIGILANCE PROGRAM IN THE BLOOD BANK OF NATIONAL INSTITUTE OF PEDIATRICS, MEXICO. IMPROVING THE DATA SINCE THE IMPLEMENTATION J.L. Salazar, D. Aguilar, A. Bravo, I.A. Ibarra, G. Escamilla National Institute of Pediatrics, Mexico P-583 ADVERSE TRANSFUSION REACTIONS-A 5-YEAR DATA OF SPS APOLLO HOSPITALS, LUDHIANA, PUNJAB, INDIA H. Narang SPS Apollo Hospitals, Ludhiana, India P-584 HAEMOVIGILANCE: ADVERSE REACTIONS TO TRANSFUSION (2004-2011) BLOOD BANK NATIONAL INSTITUTE CARDIOLOGY ‘IGNACIO CHAVEZ’ A.M. Mejia-Dominguz Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico City, Mexico

209

Posters Published

P-594 ELEVATED LEVELS OF PROCOAGULANT MICROPARTICLES IN PATIENTS WITH BETATHALASSEMIA D. Ashour, M.H. Al-Raies, W. Mostifa, F. Moftah National Blood Transifusion Servesies, Cairo, Egypt

P-586 THE FOLLOW OF PEDIATRICS TRANSFUSED PATIENTS AT THE BRAZZAVILLE UNIVERSITY HOSPITAL: NECESSITY OF HAEMOVIGILANCE A. Bokilo-Dzia, B. Angounda, F. Niama, G. Moyen Centre National de Transfusion Sanguine, Brazzaville, Congo

P-595 RECOMBINANT ACTIVATED FACTOR VIIA IN FULMINANT HEPATIC FAILURE WITH UNOS STATUS 1A PATIENTS: A SINGLE TERTIARY ACADEMIC CENTER EXPERIENCE H.P. Pham, S. Hsu, S. Jones-Parker, B. Samstein, D. Diuguid, J. Schwartz New York-Presbyterian Hospital - Columbia University Medical Center, New York, USA

Topic 7: Cellular Therapies 7.1 Stem Cell and Tissue Banking, incl. Cord Blood

P-590 INCIDENCE OF POSITIVE CULTURES IN THE BLOOD BANK'S BACTERIOLOGICAL CONTROL C. Martinez, H. Baptista, J. Noguez, R. Hernandez Médica Sur, Distrito Federal, Mexico

P-597 GAMMA-IRRADIATED MESENCHYMAL STROMAL CELLS EXHIBIT IMMUNOSUPPRESSIVE POTENTIAL IN VITRO A.V. Gouveia de Andrade, M. Schmitz, M. Odendahl, M. Bornhäuser, T. Tonn German Red Cross Blood Donor Service East, Dresden, Germany

6.7 Alternatives to Blood Transfusion

P-598 EVALUATION OF HUMAN CORD BLOOD CD34+ HEMATOPOIETIC STEM CELL DIFFERENTIATION TO MEGAKARYOCYTE ON PES NANOFIBER SCAFFOLD COMPARE TO 2-D CULTURE SYSTEM F. Sabaghi, K. Shams, N. Amirizadeh, N. Bagheri, M. Nikougoftar IBTO, Tehran, Iran

P-591 EIGHT-YEAR EXPERIENCE OF BLOODLESS SURGERY AT A TERTIARY CARE HOSPITAL IN KOREA J.W. Shin, K.I Jo, T.Y. Choi, Y.J. Park, U. Yum Soonchunhyang University Hospital, Seoul, South-Korea

Posters Published

Posters Published

P-585 A NEW APPROACH FOR TRANSFUSING PATIENTS IN SWITZERLAND H. Hustinx, C. Niederhauser, S. Lejon Crottet, P. Gowland, M. Vogt, B. Mansouri Taleghani, S. Fontana BTS SRC Berne Ltd., Berne, Switzerland

P-589 BEGINNING OF HAEMOVIGILANCE SYSTEM IN SERBIA M. Romic´ National Blood Transfusion Institute of Serbia

210

Posters Published

P-592 THE PREVALENCE OF PRE-OPERATIVE ANAEMIA IN PATIENTS UNDERGOING ELECTIVE SURGERY G.M. Carpani, M. Pugliano, M. Verga, M.L. Zighetti, N. Vozzo, D. Forlani, A. Monti, A. Panzetta AO San Paolo, Milan, Italy

P-599 HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL CAN BE ENHANCE THE RATE OF OSTEOBLASTIC DIFFERENTIATION OF BONE MARROW MESENCHYMAL STEM CELL IN VITRO R. Fadaei, N. Amirizaeh, M. Nikougoftar Zarif High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

P-593 SUCCESSFUL SECONDARY PROPHYLAXIS IN HAEMOPHILIA WITH INHIBITORS USING RFVIIA THREE TIMES PER WEEK O. Torres, G.A. Arbesú, S. Borchichi, S. Gastaldo, M. Martínez, P. Do Nascimento Instituto William Osler, Ciudad de Buenos Aires, Argentina

P-600 MESENCHYMAL STEM CELL SEPARATION FROM WHARTON’S JELLY & ITS TRANSDIFFERENTIATION INTO KERATINOCYTES M.A. El Ansary, N. Shaheen, R. Farid, I.E.M. Bishai Cairo University, Cairo, Egypt

211

Posters Published

P-608 UMBILICAL CORD BLOOD PROCESSING VOLUMES COMPARED TO TOTAL NUCLEATED CELL COUNT AND CD34+ RESULTS M.B. Fisk, R. Adams, C. Cielak, T. Traylor South Texas Blood & Tissue Center, San Antonio, USA

P-602 ISOLATION AND CHARACTERIZATION OF HUMAN UMBILICAL CORD BLOOD MESENCHYMAL STEM CELLS M. Ghorbani, M. Kheirandish, S.M. Hashemi, P. Rahimzadeh, S. Azizidoost IBTO, Tehran, Iran

P-609 EFFECT OF TIMING OF UMBILICAL CORD CLAMPING ON CORD BLOOD VOLUME COLLECTED M. Torrabadella, A. Marti, A. Senin, S. Querol, P. Ortiz, L. Puig Banc de Sang i Teixits, Barcelona, Spain

P-604 ADENOVIRUS-MEDIATED EXPRESSION OF THE NUCLEAR FACTOR ERYTHROID-2 RELATED FACTOR 2 PROTEIN WITHIN THE MSCS DECREASED THE CYTOTOXICITY AND INHIBITED THE APOPTOSIS INDUCED BY OXIDATIVE STRESSES M. Mohammadzadeh, M. Habibi Roudkenar High Institute for Research and Education in Transfusion Medicine, Tehran, Iran P-605 THE POTENTIAL IMPACT OF CELL SEPARATION METHODS ON THE FUNCTIONAL CAPABILITIES OF UCB DERIVED CD133+ CELLS M. Kheirandish, A. Noroozi Aghide, M. Ghorbani, A. Goodarzi Blood Transfusion Research Center, High Institute for Research and Education in, Tehran, Iran P-606 STANDARDIZATION AND COMPARISON OF IMMUNOSUPPRESSIVE POTENCY TESTS FOR MESENCHYMAL STROMAL CELL - BASED THERAPIES A.V. Gouveia de Andrade, M. Schmitz, M. Odendahl, M. Bornhäuser, T. Tonn German Red Cross Blood Donor Service East, Dresden, Germany P-607 REGENERATIVE MEDICINE: SYNERGIES IN CELLULAR THERAPY, BLOOD AND TISSUE BANKING M.B. Fisk South Texas Blood & Tissue Center, San Antonio, USA

Posters Published

Posters Published

P-601 OXIDATIVE PRECONDITIONING OF MESENCHYMAL STEM CELLS ENHANCES THEIR RESISTANCE AGAINST OXIDATIVE STRESS M.A. Jalili, H. Bashiri, M. Habibi Roudkenar, M. Navidrouyan, R. Halabian IBTO, Tehran, Iran

P-603 HARVESTING OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN HEMATOLOGICAL PATIENTS R. Grubovic, R. Dukovski, A. Hristova-Dimceva, S. Useini, B. Georgievski, L. Cevreska, S. Genadieva-Stavric, A. Pivkova, Z. Stojanoski, M. Grubovic Department for Stem Cell Collection, Institute for Transfusion Medicine of RM, Skopje, Macedonia

212

Posters Published

P-610 HEMATOPOIETIC MYELOID PROGENITORS CONTENT IN PERIPHERAL BLOOD APHERESIS UNITS OBTAINED OF HEALTHY DONORS AND HEMATOLOGICAL PATIENTS F. Luna-Bautista, Y. Romero, S. Arellano, E. Franco, L. Gasca Laboratory of hematopoiesis. Oncological Diseases Research Unit IMSS., Mexico DF, Mexico P-611 FLUCTUANT ALDH LEVELS IN HSCS ISOLATED FROM CORD BLOOD IN EXPANSION AND FREEZING M.H. Mohammadi Garavand, M. Aghaiipoor, S. Mortazavi, M. Nikougoftar, N. Amirizadeh, D. Rezazadeh IBTO, Tehran, Iran P-612 COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN HEALTHY DONORS R. Grubovic, B. Georgievski, R. Dukovski, L. Cevreska, A. Hristova-Dimceva, S. Genadieva-Stavric, S. Useini, A. Pivkova, A. Stojanovic, M. Grubovic Department for Stem Cell Collection, Institute for Transfusion Medicine of RM, Skopje, Macedonia P-613 EVALUATION OF THE EFFECTIVENESS OF PREPARATION AND THE VIABILITY OF STEM CELLS OBTAINED FROM UMBILICAL CORD BLOOD USING A FLOW CYTOMETER FC 500 E. Przybylska, A. Skrzypczak, K. Olbromski, H. Skalisz Blood Center Poznan, Poznan, Poland P-614 EVALUATION OF STEM CELLS QUANTITY OBTAINED IN THE PORTION OF UMBILICAL CORD BLOOD USED FOR BLOOD BANKING IN TERMS OF THEIR SUITABILITY FOR TRANSPLANTATION A. Skrzypczak, E. Przybylska, K. Olbromski, H. Skalisz Blood Center Poznan, Poznan, Poland

213

Posters Published

7.2 Collection, Processing, Storage and Release P-615 IL-15 IS ABLE TO INCREASE THE EX-VIVO EXPANSION OF CYTOKINE INDUCED KILLER CELLS P. Iudicone, G. Bonanno, D. Fioravanti, A. Pandolfi, R. Scocchera, M. Corallo, E. Cicchetti, L. Pierelli S. Camillo-Forlanini Hospital, Rome, Italy

P-623 EVALUATION OF THE SPECTRA OPTIA® APHERESIS SYSTEM MONONUCLEAR CELL (MNC) COLLECTION PROCEDURE IN MULTIPLE MYELOMA PATIENTS J. Bill, G. Long, E. Waller, S. Gregurek, G. Tricot Terumo BCT, Lakewood, CO, USA P-624 EXPERIENCE IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN THE NATIONAL INSTITUTE OF PEDIATRICS. MEXICO CITY D. Aguilar Escobar, A. Olaya Vargas, A.G. Bravo Lindoro, M. Perez, A. Del Campo Martinez, G. Escamilla, T. Flores Camacho, P. Sanchez Sanchez National Institute of Pediatrics, Mexico City, Mexico

P-619 INTRA-PROCEDURE MOBILIZATION OF CD 34+ CELLS IN THE COURSE OF APHERESIS PROCEDURES Z. Gasova Institute of Hematology and Blood Transfusion, Prague, Czech Republic

P-625 STEM CELL APHERESIS COLLECTION WITH A NOVEL APHERESIS SYSTEM FEATURING ELECTRONIC INTERPHASE MONITORING H. Bonig, S. Bräuninger, H. Bialleck, K. Thorausch, E. Seifried German Red Cross Blood Service Baden-Württemberg-Hesse, Frankfurt, Germany

P-621 IMPACT OF THE MOBILIZATION REGIMEN AND THE HARVESTING TECHNIQUE ON THE GRANULOCYTE YIELD IN HEALTHY DONORS FOR GRANULOCYTE TRANSFUSION THERAPY J. Ikemoto, S. Yoshihara, T. Fujioka, Y. Ohtsuka, N. Fujita, A. Kokubunji, N. Okamoto, J. Ono, K. Taniguchi, K. Kaida, K. Ikegame, M. Okada, T. Tanizawa, H. Ogawa, S. Kai Hyogo College of Medicine, Nishinomiya/Hyogo, Japan P-622 COMPARISON OF THE SPECTRA OPTIA® APHERESIS SYSTEM AND THE COBE SPECTRA FOR THE COLLECTION OF POLYMORPHONUCLEAR LEUKOCYTES J. Bill, L. Taylor, D. Ambruso Terumo BCT, Lakewood, CO, USA

Posters Published

Posters Published

P-618 THE USE OF CONTROLLED-RATE VS. UNCONTROLLED-RATE FREEZING IN LYMPHOCYTE AND PLATELET CRYOPRESERVATION SETTING B. Balint, M. Todorovic, D. Vucetic, B. Draskovic, G. Ostojic, N. Rafajlovski Institute for Transfusiology and Hemobiology of MMA, Belgrade, Serbia

P-620 PLASMA EXCHANGE FOR PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA-HEMOLYTIC UREMIC SYNDROME (TTP-HUS) IN PUSAN NATIONAL UNIVERSITY HOSPITAL(2003-2011) H.H. Kim, K.H. Shin, H.C. Son, E.Y. Lee Pusan National University, Busan, South-Korea

214

Posters Published

7.3 Clinical Applications P-627 AUTOLOGOUS CD133+ CELLS AS SALVAGE THERAPY FOR CRITICAL LIMB ISCHEMIA C. Perotti, V. Arici, A. Bozzani, F. Calliada, C. Del Fante, M. Cervio, G. Viarengo, M. Pagani, F. Alessandrino, F. Ragni IRCCS Fondazione Policlinico S.Matteo, Pavia, Italy P-628 AUTOLOGOUS PLASMA RICH IN PLATELET-DERIVED GROWTH FACTORS FOR TREATMENT OF REFRACTORY OCULAR GRAFT VERSUS HOST DISEASE S. Pezzotta, C. Del Fante, L. Scudeller, M. Cervio, E.R. Antoniazzi, C. Perotti Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy P-631 A NOVEL PATHWAY OF PANCREATIC CANCER COUNTERATTACK MEDIATED BY MUC4 W.B. Liang, Y. Zhu, J.J. Zhang, B. Wang Jiangsu Province Blood Center, Nanjing, China

215

Posters Published

Posters Published

P-639 THE EFFECT OF INTRODUCTION OF TYPE AND SCREEN BLOOD REQUISITION METHOD IN OUR INSTITUTION I.M. Tesic, D.S. Popov General Hospital Djodje Joanovic, Zrenjanin, Serbia

P-633 ALEMTUZUMAB (ANTI-CD52) CAN MIMIC HLA ALLOANTIBODIES IN COMPLEMENTDEPENDENT CYTOTOXICITY ASSAYS FOR SEVERAL MONTHS AFTER WITHDRAWAL OF THE DRUG E.B.M. Taaning, L.P. Ryder, H. Bruunsgaard, A.-C. Lundstedt, B.K. Jakobsen, N.S. Andersen, F.J. Vojdeman, M. Montagna, M. Regazzi, C. Geisler Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Topic 8: Clinical Immunogenetics

P-634 EXPRESSION OF HUMAN FACTOR IX IN AMNIOTIC MEMBRANE MESENCHYMAL STEM CELLS M. Paridar, N. Amirizadeh, M. Nikoogoftar, M. Khorshidfar, M. Amani High Institute for Education and Research in Transfusion Medicine, Tehran, Iran P-635 AUTOLOGOUS BONE MARROW-DERIVED AND CULTURED MESENCHYMAL STEM CELL THERAPY FOR AVASCULAR NECROSIS OF THE FEMORAL HEAD D.W. Zhao, F.Q. Lu, W.M. Wang, D.P. Cui, B.J. Wang, J. Zhou Affiliated Zhongshan Hospital of Dalian University, Dalian, China P-636 CLINICAL APPLICATION OF UCB IN CHINA F. Qin, J. He, S. Chen, F. Wang, B. Dai, G. Xu, F.-M. Zhu, H.-J. Lv Zhejiang Blood Center, Hangzhou, China P-637 EFFICIENCY OF MEDICAL PLASMAPHERESIS IN BRONCHIAL ASTHMA THERAPY B. Bakhovadinov, M.U. Gulyamova, H.H. Urunov, A.B. Hojiev Republican Scientific Center of Blood, Dushanbe, Tajikistan

Posters Published

Posters Published

P-632 TREATMENT OF AVASCULAR NECROSIS OF THE FEMORAL HEAD BY VASCULAR ENDOTHELIAL CELL GROWTH FACTOR AND BONE MORPHOGENETIC PROTEIN-2-TRANSGENIC BONE MARROW MESENCHYMAL STEM CELL D.W. Zhao, F.Q. Lu, D.P. Cui Affiliated Zhongshan Hospital of Dalian University, Dalian, China

8.1 HLA in Transfusion Medicine P-641 DISTRIBUTION OF MICA ALLELES AND HAPLOTYPES ASSOCIATED WITH HLA-A/B/DRB1 IN CHINA N. Xia, X. Xu, X. Ye Guangzhou Blood Center, Guangzhou, China P-642 HLA-DRB1 ALLELES ASSOCIATED WITH THERAPEUTIC RESPONSE IN HEPATITIS C VIRUS INFECTION A. Palacios, J. von Moreno, N. van Abraham, A. van Racca, S. van García Borrás Fac. Cs.Bioquímicas UNR, Rosario, Argentina P-643 A STUDY ON THE CORRELATION OF KILLER IMMUNOGLOBULIN-LIKE RECEPTOR GENE DIVERSITY WITH NASOPHARYNGEAL CARCINOMA IN THE SOUTHERN CHINESE HAN POPULATION L. Lu, S.Q. Gao, Z.H. Deng Shenzhen Blood Center, Shenzhen, China P-644 COMPARISON METHODOLOGIES FOR ANTI-HLA ANTIBODY SCREENING AMONG BLOOD DONORS O. Kuznetsov, A. Matveev, N. Dashkova, A. Ragimov Russian Scientific Center of Surgery named after acad. B. V. Petrovsky RAMS, Moscow, Russian Federation

P-638 CONTRIBUTION OF BONE MARROW MESENCHYMAL STEM CELLS TO HEPATIC INJURY IN A RAT MODEL Z. Feng, I. Zhao, S. Jiao QingDao Blood Center, QingDao, China

216

217

Posters Published

8.2 Histocompatibility in Stem Cell Transplantation P-646 FAMILY DONOR SEARCH - SINGLE CENTER EXPERIENCE S.M. Radojska, D.M. Hellmann, C. Scheid, B.S. Gathof University Hospital of Cologne, Cologne, Germany

P-648 COMPARISON BETWEEN THE HLA FREQUENCIES OF VOLUNTEER DONORS RECRUITED IN THE CAMPANIA BONE MARROW DONOR REGISTRY AND THE ITALIAN POPULATION (IBMDR) P.B. Minucci, C. Sabia, M. Resse, V. Crudele, A. Picascia, A. Russo, L. Sommese, F.P. De Luca, F. Cavalca, A. Casamassimi, C. Napoli Division of Immunohematology, School of Medicine, Second University of Naples, Naples, Italy P-649 ROLE OF THE KIR GENES IN THE DEVELOPMENT OF GRAFT-VERSUS-HOST-DISEASE IN PATIENTS WITH HAEMATOPOIETIC STEAM CELL TRANSPLANT E. Bravo Flores, E. Sánchez Valle, J.C. Martínez Álvarez, M. Contreras Serratos, A. Arrazola García, M.E. Pérez Rodríguez, Instituto Mexicano del Seguro Social, D.F. Mexico

P-653 COMPARING TWO DIFFERENTS KITS: LABSCREEN MIXED (ONE LAMBDA) AND LIFESCREEN LIFECODES DELUXE (GENEPROBE) CLASS I AND CLASS II ANTIBODIES C. Sabia, M. Resse, P.B. Minucci, E. Cesario, A. Casamassimi, A. Russo, F. Cavalca, F.P. De Luca, L. Sommese, C. Napoli Division of Immunohematology, School of Medicine, Second University of Naples, Naples, Italy P-655 KIDNEY TRANSPLANTATION AND IMMUNOHEMATOLOGICAL PROFILE IN NAPLES: A COORDINATING REGIONAL EXPERIENCE FROM 2000 TO 2006 V. Grimaldi, A. Picascia, P. Giannattasio, S. Federico, M. Santangelo, L. Sommese, C. Napoli Division of Immunohematology, School of Medicine, Second University of Naples, Naples, Italy

Topic 9. Novel Development 9.1 Novel Development

P-650 DISADVANTAGES IN THE TIPIFICACION OF HLA OF UMBILICAL CORD BLOOD IN THE BANK CMN ‘LA RAZA’ E. Juárez, A. Arriaga, R.M. Macias, M.L. Gasca Instituto Mexicano del Seguro Social, Mexico City, Mexico

P-656 A STEP FURTHER IN INNOVATION WITH THE TACSI WHOLE BLOOD PLATFORM: INTERNAL VALIDATION OF EXPECTED FEATURES AND BENEFITS OF A FULL AUTOMATED BLOOD COMPONENT PROCESSING MACHINE F. Bidet, R. Biset, I. De Neve, M. Imholz, M. Hirabuki, W. Mertens, K. Nackaerts Terumo Europe N.V., Leuven, Belgium

8.3 Histocompatibility in Organ Transplantation

P-657 THE EFFECT OF PHARMACOLOGICAL MOBILIZATION OF MESENCHYMAL STEM CELLS IN TREATMENT OF SKIN BURN INJURIES IN AN ANIMAL MODEL M.J. Sharifi, A. Samadikuchaksaraei, N. Nasiri, M. Soleimani, N. Azad IBTO, Tehran, Iran

P-651 SUCCESS IN THE RENAL GRAFT SURVIVAL AND ITS ASSOCIATION WITH THE HISTOCOMPATIBILITY TESTING (HLA, PRA% AND CROSSMATCH -CDC-) MADE IN CENTRAL BLOOD BANK FROM NATIONAL MEDICAL CENTRE SXXI, IMSS J.C. Martínez Álvarez, M.A. Arrazola García, R.A. Fuentes Landa, A. Suárez Cruz, R. Romero Valdiviezo, M.C. Gracida Juárez IMSS, Mexico City, Mexico

218

P-652 ASSOCIATION BETWEEN HLA-A26 AND CMV INFECTION IN HEART TRANSPLANTATION RECIPIENTS B. Damiano, M. Sessa, E. Cesario, T. Di Mauro, A. Belsito, M. Ferriero, B. Bibba, F. Ziello, I. Caiafa, S. Conte, L. Sommese, C. Maiello, G. Romano, F. Cacciatore, C. Napoli Division of Immunohematology, School of Medicine, Second University of Naples., Naples, Italy Posters Published

Posters Published

P-647 FREQUENCY OF HLA-B ALLELES IN AN IRANIAN POPULATION F. Yari, F. Sabaghi, Shaiegan, Bagheri, Zaman Vaziri, Dikloo, Sobhani Blood Transfusion Research Center, High Institute for Research and Education, Tehran, Iran

Posters Published

P-658 NEW APPROACH FOR THE EVALUATION OF PRION DECONTAMINATION PROCEDURES: IN VITRO AMPLIFICATION OF PRION ON STEEL WIRES D. Bougard, M. Bélondrade, C. Prieto, V. Béringue, J. Coste, S. Lehmann Etablissement Français du Sang - Pyrénées Méditerranée, Montpellier, France 219

Posters Published

P-659 LEUKOCYTE ADHESION DEFICIENCY TYPE III DUE TO A NOVEL MUTATION IN THE FERMT3 GENE E.B.M. Taaning, B.F. Shah, L.D. Schejbel, H.V. Marquart, L.P. Ryder, M. Ifversen, C. Heilmann, K. Müller Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Posters Published

P-660 VIABILITY OF PLATELETS STORED IN BAGS OF PVC MADE WITH DIFFERENT CONTENTS OF PLASTICIZER (TOTM) A.O. Chiera, L. Rimorini, L.E. Krause, M. Martino, E. Lara, N. Etchenique Hemotherapy Insitute of Buenos Aires Province, La Plata, Argentina P-661 DECREASED DEFORMABILITY OF ERYTHROCYTE IN BLOOD DONORS WITH THALASSEMIA MINOR W. Chen, J.W. Chen, K.S. Lin Taiwan Blood Services Foundation, Taipei, Taiwan P-662 IMPLEMENTATION OF A PRE-ANALYTICAL SYSTEM FOR FULLY AUTOMATED HANDLING OF DONOR SAMPLES D. Holm Kinggaard, U. Sprogøe, J. Georgsen Odense Universityhospital, Odense C, Denmark

220

Posters Not Published


2. Blood Donation 2.1 Blood Donor Recruitment 2.2 Blood Collection incl. Apheresis 2.3 Donor Adverse Events 3. Blood Products 3.1 Blood Processing, Storage and Release 3.2 Blood Components 3.3 Plasma Products 3.4 Pathogen Inactivation 3.5 Biologicals 4. Transfusion Transmitted Infections 4.1 Screening Strategies for TTI 4.2 Hepatitis B (HBV) 4.5 Bacteria 4.7 Newly Emerging Pathogens and other Transfusion Related 5. Immune Haematology 5.1 Red Cell Immunology: Serology 5.2 Red Cell Immunology: Molecular 5.3 Platelet Immunology 5.5 Fetal-Maternal Immunology

BP-001 - BP-005 BP-006 BP-007 BP-009 BP-010 - BP-011 BP-012 - BP-015


1. Management and Organisation 1.1 Organisational Issues 1.2 Information Technology 1.3 Cost/Effectiveness 1.4 Training and Education 1.6 Blood Supply Management and Utilization 1.8 Quality Management

BP-016 - BP-025 BP-026 - BP-027 BP-028 - BP-030

BP-031 - BP-036 BP-040 - BP-044 BP-045 - BP-047 BP-048 - BP-051 BP-052 - BP-053

BP-054 BP-055 BP-058 BP-059 - BP-061

BP-062 - BP-075 BP-076 - BP-085 BP-086 - BP-087 BP-089 - BP-093

221




Posters Not Published Topic 1: Management and Organisation

BP-094 - BP-096 BP-098 - BP-106 BP-107 - BP-110 BP-111 - BP112 BP-113 - BP-116 BP-117 - BP-118

7. Cellular Therapies 7.1 Stem Cell and Tissue Banking, incl. Cord Blood 7.3 Clinical Applications

BP-119 BP-120 - BP-121

8. Clinical Immunogenetics 8.1 HLA in Transfusion Medicine

BP-122

9. Novel Development 9.1 Novel Development

BP-123 - BP124



6. Clinical Transfusion 6.2 Therapeutic Apheresis 6.3 Evidence Based Transfusion Medicine Practice 6.4 Haemorrhage and Massive Transfusion 6.5 Adverse Events, incl. TRALI 6.6 Haemovigilance and Transfusion Safety 6.7 Alternatives to Blood Transfusion

1.1 Organisational Issues BP-001 BLOOD IN ALGERIA: CURRENT STATUS AND PROSPECTS C. Amaouz, K. Kezzal National Blood Agency, Algiers, Algeria BP-003 TRACK AND TRACE FOR BLOOD PRODUCT DURING TRANSPORTATION R. Knels, J. Neuhaus, T. Börner, T. Rühr German Red Cross Blood Donor Service, Cottbus, Germany BP-004 BLOOD DONOR COUNSELLING TO ENSURE BLOOD SAFETY AND SUFFICIENCY C.M. Reed Centers for Disease Control and Prevention, Atlanta, USA BP-005 INTRODUCTION OF THE NATIONAL BLOOD SAFETY PROGRAM IN TAJIKISTAN B. Bakhovadinov Republican Scientific Center of Blood, Dushanbe, Tajikistan

1.2 Information Technology BP-006 EVALUATION OF COMPOVISION™ IN A LARGE BLOOD COMPONENT PREPARATION LABORATORY AT HEMOMINAS FOUNDATION: A NEW TOOL FOR THE MANAGEMENT OF BLOOD COMPONENT PRODUCTION F.N. Givisiez, F.V. Basques, J.G.M. Cioffi, A.M. Ferreira, R. Omoto Fundacao Hemominas, Belo Horizonte, Brazil

222

223


1.3 Cost/Effectiveness

1.4 Training and Education BP-009 EVALUATION OF EDUCATIONAL INTERVENTION TO IMPROVE KNOWLEDGE AND PERCEPTIONS OF BLOOD DONATION ON HEALTH WORKERS, PUEBLA 2009 J. Castell, J.F. Molina Rodriguez, H.M. Lamadrid Figueroa Instituto Nacional de Salud Publica, Cuernavaca, Morl, Mexico

1.6 Blood Supply Management and Utilization BP-010 PROJECT OF IMPLEMENTATION OF THE AUTHENTICATION CODE OF THE SANGUINEOUS COMPONENTS ACCORDING TO STANDARD ISBT 128 IN THE BLOOD DONATION POINT OF THE NATIONAL INSTITUTE OF PEDIATRICS OF MEXICO M.L. Medina Macias, D.V. Aguilar Escobar, A.G. Bravo Lindoro, G. Escamilla Guerrero Instituto Nacional de Pediatria, Mexico D.F., Mexico BP-011 WASTE OF BLOOD COMPONENTS RATE, WISE OR UNWISE? H. Kaabomair, M.A. Jalali Far, B. Ghafleh Marammazi, N. Saki Jundishapoor University of Medical Science, Shooshtar, Iran

1.8 Quality Management BP-012 RESULTS FROM THE INTRODUCTION OF A BLOOD SAFETY PROGRAM IN TAJIKISTAN B. Bakhovadinov Republican Scientific Center of Blood, Dushanbe, Tajikistan

224

BP-013 VERTICAL AUDIT OF BLOOD COLLECTION AND PREPARATION PROCESS OF NATIONAL BLOOD CENTRE (NBC), SRI LANKA W.W.K. Perera National Blood Centre, Colombo 05, Sri Lanka BP-014 RISK MANAGEMENT IN INTRAOPERATIVE RED BLOOD CELL SALVAGE M. Bove, I. Casorelli, C. Berdini, A. Formichella, O. Terminali Sant’Andrea Hospital, Roma, Italy



BP-007 REAGENT COST ANALYSIS OF VITROS ECI AND ELISA TEST SYSTEMS FOR THE SCREENING OF DONOR BLOOD TO DETECT ANTI-HIV 1 & 2,HBSAG, ANTI-HCV L.E.C. Kithsiri, B.H.A.M. Jayawardena National Blood Transfusion Service, Colombo, Sri Lanka


BP-015 HUMAN SERUM BANK - FUNDAMENTAL BIOREPOSITORY FOR NATIONAL BLOOD SYSTEM Q. Park, H.J. Ro, Y.W. Park, E.J. Kim, Y.J. Cha Chung-Ang University, Seoul, South-Korea

Topic 2: Blood Donation 2.1 Blood Donor Recruitment BP-016 MY ROLE AS A BT COORDINATOR IN A RURAL NEW TEACHING HOSPITAL AND DISTRIBUTION OF ABO AND RHD BLOOD GROUPS AMONG PATIENTS THAT ATTENDED THIS HOSPITAL DURING THE PERIOD OF JULY 2010 TO MARCH 2011 I. Olajide, M.E. Borke, M.U. Nwagu DELSUTH, Oghara, Nigeria BP-017 PROFILE OF BLOOD DONORS IN DURRES REGIONAL BLOOD BANK V. Durro, S. Qyra, S. Hasbiu Ministry of Health, Tirana, Albania BP-018 CHOLESTEROL-, HDL- AND LDL-VALUES OF BLOOD DONORS - MEASURED AS PART OF A DONOR RELATIONSHIP PROGRAM FOR INTENSIVE BLOOD DONORS IN GERMAN RED CROSS BLOOD DONOR SERVICE EAST R. Knels, G. Galle, T. Blankenburg, N. Hiller, M. Hecker, R. Rothe German Red Cross Blood Donor Service, Cottbus, Germany

225


BP-019 PREVALENCE OF YOUNG DONORS AFTER EGYPT REVOLUTION, CASE STUDY IN REGIONALTRANSFUSION CENTER IN DAKHLIA, EGYPT M. Farid RBTC, Mansoura, Egypt

BP-022 KAP ASSESSMENT ON LINE: A COSTS SAVING AND EFFICIENT WAY OF MEASURING KNOWLEDGE, ATTITUDE AND PRACTICE ON BLOOD DONOR MOTIVATION, RESTRICTION, AND DONATION PRACTICE A. Los APMLos Consultancy, Groningen, Netherlands BP-023 REASONS FOR DEFERRAL AND THEIR RELATIONSHIP TO SOCIO DEMOGRAPHIC FACTORS AMONG FEMALE VOLUNTARY NON REMUNERATED BLOOD DONORS IN SRI LANKA L.E.C. Kithsiri, B.H.A.M. Jayawardena National Blood Transfusion Service, Colombo, Sri Lanka BP-024 IMPACT OF THE INFORMATION, PROMOTION AND DIFFUSION OF ALTRUISTIC BLOOD DONATION IN MEXICO S. Lima Sanchez, A. Guerra Marquez, A.R. Avalos Sanchez, S. Martinez Mercado, G. Benitez Arvizu Banco Sangre IMSS, Distrito Federal, Mexico BP-025 REAL IMPACT OF THE NAT TECHNIQUE IN THE TIMELY DIAGNOSIS OF VIRAL INFECTIONS. DOES NULL RISK EXIST? O. Torres Torres, A. Bernal, M.L. Vargas, R. Montes, D. Graciela Dominguez, G.A. Castañeda, O. Torres Torres Instituto Mexicano del Seguro Social IMSS, Guadalajara Jalisco, Mexico

226

2.2 Blood Collection including Apheresis BP-026 ANALYSIS OF WHOLE BLOOD DONATION TIME ACCORDING TO AGE, SEX, CONSTITUTIONAL CONDITIONS OF DONORS IN 2010-2011 IN BLOOD CENTER IN POZNAN N. Kalisz, A. Laba, H. Skalisz, K. Olbromski Blood Center Poznan, Poznan, Poland



BP-020 BLOOD DONOR ORGANIZATION: A PREDICTIVE MODEL OF BLOOD DONATION SATISFACTION P. Guiddi, E. Marta, S. Alfieri, V. Saturni Catholic University, Milan, Italy


BP-027 COMPARATIVE ANALYSIS OF THE PERFORMANCE OF TRIMA ACCEL SYSTEMS CELL SEPARATION IN OBTAINING PRODUCTS OF PLATELETS BY APHERESIS C. Martinez, H. Baptista, R. Hernandez, A. Martinez Médica Sur, Distrito Federal, Mexico

2.3 Donor Adverse Events BP-028 MULTIVARIED ANALYSIS OF THE ADVERSE REACTIONS TO THE DONATION (RAD) FOR PLATELET APHAERESIS: EXPERIENCE OF THREE CENTERS OF TRANSFUSIONAL MEDICINE R. Palomino Morales, S.A. Sánchez Guerrero, A.L. DÁrtote González, A. Malagón Martínez Instituto Nacional de Cancerología, México D.F., Mexico BP-029 ACTIVITIES IMPLEMENTED TO REDUCE AND PREVENT ADVERSE EVENTS IN THE DONATION: NATIONAL INSTITUTE OF CARDIOLOGY IGNACIO CHAVEZ 2008-2011. L. Luna-Mendoza Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico City, Mexico BP-030 INCIDENCE OF ADVERSE REACTIONS IN BLOOD DONATION: NATIONAL INSTITUTE OF CARDIOLOGY IGNACIO CHAVEZ, 2006-2011 L. Luna Mendoza, L. Cruz Rodriguez, A.M. Mejia Dominguez Instituto Nacional de Cardiologia “Ignacio Chavez”, Distrito Federal, Mexico

227


3.2 Blood Components

3.1 Blood processing, Storage and Release

BP-040 QUANTITATIVE DETERMINATION OF FXIA AS IMPURITIES IN THERAPEUTIC IMMUNOGLOBULINS FROM FOUR CHINESE BLOOD FRACTIONATION INDUSTRIES L. Ma, P. Sun, Y. Xie, F. Lin, G. Diao, C. Li Institute of Blood Transfusion, CAMS, Chengdu, China


BP-032 EVALUATION OF THREE DIFFERENT METHODS TO COUNT PLATELETS IN PLATELET CONCENTRATES S. Suessner, A. Ohler, D. Ecklbauer, R. Schaumberger, C. Gabriel Red Cross Blood Transfusion Service of Upper Austria, Linz, Austria BP-033 PERFORMANCE EVALUATION OF LEUCOFLEX LCRD FILTER UNDER DIFFERENT PROCESSING CONDITIONS T.G. Hvid, H.D. Jepsen, B.K. Petersen, M. Robiquet, C. Mathiesen, A. Toll, F. Persson, P. Pale, K.M. Homburg Region Zealand, Naestved, Denmark BP-034 BENEFITS OF ADDITIVE SOLUTION FOR PLATELET STORAGE IN THE MANAGEMENT OF PLATELET AND PLASMA STOCKS M. Strauss Patko, M. Balija, I. Jukic Croatian Institute of Transfusion Medicine, Zagreb, Croatia BP-035 COMPARISON BETWEEN 1 HOUR AND 2 HOURS RESTING PERIOD OF WHOLE BLOOD BEFORE FILTRATION M.I. Trinks, N. Tynngård, G. Berlin University Hospital, Linkoping, Sweden BP-036 STUDY OF PRESENT MAINTENANCE MANAGEMENT PROGRAM USING WITH BLOOD BANK REFRIGERATORS OF IRANIAN BLOOD BANK CENTERS M. Fallah Tafti, G. Karimi, H. Teimuri Naghadeh, M.E. Khayami High Institute of Reaserch and Education for Blood Therapy, IBTO, Tehran, Iran


Topic 3: Blood products

BP-031 DOES LONG-TERM STORAGE ALTER THE HAEMOSTATIC POTENTIAL AND BALANCE OF TRANSFUSION PLASMA AFTER THAWING? A. Heger, J. Römisch Octapharma PPGmbH, Vienna, Austria

228


BP-041 HEMOLYSIS DETERMINATION IN RED BLOOD CELL UNITS AS A REQUIREMENT OF QUALITY CONTROL OF THE EUROPEAN DIRECTIVE 2004/33/EC L.A. Ibarra, H.G. Baptista, C.H. Santamaría, M.C. Muñoz Médica Sur, Distrito Federal, Mexico BP-042 LIPID PEROXIDATION AND TOTAL NITRATES IN PLATELET CONCENTRATES: A PILOT STUDY I.F. Lozada Medina, J. Gutiérrez Salinas, C. Zepeda García, M. Cedillo Martínez, J.A. Treviño García, S. Hernández Rodriguez, S. Ramírez García Hospital Angeles Mocel, Distrito Federal, Mexico BP-044 STUDY OF BLOOD COMPONENTS DISCARD IN AHWAZ HOPSPITALS IN MARCH-SEPTEMBER 2010 B. Ghafle Marammazi, M.A. Jalali Far, H. Kaab Omir, N. Saki Jundishapoor University of Medical Science, Ahwaz, Iran

3.3 Plasma Products BP-045 ISOLATION AND PURIFICATION OF PROTHROMBIN COMPLEX CONCENTRATION FROM PLASMA BY ION EXCHANGER CG-6 G. Chen, H.W. Zhao, C.M. Yang, Y.Y. Duan, S. Li, L.Z. Zhao, W.T. Zhou, K. Lan, W.M. Fang, J.S. Qiu, Q. He Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China BP-046 A MODIFIED FUNCTIONAL ASSAY OF HUMAN PROTEIN C Z.K. Wang, X. Du, Y.M. Wang, C.Q. Li, F.Z. Lin, J. Yuan, H.J. Cao, X.J. Zhang, S.L. Ye, J.J. Hu Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

229


4.2 Hepatitis B (HBV)

BP-048 IMPLEMENTATION OF PATHOGEN INACTIVATED PLATELETS USING THE INTERCEPT PLATELET PROCESSING SET WITH DUAL STORAGE CONTAINERS J.E.M. Hallberg, B. Winge, E. Tennby, E.M.G. Held Hospital of Halland, Halmstad, Sweden

BP-055 DETECTION OF HBV DNA IN HEPATITIS B VIRUS SURFACE ANTIGEN NEGATIVE BLOOD DONORS BY REAL-TIME PCR G. Karimi, A. Gharehbaghian, M. Fallah Tafti, V. Vafaeian Blood Transfusion Research Center, High Institute for Research and Education, Tehran, Iran

3.5 Biologicals BP-052 THE PREPARATION OF ALBUMIN AS A BIOLOGICAL DRUG FROM HUMAN PLASMA BY FIBER FILTRATION K. Mousavi Hosseini, S. Nasiri, M.A. Jalili, M. Heidari Blood Transfusion Research Center, High Institute for Research and Educattion in, Tehran, Iran BP-053 PASTEURIZATION OF INFUSIBLE PLATELET MEMBRANE MICROVESICLES WITH SODIUM CAPRYLATE STABILIZER S. Nasiri, M. Vatani Baghdadabad, M. Heidari High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

4.5 Bacteria BP-058 COMPARISON OF THE BACT/ALERT BLOOD CULTURE SYSTEM AND MANUAL CULTURE METHOD FOR DETECTION OF AEROBIC AND FACULTATIVE ANAEROBIC BACTERIAL CONTAMINATION IN PLATELET CONCENTRATES F. Razjou, A. Dabirmoghadam Iranian Blood Transfusion Research Center, Tehran, Iran

4.7 N ewly Emerging Pathogens and other Transfusion Related Pathogens BP-059 DENGUE SCREENING IN DONORS WHO IS INITIATED TELEPHONE CALL BACKS WITH FEVER IN KAOHSIUNG CITY, TAIWAN Y.H. Lee Kaohsiung Blood Center, Kaohsiung City, Taiwan

4.1 Screening Strategies for TTI

BP-060 MICROBIOME SCREENING AND BLOOD-SAFETY-THREATENING PATHOGENS IDENTIFICATION FROM POOLED PLASMA M. He, W.P. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

BP-054 VERIFICACIÓN DE MÉTODOS DE SEROLOGÍA INFECCIOSA POR MICROELISA: DETERMINACIÓN DE ANTI-T. CRUZI, DETERMINACIÓN DE ANTICUERPOS ANTI T. PALLIDUM Y DETERMINACIÓN DE ANTICUERPOS CONTRA HEPATITIS C. M.C. Santamaria, H.B. Baptista, E. Roque Alvarez, F. Cedillo Valle Médica Sur, Cd. de México, Mexico

BP-061 MULTIPLEX REAL-TIME PCR FOR THE DETECTION HERPESVIRUSES IN HEALTHY BLOOD DONORS O. Kuznetsov, A. Matveev, N. Dashkova, A. Ragimov Russian Scientific Center of Surgery named after acad. B. V. Petrovsky RAMS, Moscow, Russian Federation

Topic 4: Transfusion Transmitted Infections



3.4 Pathogen Inactivation

BP-051 ASSESSMENT OF QUALITY OF PLASMA AFTER 2-YEAR STORAGE TIME AT A TEMPERATURE BELOW MINUS 250C AND AFTER DEFROSTING AND INACTIVATION USING METHYLENE BLUE B. Janowska-Stuchlak, K. Wolbromski, H. Skalisz Blood Center Poznan, Poznan, Poland

230


231


Topic 5: Immune haematology 5.1 Red Cell Immunology: Serology

BP-063 INFLUENCE OF TIME AND MIGRATION OF POPULATION ON FREQUENCY OF ABO AND RH-D ANTIGENS M. Cvjetkovic, A. Macura Institute of Transfusion Medicine of the Republic of Srpska, Gradiška, Bosnia-Herzegovina BP-064 PREVALANCE AND DISTRIBUTION OF ABO AND RH-D BLOOD GROUPS AMONGST THE POPULATION IN AND AROUND NEW DELHI R. Sood Delhi Heart and Lung Institute,New Delhi, New Delhi, India BP-065 HDN DUE TO ALLOIMMUNIZATION FROM TRANSFUSION-CASE REPORT T. Makarovska-Bojadzieva, J. Samonikov-Tosesvka, I. Nikoloska, E. Velkova, M. Blagoevska, O. Damevska-Todorovska, R. Apostolovska Instiute of Blood Transfusion, Skopje, Macedonia BP-066 A CASE STUDY ON HEMOLYTIC DISEASE OF THE NEW BORN - ANALYSIS AND MANAGEMENT N. Mehta, A. Chindarkar, M. Gupta Kokilaben Dhirubhai Ambani Hospital & Medical Research Center, Mumbai, India BP-067 USE OF SALIVARY HEMAGGLUTININS TO RESOLVE ABO DISCREPANCY N. Mehta, R. Salgaonkar, A. Chindarkar, M. Gupta Kokilaben Dhirubhai Ambani Hospital & Medical Research Center, Mumbai, India BP-068 FALSE NEGATIVE RESULTS OF RHD ANTIGEN IN PATIENT- CASE REPORT N. Milosavljevic-Knezevic, N. Bujandric, M. Krga-Milanovic, D. Ademovic-Sazdanic Blood Transfusion Institute Vojvodina, Novi Sad, Serbia 232

BP-071 ABO AND RH (D) BLOOD GROUP FREQUENCIES IN BLOOD DONORS AT MAJOR HOSPITAL BLOOD BANK IN LIMA PERU: A RETROSPECTIVE ANALYSIS OF 3-YEAR DATA J.A. Paredes, A.A. Pajares, S. Leon, J. Maguiña, M. Paiva, R. Kamiya, A. Sagastegui, I. Perez, H. Reyna, R. Torres, J. Cornejo, R. Zapata Edgardo Rebagliati Hospital, Lima, Peru Posters Not Published


BP-062 PREPARATION OF PANELS SELECTORS AND IDENTIFIERS WITH ANTIGENS FREQUENTLY IN THE SALVADORAN POPULATION C. Villatoro, A.C. Acevedo de Iraheta Hospital Nacional de Niños Benjamín Bloom, El Salvador, El Salvador


BP-073 A DILEMMA - IF THE PATIENT IS ‘O’ POSITIVE OR ‘O’ NEGATIVE? P. Shrivastava Lions Blood Bank Delhi, New Delhi, India BP-074 NATIONAL PHENOTYPED RED BLOOD CELL DONOR PANEL FOR ANTIBODY SCREENING AND IDENTIFICATION - 20 YEARS EXPERIENCE S. Tadic, S. Kosovic, B. Dmitrovic, B. Zivotic, S. Draskovic, O. Ciric Blood Transfusion Institute of Serbia, Belgrade, Serbia

5.2 Red Cell Immunology: Molecular BP-076 DO*A-WL AND DO*B-WL ALLELES CAN BE ASSOCIATED WITH NATIVES IN BRAZILIANS R.D.M. Person, C.P. Arnoni, F.R.M. Latini, J.G. Muniz, F.O. Carvalho, L. Castilho, W. Baleotti Jr, J.A. Barreto Colsan Associação Beneficente de Coleta de Sangue, São Paulo, Brazil BP-076a COMPARISON BETWEEN AN MOLECULAR BLOOD GENOTYPING (BLOODchip technology) AND AN TUBE HAEMAGGLUTINATION TECHNIQUE AT NATIONAL MEDICAL CENTRE BLOOD BANK “LA RAZA” IMSS M.L. Gasca-Leyva, G. Benitez-Arzivu, E.D. Juarez-Cortes, R.M. Macias-Medrano, M. Alvarez-Galan, M. Rodriguez-Bartolo, K. Sanchez-Pozos, M. Campomanes-Flores IMSS, Mexico City, Mexico BP-077 RH GENOTYPING FOR TRANSFUSION MANAGEMENT IN PATIENTS WITH SICKLE CELL DISEASE D. Garg, T. Hailemariam, Y. Song, G.H. Ishtiaq, K. Podual, S. Vege, C. Westhoff BioArray, an Immucor Company, Warren, USA

233


BP-078 MOLECULAR BACKGROUD OF RHD NEGATIVE BLOOD DONORS IN LINYI, CHINA H. Li, M. Guo, N. Song, L. Tian, J.X. Chen, Z.Q. Yao, X.J. Chen, C.L. Zhang, Q. Chen Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

BP-080 GENE FREQUENCY OF NINE BLOOD GROUP SYSTEMS FROM THE HEALTHY BLOOD DONORS IN TIBET H. Li, N. Song, L. Tian, J.X. Chen, Z.Q. Yao, X.J. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China BP-081 MOLECULAR GENETIC ANALYSIS OF ABO SUBGROUP SAMPLES IN THE KUNMING AREA,YUNNAN,CHINA R. Zhang, P.C. Su, L. Tian, N. Song, Z.Q. Yao, J.X. Chen Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China BP-082 DISTRIBUTION OF ABO BLOOD GROUP ALLELES IN THE CHINESE HAN POPULATION OF SICHUAN R. Zhang, L. Tian, N. Song, Z.Q. Yao, J.X. Chen Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China

234

BP-085 MOLECULAR CHARACTERIZATION OF THE RHD FETAL GENE IN RHESUS D NEGATIVE MOTHERS M. Xhetani, G. Zoraqi, I. Seferi Albanian National Blood Transfusion Center, Tirana, Albania Posters Not Published


BP-079 GENETIC ANALYSIS ON FREQUENCY OF ALLELES FOR ABO BLOOD GROUP SYSTEM IN TIBETAN POPULATION OF CHINA Y.P. Xin, L. Tian, N. Song, H. Li, Z.Q. Yao, J.X. Chen, X.J. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China


5.3 Platelet Immunology BP-086 EFFECTS OF CASPASE 3 INHIBITOR ON THE APOPTOSIS OF PLATELET CONCENTRATE DURING STORAGE R. Shiri Heris, F. Yari, N. Amirizadeh IBTO, Tehran, Iraq BP-087 ABOUT A REPORT FOR HPA-GPIV ANTIBODIES: BE PREGNANCY-DERIVED AND LEAD TO HYDROPS FETALIS X. Ye, X.Z. Xu, J. Deng, W.J. Xia, H.Q. Deng, Y.K. Chen, Y. Shao, J.L. Wang Guangzhou Blood Center, Guangzhou, China

5.5 Fetal Maternal Immunology BP-091 OCCURANCE OF INTRAUTERINE TRANSFUSION ADMINISTRATION IN ALLOIMMUNISATED PREGNANT WOMAN T. Gavrancic, B. Gavrancic Medical Faculty, Novi Sad, Serbia

BP-083 DETECTION OF THE RHD GENE AMONG D NEGATIVE BLOOD DONORS BY MULTIPLEX PCR-SSP IN JIANGSU, CHINA Q. Chen, R. Zeng, J.Y. Xiao, X. Yu, C.Y. Huang, J. Sun, W.A. Flegel Jiangsu Province Blood Center, Nanjing, China

BP-092 HAEMOLYTIC DISEASE OF THE NEWBORN BY ATIPICAL ANTIBODIES E. Velkova, S. Drakulevski, T. Makarovska-Bojadzieva, I. Nikoloska, J. Angelovski Institute for Transfusion Medicine, Skopje, Macedonia

BP-084 IDENTIFICATION OF PATERNAL ZYGOSITY OF GENE RHD IN COUPLES RHD POSITIVE WITH RHD NEGATIVE WOMEN. COMPARISON OF THREE METHODS H.A. Baptista-González, J.M. Sotelo Instituto Nacional de Perinatología, México, Mexico

BP-093 INDIRECT ANTIGLOBULIN TEST POSITIVITY IN A RHD (-), C(+) PREGNANT WOMAN AND OUTCOME M. Sonmezoglu, Z. Akbulut Yeditepe University Hospital, Istanbul, Turkey

235


Topic 6: Clinical transfusion 6.2 Therapeutic Apheresis

BP-096 CURRENT STATUS OF APHERESIS IN KOREA K.S. Han, J.W. Hyun, M.H. Lee, J.W. Lee, S.W. Kwon, D.W. Kim, H.O. Kim Seoul National Univ. Hospital, Seoul, South-Korea

6.3 Evidence Based Transfusion Medicine Practice BP-098 EFFICACY EVALUATION OF TRANSFUSION OF PLATELET CONCENTRATES PRODUCED AT THE BLOOD CENTER IN POZNAN INTO PATIENTS WITH HEMATOLOGIC DISEASES B. Andrys, A. Zawadzka, K. Olbromski, H. Skalisz, L. Gulinski Blood Center Poznan, Poznan, Poland BP-101 APPROPRIATENESS OF PLASMA TRANSFUSION IN THREE HOSPITALS IN SOUTHWEST OF CHINA R. Zhang, J. Lin, T. Peng, Z.J. Li, Q. Li, Y. He, J. Xiao, J.J. Li, J. Song, X.D. Ye, Y.N. Xiao, E. Deng, C.Q. Li Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking U, Chengdu, China BP-102 THE ROLE OF CLINICAL QUALITY INDICATORS IN ASSESSMENT OF BLOOD USE IN SURGICAL PATIENTS S. Oslakovic, V. Polanda Lasica County hospital Cakovec, Cakovec, Croatia BP-103 EXSANGUINOTRANSFUSION ADMINISTRATION DUE TO MN BLOOD GROUP SYSTEM ALLOIMMUNISATION T. Gavrancic, M. Milanovic, C. Gavrancic, B. Gavrancic Medical Faculty, Novi Sad, Serbia 236

BP-104 PLATELET UTILIZATION IN ICU PATIENTS M.A. Zadsar, Lotfi, A. Chegini, M. Mojtabavi, Jamali, M Nasseranipour IBTO, Tehran, Iran BP-105 TESTING FOR AND IDENTIFYING ANTIERYTHROCYTE ALLOANTIBODIES AS INCREASING THE IMMUNOLOGICAL SAFETY OF HAEMOTRANSFUSION. B. Bakhovadinov, A.B. Hojiev, D.A. Sattorova, A.Y. Tretyakova Republican Scientific Center of Blood, Dushanbe, Tajikistan



BP-095 EFFECTIVENESS OF THERAPEUTIC ERYTROCYTAPHERESIS IN A CASE OF POST- HEART TRANSPLANT POLYCYTHEMIA: CASE REPORT M. Mottola, V. Mininni, P. Bevilacqua, E. Tremiterra, B. Zuccarelli A.O.R.N.“Ospedale dei Colli”, Naples, Italy


BP-106 USE AND ABUSE OF FFP AT PREGNANT WOMEN-OUR EXPIRIENCE S.D Stambolieva Institute for Transfusion Medicine Skopje, Strumica, Macedonia

6.4 Haemorrhage and Massive Transfusion BP-107 BLOOD TRANSFUSION RATES IN TRAUMA CARE AT A REFERRAL CENTRE IN IRAN L. Kasraian, A. Tavassoli Iran Blood Transfusion Research Center, Shiraz, Iran BP-108 SUPPORTIVE SUPSTITUTE TRANSFUSION THERAPY OF RARE ILLNESS WITH MASSIVE BLEEDING AT NATIONAL BLOOD TRANSFUSION INSTITUTE, SERBIA M. Cankovic Kadijevic National Blood Transfusion Institute, Belgrade, Serbia BP-109 TRANSFUSION IN PATIENTS NEED SURGERY AND PROCEDURES CARDIAC A.M. Mejia-Dominguz, F. Barrera-Trujillo, E. Alvarez-ManillaToquero Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico City, Mexico BP-110 PLACENTA PREVIA : HAEMORHAGIE AND MASSIVE TRANSFUSION V. Jovanoska, I. Jovanoski Institute of Transfusion Medicine Republic of Macedonia, Prilep, Macedonia

237



6.7 Alternatives to Blood Transfusion

BP-111 PREVENTION OF FEBRILE NON-HEMOLYTIC TRANSFUSION REACTIONS TO LEUKOCYTEFILTERED PLATELET TRANSFUSION: A META-ANALYSIS X. Chen, Q. Yuan, L. Cheng, X.M. Fu, Y.P. Li, N.H. Wang, L. Wang, C.H. Zhou Chengdu Blood Center, Chengdu, China

BP-118 SAVING BLOOD: MANAGEMENT OF FERROPENIC ANAEMIA IN THE EMERGENCY DEPARTMENT S. Fabra, A.M. Borobia, R.M. Capilla, A.M. Martínez Virto, M. Quintana Hospital Universitario La Paz, Madrid, Spain

BP-112 CYTOKINE AND CHEMOKINE-MEDIATED ADVERSE REACTIONS IN SINGLE DONOR APHAERESIS PLATELET COMPONENT TRANSFUSIONS REVEAL NOVEL PLATELET ASSOCIATED-PRODUCTS AND LIKELY FUNCTIONS O. Garraud, K.A. Nguyen, H. Hamzeh-Cognasse, C.A. Arthaud, M.A. Eyraud, P. Chavarin, L. Absi, B. Pozzetto, F. Cognasse, O. Garraud EFS Auvergne-Loire, Saint-Etienne, France

Topic 7: Cellular Therapies

6.6 Haemovigilance and Transfusion Safety BP-113 UNUSED UNITS OF BLOOD - A COMPARATIVE STUDY J. Samonikov-Tosevska, T. Makarovska-Bojadzieva, I. Nikoloska, M. Blagoevska, E. Velkova, K. Kire Institute of Transfusin Medicine, Skopje, Macedonia BP-114 REACTIONS/COMPLICATIONS IN BLOOD DONORS PRESENTING TO CROATIAN INSTITUTE OF TRANSFUSION MEDICINE (CITM) 2007-2011 D. Šarlija, R. Štimac, C. Maglov, V. Cipek, T. Vuk, M. Balija, I. Jukic Croatian Institute of Transfusion Medicine, Zagreb, Croatia BP-115 AUDIT OF TRANSFUSION RELATED PRACTICES AND EQUIPMENTS IN 102 HOSPITALS M.S. Mirrezaie, A. Fariba, B. Hajibeigi, A. Abbasian, A. Hassan Tbtc, Tehran, Iran



6.5 Adverse Events, including TRALI

7.1 Stem Cell and Tissue Banking, incl. Cord Blood BP-119 THE ASSESSMENT OF THE CAPACITY OF COAST PROVINCIAL GENERAL HOSPITAL IN MOMBASA DISTRICT TO UNDERTAKE THE IMPLEMENTATION OF HARVESTING AND TRANSFUSION OF CORD BLOOD E. Andal Coast Province General Hospital, Mombasa, Kenya

7.3 Clinical Applications BP-120 COMPARATIVE STUDY OF DIFFERENT SCAFFOLDS FOR IN VITRO CELL GROWTH R. Rossi-Ferreira, R.A. Moraes da Silva, H. Caputo Nunes, P. Murador, L. Garcia Alvarado, H. Souza Vieira, F.C. Alves, M. Janegitz Acorci-Valério, E. Deffune Universidade Estadual Paulista - UNESP - Hospital das Clínicas, Botucatu, Brazil BP-121 EFFECT OF SDF-1?/CXCR4 AXIS ON PROMOTING RECRUITMENT OF BONE MARROW-DERIVED CELLS TO DIABETIC WOUND AREA F.Q. Lu, W.M. Wang, Y. Peng, D.P. Cui Affiliated Zhong Shan hospital of Dalian university, Dalian, China

BP-116 PROCUREMENT UNIT PLASMA INSULIN DEPENDENTDIABETES DONORS CONTROLLED, AND THE IMPACT OF VARIOUS METABOLITES IN TRANSFUSION THERAPY IN PATIENTS WITH CHRONIC DEGENERATIVE. E. Carreón Albor, G. García Martinez, L. Hidalgo Arias Centro Médico Dalinde, Distrito Federal, Mexico

238

239


Topic 8: Clinical Immunogenetics 8.1 HLA in Transfusion Medicine


BP-122 ANALYSIS THE DISTRIBUTION OF HLA-A,B,DRB1 ALLELES AND SCREENING OF HLA ANTIBODY FOR GUANGZHOU BLOOD DONORS X. Ye, W.J. Xia, H.Q. Deng, J. Deng, Y.K. Chen, X.Z. Xu, Y. Shao, J.L. Wang Guangzhou Blood Center, Guangzhou, China

Topic 9: Novel Development 9.1 Novel Development BP-123 HUMAN PLATELET NF-KAPPAB LINKS TLR2 AND PAR1 TO CYTOKINE SECRETION O. Garraud, P. Damien, F. Cognasse, B. Payrastre, S.L. Spinelli, N. Blumberg, R.P. Phipps, A. McNicol, B. Pozzetto, O. Garraud, H. Hamzeh-Cognasse EFS Auvergne-Loire, Saint-Etienne, France BP-124 THE STUDY OF DOSE UNIT OF RED BLOOD CELL TRANSFUSION D. Wang The Chinese PLA General Hospital, Beijing, China

240

Key Information

Key Information Congress Venue Cancun Center, Conventions & Exhibitions Boulevard Kukulcan KM. 9 1er Piso Zona Hotelera C.P. 77500 Cancún, Quintana Roo, México Registration Hours The registration desk will be open as of Saturday, July 7 at the Fiesta Americana Grand Coral Hotel: Saturday July 7 07.00 - 17.30 hours Sunday July 8 07.00 - 18.30 hours Key Information

As of Monday, Monday Tuesday Wednesday Thursday

July 9 the registration desk will be open at the Cancún Congress Centre: July 9 07.30 - 17.30 hours July 10 07.30 - 18.00 hours July 11 08.00 - 17.30 hours July 12 08.00 - 13.00 hours

Exhibition hours & Poster desk opening hours: Sunday July 8 18.30 - 21.00 hours Monday July 9 09.00 - 18.00 hours Tuesday July 10 09.00 - 19.00 hours Wednesday July 11 09.00 - 18.00 hours Thursday July 12 09.00 - 13.00 hours Services provided at desks in the Registration Area include: Exhibition Information: Exhibitor Desk in the Registration Area Hotel Accommodation: Last-minute availability at the Hotel Desk in the Registration Area Lost and Found: Registration desk Messages: Registration desk Tours: Tickets for sale at the Social Desk in the Registration Area Restaurant reservations: Information Desk in the Registration Area Services provided at the Exhibition Area E-mail Service: An Internet corner in the Exhibition Area on the first floor of the Cancun Centre

241

Key Information

Badges All participants and accompanying persons will receive a personal badge upon registration. You are kindly requested to wear your name badge at all times, during scientific meetings and social gatherings. Only participants who are wearing their name badge will be admitted to the lecture halls.

Key Information

Staff If you have any questions, the members of the congress staff, who can be recognised by their ISBT shirts, will be very pleased to assist you. Please do not hesitate to contact them if you have any questions.

Please note: accompanying persons and exhibitors will not be admitted to the scientific sessions. Registered accompanying persons do have access to the exhibition.

Key Information

Key Information

Name badges have been color-coded a follows: ISBT Member Red ISBT Non-Member Transparent Accompanying Persons Yellow Exhibitors Blue Press Orange Coffee and tea breaks During session-breaks coffee and tea will be served free of charge to delegates wearing name badges on the exhibition floors. Insurance The congress organiser cannot accept responsibility for accidents that might occur. Delegates are encouraged to obtain travel insurance (medical, personal accident and luggage) in their home country prior to departure. Internet There will be an internet corner in the Exhibition Area, where delegates will be able to get access to their mail. Wireless internet connection is available on the first floor of the Cancún Centre and in most hotels. Language The official Congress language will be English. Simultaneous interpretation in Spanish will be provided during the ISBT Academy Day on Sunday, July 8, in the Grand Coral Beach Hotel Lunch Lunch is included in the registration fee. Lunch will be provided in the Exhibition Area and at the entrance of the meeting rooms where the Satellite Symposia will take place. 242

243

Key Information

Key Information

244

General Information

General Information Time Cancún is in the Central Standard Time (CST) zone.

Weather The average minimum and maximum temperatures are 24° to 33° C (75° a 91° F) from July to September.

Dress Code The dress code for the congress is business casual. Please note the Congress Center rooms may be cool, therefore a jacket or wrap could be required.

Currency As the Mexican Peso is strongly related to the US-Dollar, it is recommended to change US-Dollar in cash or traveller checks for Mexican pesos on arrival at the airport in Cancún. Otherwise an exchange will be time consuming, especially outside of tourist destinations. The exchange rate is about $13.50 MP per $1.00 USD The Mexican currency is called Peso ($) with bills of $1,000, $500, 200, 100, 50 and 20 and coins of 10, 5, 2, 1, 0.50, 0.20, 0.10 and 0.05. Credit cards (Eurocard/Mastercard, Visa and American Express) are widely accepted. General Information

Electricity supply The electricity standard in Cancún is 110 volts AC, the same as in the United States and Canada. Even though many places have three-pronged polarized outlets, it is recommendable that you bring an adapter.

Hotel Check out Policy Normal check out time at hotels is 12.00 hours.

Medical care Clinics and hospitals provide 24 hours emergency services. The national emergency phone numbers are 060 and 066. Hotels have a doctor on call through the reception.

Smoking Federal regulations establish that smoking is prohibited in all indoor public spaces.

245

General Information

General Information

Shopping in Cancún

Taxi

In Cancún you will find everything from ultra-chic designer stores and famous brand names, to flea markets and souvenir shops selling Mexican local handcrafts. Cancun shopping is duty free so you can find some real bargains on cosmetics and fine jewelry. Most shops and department stores are open from Monday to Saturday between 10.00 and 18.00 hours, closed on Sundays. Larger shops and shopping malls are open until 21.00 hours from Monday to Saturday, closed on Sundays.

The approximate cost for a taxi from the airport to the Cancún Center is 500 Mexican pesos (50 US dollars)

Restaurants

Used toilet paper should be thrown in the bins provided in each toilet and not in the toilet pan.

Tipping Although all prices officially include a service charge, tipping is recommended.

Toilets in the Cancun Centre

Cancún restaurants include various gourmet cuisines, such as French, Italian, American, Argentinean, and Japanese, among others. You can find just about any dish you want here in the atmosphere you prefer.

General Information

General Information

Please find below a brief list of some recommended restaurants: - Bubba Gump - Capt. Charlie's - Carlos'n Charlie's - Casa Rolandi - Chokos & Tere - El Cambalache - Gustino - Hacienda El Mortero - La Habichuela - La Madonna - Lorenzillo's

Talking Stick At the Opening Ceremony the President of ISBT offers the Talking stick to the President of the Congress. This tradition is inherited from the XXVllth International Congress of ISBT in Vancouver, Canada in 2002 when the Local Organising committee offered to ISBT the Talking Stick. Talking sticks were used by West Coast natives in Canada during Potlatches and other ceremonial occasions as a symbol of speaking authority and respect for communication by chiefs and elders.

Tap water Bottled water is recommended and most hotels and restaurants provide it. It is recommended to avoid drinks with ice cubes, except in restaurants and hotels.

246

247

General Information

General Information

248

Social Programme

Social Programme Sunday July 8 17.45 - 18.30 hours

Gran Cancun, Cancun Centre

Opening Ceremony All delegates and exhibitors are welcome to attend 17.45 - 17.55 17.55 - 18.05 18.05 - 18.10

Welcome address by Silvano Wendel, ISBT President Welcome address by Julio Martinez Alvarez, Congress President Presentation of the Talking Stick by the ISBT President to the Congress President 18.10 - 18.20 Presentation of ISBT Awards and Prizes ISBT Award Hector Rodriguez Moyado Joyce Poole Marion Reid ISBT Award for Developing Countries Sri Lanka National Blood Transfusion Service Vox Sanguinis Best Paper Prize John-Paul Tung 18.20 - 18.50 Mayan Show You will be able to learn about the Mayan culture through ancient ceremonial dance rituals to traditional native music. Live performances exhibit stunning wardrobe and elaborately feathered headdresses, each a uniquely handcrafted work of art. According to ancient tradition, each design exclusively utilizes natural materials including leather, shell, semi-precious stones, and exotic feathers. 18.50 All delegates are invited to proceed to the Welcome Reception in the Exhibition Area. Social Programme

249

Social Programme

18.50 - 21.00 hours

Exhibition Area

Opening of the Trade Exhibition and Welcome Cocktail Reception A cocktail reception will be held at the Exhibition Area. The reception will permit the delegates to meet old friends and colleagues and make new acquaintances during the evening while enjoying conversations. Delegates are welcomed by the President of the ISBT and the Chairman of the Local Organising Committee.

Social Programme

Wednesday July 11 19.30 hours

Grand Coral Beach Hotel

Congress Party (tickets are available at the registration desk) The Mexican Party in the pool area of the Fiesta Americana Grand Coral Hotel will be held in the evening of July 11. The Fiesta Americana Grand Coral is located on a beautiful shore side overlooking the Caribbean Sea, in the heart of Cancún’s recreational and commercial centers. You will experience what we call a “Kermess”, a popular Mexican outdoor party with dances, raffles, tournaments, food and drinks. You will learn something about Mexican handcrafts and candies and you will enjoy the flavour of a Mexican small town. Please join us for the party!

Social Programme

Social Programme

250

251

Social Programme

Social Programme

252

Cancun Center Floor Plan Ground floor

Main



Entrance

253

Floor Plan

Floor Plan

Floor Plan

Cancun Center Floor Plan First Floor

254

Cancun Center Floor Plan Second Floor

255

Floor Plan

Floor Plan

Floor Plan

Floor Plan

Cancun Center Floor Plan Third Floor

Exhibition Floor Plan First Floor

Primer piso - First floor

256

257

Floor Plan

Floor Plan

Floor Plan

Exhibition Floor Plan Ground Floor

Planta baja - Ground floor

Floor Plan

Floor Plan

258

List of Exhibitors and Exhibition Guide

List of Exhibitors Booth number Company name List of Exhibitors and Exhibition Guide

004 005 006 008 010 010 010 014 019 020 021 022 024 026 028 035 039 040 041 043 045 047 049 051 052 053 054 056 059 060 061 062 064 066 075

Gamma-Service Medical GmbH JMS North America corp. Best Theratronics Ltd. Thermo Scientific Ashland Inc. (formerly ISP) LMB Soft d.o.o LMB_Technologie GmbH ACON Laboratories, Inc. Lab21 Healthcare Ltd Cerus Europe BV Hettich, Andreas GmbH & Co KG Octapharma AG Terumo BCT MAK-SYSTEM Corp Dometic Medical Systems MTC INVITRO DIAGNOSTICS AG NanoEnTek Inc Barkey GmbH & Co KG Instituto LICON Grifols Haemonetics Corporation Novartis Diagnostics Immucor, Inc. Diagast OrSense Ltd. EDQM, Council of Europe Sanquin Blood Supply Hemasoft America, Corp. AABB Safetran Biomedical Inc. LightIntegra Technology Inc Fenwal, Inc. Roche Bio-Rad DAY medical SA 259



Exhibitors and booth numbers

260

059 AABB 8101 Glenbrook Road 20814 Bethesda, MD United States of America Contact: Micaella Novick T: +1 301 215 6538 E: [email protected] W: www.aabb.org



076 PRESVAC SRL 079 Fresenius Kabi Deutschland GmbH 080 LABORATORIOS DAI de MEXICO, S.A. DE C.V. 081 DiaSorin S.p.A. 082 Asahi Kasei Medical Co., LTD. 086 Kawasumi Laboratories, Inc. 088 Macopharma 089 HELMER 092 Abbott Laboratories- Diagnostics Division 096 V.I.P.S. SA 099 Siemens Healthcare Diagnostics 100 Gen-Probe Incorporated 101 Life Technologies 103 Gilardoni S.p.A. 104 Informatica Tesi de Italia, S.A. de C.V 109 Sichuan Nigale Biomedical Co., Ltd. 111 Association of Donor Recruitment Professionals 113 Wiley-Blackwell 114 Masimo 116 Ortho Clinical Diagnostics 117 HemoCue AB 119 inno-train Diagnostik GmbH 120 GFE Blut mbH 121 Nanjing Shuangwei Biotechnology Co., Ltd. 122 MEDINFO INTERNATIONAL HEMOSERVICE 124 Healthcare-ID 126 HLL LIFECARE LTD 128 ICCBBA 132 SIFIN Institut für Immunpraeparate und Naehrmedien GmbH Berlin 133 Cryo Life Science Technologies GmbH 134 Sigma Laborzentrifugen GmbH 135 Delcon s.r.l. 136 ISBT Central Office 138 ITL Corporation 140 Asociación Mexicana de Medicina Transfusional A.C

F: +1 301 215 5732

AABB is an international association representing over 10,000 individuals and institutions involved in the fields of transfusion medicine and cellular therapies. For more than 60 years, AABB has been a leader in providing professional development, standard setting and accreditation. Visit the AABB booth to learn more about all of the resources available to cellular therapy professionals, transplant nurses and physicians, and those involved with transfusion who would like to learn more about patient blood management initiatives. 092 Abbott Laboratories- Diagnostics Division 100 Abbott Park Road 60064, Abbott Park, IL United States of America Contact: Marc Lingnau, Ana Paula Guimaraes T: +1 847 937 9785 / +1 847 935 2676 E: [email protected] / [email protected] W: www.abbottdiagnostics.com

F: +1 847 937 8617

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 69,000 customers in more than 100 countries, Abbott’s diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company’s commitment to improving patient care and lowering costs.

261



014 ACON Laboratories, Inc. 10125 Mesa Rim Road 92121, San Diego, CA United States of America

F: +1 858 200 0729

A leading manufacturer in high quality, competitively-priced, diagnostic and medical products consisting of Diabetes Care including Glucose Meters, Strips and Lancing Devices; Clinical Chemistry including Urinalysis Reagent Strips, Analyzers, Urine Controls, Hemoglobin Testing Systems, UTI Home Tests, FOB Reagent Strips, and Breath and Saliva Alcohol Tests. We also provide Immunoassay ELISA products including HIV 1/2/O, HAV, HBV, HCV, HEV, Syphilis, and many more. All products are manufactured at our US-FDA licensed, GMP, ISO/EN certified facility. We specialize in OEM packaging. 082 Asahi Kasei Medical Co., LTD. 1-105 Kanda Jinbocho, Chiyoda-ku 101-8101, Tokyo Japan T: +81 332 963 795 F: +81 332 963 792 E: [email protected] W: www.asahi-kasei.co.jp/medical/en/ Asahi Kasei Medical is a world leader in research, development, and production of medical devices for blood treatment and purification. Asahi Kasei Medical, a pioneer in leukoreduction, is also one of the world leading suppliers of virus removal filters for biopharmaceuticals. Our core competence is based on unique and advanced membrane separation and adsorption technologies that enable to present innovative solutions of a wide range of Sepacell™ filters for whole blood, red cells and platelets for your various needs.

262

Contact: Rosemarie Fairman T: +1 973 628 3383 E: [email protected] W: www.radsure.com



Contact: Maria Cuevas T: +1 858 875 8000 E: [email protected] W: www.aconlabs.com

010 Ashland Inc. (formerly ISP) 1361 Alps Road 07470, Wayne, NJ United States of America

F: +1 973 628 4185

Radiation indicator and dosimetry products, manufactured and marketed by ASI, provide a twopart quality system to assure compliance with regulations on blood irradiation: (1) RAD-SURETM Blood Irradiation Indicators, with ISBT 128 bar coded lot numbers, attach to individual units of blood and provide positive, visual verification of treatment before and after each irradiation cycle; (2) DOSE-MAPTM with NEW enhanced report, measures and maps absorbed dose to validate the performance of blood irradiators. RAD-SURETM UVA indicators are also available. 140 Asociación Mexicana de Medicina Transfusional A.C. A. Insurgentes Sur 1650 Desp. 602. Col. Florida Contact: Julio César Martínez Álvarez T: +55 46 23 96 81 E: [email protected] W: www.ammtac.org

F: +55 54 40 05 04

AMMTAC is celebrating the first ten years and since its foundation, the main interest is to keep the mission which is promote continuous training and retraining of personnel involved in transfusion medicine through high level educational activities, consensus an discussion forums for the exchange of ideas, scientific development, technological and academic for the members to improve transfusion safety in Mexico.

263



111 Association of Donor Recruitment Professionals Professionals (ADRP)

ADRP is committed to being a leader in providing education, development and resources for the donor recruitment profession. The Association of Donor Recruitment Professionals (ADRP) has more than 500 members from countries across the globe. The most important thing ADRP has to offer is education and development. This means, most importantly, that recruitment professionals share solutions, ideas, skills, techniques, problems, concerns and support. In short, ADRP members are there for each other. 040 Barkey GmbH & Co KG Gewerbestrasse 8 D-33818, Leopoldshoehe Germany Contact: Mr. Christian Barkey T: +49 520 298 010 E: [email protected] W: www.barkey.de

Best® Theratronics is the world’s leading manufacturer of blood irradiators to prevent graftversus-host disease. Offering both gamma and x-ray, our long history of reliability, support and high-quality products will meet your needs. Our Gammacell® 1000 Elite and 3000 Elan have been considered the “Gold Standard” in countless clinics worldwide for decades, as they are the industry’s dependable Workhorse irradiators. Likewise, the Raycell® Mk2 dual x-ray tubes deliver unparalleled dose uniformity across its entire 2.0 or 3.5 litre canisters. 066 Bio-Rad 3 blvd Raymond Poincaré 92430, Marnes-la-Coquette France

F: +49 520 298 010

Barkey is a leading German company for thawing plasma and warming blood technologies. For more than 30 years we develop warming products for blood banks and hospitals. Please come and see the latest version of Barkey plasmatherm. The only plasma thawing device worldwide which meet the newest FDA/AABB standards(2011). Quality made in GERMANY.

264

Contact: Dan Aitkenhead, Area Sales Manager T: +1 613 591 2100 *1080 F: +1 613 591 6627 E: [email protected] W: www.theratronics.com



Contact: Deborah Swift T: +1 512 658 9414 E: [email protected] W: www.adrp.org

006 Best Theratronics Ltd. 413 March Road K2K 0E4, Ottawa Canada

T: +33 147 956 261 E: [email protected] W: www.bio-rad.com

F: + 33 147 958 140

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a multinational manufacturer and distributor of Clinical Diagnostics (Instruments and kits for microbiology, Infectious diseases testing, Molecular diagnosics but also Diabetes monitoring, Quality controls, Toxicology, Autoimmune diseases, Immunohematology) and Life Science research products (Instruments and reagents for electrophoresis, Liquid chromatography, Amplification, Food testing,…). Bio-Rad has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative products and services to the clinical diagnostics and the life science research markets. Founded in 1952, Bio-Rad has a global team of more than 7,000 employees and serves more than100,000 research and industry customers worldwide through its global network of operations.

265



075 DAY medical SA Chemin de la Plaine 21 1580, Avenches Switzerland

T: +31 334 960 600 F: +31 334 960 606 E: [email protected] W: www.cerus.com / www.interceptbloodsystem.com

Contact: Pascal Gauch T: +41 266 767 000 E: [email protected] W: www.day-medical.com

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development. 133 Cryo Life Science Technologies GmbH Wirtschaftspark 5 9130, Poggersdorf Austria Contact: Dr. Georg H. Thiessen T: +43 422 482 052 E: [email protected] W: www.clst-austria.com

F: +41 266 767 001

DAY medical SA is located in Avenches (Switzerland) near Morat, Fribourg and Bern. Our premises consists of a large production area including the latest production technologies, all designed for a continuous production flow. Training facilities, service and reference laboratories, are all in place with the goal of providing our customers with the highest level of service. Our goal is to provide a new gel test generation for blood transfusion centres and hospital blood group serology laboratories. We have developed totally new automated procedures that more than fulfill the stringent requirements of today and those of the future. 135 Delcon s.r.l. Via Matteucci 25/27 20862, Arcore Italy

F: +43 422 482 052 24

CLST is a customer oriented provider of equipment for controlled rate freezing, storage and transport of medical and biological materials. Our objective is to assist our customers with the delivery of secure and cost-effective turn-key solutions. All products are offering the necessary GLP/MDD/CE documentations and are certified according to the medical device directives (MDD) and comply with the GLP requirements: Our cryo logistic line consists of the following major products: Shock freezer systems (KLF), Mobile transportation systems (KLT) and Cryogenic storage systems (KLS) for long term storage +4°C down to -196°C.

266



020 Cerus Europe BV Stationsstraat 79-D 3811 MH, Amersfoort the Netherlands

Contact: Barbara Sala T: +39 039 617 670 E: [email protected] W: www.delcon.it

F: +39 039 617 677

Delcon is a manufacturer of blood bank equipment. The company mainly operates focusing on: - Design and production of blood bank equipment, medical devices for hospitals laboratories and industry, lab. refrigerators and freezers. - Design and production of OEM equipment. - Distribution of medical devices for hospitals and laboratories. Delcon is based in the north of Italy with headquarter in Arcore, close to Milan. Here are located commercial, marketing and administration offices while the factory, with R&D and production departments, is located near Bergamo.

267



028 Dometic Medical Systems 17, Op der Hei 9809, Hosingen Luxembourg

T: +33 320 965 353 E: [email protected] W: www.diagast.com

Contact: Luc Provost T: +352 920 7311 F: +352 920 731 300 E: [email protected] W: www.dometic.lu

F: +33 320 965 354

DIAGAST develops, manufactures and markets innovative In Vitro Diagnostics reagents and systems for use in blood banks & transfusion centers as well as public and private laboratories. DIAGAST focuses on ImmunoHaematology especially in transfusion compatibility. DIAGAST welcomes you on its booth to discover 3 ranges of products: -The E.M.® Technology range with Qwalys®, the fully-automated system, - The manual range with CE ready-to-use reagents, -The O.E.M. range (from concentrated bulk to fully customized semi-finished products). See you there! 081 DiaSorin S.p.A. Via Crescentino snc 13040, Saluggia (VC) Italy T: +39 016 148 7526 E: [email protected] W: www.diasorin.com

F: +39 016 148 7670

DiaSorin develops, produces, and distributes worldwide immunoassays for clinical diagnostics. It comprises of 28 companies, 6 industrial sites in Saluggia (Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK), Johannesburg (SA) and 4 research facilities. The Group is present in more than 60 countries, offering a broad array of high quality products related to specialty infectious diseases, hepatitis and retroviruses, bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

268



051 Diagast Parc Eurasanté - 251, avenue Eugène Avinée BP9 - 59374, Loos Cedex France

Dometic Medical Systems is specialized in research, development and manufacturing of special refrigerators, deep freezers, storage & transport concepts.Dometic’s product family “Blood Safety” comprises different activities from collection to transfusion. With the “Blood Cold Chain”, a comprehensive mix of products which strictly observes international standards, blood is kept safe through precisely temperature controlled transport and storage solutions. The newly developed Blood Traceability system “Dometic powered by Biolog” with RFID technology, provides a complete traceability and identification of RBCC’s and avoids retranscription errors. 053 EDQM, Council of Europe 7 allée Kastner, CS 30026 67081, Strasbourg France T: +33 388 413 030 F: + 33 388 412 771 W: www.edqm.eu / http://tots.edqm.eu/entry.htm The EDQM has as a mission the protection and promotion of public and animal health through enabling the development, supporting the implementation, and monitoring the application of quality standards for safe medicines and their safe use. Its standards are recognised as a scientific benchmark worldwide. The European Pharmacopoeia is legally-binding in its Member States. Similarly, the EDQM develops guidance and standards in the areas of blood transfusion, organ transplantations and consumer health issues. 16th Edition Guide to the Preparation, Use and QA of Blood Components.

269


004 Gamma-Service Medical GmbH Bautzner Strasse 67 D-04347, Leipzig Germany

Contact: Donatella Manca T: +32 104 819 11 W: www.fenwalinc.com

T: +49 341 463 728 00 E: [email protected] W: www.gamma-medical.de

Fenwal, Inc. is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components. Fenwal is unique in the depth of its experience and commitment to transfusion medicine. The company offers the broadest range of products for the automated and manual collection of blood and blood components. Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories. Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components. Today, the company’s products and advanced collection and separation technologies are used to help treat patients on six continents. Fenwal, Inc. is based in Lake Zurich, Illinois. Fenwal Europe is based in MontSaint-Guibert, Belgium. For more information, please visit www.fenwalinc.com.

Gamma-Service Medical GmbH is a global active isotope technology company. We are manufacturer of equipment like the self-contained Gamma Irradiation device BIOBEAM for Blood Irradiation. Our quality management system is certified according to EN ISO 13485: 2003 and AC: 2009.

Contact: Brigitte-Sonja Borchers / Anne-Kathrin Staehr T: +49 6172 686 0 F: +49 6172 686 2628 E: [email protected] W: www.fresenius-kabi.com Fresenius Kabi is dedicated to the therapy and care of critically and chronically ill patients inside and outside the hospital by providing I.V. drugs, infusion therapies, clinical nutrition and related medical devices. For transfusion technology, Fresenius Kabi offers a broad range of products used by blood banks and blood donation units to produce blood products. The company applies its long-standing expertise in pharmaceuticals and medical devices to support clinical staff and care professionals in the best therapy of patients.

F: +49 341 463 728 22



062 Fenwal, Inc. Fenwal Europe, Rue Mont-Saint-Guibert 2-4 1435, Mont-Saint-Guibert Belgium

079 Fresenius Kabi Deutschland GmbH Else-Kroener-Strasse 1 D-61352, Bad Homburg Germany

270


120 GFE Blut mbH Altenhöferallee 3 D-60438, Frankfurt Germany T: +49 699 510 327 30 E: [email protected] W: www.gfeblut.com

F: +49 699 510 327 20

The company GFE Blut mbH researches, develops and distributes diagnostic test kits and automation solutions for blood donor services. The CE-certified virus detection methods are based on Nucleic Acid Amplification Technology (NAT). A high degree of flexibility and throughput are achieved by either testing individual samples or sample pools consisting of 2 to 96 donations for contamination with six transfusion relevant viruses (HCV, HIV -1/-2, HBV, HAV, PB19) simultaneously. A new test for West Nile Virus (WNV) was released in May this year. Further tests for Cytomegalovirus (CMV) are currently in development or in the case of Chikungunya virus (CHIKV) have recently been completed. These assays are designed to be used manually, as well as semi-automated or fully automated on GFE Blut platforms. With a routine testing of 2.5 million blood donation samples per year, more than half of the blood supply in Germany is already tested with GFE Blut detection methods.

271



103 Gilardoni S.p.A. Via Arturo Gilardoni, 1 23826, Mandello del Lario (LC) Italy

W: www.haemonetics.com F: +39 341 735 046

Gilardoni S.p.A. was established in Italy in 1947 and today ranks among the leading Italian providers of x-ray and ultrasonic products, components and services in medical, non-destructive testing and security sectors. We are based in Milan, Italy and employ approximately 250 people who provide R&D, manufacturing, distribution and service on a global scale. Gilardoni products are installed and serviced all over the world -- North America, Europe, Eastern Europe, South America, Africa, Australia and Asia. 043 Grifols Parc Empresarial Can Sant Joan, Av. de la Generalitat, 152-158 8174, Barcelona Spain T: +34 935 710 822 E: [email protected] W: www.grifols.com

F: +34 935 710 722

Grifols has been present in the healthcare field since 1940, creating innovative products and services based on our ethical values and deep-rooted responsibility. Grifols’ activities focus on fulfilling the needs of healthcare professionals working in therapeutics, pharmacy, diagnostics and blood banking. Grifols is committed to ensuring safety and quality in Transfusion Medicine, from the moment of donation to transfusion. In the field of blood banking Grifols offers standard blood bags, leukoreduction systems (Leucored®), systems for inactivation of blood components , blood typing instruments such as Erytra® and WADiana®, DG Gel® cards and MDmulticard®, blood bank software equipment and hemovigilance tools. More recently, following the increasing need for blood group genotyping, Grifols offers BLOODchipID. For more than 60 years, Grifols has developed, manufactured and marketed products of demonstrated efficacy, quality and safety contributing to improve human health, life expectancy and quality of life.

272



Contact: Mrs. Germana Villa T: +39 341 705 111 E: [email protected] W: www.gilardoni.it

045 Haemonetics Corporation 400 Wood Road 02184, Braintree, MA United States of America

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics visit our web site at http://www.haemonetics.com 124 Healthcare ID 1635 Barclay Boulevard 60089 Buffalo Grove, Illinois United States of America Contact: Bryan Sadorf T: +1 847 465 9935 E: [email protected] W: www.healthcare-id.com

F: +1 847 465 9940

Healthcare-ID develops and markets products to meet the blood center's need for automating entry of information at fixed and mobile collection sites. This helps assure accuracy, and drives efficiencies in blood center operations. Healthcare-ID’s Donor-ID WebTM modules interface to most major blood center data management systems. These modules include Registration, Health History, CASI, Internet CASI, Physical Exam, Daily QC, Phlebotomy, Shipping, Survey, and Donor Adverse Reaction (as developed with the AABB biovigilence committee). For more information please visit www.healthcare-id.com .

273



089 HELMER 14395 Bergen Boulevard 46060, Noblesville, IN United States of America

F: +1 317 776 9527

Established in 1977, Helmer is a manufacturer and worldwide distributor of high quality laboratory equipment and refrigerated products for the Blood Bank and Clinical Laboratory. We have combined our experience and innovation to bring you the most advanced line of temperature controlled equipment today. Our products include: Platelet Storage Systems, Plasma Thawing Systems, Cell Washing Systems, Blood Bank and Laboratory Refrigerators, and Plasma Storage and Laboratory Freezers. For more information, visit our website at www.helmerinc.com. 056 Hemasoft America, Corp. 12982 SW 89th Av. 33176, Miami, FL United States of America Contact: Bruno Rousselin T: +1 786 600 1285 E: [email protected] W: www.hemasfoft.com Hemasoft is an International IT Company specialized in designing, developing and implementing software solutions for Blood Centers, Blood Banks, Transfusion Services, Cell Therapy and Clinical Laboratories. e-Delphyn provides Transfusion Facilities with a full Arm-to-Arm traceability from the Donor Recruitment and Collection to Patient Transfusion Confirmation at the bed side. Our Webenabled software suite e-Delphyn has been developed according to international requirements and standards. Recognized for its features and functionality, e-Delphyn is now deployed and used in more than 500 locations in 40 different countries supporting multiple languages such as English, Arabic, Chinese, French and many others. With recent National deployments of the application in several countries, e-Delphyn positions itself as one of the best international solutions for transfusion medicine.

274

Contact: Pia Åberg T: +46 431 481 200 E: [email protected] W: www.hemocue.com



Contact: Richard Forero T: +1 317 773 9073 E: [email protected] W: www.helmerinc.com

117 HemoCue AB Kuvettgatan 1, Box 1204 26223, Ängelholm Sweden

F: +46 431 481 225

The HemoCue family of companies, acquired by Quest Diagnostics in 2007, is a global leader in a field of diagnostics known as near patient, or point-of-care, testing. In 1982, HemoCue AB, based in Ängelholm, Sweden, introduced the first system making accurate hemoglobin testing possible in near-patient settings. Since then, more than 350,000 HemoCue systems have been sold worldwide. The company also manufactures point-of-care tests for glucose, urine albumin, total and differential white blood cell count. HemoCue is present in more than 130 countries world wide. 021 Hettich, Andreas GmbH & Co KG Foehrenstr. 12 D-78532, Tuttlingen Germany Contact: Mrs. Anja Klahn T: +49 746 170 50 E: [email protected] W: www.hettichlab.com

F: +49 746 170 512 2

The development of modern laboratory centrifuges is closely linked to the history of the HettichZentrifugen company. Hettich’s roots go back more than one hundred years. Today’s product range comprises a complete program of centrifuges for virtually every centrifuging task required in practice: e.g. microlitre, hematocrit, benchtop, underbench, floorstanding, blood bank, robotic centrifuges, refrigerated and non-refrigerated as well as cell washers.

275


049 Immucor, Inc. 3130 Gateway Drive 30091, Norcross, GA United States of America

Contact: Kesavan U.K. T: +91 944 634 6548 E: [email protected] W: www.lifecarehll.com

Contact: Christie Otis - Director, Worldwide Serology Marketing T: +1 770 441 2051 F: +1 770 441 3807 E: [email protected] W: www.immucor.com

HLL Lifecare Limited set up its Blood Bag manufacturing facility in the year 1995 at Akkulam, Thiruvananthapuram. The state of art manufacturing facility guarantees HL Haemopack Blood Bag system to be distinct & the best. The facility is equipped with Class 10,000 Clean Rooms and critical operations are performed in Class 100 Laminar Air flow benches. HLL offers a wide range of Blood Bag system which includes Single, Double, Triple, Quadruple bags in varying capacities ranging from 100ml to 500ml. Variants like Bags with Leukodepletion filters, Sampling port, Diversion bag, Needle injury protector, Top and bottom outlet bag and Autologous Blood bags also forms part of our product range HLL, Akkulam Factory has ISO 9001-2000 certification from DNV, the product CE marking from DNV AS, Norway and the Environmental Management System ISO 14001 & OHSAS 18001 certifications from TUV NORD CERT GmbH.The Blood bag is designed for efficient and safe collection, identification, storage and separation of blood components in a closed system and infusion of contents. The device has adequate provision for suspension from all sides, which does not interfere in use.

Immucor is a global leader in pre-transfusion diagnostics providing a complete line of traditional reagents, unique specialty products and full automation for immunohematology testing. Our Scalable Solutions include Echo®: for small- to medium-sized laboratories, NEO®: for larger laboratories and ImmuLINK™, a state of the art data management tool. We improve laboratory efficiency by offering a broad test menu coupled with high throughput, quick turnaround time, and flexible sample handling. Immucor’s BioArray Solutions® product portfolio offers cutting edge molecular technology for donor and patient testing.

Contact: Mrs. Pat Distler / Mr. Erwin Cabana T: +1 909 793 6516 F: +1 909 793 6214 E: [email protected] W: www.iccbba.org ISBT 128 is the global standard for the identification, labeling, and information processing of human blood, cell, tissue, and organ products across international borders and disparate health care systems. The standard has been designed and perfected over a period of almost two decades to ensure the highest levels of accuracy, safety, and efficiency for the benefit of donors, patients, and health care professionals around the world.



126 HLL LIFECARE LTD Plot NO 16-A-1 682037, Cochin India

128 ICCBBA P.O. Box 11309 92423-1309, San Bernardino, CA United States of America

276


104 Informatica Tesi de Italia, S.A. de C.V Bosque de Ciruelos No. 168 Piso 8 Col. Bosques de las Lomas 11700, Mexico, D.F. Mexico Contact: Ing. Edgar de la Mora, Ing. Fernando Prado T: +52 555 596 6616 F: +52 555 596 6626 E: [email protected] W: www.tesi.mi.it Since 31 years TESI designs, develops, markets and supports innovative information systems offering to public and private health institutions: - Clinical Information Systems for Hospitals and Clinics, - Blood Bank and Transfusion Centers Information Systems, - Laboratory Information Systems (LIS), - Radiology Information Systems (RIS/PACS), - Clinical Image Management (Endoscopy, Anatomical Pathology, Surgical Workflow Management, etc.), - WEB Portals for Internet/Intranet access to diagnostic and clinical services providers, and for patient medical data management, - Information Systems for Quality Systems Management and Risk Management in the Health Care Institutions.

277



119 inno-train Diagnostik GmbH Niederhöchstädter Str. 62 D-61476, Kronberg Germany

F: +49 617 360 7950

The inno-train Diagnostik GmbH is specialized in the fields of transfusion medicine and immunogenetics. As the first commercial supplier we manufacture molecular IVD test systems for blood group typings since 1998. Furthermore we offer a complete product range for HLAtypings including serological test systems, PCR-SSP and PCR-SSO methods and sequencing kits. With our latest FluoGene product line we are once again the first company offering a CE marked automation for RBC-, HPA- and HLA-typings based on fluorescent endpoint detection. 041 Instituto LICON Viveros del Rocío 33 54080, State of Mexico Mexico Contact: Leticia Contreras/ Enrique Sanchez T: EUA - +52 555 365 6577 F: +52 555 365 6578 E: [email protected] W: www.institutolicon.com.mx Instituto LICON is part of the Mexican corporate group Laboratorios LICON, that provides reagents and immunohematology specialized instruments. Supply SeraCare third party controls, panels, and characterized disease state materials for method validation, monitoring, training, troubleshooting and meeting regulatory requirements for infectious diseases in serology and molecular tests. Instituto LICON provides dedicated courses and practical workshops for latinamerican professionals specialized in immunohematology and clinical diagnostic topics. Also provides ISO/IEC 17043:2010 accredited Proficiency Testing Programs with surveys for immunohematology, infectious diseases, viral load and NAT tests.



Contact: Dr. Sabrina König T: +49 617 360 7930 E: [email protected] W: www.inno-train.de

136 International Society of Blood Transfusion ISBT Central Office Marnixstraat 317 1016 TB Amsterdam The Netherlands T: + 31 20 7601 760 E: [email protected] W: www.isbtweb.org ISBT is facilitating knowledge about transfusion medicine to serve the interest of donors and patients. This is achieved by sharing information through a worldwide network of specialists in the field. The Society is well established and truly global bringing together professionals in transfusion medicine in over 97 countries worldwide. ISBT’s aims include: to connect with blood transfusion professionals; to provide opportunities for exchanging information on all aspects of transfusion medicine and associated disciplines; to promote and maintain high ethical, medical and scientific standards in transfusion medicine; to promote safe and sufficient transfusion therapy globally. The ISBT congresses help to encourage (new) members to share information in the transfusion medicine field and the Working Parties give the opportunity to participate in discussion in a particular topic. The ISBT Academy was established to support educational activities around the world. The Working Parties focus on the study of specific topics related to transfusion medicine and science and produce specified documentation. Every Working Party meets at least once a year and discusses the latest developments in their field. Action points are developed to ensure that the available information of their specific topic is kept up to date. The 23rd Regional Congress of the ISBT will take place in Amsterdam, The Netherlands, June 2 - 5, 2013 E: [email protected] W: www.isbtweb.org/amsterdam The 24th Regional Congress of the ISBT will take place in Kuala Lumpur, Malaysia, December 1 - 4, 2013 E: [email protected] W: www.isbtweb.org/malaysia The 33rd International Congress of the ISBT will take place in Seoul, South-Korea, June 1 - 5, 2014

278

279



086 Kawasumi Laboratories, Inc. Shinagawa Intercity Tower B, 2-15-2, Konan, Minato-ku Tokyo 108-6109 Japan

T: +1 703 435 6700 E: [email protected] W: www.itlcorporation.com

T: +81 3 5769 2656 E: [email protected] W: www.kawasumi.jp

F: +1 703 435 6717

Committed to healthcare workers’ safety, ITL Specializes in the design and manufacture of safety products for blood and biological sample collections, sample transfer, testing and sample management processes. ITL’s blood banking and laboratory products are used around the world to improve sharps safety, exposure control and best practice techniques. 005 JMS North America corp. 480 Sawgrass Corporate Parlway, suite 120 33325, Sunrise, Florida United States of America Contact: Tomas de la Hoz T: +1 954 689 9280 E: [email protected] W: www.jmsna.net

F: +1 954 689 9289

JMS has manufactured Blood bags since 1969. We have an impressive reputation for reliability, safety and superior product quality to meet the stringent requirements of blood banks and transfusion services. JMS Blood Management portfolio includes: Blood Bags (singles, doubles, triples, and quadruples), CPDA-1/CPD-SAGM, Transfer, Cord and Autologous Bags, Top&Top/TBEX systems, Transfusion sets, Manual and Automated separation of components and many other accessories. JMS NA’s mission is to provide products and services that offer optimal solutions for patients and medical professionals.

280

F: +81 3 5769 2761



138 ITL Corporation 1925 Isaac Newton Square East, Suite 480 20190 Reston, VA United States of America

Blood collection and transfusion systems at the price you expect at quality beyond your expectations! Since 1957, Kawasumi has been providing phlebotomists and clinicians worldwide with blood collection and transfusion systems. We are renowned for our consistently superior quality and unsurpassed affordability. Kawasumi has everything you need for the efficient and safe operation of your practice. Visit the Kawasumi booth and see how we have helped thousands of people just like you! 019 Lab21 Healthcare Ltd 184 Cambridge Science Park CB4 0GA, Cambridge United Kingdom Contact: Barbara Fallowfield T: +44 163 855 2882 E: [email protected] W: www.lab21.com

F: +44 163 855 2375

Lab21 Healthcare is a global provider of diagnostic products, supporting screening and diagnostic laboratories. The company has become a leading supplier to national blood supply services for syphilis testing, screening more than 70% of donations throughout western Europe. The Lab21 Malaria antibody test is well established around the world for use in screening blood donations from donors returning from high-risk areas. Lab21 can now offer total antibody screening for CMV in both EIA and haemagglutination formats for use on various automated platforms commonly used in blood testing laboratories.

281


080 LABORATORIOS DAI de MEXICO, S.A. DE C.V. Alvaro Obregon No: 190 2º. Piso Col. Roma 6700, Mexico City Mexico

061 LightIntegra Technology Inc 650-999 West Broadway V5Z 1K5, Vancouver British Columbia Canada

Contact: Jose Antonio Olivera B. T: +52 552 624 2500 E: [email protected] W: www.labdai.com

Contact: Audrey Labrie T: +1 778 317 9534 E: [email protected] W: www.lightintegra.com

F: +52 552 624 2500



282


F: +1 604 628 7880

Laboratorios DAI is a multinational Group of companies specialized in the distribution of High quality products and services for the transfusional medicine market with subsidiaries in Venezuela, Colombia, Costa Rica and Mexico. LABDAI Group companies cover all areas of the blood bank, including serology tests , immunohematology, Blood Bags Systems and separation machines, centrifuges, sterile tube welder (TCD), Blood bank software and refrigeration just to name a few. We also implement systems for Cord Blood and Tissue banks products and managements.

LightIntegra Technology manufactures ThromboLUX, a medical device designed to determine platelet quality during processing, after pathogen inactivation, or immediately prior to transfusion. ThromboLUX is the first device that can be used for a rapid, routine determination of platelet quality. By helping to avoid ineffective platelet transfusions, currently estimated as 17-36% of all transfusions, the device promises to improve patient outcomes and safety, thereby significantly lowering patient care costs.

101 Life Technologies Av. Paseo de la Reforma no. 505 piso 42 suite D Col. Cuauhtémoc, Del. Cuauhtémoc. 06500, México, D.F. México

010 LMB Soft d.o.o Bul.Nikole Tesle b.b. 18000, Nis Serbia

Contact: Dra. Sandra Balladares – Gerente General / Lic. Nathalie Femat - Marketing T: 52 (55) 30983800 F: 52 (55) 30983815 E: [email protected] W: www.lifetechnologies.com

Contact: Dragan Jankovic T: +381 185 776 40 F: +381 185 776 40,ext 13 E: [email protected] / [email protected] W: www.lmbsoft.rs / www.lmb.de

Life Technologies (formerly Invitrogen and Applied Biosystems) is a global solutions provider of consumables, instruments, and services that support scientists at the forefront of discovery. As your trusted scientific partner, Life Technologies is committed to providing you with an extraordinary customer experience by reliably delivering what you need when you need it.

Lmb Soft is the specialist for hardware and software development of high-tech solutions in the field of blood banking. The core product line of blood separators was designed with an outstanding degree of excellence, depending on the long experience and profound know-how if its employees

283



010 LMB Technologie GmbH Möslstraße 17 D-85445, Schwaig Germany

F: +49 812 2880 966 0

For more than 30 years now Lmb is a reliable partner for products used in blood banks and transfusion centres. The portfolio covers solutions for blood separation, blood donation, transport and storage of blood and beyond that individual, customized developments. 088 Macopharma 200 Chaussée Fernand Forest 59200, Tourcoing France Contact: Véronqiue Lutun T: +33 320 118 400 E: [email protected] W: www.macopharma.com Macopharma is a successful and innovative company in transfusion and infusion medicine. The company has become one of the largest suppliers of blood bags and in-line systems for leucodepletion worldwide. Within the field of blood processing MacoPharma with its extensive experience offers innovative solutions from blood collection through component processing to patient transfusion. Investments in research and development as well as partnerships with blood centers, universities and biotechnology companies enable Maco Pharma to present inventive solutions for pathogen reduction as well as for the expanding field of cell therapy.

284

Contact: Poline Y. Matti T: +1 847 803 4863 E: [email protected] W: www.MAK-System.net



Contact: Gabriel Elmer T: +49 812 2880 960 E: [email protected] W: www.lmb.de

026 MAK-SYSTEM Corp 2720 River Road Suite 225 60018, Des Plaines United States of America

F: +1 847 803 4808

MAK-SYSTEM International Group is a leading medical information technology company providing a broad portfolio of information management systems to healthcare organizations worldwide. Since its inception in 1984, MAK-SYSTEM has specialized in designing innovative software solutions that deliver superior functionality to the blood banking and blood transfusion, Plasma, Tissue, Cord sector. With more than 850 installations in over 45 countries among which are 24 nationwide implementations, MAK-SYSTEM is uniquely positioned to provide blood banks and hospital transfusion services with the most comprehensive combination of software functionality, support services and technology solutions to safeguard and optimize the entire blood management process. 122 MEDINFO INTERNATIONAL HEMOSERVICE 2-4 rue Jules Belleudy 06200, Nice France Contact: Kamel Ketari T: +33 493 144 601 E: [email protected] W: www.medinfo.fr

F: +33 493 144 675

MEDINFO is one of the leading companies specialized in the field of software for Blood Transfusion and cell therapy. Our software meets all the needs of Blood Transfusion Centres, Blood Banks and Transplant laboratories. It was developed in order to increase the patient safety, help the user to comply with his procedure and to manage an efficient traceability. It is comprehensive systems covering the whole transfusion (transplant) process from the blood collection (or Transplant request) up to the transfusion (transplant) of the patient. Many Blood Transfusion Centres, Blood Banks and Transplant laboratories, all over the world, have chosen our software to manage their activities: NBS in England, CTSA in France and many others in Belgium, Brazil, Chile, Romania, Saudi Arabia, Spain, Thailand, Tunisia, etc.

285



035 MTC INVITRO DIAGNOSTICS AG Ampèrestr. 2a D-64625, Bensheim Germany

F: +49 625 184 829 880

MTC - Micro Typing Concepts - is a manufacturer of clinical diagnostic products specializing in gel technology for blood grouping and other immunohematology applications. MTC INVITRO offers a full range of different technologies for blood grouping including the INVITROGEL TEST-SYSTEM, the gel centrifugation system with 6 column gel cards INVITROGEL and 8 column gel cards INVITROOCTA, microplates, liquid reagents and lateral flow technology INVITROFLOW plus the fully automated analyzers INVITROLYZER. 121 Nanjing Shuangwei Biotechnology Co., Ltd. New & High Technology Industry Development Zone 210061, Nanjing China Contact: Mr. Yaochun Wu T: +86 255 884 7598 E: [email protected] W: www.shuangweibio.com

F: +86 255 874 5107

Since 1993, Shuangwei Biotechnology has been dedicated to reducing risks of blood transfusion by advanced filtration technologies. Our CE-marked leukocyte reduction filters have been widely used in more than 15 countries. As a reliable supplier of whole blood filters and SOFT housing RBC filters, SHUANGWEI has established cooperation with Terumo and Fresenius in China, and other good blood bag manufacturers around the world. Our pathogen inactivation system (Methylene Blue) system will be used by more and more blood centers soon.

286

Contact: Jacob Jung T: +1 617 965 1414 E: [email protected] W: www.digital-bio.com



Contact: Ms. María del Pilar Barrientos T: +49 625 184 8290 E: [email protected] W: www.mtcinvitro.com

039 NanoEnTek Inc 300 Washington St, STE 416 2458, Newton, MA United States of America

F: +1 617 965 1415

Digital-Bio is the world first truly portable automatic WBC counter manufacturer. ADAM-rWBC is an analyzing device that counts the number of residual leukocytes in a blood type solution for transfusion done in hospitals, blood banks, etc. Targeting leukocyte, ADAM-rWBC uses fluorescent to dye cells, counts them 203 times and by calculating the average of counting results, ADAMrWBC produces the most accurate results in the test of residual leukocyte concentration of leukocyte removal blood. Combined with a disposable microchip, the operation of ADAM-rWBC is now extremely simple, easy and cost-effective. Cleaning and warm-up time is no longer necessary. The disposable chip greatly reduces the risk of the exposure to hazardous blood samples or virusinfected cells, etc 047 Novartis Diagnostics 4560 Horton Street 94608, Emeryville, California United States of America Contact: Martina Wagner T: +1 510 923 4958 E: [email protected] W: www.novartis.diagnostics.com Novartis Diagnostics commercializes highly sensitive NAT products, developed in collaboration with Gen Probe, Inc., to test blood and plasma donations for HIV, Hepatitis and West Nile Virus. We also are a leading manufacturer of immunoassay reagents and test kits used in diagnostic and blood bank labs.

287



116 Ortho Clinical Diagnostics 1001 US Highway 202 8869, Raritan, NJ United States of America

Contact: Andrea Neisser-Svae / Mirjam Steinegger T: +41 554 512 121 F: +41 554 512 110 E: [email protected] / [email protected] W: www.octapharma.com

Contact: Heather Pace, WW Marketing Manager, Transfusion Medicine; Tony Hardiman, WW Marketing Director, Donor Screening T: +1 800 828 6316 F: +1 585 453 3660 E: [email protected] W: www.orthoclinical.com

Octapharma is a Swiss-based, independent, global human plasma fractionation specialist with a wide range of innovative products. Its core business is the development, production and sale of high quality human plasma proteins. The intensive care product portfolio includes: octaplex®, S/D treated, nanofiltered Prothrombin Complex Concentrate, for Vitamin-K dependent coagulation factors deficiencies; octaplasLG®, biopharmaceutical plasma for transfusion; atenativ®, S/D, heat-treated and heparin free Antithrombin concentrate; albunorm, and human albumin. 052 OrSense Ltd. 5 Golda Meir St. 74140, Nes Ziona Israel Contact: Dahlia Sterling T: +972 549 090 628 E: [email protected] W: www.Orsense.com

Ortho Clinical Diagnostics serves the transfusion medicine community and laboratories around the world. We’re a leading provider of total solutions for screening, diagnosing, monitoring and confirming diseases early before they put lives at risk. Our single focus is to help hospitals, laboratories and blood centers worldwide deliver results that help patients experience a better quality of life. 076 PRESVAC SRL Calle 34 ( Ex Francia ) Nro. 3917 B1650ihm San Martin – Pcia. De Bs As Argentina

F: +972 894 655 02

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 40 countries worldwide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. OrSense‘s s products are based on its proprietary Occlusion Spectroscopy technology.

288



022 Octapharma AG Seidenstrasse 2 8853, Lachen Switzerland

Contact: Gustavo Parisi T: +54 11 4755 7780 / 4004 E: [email protected] W: www.presvac.net

F: +54 11 4755 7780 / 4004

Established in 1965 to serve the life science industry, Presvac is a manufacturer of high quality blood banks equipments. We manufacture Refrigerated centrifuges, Table top centrifuges, Blood shaker with scale. Donor chairs. Refrigerators, Freezers, Platelet Storage, and Plasma Thawing Systems.

289



064 Roche 4300 Hacienda Drive 94588, Pleasanton, California United States of America

F: +1 925 225 0875

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s leader of in-vitro diagnostics (IVD), with proven nucleic acid amplification technology (NAT) expertise in blood screening. Roche Diagnostics is recognized for highly flexible and efficient pre-analytical and analytical testing solutions on cobas® modular platforms for commercial and hospital laboratories of all sizes. Roche, a leading expert in the infectious disease diagnostics and screening, now expands its serology portfolio into blood screening (in selected countries). To learn more about Roche’s expanded solutions portfolio for blood screening, please stop by our booth (064) and explore how we innovate healthcare! To check availability of products within your country or for more information, please visit www.roche.com/about_roche/business_fields/about-diagnostics.htm or contact your local Roche representative.

Contact: Von Lammers T: +31 205 123 599 E: [email protected] W: www.sanquinreagents.com

F: +31 20 512 3570

From its start as a pioneer in blood transfusion over 60 years ago, Sanquin (formerly CLB) has developed into a cornerstone of the public health sector in the Netherlands. Sanquin Reagents develops and produces a comprehensive line of reagents for diagnostic purposes and for use in research according to ISO 9001 and ISO 13485 standards. Products of Sanquin Reagents are distributed in over 35 countries worldwide. 109 Sichuan Nigale Biomedical Co., Ltd. No. 306, 3/F, Building 2nd, No. 825 Jin Cheng Ave. Hi-Tech. District 610041, Chengdu China

060 Safetran Biomedical Inc. 3F, No.3, Alley 16, Lane 120, Lide Road, Beitou Dist. 112, Taipei City Taiwan

Contact: Nick Liu T: +86 288 512 2235 / +86 139 116 37793 / +86 139 800 84635 F: +86 286 155 0163 E: [email protected] / [email protected] W: www.nigale.en.alibaba.com

Contact: Eve Yu T: +886 228 761 362 E: [email protected] W: www.safetran.com.tw

Nigale is an enterprise specialized in manufacturing automated blood processing devices and disposable kits.Our entire products have Chinese SFDA certificates, GMP, ISO13485 and CE marks. Nigale products are mainly used in blood cells separating & filtering，plasma exchanging therapy as well as operation room and clinical therapies in hospitals.

F: +886 228 765 955



Contact: Jessica Brillant T: +1 925 730 8503 E: [email protected] W: www.roche.com

054 Sanquin Blood Supply Plesmanlaan 125 1066 CX, Amsterdam the Netherlands

Safetran Biomedical Inc., established on December 1st, 2008, is a Taiwan-based medical device company dedicated to the development of safe blood transfusion platform. Safetran provides a range of state-of-the-art products in transfusion field including: 1. Blood components Apheresis and collection system. 2. Leukocyte reduction filter with removal rate reaching 99.99% and good recovery rate (>85%). 3. Transfusion sets providing high quality products and safety for blood transfusion.

290

291



099 Siemens Healthcare Diagnostics 511 Benedict Avenue NY 10591-5005, Tarrytown United States of America

F: +49 642 139 4579

Siemens Healthcare Diagnostics offers a comprehensive portfolio of performance-driven systems, unmatched test menu, and information technology solutions for the in vitro diagnostic needs of hospital labs, reference labs, physician office labs, and point-of-care testing. We provide clinicians with the vital information they need for accurate diagnosis, treatment, and monitoring of patients. Our diagnostic solutions—chemistry, immunoassay, automation, hematology, hemostasis, microbiology, diabetes, urinalysis, blood gas, and molecular testing—are designed to streamline workflow, enhance operational efficiency, and support improved patient care. To learn more about Siemens Healthcare Diagnostics, please visit our Booth # 099 or visit our website at www. siemens.com/diagnostics. 132 SIFIN Institut für Immunpraeparate und Naehrmedien GmbH Berlin Berliner Allee 317 - 321 D-13088, Berlin Germany Contact: Susanne Dahler T: +49 309 270 300 E: [email protected] W: www.sifin.de

F: +49 309 270 3030

The roots of SIFIN, founded 1991, go back to the early 19th century. Under Bismarck it bore the name Berlin Institute for Vaccinations. Today the range of SIFIN products includes bacteriological test reagents, culture media, monoclonal antibodies and products for blood grouping, such as Serafol® bedside cards for identity check, ready-to-use test reagents, kits or containers for the PK® system, blood grouping reagents and FFMU concentrates or ready-to-use reagents based on SIFIN clones.

292

Contact: Renate Wauge T: +49 552 250 078 260 E: [email protected] W: www.sigma-zentrifugen.de



Contact: Frank Luebben T: +49 642 139 4448 E: [email protected] W: www.siemens.com/diagnostics

134 Sigma Laborzentrifugen GmbH An der Unteren Söse 50 D-37520, Osterode Germany

F: +49 552 250 079 260

A comprehensive range of high-quality centrifuges is available from Sigma Laborzentrifugen GmbH. The product range encompasses centrifuges from 48 ml to 12 l capacity. Wide spectrum of accessories for dedicated applications. Instruments for blood banks feature high throughput and extremely reliable operation, IQ/OQ and protected programming. Sigma 8KB, refrigerated floorstanding centrifuge for blood banks, capacity up to 12 blood bags (12 l) in swing-out rotor; data interface for quality management. Sigma 4-5L, new instrument for high throughput operation in clinical laboratories. 024 Terumo BCT 10811 W. Collins Avenue 80215, Lakewood, Colorado United States of America Contact: Tara Jones T: + 877 339 4228 F: +1 866 715 6768 E: [email protected] W: www.terumobct.com CaridianBCT and Terumo Transfusion have united to become Terumo BCT, a global leader in blood component and cellular technologies. We believe in the potential of blood and cell therapies to do even more for the world than they do today. As we strive to make even safer, higher-quality transfusions available, we can help our customers bring even more treatment options to patients with advanced blood therapies and we can help researchers develop cell therapies that may fundamentally improve health care.

293



113 Wiley-Blackwell 350 Main Street 02148, Malden, MA United States of America

Contact: Kristi Fugate, Director, Global Tradeshows and Events, Laboratory Products Group T: +1 781 622 1000 F: +1 781 622 1207 W: www.thermoscientific.com

Contact: Daisy Guerrero T: +1 781 388 8313 E: [email protected] W: www.wiley.com

Demand Thermo Scientific products to accelerate discovery and move science forward. The Thermo Scientific portfolio includes a broad array of high-quality instruments, reagents, laboratory consumables, equipment, and services - designed to help you run your laboratory at peak performance, from start to finish. See the entire Thermo Scientific line up at www.thermoscientific.com 096 V.I.P.S. SA Avenue de la Gare 26 2013, Colombier Switzerland Contact: Gerard Lopez T: +41 328 430 330 E: [email protected] W: www.vipsmedical.com



008 Thermo Scientific 81 Wyman Street 2454, Waltham, MA United States of America

F: +1 781 338 8313

Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes over 1,400 peer-reviewed journals as well as 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or http://onlinelibrary.wiley.com/

F: +41 328 430 331

VIPS is committed to deliver to Blood Transfusion Establishments worldwide, an integrated, semi-automated and secured solution for the viral inactivation of cryoprecipitate and plasma, in compliance with global quality standards. The initiation and development of the VIPS project was primarily dedicated towards developing countries by enabling easier access to safer and regular treatment of serious bleeding disorders such as Haemophilia - it is well known that 75% of patients in these countries does not receive safe or sufficient treatment. The project is also of major interest to Blood Transfusion Establishments in highly developed countries, allowing them to virally-inactivate plasma and cryoprecipitate by Solvent-Detergent in an independent and costeffective manner.

294

295



296

Speakers Index

Speakers Index

Speakers Index

Agarwal S. 5C-S38-01 Akkok C.A. 5C-S39-02 Alcantara-Quintero L.E. 3D-S18-04 Allain J-P. 4C-S26-01 Ang A.L. 3A-S3-02 Anstee D.J. 3B-PL1 Araujo P.R.B. 6A-S49-05 Arcuri A. 6A-S48-03 Armstrong B.C. 2A-D1-02 Arnaud L. 5D-S42-01 Bahgat M.T. 5C-S41-04 Bartelmaos T. 5A-S33-03 Bell B.M. 5C-S40-04 Beltran M. 3C-S12-01 Benjamin R. 3D-S16-03 Bertrand G. 5C-S37-02 Biagini S. 3D-S14-05 Bianco C. 3A-S5-01 Bisbe E. 6A-S50-01 Bloch E.M. 4B-S19-03 Bohonek M. 4C-S30-02 Branch D.R. 4B-S19-04 Briggs L. 5D-S46-02 Brooks P. 2B-D3-01 Bruhn R.L. 6A-S49-02 Buenz E. 4B-S22-03 Burnouf T. 2D-D7-02 Campos de Carvalho A.C. 5D-S47-01 Carbonne B. 2D-D8-02 4B-S19-02 Castro E. 3D-S16-01 Caulfield J. 4C-S29-03 Choudhury N. 5C-S38-04 Collin M. 4B-S19-01 Colombo F. 3D-S18-05 Conti F. 3D-S13-03 Contreras M. 2A-D1-03 Cruz J.R. 4C-S28-02 Dai B. 5C-S41-01 297

Speakers Index

298

4C-S25-02

Iudicone Jackson Jain Jayasekara Jones Kaplan Karamatic Crew Kiss Knels Koh Krusius Kumpel Kwon Laperche Leiby Lo Londero Loper Madrigal Manzini Martinez Meyer Meyer Miller Mitchell Moghaddam Montaño-Figueroa Müller-Kuller Muniz Diaz Murphy Nakamura Nance Natukunda Ness Niederhauser Noel Noizat-Pirenne Nussbaumer

P. 4B-S24-04 G.S. 3A-S2-01 A. 6A-S48-02 S. 5C-S41-05 M. 3A-S2-02 C. 2D-D8-03 V. 5D-S42-03 J. 2C-D5-01 R. 5D-S46-03 M.B.C. 4B-S24-01 5A-S36-02 T. 3A-S5-03 B.M. 2D-D8-01 S.Y. 3C-S12-04 S. 4C-S26-02 D.A. 4B-S20-03 Y.M.D. 4A-PL2-02 D. 5C-S37-03 K. 5A-S36-01 A. 3B-PL3 P. 4B-S22-04 F. 6A-S48-05 S 3A-S1-01 M.A.S. 4C-S27-02 J. 4B-S24-02 C. 3A-S4-04 M. 5D-S45-04 E.H. 3D-S18-02 T. 5D-S46-04 E. 5D-S45-03 M.F. 4C-S29-02 Y. 5A-S31-03 S. 5D-S45-01 B. 3D-S15-01 P.M. 5A-S35-02 C. 6A-S49-04 E. 5C-S39-01 F. 3D-S15-02 W. 5A-S33-02

Speakers Index

Speakers Index

Daigneault S. 3A-S4-01 Daniels G. 4C-S25-04 Dann E.J. 5A-S33-04 de Haas M. 2C-D6-03 3A-S1-02 Dean M. 5D-S44-04 Devine D. 3C-S10-05 Donnet T. 3C-S10-03 Dziegiel M.H. 4C-S25-01 Eder F. 3D-S14-02 5A-S34-01 Edgren A. 4C-S28-03 Faber J.C. 3C-S11-02 Flanagan P. 6B-PL5-02 Folléa G. 4B-S23-01 5C-S38-02 Fontaneo-Wendel R. 3D-S13-02 Fournier-Wirth C. 5A-S32-04 Franklin M. 6B-PL5-01 Fraser F. 3A-S3-01 Frenkel O. 3D-S13-01 Fung Y.L. 3A-S3-03 3C-S7-01 Garcia Gutierrez M. 3A-S4-03 Garratty G. 2C-D6-01 Garraud O. 6A-S48-04 Gathof B. 5C-S38-05 Germain M. 5C-S40-02 Gharehbaghian A. 4C-S28-01 Goldman M. 5A-S35-03 5C-S40-03 Gunter K.C. 5D-S47-02 Hechler B. 4C-S30-01 Heddle N. 5B-PL4-2 Hellstern P. 4B-S21-04 Hendrickson J. 4B-S21-01 Henry M. 3C-S8-01 Hess R. 2B-D3-03 Hod E.A. 3C-S8-02 Hohberger C.P. 5D-S46-01 Horn P. 4A-PL2-01 5A-S36-03 Husebekk A. 5C-S37-01 Hyland C.A. 4C-S25-05

Speakers Index

299

Speakers Index

300

C. 5D-S45-02 M.L. 2B-D4-02 J.S. 5A-S31-02 J.-C. 4C-S27-04 A.K.K. 4B-S20-01 A. 2D-D7-01 O.B. 6A-S51-04 O. 5D-S44-02 T. 3D-S15-03 J. 2C-D6-02 5D-S45-05 B.W. 4C-S27-03 L. 3D-S18-01 S.M. 3C-S10-04 5A-S32-03 C. 4B-S20-02 R. 6A-S51-02 M.E. 2B-D4-03 5D-S42-02 M. 6A-S49-01 G. 4C-S27-01 P. 3C-S11-03 J. 3A-S2-03 5C-S39-03 E.C. 5D-S43-04 S.A. 3C-S9-03 P.E. 5C-S38-03 S. 3D-S14-01 V. 5A-S34-03 T.E. 4C-S29-04 A. 5D-S42-04 M. 5A-S32-01 P. 4C-S30-05 C. 4C-S26-03 C. 2A-D2-02 E. 5D-S47-03 M. 5C-S41-02 A. 4C-S30-06 W. 6A-S48-01 B.H. 6A-S51-01 M.A. 5D-S43-01 E. 3D-S14-03

Singh Smith Solheim Souksakone Spínola Sprogøe Stanworth Steffensen St-Louis Storry Storry Stramer Strengers Tan Tan Telen Thomas Titlestad Triulzi Tung van de Watering van den Burg van der Meer Vermeulen Vinelli Voorn Vrielink Vuk Wagner Wallis Wang Waters Waters Wendel Weyrich White Wiersum-Osselton Wikman

Y. 4C-S28-05 G. 4C-S28-04 B.G. 3D-S16-02 C. 3A-S5-02 A.I. 5D-S44-05 U. 4B-S19-05 S. 2B-D3-02 4B-S21-02 R. 5C-S37-05 R. 3C-S8-03 J.R. 2B-D4-01 J. 3A-S1-03 L. 5D-S43-03 P. 2A-D2-01 2D-D7-03 C. 3A-S4-02 J.C.G. 3D-S15-04 J. 5A-S31-01 D.W. 2C-D5-03 6A-S50-02 K. 5D-S44-01 D. 5B-PL4-1 5B-PL4-3 J.P. 3D-S14-05 L.M.G. 5B-PL4-1 5B-PL4-1 P. 3C-S9-04 4B-S22-01 P.F. 3C-S10-01 4C-S30-04 M. 3C-S12-03 6A-S49-03 E. 3C-S11-01 V.M.A. 5D-S44-03 H. 4B-S22-02 T. 2A-D2-03 F.F. 3C-S8-04 J.P. 2C-D5-02 3C-S9-01 J. 3C-S12-02 J.H. 4C-S29-01 N. 5C-S41-03 S. 3A-S2-04 S. 3B-PL2 J.L. 5C-S37-04 J.C. 3C-S11-04 5A-S35-01 T. 4C-S25-03

Speakers Index

Tab_3 Index Speakers

Olsen Olsson O'Neill Osselaer Owusu-Ofori Padilla Pedersen Peñuela Briceño Peyrard Poole Prick Querol-Giner Ramirez-Arcos Rayner Reddy Reid Rios Roberts Robillard Rojo Sabino Sánchez-Guerrero Sánchez-Montero Santoso Saturni Scanes Scharberg Schmidt Schubert Seed Seidl Seifried Sekhar Seltsam Semple Shaz Shikanai Yasuda Shimada

Speakers Index

5A-S35-04

5C-S40-01 301

Speakers Index

Speakers Index

Wong Wood Xie Yang Yazer Yin Yipp Zaheer Zatta Zhu Zito Zubair

302

H.K. 5A-S34-04 E.M. 3C-S9-02 5A-S32-02 R.F. 3C-S10-02 J. 4B-S24-03 M.H. 4B-S23-02 5A-S33-01 J.P. 3D-S18-03 B. 3C-S7-02 H.A. 2A-D1-01 A.J. 4B-S21-03 Z. 6A-S51-03 E. 5A-S34-02 A. 4C-S30-03